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"You can discover what your enemy fears most by observing the means he use, 1.0 
frighten you. " 
Eric Hoffer 
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ABTRACT OF THESIS 
There is little doubt that tumour-specific antigens exist for most human cancers though 
it is still unclear why these antigens do not cause tumour rejection. A successful 
immune response against a tumour is dependent on the detection of that tumour and the 
ability of the host immune system to mount an effective response. Clearly, malignant 
cells have evolved to evade the natural host defence mechanisms. Multiple Myeloma 
(MM) is a mature peripheral B cell malignancy with many defects in the host immune 
system including quantitative and qualitative abnormalities of both cell-mediated and 
humoral immunity. However, as yet, the mechanism(s) that induce these abnormalities 
of the immune system remain to be determined. Before immunotherapy can be applied 
on an entirely rational basis more knowledge is required as to why the immune system 
fails to identify multiple myeloma plasma cells as foreign. 
The data presented in this thesis demonstrates that the malignant plasma cells of 
mUltiple myeloma are capable of suppressing the activation of T lymphocytes. The 
myeloma cells prevent activation of T cells from healthy donors by allo-antigen, 
mitogen and IL-2, mediated by the production of a soluble, immuno-suppressive factor. 
This factor was responsible for inducing cell cycle arrest and failure of the T cells to 
progress into the autocrine IL-2 autocrine pathway, which is of critical importance in 
the activation of T cells. To further investigate this interaction an in vitro model system 
was developed to examine the key stages of T cell activation and homeostasis. 
Myeloma cells constitutively expressed high levels of TGF-f31 mRNA transcripts as 
detected by RT-PCR, which were translated into latent protein and secreted as detected 
by immunohistochemistry and ELISA, respectively. The reversal of the immuno-
suppression induced by the myeloma cells using the specific TGF-f31 antagonist, 
Latency Associated Peptide, confirmed that TGF-f31 is a major factor in myeloma-
associated suppression ofT lymphocyte activation. 
It was demonstrated that the myeloma cells prevent the T cells, upon activation, from 
up-regulating the surface expression of the a-chain of the IL-2R thus preventing the 
formation of the high-affinity receptor. The reduced expression of IL-2Ra resulted from 
altered transcription of the a-chain gene in response to re-stimulation of primary T cells 
with IL-2. When signalling events in primary T cells responding to re-stimulation with 
IL-2 was examined, myeloma cells inhibited the phosphorylation of both ST AT3 and 
STAT5. However, using a novel IL-2-dependent T cell line (IDBL), which does not 
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require the expression of the high affinity IL-2R for its responses to IL-2, it was shown 
that these cells are insensitive to the myeloma-derived TGF-p, in terms of DNA 
synthesis and proliferation, despite demonstrating failure of phosphorylation ofSTATS. 
It was demonstrated that phosphorylation of STAT3 was unchanged when IDBL cells 
were co-cultured with myeloma cell lines. However when the a-chain of the IL-2R was 
presented inter-cellularly in trans, this induced a susceptibility of the IDBL cells to 
HMCLs. This susceptibility resulted from failure of STAT3 phosphorylation associated 
with down-regulation of bcl-2 and pim-l genes. As a consequence, the IDBL cells 
demonstrated reduced DNA synthesis and proliferation, similar to that seen with 
primary PBL, when IL-2Ra was presented in a an inter-cellular fashion. 
Taken together, these features demonstrate that the presence of the a-chain of the IL-2R 
presented inter-cellularly in trans, whether from a transfectant in the case ofIDBL cells 
or from CD2S+ T cells in the heterogeneous population of primary T cells, assists the 
susceptibility of activating T cells to myeloma-derived TGF-p resulting in growth arrest 
and failure to enter the autocrine IL-2 pathway. This suggests a role of the a-chain of 
the IL-2R in regulating the immune responses, here potentiating the T cell suppressive 
effects of myeloma-derived TGF-pl. The experimental data presented in this thesis has 
addressed the issue of the interaction of myeloma tumour cells with T lymphocytes, 
indicating a potential mechanism that may propagate the immune privilege of the 
tumour clone. This highlights areas that might be targeted by further research studies in 
anticipation of designing new therapeutic strategies. 
Word Count: 54,886 words 
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CHAPTER! 
Introduction and Review 
1 
Although there is little doubt that tumour-specific antigens exist for most human 
cancers, it is still unclear why these antigens do not cause tumour rejection. A 
successful immune response against a tumour is dependent on the detection of that 
tumour and the ability of the host immune system to mount an effective response. 
Clearly, malignant cells have evolved to evade the natural defence mechanisms 
resulting in growth and dissemination at the expense of the host. It is essential that the 
mechanisms employed by tumour cells to evade immune regulation be identified so that 
immunotherapy strategies can be designed which will realise their promise. In the 
context of Multiple Myeloma (MM), this universally fatal mature B cell malignancy 
could potentially be a target for directed immunotherapy and as such a better 
understanding of the basic immunology associated will greatly assist the search for 
novel treatment approaches. 
1.1 MULTIPLE MYELOMA: CLINICO-PATHOLOGICAL FEATURES 
Plasma cell dyscrasias are a heterogeneous group of disorders that are characterised by 
the clonal expansion of terminally differentiated B cells. These clonal plasma cells 
produce a monoclonal immunoglobulin (paraprotein == M-component == clonal idiotype) 
that can be detected in both serum and urine (Boccadoro & Pileri, 1995). In the 
malignant form, the expansion is uncontrolled and this is responsible for the clinical 
manifestations, namely bone marrow failure, lytic bone disease and renal failure. Overt 
MM is the commonest form of plasma cell dyscrasia. MM was first reported by Dr 
Samuel Solly in his communication to the Royal Medical Chirugical Society in London 
(Solly, 1844) though Dr William MacIntyre is frequently credited with the first 
description when he reported a case of light chain myeloma (MacIntyre, 1850). 
However, it wasn't until 1873 that the disease was referred to as Multiple Myeloma by 
Dr Rustizky to indicate the multiple nature of the bone marrow tumours (Tricot, 2000). 
In 1900 Dr Wright discovered that the homogeneous cellular infiltrate seen in the bone 
marrow of patients with multiple myeloma was in fact a tumour of plasma cells. 
Multiple myeloma has an incidence of 3-4 new cases per 100,000 population per annum 
though this incidence demonstrates ethnic variation: the incidence is lowest in Chinese 
races at 11100,000 and highest in European races at 4/100,000 (Reidel et ai, 1991). 
Furthermore, the disease is commoner in Afro-American individuals compared to 
Caucasoid individuals with a male:female ratio of 3:2. In the 1960s, the disease 
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presented most commonly with back pain, reported in up to 70% of patients. Owing to 
increased awareness of the disease and availability of rapid biochemical analysis, less 
than 40% of patients now present with symptomatic bone disease and at least 20% of 
patients are now diagnosed whilst totally asymptomatic (Dimopoulos et aI, 1992). 
Multiple myeloma is an incurable disease, except in certain patients treated with 
allogeneic haematopoietic stem cell transplantation (Tricot et aI, 1996). The survival of 
patients with MM is variable and can range from a few months to several years, though 
without therapy, the median survival is 7 months from diagnosis (Osgood, 1960). The 
median survival with treatment is 2.5-3 years but this may be prolonged in younger 
patients treated with dose intensive chemotherapy (Bersagel, 1995). However, only 
3.5% of patients with multiple myeloma are alive at 10 years. The use of a number of 
clinical prognostic indicators reflecting tumour burden have been used to formulate a 
basic staging system, the Durie Salmon clinical staging system (Durie et al, 1982). This 
system, based on the presence of bone marrow failure, renal dysfunction and the extent 
of lytic bone disease, could separate patients prognostically in to early stage disease 
(low tumour burden) with a median survival of 5 years and those with advanced stage 
disease (high tumour burden) with a median survival of 15 months. The addition of 
biological variables such a P2-microglobulin, CRP (indicator of IL-6 levels) and 
cytogenetic abnormalities may further refine this crude clinical staging system to allow 
the identification of those patients who will demonstrate the best response to 
conventional therapy (Davies et aI, 1997). Mutations of oncogenes such as N- & K-Ras, 
and the tumour suppressor gene, p53, have limited prognostic predictability as these 
events are most frequently encountered in the advanced stages of disease and are 
relatively rare events at presentation. Altered expression of the cell cycle regulator, 
pRb, may be of significance, especially as this is located on chromosome 13. 
Abnormalities of chromosome 13 in MM are associated with a poor prognosis (Hallek, 
1998). However, it is not clear whether the deletions of chromosome 13 are related to 
abnormalities of pRb as the regions involved in the deletions are quite extensive and 
may involve other tumour suppressor genes. 
Plasma cells in Myeloma 
The plasma cell infiltration of bone marrow (BM) is largely diagnosed through 
morphological examination of BM aspirates although increasingly the use of paraffin-
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embedded biopsy sections, flow cytometry, in situ hydridisation studies and the use of 
magnetic resonance imaging are providing an better evaluation of the extent of marrow 
infiltration (Figure 1.1). The minimal diagnostic criterion is a plasma cell population of 
10-15% of the total cell count (Kyle, 1992). However, the situation varies greatly 
amongst patients: 35% of patients have fewer than 30% BM plasma cells, 11 % of 
patients have less than 10% and 3% had fewer than 5% (Bartl et aI, 1995). This merely 
reflects the patchy nature of this disease and its dissemination throughout the marrow 
cavity. The plasma cell morphology demonstrates features that enable confident 
identification of atypical plasma cells: nuclear-cytoplasmic asynchrony, nuclear 
abnormalities including multiple nuclei and nucleoli and variations in size and 
cytoplasmic staining. 
The exact origin of these clonal plasma cells is still the source of considerable debate 
and the existence of a "myeloma stem cell" has yet to be proven conclusively. Normal 
BM plasma cells are derived from B cells that have passed through the germinal centre 
of a lymphoid organ and undergo somatic hypermutation and class switching of their 
immunoglobulin (Ig) heavy chain genes (Davis et aI, 1997). Following antigen-
selection, only B cells with high affinity for the presented antigens survive, whereas the 
remaining B cell clones undergo apoptosis. The plasma cells of multiple myeloma 
demonstrate rearranged Ig genes that are extensively somatically hypermutated in a 
manner compatible with antigen selection, with no evidence that the process of 
hypermutation is continuing (Hallek et aI, 1998). However, myeloma cells have a 
significantly lower rate of Ig secretion compared with normal plasma cells. It has been 
proposed that the development of malignant plasma cell expansions result from a multi-
step transformation, which further clouds the issue of the putative "myeloma stem cell" 
(Hallek et al, 1998). It is still not clear whether the oncogenic events resulting in the 
development of MM occur after the normal maturation process which generates long-
lived plasma cells (Ig gene rearrangement, somatic hypermutation and switch 
recombination) or in fact these events do not interfere with this process (Bakkus et al, 
1994). 
MM is a slow growmg tumour and using the incorporation of DNA precursors 
e[H]thymidine or bromodeoxyuridine), a labeling index can be calculated as the 
percentage of plasma cells actively entering S phase of cell cycle (Kyle, 1992). Using 
this technique, only 1-3% of plasma cells are cycling compared to much higher values 
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Figure 1.1. Bone marrow plasma cell infiltrate in multiple myeloma. The morphology 
of bone marrow aspirate (A- Geimsa, X400) and histology of paraffin-embedded 
marrow trephine biopsy (B- H&E, X200) demonstrate atypical plasma cells with bi-
nucleate fonns (arrow) and prominent nucleoli easily identified. 
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detected in reactive plasma cell expansions. However, as a biological variable it has not 
been shown to correlate with survival (Davies et aI, 1997). Perhaps of more interest is 
the role of programmed cell death or apoptosis. Apoptosis plays a pivotal role in the 
nonnal development of B cells, especially for the deletion of autoreactive B cells 
(Hallek et al, 1998). Bc1-2 is a membrane protein associated with the outer membrane of 
mitochondria and nuclei and regulates apoptosis (Korsmeyer, 1992). Over-expression of 
bc1-2 in cancer cells can result in chemoresistance and protection from apoptosis and 
recent work has shown the existence of several bcl-2-related proteins in cancer cells that 
can inhibit (Bel-XL, Mel-I, NR-13, AI, Bcl-W) or enhance (Bax, Bcl-Xs, Bak, Bad) 
apoptosis (Gajewski, 1996). 
Expression of bc1-2 is thought to play an important role in B-cell malignancies, 
especially in follicular lymphoma, where more than 80% of the patients have the 
translocation t(14;18), which results in overexpression of bcl-2 (Hennine et al, 1996). 
This translocation occurs at lower frequency (0% to 15%) in MM, but despite this an 
over-expression of bcl-2 is seen in the majority of fresh plasma cells from patients with 
MM and in human myeloma cell lines (Pettersson et al, 1992; Ong et al, 1995). High 
levels of bc1-2 protein are likely to mediate the resistance of MM cells to apoptosis 
induced by dexamethasone, IL-6 deprivation or other drugs (Tian et al, 1996). However, 
when bcl-2 expression was examined in relationship to patient survival, no correlation 
was evident (Ong et al, 1995). 
Adhesion Molecules and Other Cell-Surface Antigens 
The differentiation of lymphoid precursor cells into mature B lymphocytes is 
accompanied by characteristic changes of cell-surface antigens. The application of high 
resolution, multiparameter flow cytometry has been used to identify and characterize 
normal plasma cells in the human BM. Plasma cells exist in at least two different 
subpopulations, early Iymphoplasmacytoid cells and late mature plasma cells (Terstapen 
et aI, 1990). These two populations appeared phenotypically different, but both strongly 
express CD38. Mature, normal plasma cells show a very heterogeneous 
immunophenotype in that they can express early B-cell antigens (CDI9, CD20, CDI0), 
myeloid antigens (CDI3, CD33), HLA-DR, common haematopoietic antigens (CD45), 
and adhesion molecules (CD 11 b, CD 11 c). 
The neoplastic cells of MM probably follow a similar maturational pattern to the normal 
counterpart. Although the MM "stem cell" is unknown, there is evidence for cell clones 
6 
in patients with MM that show the immunophenotype of early B-cell precursors, which 
express CD38 at high levels, as well as CDIO, CD34, CDI9, and CD20 (Boccadoro & 
Pileri, 1995). Myeloma cells show a similar heterogeneity in their immunophenotype as 
their normal counterparts, according to their differentiation stage. Immature myeloma 
cells (CD38++/CD45Iow/CD4gel appear to express the same clonal idiotype as mature 
cells (CD38++/CD45-/CD4ge1. Whether CD34 is expressed on MM cells remains 
controversial and published studies indicating the expression of the stem cell antigen on 
clonally-related cells in myeloma balance those reports which state that MM cells do 
not express CD34 and this may be explained by technical differences (Davies et al, 
1997). 
Syndecan-l (CDI38) is a heparan sulfate-bearing proteoglycan present on the surface of 
myeloma cells where it mediates myeloma cell-cell and cell-extracellular matrix 
adhesion (Cook et aI, 1997). It has been reported that some cells demonstrate striking 
localization of syndecan-l to a single small membrane protrusion (uropod), with the 
remainder of the cell surface being mostly negative for syndecan-l (Borset et al, 2000). 
In addition to syndecan-l, several other cell surface molecules localize specifically to 
the uropod, including CD44 and CD54. The functional importance of these observations 
are speCUlative but these molecules may be involved in mediating cellular migration, 
cell-cell and cell-matrix interactions and attachment of heparin-binding proteins, like 
hepatocyte growth factor or osteoprotegerin (Dhodapkar & Sanderson, 1999; Borset et 
aI, 2000). Myeloma cells also shed syndecan-l and this soluble form has been shown to 
induce apoptosis of HMCLs and high serum levels correlate with a poor prognosis, 
suggesting a regulatory role of syndecan-l in the growth of myeloma cells ( Dhodapkar 
et aI, 1998; Seidl et al, 2000). 
It is believed that myeloma cells originate outside the BM and give rise to plasma cells 
upon migration, using expression of unique adhesion molecules to interact with the 
marrow microenvironment (Vidriales et al, 1996). Despite the similarity of most 
antigens expressed on myeloma cells and normal plasma cells, some of the antigens 
detectable on myeloma cells are rather unique. For example, the adhesion molecule 
CD56, normally found on NK cells is the 140-kD isoform of N-CAM, is highly 
expressed on some myeloma cells but not on normal mature plasma cells (reviewed by 
Cook et aI, 1997). It seems to mediate adhesion of myeloma cells to each other 
(homotypic adhesion). The expression of adhesion molecules and other cell-surface 
molecules such as CD49d, CD54, CD44, CD58, ICAM-l and CD29 are important for 
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the communication of MM cells with the BM micro-environment. The interaction of 
MM cells with BM stromal cells (BMSCs), mediated by these adhesion molecules 
results in IL-6 secretion by BMSCs from both normal and MM patients resulting from 
up-regulation of IL-6 gene transcription conferred by NF-KB binding to the IL-6 
promoter (Chauhan et al 1996). One of the cell-surface molecules triggering IL-6 
secretion in MM cells is CD40, a member of the TNF receptor superfamily that is 
expressed by various lymphoid malignancies (Banchereau et aI, 1994). Activation of 
CD40 induces the clonogenic growth and enhances the survival of MM cells in vitro 
(Tong et aI, 1994). Stimulation ofCD40 by its ligand, CD40L, stimulates the secretion 
of IL-6 from MM cells and cell lines, suggesting the possibility for induction of IL-6-
mediated autocrine MM cell growth (Tong & Stone, 1996). However, the source of 
CD40 stimulation in the BM stroma remains unknown; expression of CD40L seems to 
be restricted to T lymphocytes, but its expression on BMSCs has not been investigated. 
Cytokines and growth factors. 
The proliferation, differentiation, and function of lympho-haematopoietic cells is 
regulated by a complex network of growth factors and cell surface molecules which 
establish a fine-tuned communication between stromal cells and lympho-haematopoietic 
precursors in the BM (Sieff, 1990). These growth factors bind to specific cell-surface 
receptors that belong to different families, the receptor tyrosine kinases and the 
haematopoietic cytokine receptors (Miyajima et aI, 1992). The nature of the biological 
response to any growth factor is defined by the tissue or lineage distribution of growth 
factor receptors and by distinct transmembrane signalling events in which tyrosine 
kinases playa pivotal role. 
The malignant plasma cells in MM are localized in the bone marrow (BM) in close 
association with stromal cells, and are rarely found in other locations. The pathogenesis 
of MM depends on the presence of growth factors that support the survival, 
proliferation, and differentiation of MM cells in the BM during the different disease 
stages (Klein, 1995). The cytokines involved in MM pathogenesis are similar to those 
mediating the proliferation of normal early plasma cells (plasmablasts), and their 
differentiation to mature plasma cells. Interleukin-6 (IL-6) is of particular importance 
during this process. 
s 
. 
Interleukin-6 (IL-6) - IL-6 is a cytokine that has pleiotropic effects on haematopoietic 
and non-haematopoietic cells (Hirano et aI, 1990). It induces purified B cells to 
differentiate into Ig-secreting plasma cells (Klein, 1995). The evidence that IL-6 is 
involved in MM pathogenesis was established by the following experimental and 
clinical findings: (1) IL-6 could induce in vitro growth of myeloma cells freshly isolated 
from patients, (2) myeloma cells spontaneously produced IL-6 and expressed IL-6R, (3) 
anti-IL6 antibodies inhibited the growth of MM cells or cell lines in vitro, and (4) 
treatment of MM patients with MoAbs to IL-6 showed some anti-tumour effect (Zang et 
aI, 1992; Klein, 1995). IL-6 supports the survival and/or expansion of MM cells not 
only by stimulating cell division, but also by preventing programmed cell death 
(apoptosis) which can be induced by serum starvation, or by treatment with 
dexamethasone and anti-Fas antibodies (Lichtenstein et aI, 1995; Chauhan et aI, 1997). 
Similarly IL-6R antagonists, which block the activation of MM cells by IL-6, act as pro-
apoptotic factors for MM cells (Demartis et aI, 1996). There is still some controversy 
about the source of IL-6 provided as a MM growth factor during disease progression. 
Some investigators have found IL-6 to be produced by the tumour itself in an autocrine 
manner, but stronger evidence supports the notion of paracrine IL-6 secretion by the 
tumour microenvironment in the BM (Klein, 1995). IL-6 is probably produced in large 
amounts by BM stroma cells (BMSC), osteoblasts, and osteoclasts (Caligaris-Cappio et 
aI, 1992). The IL-6 secretion by BMSCs seems to be regulated by cytokines like IL-l p 
secreted by the tumour as antibodies to IL-l p or the use of the IL-l preceptor 
antagonists were able to block the IL-6 production in short-term cultures of BM cells 
from MM patients (Klein, 1995). The synergistic interaction of IL-6 and TGF-p on the 
maintenance of the malignant clone is discussed below. 
IL-6 Receptor (IL-6R) - Stimulation of cells by IL-6 requires binding to the IL-6R 
which is composed of at least two subunits, the a.- and p-chains (IL-6Ra. & IL-6Rp or 
gp130, respectively). Binding of IL-6 to IL-6Ra induces the tyrosine phosphorylation 
and dimerisation with gp130 (Klein, 1995). gp130 is the common p-subunit shared by 
the receptors for ciliary neurotropic factor (CNTF), oncostatin M (OSM), leukemia 
inhibitory factor (LIF), IL-Il, cardiotrophin 1, and IL-6 and is essential for transmitting 
their respective signals. Accordingly, these six cytokines share some biological 
functions with IL-6, and some MM cell lines respond to LIF, OSM, or CNTF if the 
appropriate receptor a-chain is expressed. In some MM patients, IL-l1 levels may also 
9 
be elevated in the BM, but the effects of IL-ll and of the other three cytokines on the 
growth of MM cells in vivo remain uncertain and have not been studied in the same 
depth as the effects of IL-6 (Klein, 1995). Another potential mechanism contributing to 
the growth and expansion of MM is the agonistic effect of the soluble IL-6Ra that 
enhances the sensitivity of myeloma cell lines to the effects of IL-6 (Gaillard et al, 
1993). Soluble IL-6Ra is generated by receptor shedding from the cell membrane or by 
alternative RNA splicing. While high serum levels of IL-6 were shown to predict a poor 
prognosis or to reflect an active disease in MM the prognostic importance of serum It-
6R is somewhat lacking (Pulkki et al, 1996). 
Interleukin-15 (IL-I5) - IL-15 is a monocyte/macrophage-derived T cell stimulatory 
cytokine that can enhance cytotoxic T cell proliferation, regulate NK cell survival and 
regulate proliferation and differentiation in pre-activated B cells (reviewed by Ma et al, 
2000). IL-15 has also been shown to inhibit anti-Fas and dexamethasone-induce 
apoptosis of T cells. IL-15 not only shares many biological properties of IL-2 but also 
signals through the p and 'Yc chains of the IL-2R though utilises its own high affinity a 
chain (lL-15Ra). Some investigators have recently shown that fresh MM plasma cells 
constitutively express IL-15Ra and IL-15 (Tinhofer et al, 2000). Using monoclonal 
antibody blocking experiments, the authors demonstrated that autocrine IL-15 prevented 
spontaneous apoptosis and augmented cell survival in IL-6-depleted fresh MM plasma 
cells and cell lines. Furthermore, the authors reported that IL-15 treatment of fresh MM 
plasma cells reduced anti-Fas and chemotherapy-induced (doxorubicin and vincristine) 
apoptosis but not that associated with dexamethasone treatment. As such, IL-15 could 
potentially playa role in the cytokine milieu that supports clonal expansion and survival 
of the malignant cells in multiple myeloma. 
Other Stimulatory Cytokines - Granulocyte colony-stimulating factor (G-CSF) is a 
haematopoietic growth factor with structural homology to IL-6 (Cosman et aI, 1990). 
Moreover, the G-CSF receptor shares some homology with gp130. Both G-CSF and IL-
6 induce activation of NF-IL-6, a transcription factor involved in the synthesis of IL-6 
and G-CSF is a potent growth factor for freshly explanted myeloma cells and MM cell 
lines (Klein, 1995). The mechanism of action by which G-CSF mediates MM growth is 
unknown. Granulocyte-macrophage-CSF (GM-CSF), IL-3, stem cell factor (SCF), 
tumour necrosis factor-a (mF-a), hepatocyte growth factor (HGF), and insulin-like 
growth factor I and 2 (lGF-1 and IGF-2) are also potential MM growth factors, because 
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they were shown to stimulate growth and/or specific intracellular signalling events of 
MM cells or cell lines in vitro, often in a synergistic manner with IL-6 (Hallek et al, 
1998). 
Inhibitory Cytokines - Some growth factors commonly found in the BM 
microenviroment inhibit the growth ofMM cells. For example, Interferon-y (IFN-y) was 
reported to inhibit IL-6-dependent proliferation of fresh MM cells (Klein, 1995). It did 
not affect the endogenous IL-6 production by MM cells, but IFN-y can interfere with 
IL-6 transmembrane signalling, resulting in enhanced apoptosis. Interestingly, IFN-y 
also inhibits cytokine-mediated bone resorption, which is a recurring clinical problem 
resulting in significant morbidity and mortality in MM (Klein, 1995). IFN-13 and IFN-a 
were both shown to inhibit the proliferation of the MM cell line U266 (Berger et al, 
1997). These effects are mediated, at least in part, by a down-modulation of the IL-6R 
and as a consequence, IFN-13 reduces the IL-6-dependent tyrosine phosphorylation and 
activation of several signalling proteins, including Ras. 
Taken together, a variety of growth factors promote and some inhibit the growth of 
myeloma cells in vitro and/or in vivo. It is difficult to clarify the functional relevance of 
these redundant growth factor effects on MM cells. Moreover, it seems important to 
emphasize that the expression of the various cytokine receptors may vary among 
individual patients, and also among different tumour cells in a given patient. 
Nevertheless, IL-6 clearly seems to be the most important stimulatory factor of these 
cytokines, because the biologically active IL-6 concentrations found in vitro and in vivo 
are 500- to 5,000-fold higher than the concentrations of other MM growth factors 
(Klein, 1995). 
1.2 IMMUNE REGULATION IN MULTIPLE MYELOMA 
There is a high incidence of infection-related mortality in patients with myeloma and 
the pathogenesis of tumour-associated immune deficiency is important. Furthermore, 
clearly there is a breakdown in the normal regulatory control of the malignant B cell 
compartment that is a hallmark of disease progression. Attempts by the host immune 
system to regain control have been suggested by the observed better prognosis 
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associated with higher serum levels of interleukin-2 (Cimino et al, 1990). None-the-less 
evidence exists to suggest that phenotypic and functional changes occur in T -cells, B-
cells, macrophages and NKJLAK cells (Mellstedt et al, 1982; Lauria et aI, 1984; 
Massaia et aI, 1988; Wen et aI, 1990). This suggests that any interaction between the 
host immune system and the MM cells may be flawed at a fundamental level. 
Destruction of immune targets requires the activation of efficient, immune-competent 
T cells. Such an induction is postulated to require a two-signal system for efficient 
activation (Geppert et aI, 1990). Following the interaction of cellular adhesion 
molecules and their ligands, the initial signal (Signal 1) is generated by T cell 
recognition of antigenic peptides (Ag) presented with major histocompatibility complex 
molecules (MHC) via T cell receptors (Bjorkman et aI, 1987). Following this AglMHC-
restricted signal, a second non-MHC-restricted signal (Signal 2) is generated via 
co-stimulatory pathways, which determines whether the TCR complex engagement 
results in functional activation or clonal anergy (Geppert et al, 1999). Several 
co-stimulatory pathways may exist but one important pathway is the interaction of 
CD80 and CD86 expressed on B cells and antigen presenting cells (APC) with their 
ligands CD28 and CTLA-4, expressed on T cells (Linsley et aI, 1991; Schwartz, 1992). 
Providing that this second or co-stimulatory signal is received then signalling from the 
TCR-CD3 complex (particularly via CD3t; chains) is transmitted from the cell 
membrane to protein tyrosine kinases (especially p561ck and ZAP70, reviewed by 
Robey & Allison, 1995). These act on many intra-cellular pathways culminating in the 
up-regulation of new genes required by T cells to become activated, including proto-
oncogenes (pim-J, c-fos, c-myc) and cytokines involved in the immune response e.g. IL-
2 and its receptor complex (IL-2Rapyc), IL-3, IL-4, IL-5, IL-6 (Ullman et al, 1990). 
Clearly, tumour cells can interfere with this activation process at any stage either by a 
single method or an orchestrated manipulation of the recognition and effector 
mechanisms (Figure 1.2). I will review the current published literature in discussion of 
how myeloma tumour cells may interact with the host immune system. This forms the 
rationale behind the experimental studies presented in this thesis. 
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TUMOUR CELL T LYMPHOCYTE 
Figure 1.2. Interactions between tumour cells and the host immune system. Potential 
defects in the recognition of tumour cells as immune targets: 1 - Defects in inter-cellular 
adhesion. 2 - Lack of MHC molecules, defective antigen processing/presentation, 
absent/silent antigens (Signal 1). 3 - Absence of co-stimulatory molecules (Signal 2). 4 
- Mediation of apoptosis or prevention of activation by soluble factors or cytokines. 
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EVADING DETECTION 
T Lymphocytes - Ineffective Policemen? 
Patients with multiple myeloma have altered distribution of CD4 and CD8 lymphoid 
subsets (Mellstedt et al, 1982; Lauria et al, 1984; Massaia et al, 1988). The imbalance of 
the CD4:CD8 ratio relates predominantly to a reduction, both in percentage and 
absolute numbers of CD4+ cells particularly the naive CD4+ /CD45RA + cells (Serra et al, 
1988; San Miguel et aI, 1992). These reports demonstrate that the observed decrease in 
CD4+ T cells is more pronounced in patients with advanced disease and decreased 
numbers of CD4+ T cells (<700xl06/litre) are associated with a significantly lower 
survival rate and increased probability of relapse. With regard to CD8+ T cells, although 
increased numbers of cytotoxic T cells have been reported in patients escaping from 
plateau phase this increase is only in relative percentage to CD4+ cells and not in 
absolute numbers (Hicks et al, 1989). 
T cells within bone marrow mononuclear cell fractions from patients with myeloma 
showed increased proliferative responses to anti-CD3 monoclonal antibody stimulation 
compared with healthy, age-matched controls with demonstrable anti-plasma cell 
activity. This was thought to imply an immunoregulatory role for such T cells (Massaia 
et aI, 1993). Certainly, peripheral blood lymphocytes from patients with myeloma have 
been shown to be capable of proliferative responses to autologous tumour cells and with 
high effector:target cell ratios cytotoxicity could be demonstrated (Mackenzie & 
Paglieroni, 1977; Paglieroni & MacKenzie, 1979). The idiotypic immunoglobulin may 
be regarded as a tumour specific antigen and as such, proliferation and differentiation of 
idiotype-expressing malignant B cells may accordingly be under regulation by idiotypic 
reactive T cells. In animal plasmacytoma models, T cells can be shown to regulate the 
growth of the plasma cells by specific recognition of the idiotype antigen (Bergenbrant 
et al, 1993). Furthermore, evidence of T cell tumour recognition is suggested by the 
growth of T cell clones by stimulation with IL-2 and F(ab')2 fragments derived from 
autologous idiotype, and the production of cytokines such as interferon-y, IL-2 and IL-4 
by peripheral blood T cells after stimulation with autologous idiotype (Osterborg et al, 
1991). 
Several investigators have studied oligoclonal peripheral blood T cell expansions in 
patients with MM. In one study, using monoclonal antibody immunostaining ofTCR p 
chain usage, 79% of patients demonstrated oligoclonal T cell expansions that were 
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stable over a median follow-up of 18 months (Raitakari et ai, 2000). The TCR ~ chain 
usage was random amongst the 21 variable regions studied. When the phenotype of 
these expanded clones was examined, the T cells were found to be predominantly 
CD3+/CD8+/CD57+CD28" cells expressing high levels of perf orin but normal levels of 
both Fas and bcl-2. Other groups have demonstrated that the clonal CD8+ T cells do in 
fact restrict the TCR ~ chain usage to V~3, V~5.2 or a combination of both though this 
was more commonly seen in patients with low tumour burden i.e. after treatment and 
with early stage disease (Yi et aI, 1997B). However, this same group demonstrated that 
these oligoclonal CD8+ cell expansions did not demonstrate idiotypic reactivity though 
non-expanded V~22 restricted CD8+ cells did. The antigen specificity of the clonal 
CD8+ cells remain uncharacterised but may represent chronic antigenic stimulation by 
other tumour associated antigens. It has previously been shown that CD8+/CD28" T 
cells in the peripheral blood of HN -infected patients and normal individuals 
preferentially express CD57 and contained active cytolytic T cells which demonstrate 
~xpanded clones as determined by TCR V~ usage and this is thought to result from 
chronic antigen exposure (Mugnaini et aI, 1999). 
The presence of these oligoclonal T cells and idiotype-reactive T cells have beert· . 
identified as an independent prognostic factor (Halapi et aI, 1997). The inability to 
generate ''tumour reactive" T cells in vitro whilst clinical evidence fails to den1btistrQtc 
that these cells have an ability to keep the disease under control in vivo serves to sugg~st 
" that tumour cells are often antigenic but not immunogenic. The ability to recognise and 
i~ I 
eliminate tumour cells may be compromised in cancer patients by many factors 
including inadequate antigen presentation and tumour-derived immunosuppressive 
factors. T cells of patients with myeloma have abnormalities in signalling Il10lecules 
particularly PKC-a and NFKB (Bianchi et ai, 1997) and enhanced susceptipility to 
apoptosis results from increased surface Fas expression and reduced intracellqJar bcl-2 
levels (Massaia et ai, 1995). Taken together, these features represent a fundamental 
defect in the T cells. In order to achieve the maximal effect from immunotherapy 
strategies, a fuller understanding of the biological interplay between myeloma tumour 
cells, which presumably cause these defects and immune effectors is mandatory. 
Altered Co-stimulation Molecules - The unseen enemy .. 
T cell activation is accomplished with specific Q,qtigen presentation (Signal 1) 
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associated with co-stimulatory (Signal 2) cell-cell interaction (Schwartz, 1989; Geppert 
et aI, 1990). Tumour cells may evade detection by disrupting this process either at the 
cell-cell interaction, antigen processing/presentation or co-stimulation phases. Myeloma 
tumour cells express an array of surface adhesion molecules involved in both cell-
stroma and cell-cell interaction (Cook et aI, 1997). In a study in this lab, a panel of 
human myeloma cell lines demonstrated surface expression of both HLA-ABC and 
HLA-DR (Table 1.1) similar to studies of MHC surface expression on freshly isolated 
cells from patients with mUltiple myeloma (San Miguel et aI, 1991; Yi e tal, 1997). 
However, significant surface expression of the co-stimulatory molecules CD80 and 
CD86 was not detected nor was the expression of CD80 and CD86 mRNA transcripts 
detected by RT-PCR (Table 1.1). These results are similar to those reported by other 
groups though variable expression has been reported between human myeloma cell 
lines (HMCL) and fresh tumour cells from patients which might represent the level of 
maturation or the state of activation (Gray & Woodlief, 1994; Pellat-Deceunynck et aI, 
1994; San Miguel et aI, 1995). 
Interestingly, plasma cells from myeloma patients, plasmacytomas and HMCL 
demonstrate constitutive surface expression of CD28, a molecule found on the majority 
of CD4 T cells and approximately half of CD8 T cells (Pellat-Deceunynck et aI, 1994; 
Robillard et aI, 1998). Myeloma cells express a similar density of CD28 antigen to that 
of normal T cells and it has been demonstrated to be able to bind B7-Ig chimeric 
proteins (Zhang et aI 1998). Blockade of CD28 signalling failed to aIter the 
proliferation, survival, differentiation or surface expression of antigens and cytokine 
receptors by myeloma cells. However, the CD28 molecule was demonstrated to be 
functionally active by binding of the p85 sub-unit of PI-3K to CD28 being triggered by 
CD80-transfected cells. Whether CD28 has a role in auto-stimulation of the tumour 
clone or contributes to a down-regulation of the immune control of the maIignant 
plasma cells in vivo remains to be elucidated. However, fresh tumour cells from patients 
with early and plateau disease are CD28" compared with fresh tumour cells from 
patients with aggressive disease that were CD28+ (Pellat-Deceunynck et aI, 1994). The 
relevance of these findings in vivo and their effect on the host's ability to generate 
competent immune responses remains unclear. 
Can Myeloma Cells Present Antigen? 
The myeloma-derived idiotype (Id) is a tumour specific antigen that can be recognised 
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CD80 CD86 Surface antigen expression 
Cell Line mRNA mRNA CD80 CD86 CD28 CD40 "LA "LA 
I II 
JIM-3 Neg Neg N N ++ ++ +++ N 
JIM-1 Neg Neg N N +++ ++ +++ ++ 
JJN Neg Neg N N ++ ++ +++ +++ 
U266 Neg Neg N N +++ ++ +++ +++ 
RPMI- NT NT N N ++ ++ +++ +++ 
8226 
EJN NT NT N N ++ ++ +++ ++ 
Table 1.1. Expression of surface molecules involved in providing T cell co-stimulation 
(Signal 2) by human myeloma cell lines using monoclonal antibody immunostaining 
and flow cytometry (from Cook et al, 1997). The presence of CD80 and CD86 mRNA 
as detected by RT-PCR using cell line-derived total RNA. Key: N- <20% cells positive, 
+- 20-40% cells positive, ++- 40-70% cells positive, +++- 75-100% cells positive, NT-
not tested. 
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by antigen-specific T cells in the fonn of peptides bound to MHC molecules (class I and 
II). Professional antigen presenting cells such as dendritic cells can efficiently present 
the Id (Dabadghoa et al, 1997). However, despite the high production of Id by the clonal 
plasma cells, a clinically significant naturally occurring immune response has rarely 
been demonstrated. In addition to the variable surface expression of co-stimulatory 
molecules and the potential for an immunologically hostile microenvironment (see 
below), MM tumour cells may function as poor antigen presenting cells. Several studies 
have shown that fresh MM tumour cells can induce a poor allogeneic MLR which was 
augmented by anti-CD28 MoAb or pre-treating the tumour cells with CD40L or TNFa 
and interferon-y (Quing et al, 1997; Schultze, 1997). The T cell proliferative responses 
arose predominantly from the CD8+ lymphocyte compartment and were considerably 
reduced compared to standard MLR responses. 
The ability of malignant plasma cells to process and present recall antigens (purified 
protein derivative and tetanus toxoid) to autologous T cells with the generation of 
proliferative responses and IFN-y secretion has been demonstrated (Quing et ai, 1997). 
However, when MM cells were used alone to stimulate autologous T cells, no 
proliferative response directed towards the tumour cells was demonstrated despite the 
addition of anti-CD28 MoAb (Schultze, 1997). This unresponsiveness· was partly 
reversed when the tumour cells were pre-activated with CD40L then used to stimulate 
an autologous reaction. These features suggest that myeloma tumour cells have the 
capacity, if stimulated appropriately, to process and present antigens that can be 
recognised by T cells, at least in vitro. This implies that T cells, especially tumour-
specific T cells, may play a role in the in vivo tumour regulation of growth and 
differentiation. However, the fact that the majority of tumour cells are not destroyed in 
patients with MM suggests that at least in vivo, this attempt at regulation may indeed be 
hampered either by insufficient co-stimulatory molecules in vivo or that specific 
peripheral tolerance has been induced, as has been observed in other human B cell 
malignancies (Cardoso et al, 1996). 
Antigen Silencing 
Assuming there is a clonal origin and a series of genetic modifications involved in the 
development of neoplastic cells it is reasonable to expect that tumour cells express 
multiple cellular proteins that are distinctive from the tissues from which they are 
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derived. However, cytotoxic T lymphocytes (CTL) are not active in vivo against most of 
these epitopes despite the association of these antigens with MHC molecules (Chen, 
1998). This results in limited T cell responses to a reduced number of antigens out of a 
larger available pool - a phenomenon known as "immunodominance". Silent tumour 
antigens are natural peptides presented in association with MHC molecules that are not 
immunogenic during the clonal expansion of the tumour cells. Despite these antigens 
failing to be immunogenic in vivo, they are fully competent targets for CTL lysis 
(Koeppeb et ai, 1993). 
Many factors contribute to antigen silencing including altered TCR ligand peptide 
affinity, TCR occupancy thresholds, levels of co-stimulatory and adhesive molecules 
and the status of the T cells (naive vs. memory). When taken together, a "compensation 
model" of CTL activation is evident: weak antigenic signals may require a larger degree 
of adhesion/co-stimulation than stronger antigenic signals. This, coupled with a 
potentially immunologically hostile environment may provide a route for evading 
immunological surveillance. With respect to multiple myeloma, little if any data exist 
regarding the existence of silent antigens. If present then these might provide a useful 
source of antigenic material to stimulate CTL responses in vitro particularly if the 
amino acid structure can be subtly modified to improve their immunogenicity and 
dendritic cells are employed as professional antigen presenting cells (Lippford et ai, 
1995; Paglia et al, 1996). This is particularly important as silent antigens work in the 
induction phase, not in the effector phase of the immune response and thus pre-activated 
CTLs against these antigens may operate with improved efficiency as has been shown 
in a murine lymphoma model (Johnston et ai, 1996). Further research in myeloma is 
needed to identify silent antigens, if such exist, which might provide suitable targets for 
the design of immunotherapy strategies. 
ATTACK IS THE BEST FORM OF DEFENCE. 
Tumour-derived Cytokines and Immunosuppression 
An array of cytokines and immune-modulating agents have been reported by many 
investigators in the field of tumour immunobiology (Czarniecki et ai, 1988). In 
particular, B cells can produce a large number of cytokines both in disease and health 
which can direct the immune system into a pro-inflammatory or a humoral response 
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(reviewed in Pistola, 1997). These include interleukin 10 (IL-I0), transforming growth 
factor beta (TGF-~), Fas and FasL, vascular endothelial growth factors (VEGF), and 
MUC-l. The effects of the cytokines are summarised in Table 1.2. 
I.IL-JO 
This is a pleiotropic cytokine produced by B cells, monocytes, macrophages and 
keratinocytes which inhibits synthesis of the pro-inflammatory cytokines IL-l, IL-6, IL-
8, IL-12, TNF-a. and GM-CSF (Huhn et al, 1996). Originally identified in mouse T 
helper cells, murine IL-IO was referred to as CSIF (Cytokine Synthesis Inhibitory 
Factor) and was shown to be a product of Th2 T helper cells which inhibited cytokine 
production by Thl cells (Fiorentino et aI, 1989). Murine and human IL-lO share 73% 
amino acid homology including hydrophobic leader sequences and although hulL-lOis 
active on murine T cells, muIL-I0 appears not to be significantly active in human cells 
(Geissler, 1996). It is interesting to note that IL-IO proteins and cDNA reveals a strong 
predicted amino acid sequence homology (84%) to BCRFI, an as yet uncharacterised 
open reading frame in the Epstein-Barr viral genome. It has been proposed that that the 
BCRFI gene represents a cytokine gene that assists the virus to evade or attenuate the 
host defences (Viera et al, 1991). Multiple roles have been suggested for IL-I0 
including inhibition of monocytes/macrophages and T cell effector function. However, 
IL-tO's effects are not all inhibitory since it can enhance the viability and proliferation 
of B cells and differentiation (Huhn et al, 1996). IL-t 0 is the most potent inducer of 
immunoglobulin secretion in various B cell activation systems in vitro (Rousset et al, 
1992). 
IL-IO is spontaneously secreted by a variety of human tumours and local secretion by 
tumour cells can render themselves insensitive to CTL lysis (Becker et ai, 1994; 
Matsuda et aI, 1994). In multiple myeloma the role of IL-I0 is less clear. Normal B 
cells differentiating to Ig-secreting B cells lose IL-I0 mRNA transcripts, though 
terminally differentiated plasma cells retain expression of the IL-I0R (Mathes et al, 
1995). Some investigators have demonstrated that IL-I0 is a growth factor for 
malignant plasmablastic cell lines and that IL-I0-dependent MM cell lines can be 
generated (Lu et al, 1995). This growth promoting activity is independent of IL-6, 
though these IL-l O-dependent MM cell lines demonstrated a plasmablastic morphology 
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Effect TGF-p IL-IO VEGF 
Inhibition of T-cell growth + - + 
Inhibition of CTL differentiation + +1- + 
Inhibition ofT cell cytokine production + + -
Induction of T-cell anergy + - -
Shift in the T h 1-T h2 balance towards Th2 + + -
Down-regulation of adhesion/co-stimulatory + + -
molecules 
Table 1.2. The effects of cytokines on immune effector cells. Key: TGF-
13, transforming growth factor beta; Th, T helper lymphocyte; VEGF, vascular 
endothelial growth factor. 
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and low Ig secretion. This suggests that these cell lines were more primitive than the 
mature malignant plasma cells seen in the disease in vivo and the addition oflL-IO to 
the culture system did not induce terminal maturation of these cell lines. These same 
investigators, using a sensitive ELISA assay, demonstrated a low level of serum IL-IO 
in patients with stable disease (3.3%) compared to a higher level of detection in patients 
with terminal phase disease and plasma cell leukaemia (60%). Similarly, other 
investigators have demonstrated that serum IL-I0 levels are higher in patients with 
mUltiple myeloma compared with control patients and that serum IL-I 0 levels correlate 
with the paraprotein level (Arneglio et al, 1995). Thus the role of IL-I0 in the 
pathogenesis and immune dysfunction in MM remains uncertain. However, this 
cytokine may be involved in the later phases of the disease associated with widespread 
dissemination of tumour cells and deterioration of clinical status. 
II. TGF- P 
Transforming growth factor-beta (TGF-J3) was originally purified from platelets and 
found to mediate anchorage-independent growth of fibroblasts and playa key role in the 
growth and differentiation of epithelial cells (reviewed in Letterio & Roberts, 1998). 
TGF-J3 is a pleiotropic cytokine that can affect a wide variety of tissues and cells. There 
are five isoforms ofTGF-J3 (TGF-J31-5) which signal through the same serine-threonine 
kinase receptors (TGF-J3R I and II). TGF-J3 has effects on all of the mediators of the 
immune response - T cells, B cells, monocytes/macrophages and dendritic cells. TGF-
J3 is a potent immunosuppressive cytokine and influences all stages of T lymphocyte 
development and differentiation through to their activation and proliferation, the exact 
effect being determined by the stage of maturation of the T cell. A subset of T helper 
cells (Th3) produce TGF-J3 (Chen et aI, 1994; Bridoux et aI, 1997; Letterio & Roberts, 
1998) upon activation, in addition to IL-4 and IL-I0, and these may represent a sub-
group of cells capable of suppressing the inflammatory response to limit tissue damage. 
Exogenous TGF-J3 inhibits T cell proliferation by down-regulating IL-2 mediated-
signals mediated through reduced tyrosine phosphorylation of proteins of 120, 100, 85, 
75 and 50 kDa and inhibition of IL-2 mediated phosphorylation of the retinoblastoma 
susceptibility gene product, which is pivotal in the progression of cell cycle (Wahl et al, 
1989; Fontana et al, 1989; Ahuja et ai, 1993; Becker et al, 1994). However, in contrast 
to these inhibitory functions, a growing body of evidence is being produced to suggest 
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that TGF-~ can also enhance T cell growth, especially those with naive phenotypes and 
promote effector function through enhancement of cytokines and inhibition of apoptosis 
(Kerhl et ai, 1986; Cerwenka et al, 1996). TGF-~ suppresses normal B cell proliferation 
and immunoglobulin production, induces apoptosis of pre-B cells mediated through 
interactions with stromal cells and suppresses haematopoiesis through antagonism of 
stem cell factor (Heinrich et ai, 1995; Letterio & Roberts, 1998). TGF -~ has been 
reported to account for the profound suppressive effects on normal haematopoietic stem 
cells and B cell function associated with malignancy (Demynck et aI, 1987). 
In mUltiple myeloma, several studies have shown TGF-~ mRNA in tumour cells and 
derived cell lines (Mathes et aI, 1993; Klein, 1995; Mathes et al, 1995; Urashima et ai, 
1996). Some investigators have shown that the level of TGF-~ secreted by MM cells is 
greater than normal B cells and CD40L-activated B cells and that BM stromal cells 
from MM patients secrete more TGF-~ than BM stromal cells from normal control 
subjects (Urashima et ai, 1996). Other groups have demonstrated high serum levels of 
TGF-~ in patients with MM using ELISA assays and there is a suggestion that serum 
levels correlate with the extent of myeloma bone disease (Hang et aI, 1995; Kroning et 
aI, 1997). In contrast to its effects on normal B cells, TGF-~ does not decrease the 
proliferation of MM cells and may even augment IL-6 secretion and related 
proliferation (Urashima et aI, 1996). The exact role of TGF-~ in the pathogenesis is 
unclear, although data is emerging that indicates TGF-~ is a major cytokine involved in 
the maintenance and survival of the malignant clone in myeloma. This may be mediated 
through autocrine/paracrine IL-6 and other, as yet, poorly understood interactions with 
the stromal elements in the bone marrow micro-environment. It is also possible that 
TGF-~ contributes to both the identified cellular and humoral immune deficiencies 
associated with this disease as well as the bone marrow failure associated with high 
tumour burden (Boccadoro & Pileri, 1995). 
III. FaslFas ligand 
Fas (Apo-lICD95) is a member of the lNF receptor/nerve growth factor receptor 
family and it regulates apoptosis through interaction with its ligand, FasL, which is also 
a member of the lNFRlNGFR family and can act both in the membrane bound and 
soluble forms (Oehm et ai, 1992; Suda et aI, 1993; Nagata & Goldstein, 1995). Fas is 
present on the cell surface of a variety of cells including activated T cells. FasL is 
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constitutively expressed in sites of immune privilege such as the eye, the spleen and at a 
low level in the thymus and more recently it has been described on the surface of 
tumour cells (Tanaka et ai, 1996). The recognised role of FasIFasL in the immune 
system lies in the process of acquisition of self tolerance through clonal deletion of 
thymocytes and T cell mediated cell killing as part of the host defence against virally 
infected or transformed cells (Alderson et aI, 1995; Rensing-Ehl et ai, 1995). Recently 
it has been shown that FasL engagement inhibited CD4+ T-cell proliferation, cell-cycle 
progression and IL-2 secretion in vitro and prevented superantigen-mediated CD4+ T-
cell expansion in a murine model (Desbarats et ai, 1998). Thus with the acquisition by 
tumour cells of FasL, the active suppression of tumour-specific Fas+ T cells might be an 
active mechanism of escape from immune surveillance. However this "counter attack" 
or immune privilege mediated by FaslFasL interactions in immune evasion by human 
cancers is more complicated than first thought and is rapidly becoming an established 
area of tumour immunology research. Disarming this counter-attack might offer a 
potential for therapeutic intervention (reviewed in O'Connell et aI, 1999). 
In myeloma, some investigators have demonstrated the expression of both Fas and its 
ligand, FasL on the surface of myeloma cell lines (Villunger et ai, 1997). The FasL was 
shown to be functionally active in inducing apoptosis in Fas-sensitive T-cell acute 
lymphoblastic leukaemia cell line. One question is raised by these and other similar 
findings: why do the tumour cells which are Fas + lFasL + not commit autocrine "suicide" 
or juxtacrine "fractricide''? It is possible that this does not happen because of an 
intrinsic resistance to Fas-mediated apoptosis. Many mechanisms have been proposed 
to account for this e.g. expression of antagonistic soluble Fas, failure to establish death-
inducing signalling complexes (DISCs), altered regulation and function of the caspases, 
the exact pathways involved remain uncertain (Alderson et ai, 1995; Nagata, 1996; 
O'Connell et aI, 1999). The understanding of Fas resistance and counterattack is 
fundamental to designing interventional strategies to disarming this system for effective 
cancer management and we await the developments in this field with anticipation. 
IV. Vascular Endothelial Growth Factors (VEGF) 
VEGF is a 34-42 kDa cytokine produced in large amounts by most tumours and 
previously recognised mainly for its angiogenic properties (Toi et ai, 1996). It 
stimulates the proliferation of endothelial cells and thus has a pivotal role in tumour 
neovascularisation. More recently it has been shown to have a profound inhibitory 
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effect on haemopoiesis (Gabrilovish et al, 1996). In particular, VEGF have been shown 
to responsible for defective dendritic cell (DC) maturation in vivo. VEGF binds to 
haemopoietic progenitor cells through specific binding to its receptor, Flt-l which 
blocks activation of the transcription factor NF-lCB (Oyama et ai, 1998). NF-lCB is 
composed of 50-65 kDa subunits which bind to a 10 bp motif in the promoter sequence 
in responsive genes and include p50, p52, p65 (ReIA), cRel and RelB. It has been 
shown that reduced DC generation results from targeted disruption of RelB (Weigh et 
al,1995). 
VEGF mRNA transcripts have been detected in both fresh MM tumour cells and 
HMCL (Danbar et aI, 1998). Interestingly, the investigators demonstrated that when 
HMCL were cultured with excess rhIL-6, there was an increase in the level of VEGF 
mRNA, and when VEGF was added to cultures of human bone marrow stromal cells 
there was an increase in IL-6 production. Thus MM tumour cells may produce VEGF to 
stimulate the stromal cells to produce the growth and differentiating agent, IL-6, for the 
malignant clone and in addition, this cytokine may serve to "disarm" the potent antigen-
presenting DC from stimulating a host reaction. Despite this in vivo effect on progenitor 
cells, DCs can be generated from the peripheral blood DC-progenitor cells of patients 
with MM and that these DCs are both functionally and phenotypically similar to those 
generated from healthy donors (Tarte et al, 1997). This is an area of the biology of 
multiple myeloma that warrants further investigative research. 
V. Muc-l 
Cell surface mucins play a significant role in cell-cell communication (Parry et aI, 
1990). The muc-l mucin is a high molecular weight glycoprotein consisting of a core 
protein with highly branched carbohydrate side chains and is expressed on the apical 
surface of a number of epithelial cells, including malignant cells (Zotter et al, 1988). In 
malignant cells, there exists variable glycosylation of the core protein and a high level 
of expression of this under-glycosylated muc-l is associated with high metatstatic 
potential and poor prognostic index in epithelial malignancies (Kobayashi et aI, 1992). 
Muc-l is a ligand for ICAM-l and high levels of expression may induce 
immunosuppression or anergy by interaction with its ligand on T cells (Regimbald et al, 
1996). Furthermore, muc-l expressed and shed by breast cancer cells has been shown to 
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induce apoptosis in T cells which may be rescued by IL-2 (Gimmi et al, 1996; Agrawal 
et al, 1998). 
Myeloma ceIls, both fresh cells and HMCLs, express muc-l which can be up-regulated 
by dexamethasone (Treon et aI, 1999). They can also produce a soluble variant that is 
capable of suppressing an alloantigen T cell response. It has been shown that HLA-
unrestricted CTL can be generated from PBMNC of some MM patients which directly 
recognise the under-glycosylated form of muc-l and demonstrated direct cytotoxic 
capability against muc-l+ MM and breast cancer ceIl lines (Noto et aI, 1997). However, 
it is worthy of note that this phenomenon was demonstrated in only 2 of the 6 patients 
tested which may suggest that muc-l may limit the generation of adequate populations 
of immune effector cells. The data currently available on the pathogenic role of muc-l 
in MM is limited and the role that muc-l plays in immuno-suppression remains to be 
clarified. 
1.3 TUMOUR TOLERANCE- The "Danger" of "Self' ignorance. 
Illustrated above are many potential mechanisms that may allow evasion of immune 
regulation of the malignant clone, which either work alone or in orchestration. How 
then do these facts fit with the theories/paradigms of balancing immunity and tolerance 
in the human immune system? Whether you are a "Danger theorist" (Matzinger, 1998) 
or a "self-nonself' proponent (Janeway, 1992), clearly the host's immune system can 
not or will not identify the tumour as an immunological threat and deal with it 
appropriately, as it would with infection and parasitism. In the expanded "self-nonself' 
model of immune responses, it is believed that antigen drives the immune response. As 
such, immunological tolerance is ensured by eliminating or inhibiting specific reactive 
lymphocytes and this results from a balance of antigen presentation (Goodnow, 1996). 
Not all self-reactive lymphocytes are eliminated and many are retained with a wide 
variety of conditional and potentially flexible restraints, namely reduced or increased 
antigenic triggering thresholds, inhibition of their immune effector function and 
constraints of the migratory capacity. The antigen presentation is further tuned by the 
relative amount and avidity of antigen, the timing of antigenic exposure and the 
presence of co-stimulation, either by cell-surface moleucles e.g. CD80/CD86 or 
cytokines e.g. IL-2 (Goodnow, 1996). 
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Proponents of the "self-nonself' model of immunity and tolerance firmly believe that 
immune responses are antigen driven and that tumourogenic events are frequent but 
evolutionary distinct antigens reacting with pattern recognition receptors of the immune 
cells results in effective eradication i.e. immune surveillance (Matzinger, 1998). The 
idea of tumour growth therefore results from a break-down in this immune surveillance, 
either related to antigen delivery (in terms of quantity, avidity, timing, etc). As such, in 
the context of MM, if the idiotype is a tumour-specific antigen capable of generating 
immune responses, then there is chronic exposure of the host immune effector cells to 
high levels of antigen, which may "de-sensitise" or tolerise the immune response. This 
may be suggested by the lack of immune dysfunction seen in monoclonal gammopathy 
of undetermined significance (MGUS) where the idiotype concentration is considerably 
lower compared with MM (Boccadoro & Pileri, 1995). In addition to alterations in 
tuning of antigen-driven responses, under the auspices of the expanded "self-nonself' 
model, defects in immune surveillance can also arise from loss of tumour antigen or by 
suppressing the effector arm of the immune response, mediated by cytokines like IL-I0 
and TGF-J3. 
However, "Danger theorists" maintain that the central drive to the immune system, 
whether in response to tumour, infection or parasitism, results from the appropriate 
presentation of signal 2 in context of suitable antigens, resulting in an effective immune 
response. In terms of malignant cell growth, the lack of necrotic cell death within the 
tumour clone, fails to provide the appropriate signal 2 stimulation and therefore, a lack 
of immune response (P Matzinger, 2000, personal communication). In MM, as 
indicated above, there is a lack· of cell-surface co-stimulatory molecules on the 
myeloma cells that prevents satisfactory APC function. Similarly, if the tumour cells 
secrete VEGF, this limits the differentiation and maturation of professional APCs. 
However, this does not adequately explain either the tumour-associated immune 
dysfunction or the significance of tumour cell-derived immune modulating cytokines. In 
respect to the latter, the production of cytokines such as IL-I0 and TGF-J3 are inherent 
properties of the cells from which the malignant clone has evolved and are not escape 
mechanisms adapted by the tumour cells to survive a potentially hostile enviroment (P 
Matzinger, 2000, personal communication). However, the former aspect, namely the 
tumour-associated immune dysfunction seen with many malignancies, is not explained 
under this model. However, ifIL-2 is considered as a signal 2 (Goodnow, 1996), TGF-J3 
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can inhibit IL-2-mediated stimulation of T cells and may represent a block to the 
appropriate delivery of Signal 2 to ensure a useful immune response. 
It therefore may not be possible to account for tumour immune tolerance under one 
paradigm or another, a fact which may have its roots in the diverse interplay of the 
innate and adaptive immune systems which have evolved in man (Vance, 2000). It is 
likely that a number of tumour mechanisms are involved in the evasion of immune 
regulation by myeloma cells. In the field of immunotherapy, the key issue is which of 
the mechanisms, if any, exerts the major tolerising effect and can this be reversed or 
even circumvented. Therefore, central to this is a greater understanding of the influence 
that myeloma cells may exert on immune effectors including at the molecular level. 
THESIS AIMS 
The aim of the work presented in this thesis is to establish what influence myeloma 
cells exert on the functional capacity of T cells. In the investigation of this interaction, I 
will present evidence to support the theory that myeloma cells inhibit the activation ofT 
cells through the production of a soluble immunosuppressive factor, TGF-pl, and that 
this prevents activation of T cells by interfering with entry into the IL-2 autocrine 
pathway. The work presented in this thesis may assist in the design of novel treatment 
strategies using immune effector cells in attempting to eradicate the disease or at least, 
maintain long-term disease-free survival for these patients. 
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CHAPTER 2 
General Materials and Methods 
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GENERAL MATERIALS AND METHODS 
All solutions used in this thesis are detailed in appendix 1. 
2.1 TISSUE CULTURE 
All cell culture work was performed under sterile conditions with all manipulation of 
cell suspensions being conducted under laminar flow. All plastics were sterile. Cell 
lines were maintained in ventilated tissue culture flasks in a humidified incubator with 
5% CO2• Cell suspensions were replenished with fresh complete medium (CM) every 3-
4 days. For human T cell lines, every 10 days non-viable cells were removed by density 
centrifugation (Ficoll-Hypaque; Lymphoprep, Nycomed, Norway). Cells were 
maintained at 104_105 cells/ml by sub-culturing. When HMCLs were used in the 
experimental studies, they were treated with mitomycin-C to prevent proliferation but to 
preserve protein synthesis. Cells were pelleted from suspension by centrifugation at 
1,5000 for 5 minutes. The cells were re-suspended in 50 ~glml of mitomycin-C 
(Sigma, UK). The cells were incubated at 37°C for 30 minutes before being washed x3 
inCM. 
Peripheral blood mononuclear cells (PBMNC) and peripheral blood lymphocytes (PBL) 
were isolated fresh from healthy volunteers, after informed consent. Venous blood was 
collected into preservative-free heparin or sodium citrate and immediately layered onto 
Ficoll-Hypaque that had been allowed to equilibrate with room temperature. The 
samples were then separated by centrifugation at 15000 for 30 minutes (no brake). The 
buffy coat was removed from the packed red cell/plasma interface by pipetting and 
isolated PBMNC were then washed x3 in PBS with the last 2 washes employing 
centrifugation at a speed of 9000 for 5 minutes to remove contaminating platelets. Cells 
were then counted and re-suspended at the appropriate concentration in CM. When PBL 
isolation was required, the above procedure was performed and isolated PBMNC re-
suspended in CM were plated in 75cl culture flasks and incubated at 37°C for 2 hours. 
After this time period, non-adherent cells were removed and contained >90% 
lymphocytes, both B and T cells. When PBMNC were used as stimulators in MLR 
reactions, they were treated with mitomycin-C as above except the mitomycin-C was 
used at a concentration of 25 ~g1ml. 
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PROLIFERATION ASSAYS 
Proliferation of cultured cells was assessed by 3[H] thymidine uptake (reviewed by 
Hellerstein, 1999). Proliferation assays were cultured in quadruplicate in 96-well 
microtitre plates. Proliferation was assessed by the addition of O.SJ..lCi of tritiated 
thymidine (eH]-dThd) in the last 18 hours of incubation. Incorporated radio label was 
assessed by harvesting the 96 well micro titre plate onto nitrocellulose filters (packard 
Instruments, The Netherlands) using a Micromaster 196 cell harvester (packard 
Instruments) and analysed using a Packard Matrix 96 counter. 
2.2 FLOW CYTOMETRY 
PBMNC from normal healthy donors, T cell lines and human myeloma cell lines were 
phenotyped by direct immunofluorescence using a F ACScan flow cytometer (Becton 
Dickinson). The methodologies employed were based on those reported described by 
Shapiro (1988). Cells were analysed by single and double immunofluorescence staining 
using direct immunoconjugates of either fluorescence isothiocyanate (FITC) or R-
Phycoerythrin (PE). Details of the specific monoclonal anti-human antibodies (MoAb) 
used in FACS analysis are detailed in Table 3.1 
Cells to be analysed by immunofluorescence staining were isolated from the specific 
culture conditions and washed three times in cold PBS. Cells were re-suspended at a 
concentration of 0.S-lxl0'/ml. For single parameter staining SOJlI of cell suspension 
(SxlOs cells) was incubated with the appropriate quantity of MoAb at 4°C in the dark 
for 30 minutes. For background/non-specific antibody uptake an appropriate isotype 
negative control was added instead of the test MoAb. The samples were then washed 
once in PBS and re-suspended in 200J..lI of PBS before analysis. If the cells were not 
immediately analysed, the cells were re-suspended in Cell Fix (Becton Dickinson), 
which contained 1% w/v paraformaldehyde, and stored at 4°C in the dark until 
analysed. Cells for double staining were treated as a~ove except that appropriate 
quantities of each MoAb were added to the SOJlI of cell suspension. For compensation 
adjustments when calibrating the flow cytometer, samples stained with only one direct 
immunoconjugate MoAb and the opposite isotype immunoconjugate control MoAb e.g. 
anti-human CD3-FITC MoAb and PE-conjugated isotype control MoAb were added to 
the cell suspension. 
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The flow cytometer (FACScan, Becton Dickinson) is equipped with a single argon laser 
that emits a 488nm wavelength beam. Cells pass through the laser beam in a single 
stream as a result of a hydraulic pressure and fluid sheath system. As the cell passes 
through the laser beam, changes occur in the laser radiation which are measured by two 
detectors which detect light scatter and three photomultiplier tubes (PMTs) which detect 
fluorescent signals (Figure 2.1). This detection system measures the cell size (forward 
scatter; FSC), cytosolic complexity/granularity (side scatter; SSC) and fluorescence 
(FL1, FL2, FL3). As the cell enters the laser beam, the light is refracted around the cell 
with the degree of refraction correlating directly with the cell size i.e the greater the 
laser beam refraction, the larger the cell (FSC). Cytosolic organelles and granules cause 
the laser beam to be refracted at 90° to the incident laser axis (SSC) and the amplitude 
of the side scatter reflects the degree of cell granularity. 
There are at least nine commercially available fluorochromes conjugated to MoAb for 
flow cytometry analysis. The exhibit variable absorbance and emission spectra (440-
750 nm). The two most commonly used fluorochromes are fluorescence isothiocynate 
(FITC; 389 kDa with an absorbance maximum at 495 nm, emission maximum 520 nm 
when excited by 488 nm light) and phycoerythrin (R-PE; 240kDa with an absorbance 
maximum at 564 nm, emission maximum 576 nm when excited by 488 nm light). 
Detectors were set at appropriate wavelengths to measure the emitted light from the 
excited fluorochromes (FITC: FL1; R-PE: FL2). Before analysis of each set of samples, 
the cytometer was first calibrated using negative controls. The mononuclear cell 
suspension was prepared as described above. Whilst in acquisition mode, FSC vs. SSC 
(size vs. granularity) dot plots were obtained using linear scales allowing dead cells, 
residual RBCs and cellular debris to be gated out. The fluorescence emitted from the 
excited immunoconjugate fluorochromes was measured using a 10glO scale with FLI 
and FL2 detectors being set typically at 580-620 meV and 500-540 meV, respectively. 
When performing simultaneous, multi-colour, immunofluorescence analysis using a 
flow cytometer, intrinsic spectral overlap of the different fluorochromes used, if 
uncorrected, will lead to emission of a given fluorochromes into an inappropriate 
detector. This lack of compensation of spectral overlap can result in misinterpretation of 
data. However, compensation for this spectral overlap can be achieved by electronic 
subtraction of the unwanted signal. FITC is detected as a green signal by the FLI 
detector when a 488nm wavelength argon laser is used to excited the fluorochromes and 
R-PE is measured as an orange signal by FL2 detector. The peak emission ofFITC is 
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FIGURE 2.1. Diagrammatic representation of a single laser flow cytometer with five 
parameters of detection (modified from R&D Systems Product catalogue, UK). 
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530 run and R-PE is 575 run and a significant amount of orange fluorescence is present 
in the FITC emission and some green fluorescence is present in the orange emission 
(Figure 2.2). Compensation allows the electronic subtraction of these spectral overlaps. 
Compensation was set using isotype negative immunoconjugate-stained cells to set the 
background autofluorescence to within the first decade on a log scale. Next cells stained 
with single immunoconjugates were acquired by the cytometer whilst monitoring a 2-
colour dot plot. The compensation settings were adjusted so that positively stained cells 
were directly in line with the isotype negative control cells and parallel with the 
appropriate axis e.g. for a PE-stained population, adjust the FLI-%FL2 setting up/down 
until the FL2 positive population is vertically aligned with the FL2 negative population. 
This was then repeated using the other fluorochromes. 
Data collected by the flow cytometer was analysed using Cell Quest software (Becton 
Dickinson). Once calibrated, the flow cytometer was set to acquire 10,000 cells in the 
gates specified. The data were analysed using frequency histograms (for single stained 
populations) and dot plots (for double stained populations) with markers and quadrants 
being set on isotype negative controls. 
2.3 GENERATION OF AN IL-2-DEPENDENT HUMAN LYMPHOBLASTOID 
CELL LINE (IDBL CELL LINE) 
The IDBL cell line is a novel human IL-2-dependent cell line that was generated from 
mitogen-activated PBL rendered IL-2 dependent. From 450mls of citrated whole blood 
(from a donor provided and virally screened by The Scottish National Blood 
Transfusion Service) PBMNC were prepared using Ficoll-Hypaque and centrifugation 
at 15000 for 30 minutes. The PBMNC were removed by careful pipetting of the 
interface layer and washed x3 in PBS, the second and third centrifugation steps were 
performed at 9000 to remove contaminating platelets. The PBMNC were then counted 
and 2 aliquots of 107 cells (to be used as autologous antigen presenting 
cells/stimulators) were re-suspended in cryopreservation medium and stored in the 
vapour phase of liquid N2 until required. The remaining PBMNC (2xl08 cells) were re-
suspended at Ixl06 cells/ml in CM containing Con A 5Jlg. The PBMNC were cultured 
at 37oC/5%C02 for 7 days when the medium was replaced with CM and rhIL-2 20U/ml 
and cultured for a further 7 days. After this period, viable cells were recovered by 
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FIGURE 2.2. Emission spectra of FITC and R-PE demonstrating spectral overlap and 
the need for electronic detector compensation. 
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density gradient centrifugation. An aliquot of cryopreserved PBMNC, to be used a 
stimulators, were thawed in a 37°C water bath and the cells were washed x3 in warm 
CM. The stimulator cells were then incubated in 25J.lglml mitomycin-C for 30 minutes 
at 37°C. The cells were washed x3 in warm CM and re-suspended in CM containing 
Con A 5J.lg, and the recovered viable lymphoblasts were added to the stimulators. The 
IL-2 stimulated lymphoblasts and the autologous APCs were co-cultured with Con A 
for 7 days when the medium was replaced with CM and rhIL-2 20 U/ml and cultured 
for a further 7 days. The 14 day cycle of autologous APC stimulation and IL-2 
expansion was repeated once more. The lymphoblasts were then expanded by CMlrhIL-
2 in bulk cell suspension. Aliquots of the IDBL cell line were then stored in 
cryopreservation medium in the liquid phase of liquid N2 until required. On-going cell 
cultures were maintained at a low passage number (6-30) and the cell concentration was 
kept at 1-5xlOs/ml. The cell line was stimulated with rhIL-2 20 U/ml every 3-4 days. 
The IDBL cell line was then characterised both phenotypically and with regard to 
cytokine/cytokine receptor expression by immunofluorescent flow cytometry and RT-
PCR, respectively. Prior to use in any experiments, the cells were pelleted from the IL-
2-supplemented CM and re-suspended in fresh CM alone and cultured for 18 hours to 
permit cell cycle synchronisation. 
2.4 MOLECULAR BIOLOGY 
RNA EXTRACTION 
The reliability of methodologies to detect gene mRNA transcripts are dependent on 
many factors including the quality and quantity of RNA extracted. Total RNA from 
bulk cell populations of interest was extracted using the TRIzol reagent (Gibco BRL) 
for total RNA extraction. For all RNA work, glassware, tubes, aqueous solutions and 
pipette tips were autoclaved before use. Cell suspensions were pelleted at 10000 rpm in 
a microfuge and the supernatant decanted. The pellets were re-suspended in TRIzol, 
Iml of reagent per 5-10 x106 cells and vortexed for 60 seconds. The homogenised 
samples were incubated on ice for 10 minutes to allow complete dissociation of 
nuc1eoproteins and then 0.2 mls of chloroform was added per 1 ml ofTRIzol. The tubes 
were capped and shaken vigorously for 15 seconds and the mixture was then allowed to 
separate for 5 minutes at room temperature. The samples were centrifuged at 11000 rpm 
for 5 minutes. Following centrifugation, the mixture separated into a lower red, phenol-
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chloroform phase, an interphase of protein and a colourless upper aqueous phase 
containing nucleic acids. The volume of the aqueous phase was approximately 60% of 
the volume of TRIzol added and this aqueous phase was carefully removed without 
disturbing the interphase layer and transferred to a separate eppendorf tube. Isopropanol 
(0.5 mls per Iml of TRIzol used) was added to precipitate the RNA. The sample was 
agitated and incubated at room temperature for 10 minutes. The samples were 
centrifuged at 11000 rpm for 5 minutes. The precipitated RNA often formed a gel-like 
pellet and after the supernatant was decanted, this pellet was re-suspended in 1 ml of 
75% ethanol per Iml TRIzol used. The samples were mixed completely before being 
centrifuged at 7500 for 5 minutes. The supernatant was removed and the pellet was then 
air-dried (for approximately 30 minutes) at room temperature. The RNA was dissolved 
in 20 I.d of RNase-free water and was then heated at 65°C for 10 minutes to disable 
secondary structures and the samples were then spun and placed on ice prior to 
determining the yield and quality of RNA. 
The yield and purity of total RNA was assessed by spectrophotometry (Sambrook et aI, 
1989). An absorbance reading of 1 at 260nm (A26o) represents 40Ilg/ml oftotal RNA (or 
single stranded DNA) and the concentration of RNA (f.lglml) can be determined by 
multiplying the A260 value obtained by 40. The purity of the RNA solution can be 
assessed by the ratio of absorbance at 260 nm and 280 nm (A28o- the absorbance 
maximum for proteins). Typically the A2601A28o ratio was in the range of 1.65-1.95 in all 
RNA isolations in these studies. 5f.ll of total RNA solution was diluted in 495f.l1 of 
distilled water for spectrophotometry. The integrity of the total RNA was also examined 
by agarose gel electrophoresis under denaturing conditions (Sambook et aI, 1989). 
Denaturing gels were prepared using 1.2g of agarose, lOmls 10xMOPS and 85mls of 
ultrapure H20 which was then heated in a microwave. Following heating the mixture 
was allowed to cool to "hand-hot" temperature when 5 mls of 37% formaldehyde 
solution was added and the mixture was allowed to set in a suitable gel-sized tank. RNA 
samples, 5-10 f.lg in 12 III were mixed with 13f.l1 of Northern Loading buffer and If.ll of 
Imglml ethidium bromide and heated to 65°C for 15 minutes to denature. Following 
denaturing, the samples were pulse-spun in a microfuge and chilled on ice before 
loading into the wells of the denaturing gel. The gels were run using Ix MOPS buffer at 
18-24V over 4-6 hours (until the dye front had traversed 2/3 of the gel). The gel 
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188 ribosomal 
RNA 
128 ribosomal 
RNA 
M 1 2 3 
FIGURE 2.3. Verification of total RNA quality by gel electrophoresis under denaturing 
conditions. Lane 1 represents RNA extracted from PBL stimulated with Con A for 72 
hours and lane 2 represents RNA from resting PBL that has degraded. Lane 3 represents 
RNA extracted from a Chinese hamster ovary cell line indicating species-specific 
differences in the size of the ribosomal bands. 
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image was captured using UViphoto software. A representative example demonstrating 
the 18S and 12S ribosomal RNA bands is illustrated in Figure 2.3 image captured using 
UViphoto software. 
eDNA SYNTHESIS 
First strand eDNA synthesis was carried out by reverse transcription using the 
Superscript system (Life technologies Ltd), following the manufacturer's instructions. 
5J.lg of RNA in 12J.lI of RNase-free H20 was decanted into a200J.lI PCR tube and IJ.lI of 
500 J.lglml olio dT12-18 primer was added. This reaction mixture was heated to 70°C for 
10 minutes using a PCR Express thennal cycler (Hybaid, UK), pulse spun in a 
microfuge and chilled on ice. The resulting mixture was then reverse transcribed by the 
addition of the following: 
4 J.lI xI 0 1 st stage buffer (Gibco, UK) 
2 J.lI O.IM Dithiothreitol (DTT)(Gibco, UK) 
1 J.lI of 100mM dNTP 
1 J.lI of Superscipt II reverse transcriptase (Gibco, UK) 
The mixture was then incubated at 42°C for 50 minutes in the PCR express machine and 
the reaction was tenninated by denaturing the reverse transcriptase by heating the 
mixtures to 90°C for 5 minutes, before being pulse spun and chilled on ice. The eDNA 
was either used immediately for downstream PCR amplification or stored at -20°C until 
required. 
PRIMER DESIGN AND VERIFICATION 
Almost all the primer pairs used in these studies were either published sequences with 
ideal reactions conditions or in-house primer pairs with previously identified reaction 
conditions. However, I wished to amplify a larger IL-2Ra sequence so that I could 
discriminate the IL-2Ra PCR product from the IL-2Ryc product by a significant size 
variation and as such, needed new sense and anti-sense primers. Similarly, published 
primer pairs were not available for the human pim-l oncogene. Therefore, primer pairs 
for both these loci had to be designed. Sense and anti-sense primer sequences were 
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designed using cDNA sequences of the gene of interest on Entrez Browser Database. 
This revealed the following sequences: 
IL-2Ra 
5' Primer: 5'-GGGTIGATGTCATGACTGTAG 
3' Primer: 5' -GCTGCTGAA TCTICTGACTC 
Amplifies a 781 bp product. 
Pim-l 
5' Primer: 5'-GTCCAAAATCAACTCGCTI 
3' Primer: 5'-CGGCGACAGGCTGTGGA 
Amplifies a 918 bp product. 
Using eDNA synthesised from total RNA isolated from mitogen-activated peripheral 
blood lymphocytes (PBL), the PCR conditions were optimised for both gene primer 
pairs in terms of the annealing temperatures and MgCh concentration. The melting 
temperatures (Tm) were predicted to range from 55°C to 6SoC and an annealing 
temperature of 60°C was found to be suitable for both gene primer pairs. The optimal 
MgCh concentration was demonstrated to be 2.5J.lI of 50mM solution per 50 J.lI reaction 
(Figure 2.4). 
Confirmation of specificity of PCR products was performed using enzyme restriction 
digest. Amplified products were generated using eDNA from mitogen-activated PBL. 
The products were visualised by 2% agarose gel electrophoresis and the products were 
extracted from the gel (see below). Suitable restriction enzymes were selected based on 
restriction site analysis of the PCR products using Primer Detective software. The pim-l 
PCR product was restriction digested by the enzyme BamH I which cut the product into 
3 fragments: 51, 241 and 626 bps in length. Gel extracts were re-suspended in RNAse-
free H20 and the eDNA quantified by spectrophotometry. 2J.lg of cDNA was placed in a 
sterile PCR tube with IJ.lI of BamH I (Gibco), 2J.lI of xlO Enzyme buffer (Gibco) with 
sufficient RNAse-free H20 to make the reaction mixture up to a final volume of 20J.l1. 
The reaction mixture was incubated at 37°C in a water bath for 2 hours then the 
products of the restriction digest were visualised by electreophoresis on a 2% agarose 
gel (Figure 2.5). The PCR product for the newly designed IL-2Ra primer pairs were 
digested using the restriction enzyme Hae III which cut the oligonucleotide into 3 
fragments: 112, 173 and 496 bps in length (data not shown). 
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M 3.01l1 
Pim-l 
Figure 2.4. The effect of altering the MgCh concentration on optimising PCR 
conditions for the pim-l sense and anti-sense primers. Key: M-markers, H20- PCR 
negative control, 1.5-3.0J.ll- volume of 50mM MgCh solution per 50J.ll PCR reaction. 
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M Blank Actin No BamHI 
Enzyme 
• __ Pim-l 918 bps 
.. _ 626 bps 
.. _ 241 bps 
.. _ 51 bps 
FIGURE 2.5. Restriction digest of gel-purified PCR products derived from pim-l sense 
and anti-sense primers. cDNA derived from activated PBL was amplified using 
oligonucleotide primers which identified a sequence of the pim-l oncogene and after 
purification, the PCR products were digested by BamH I restriction enzyme resulting in 
3 fragments: 51 , 241 and 626 bps in length. The 51 bp fragment being small is difficult 
to identify from the primer dimer band and the 241 bp band is faint. Hae ill enzyme 
alone was used as a control. 
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PCR AMPLIFICATION AND PRODUCT VISUALIZATION 
PCR amplification from cDNA was performed according to the previously published 
methodology (Innis & Gelfand, 1990). 5f.lg ofmRNA was used in each eDNA synthesis 
and 2 f.ll of eDNA reaction mixture (equivalent to 0.5 f.lg of mRNA) was used in each 
PCR amplification. Negative control samples were included in which cDNA solution 
was replaced by RNase-free H20. PCR was carried out in 50 f.ll reaction volumes as 
follows: 
5 f.lll0X PCR buffer (Hybaid,UK) 
2 f.l150mM MgCh (Hybaid,UK) 
2 f.ll cDNA 
1 f.ll 25 f.lM Sense primer 
1 f.l125 f.lM Anti-sense primer 
1 f.ll 10mM dNTP (Life technologies Ltd) 
0.4 f.ll (2U) AGS Gold Taq polymerase (Hybaid,UK) 
37.6f.ll f.ll dH20 
Samples were amplified using a PCR Express thermal cycler (Hybaid,UK) and the 
annealing temperature for the amplification reactions was 60°C. The reaction mixtures 
were heated to 95°C for 5 minutes to dissociate all double stranded species. The 
amplification consisted of 30 cycles (unless otherwise stated) as follows: 9SoC for 1 
minute (denaturation); 60°C for 1 minute (primer annealing); 72°C for 1 minute 
(extension). A final incubation at 72°C for 5 minutes was carried out to ensure complete 
extension of the PCR products and following amplification, products were visualised by 
gel electrophoresis. 
The products were analysed by electrophoresis on a 2% agarose gel: l.4g of 
electrophoresis grade agarose was dissolved in 70 mls of xl TBE running buffer by 
heating in a 650W microwave for 60 seconds. This was allowed to cool to hand-hot 
temperature and 1 f.ll of ethidium bromide (10 mg/ml) was added. The gel was poured 
into the mould of a BioRad Electrophoresis Gel tank (BioRad, UK) and once set, the 
tank was filled with xl TBE running buffer until the gel was completely covered. 10 f.ll 
of gel loading buffer (Life Technologies) was added to each peR mixture and 25 f.llof 
PCR mixturelloading buffer were loaded into each well. 10 f.ll of 1 Kb DNA ladder 
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(Hybaid), which contained suitably sized fragments to confinn peR product 
identification by size. 1 J.lI of ethidium bromide (10 mg/ml) was added to the TBE 
running buffer and the gel was electrophoresed at 100V for 1-2 hours and the gels 
images illuminated by UV light were captured using UViphoto imaging software. 
GEL EXTRACTION 
The DNA from peR reactions was purified from amplification reactions visualised on 
2% agarose gel, using the QIAquick Gel Extraction Kit (Qiagen,UK) following the 
manufacturers instructions. The protocol is designed to extract single or double stranded 
DNA of 100-10,000 bp from TBE agarose gels. Under ultraviolet light, the peR 
product of interest was excised from the gel using a sterilised scalpel blade. The gel 
slice was weighed in a Falcon tube (usually 300 mg == 300 J.lI of melted gel). To this, 3 
volumes (900 J.lI) of Buffer QXl was added and incubated at 500e for 10 minutes in a 
water bath. The tubes were mixed gently at regular intervals and once the gel had 
dissolved, 1 gel volume of isopropanol was added to the mixture and gently agitated. 
The pH was checked with a pH strip as maximum absorbance of DNA occurs at 
pH<7.5. If the pH was found to be >7.5, then 10 J.lI of sodium acetate (PH 5.0) was 
added and the pH was rechecked. A QIAquick spin column was placed in a 2m1 
collection tube and the sample was loaded to a maximum of 800 J.lllload, with mUltiple 
loading required for larger samples. The QIAquick column was then spun at 10,000g 
for 1 minute and the flow-through was discarded. The column was replaced in the 2 ml 
collection tube and 500 J.lI of Buffer QXI was added and the column was spun at 
10,OOOg for 1 minute. The flow-through was discarded and 750 J.lI of Buffer PE was 
added and centrifuged again for 10,000g for 1 minute. The flow-through was discarded 
and the column spun again at 10,OOOg for 1 minute, after which the column was placed 
in a sterile 1.5 ml Eppendorf tube and 50 J.lI of H20 was added to the centre of the 
column. The column was left standing at room temperature for 1 minute before being 
spun at 10,000g for 1 minute. The purified peR products were then used in downstream 
applications. 
2.5 STATISTICAL ANALYSIS 
Where data represents more than 3 observations, data are presented as a mean± standard 
error of the mean (SEM). For statistical analysis of the experimental data, Microsoft 
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Excel Analysis ToolPak software (Microsoft Office2000 Small Business) was used. 
Direct comparisons of data sets were performed using a two-sample student I-test 
(heteroscedastic I-test). When analysis of how changes within one data set compare to 
changes within another data set, the correlation between the two data sets was 
calculated and variability between two data sets was analysed by linear regression 
analysis (the software utilises the "least squares" methodology). The statistical 
significance of the difference between two data sets is expressed as a probability or p 
value. Statistical significance is attached to differences between data sets if the p<O.05, 
with the greater significance being attached to the lesser p value. 
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CHAPTER 3 
Soluble factors from Multiple Myeloma cells inhibit the activation of 
T -lymphocytes 
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3.1 INTRODUCTION 
Multiple myeloma is a clonal malignant disorder of terminally differentiated B cells 
which in addition to the main disease characteristics of bone marrow failure, 
paraproteinaemia and osteolytic bone disease is associated with abnormalities of the 
immune system, both cellular and humoral (Lauria et al, 1984). A number of phenotypic 
and functional alterations are representative of a host/tumour interaction in peripheral 
blood T lymphocytes (PBL) of patients with this disease have been described. Amongst 
these are the clonal expansion ofCD4+ and CD8+ T cells (Janson et aI, 1991; Halapi et 
aI, 1997) which produce high levels of IL-2 and Interferon-y with restricted usage of V (l 
and V13 segments (Dianzani et aI, 1988; Massaia et al, 1991). These features are 
suggestive of the potential for T cell responses against myeloma cells as surveillance by 
the immune system. T cell responses could explain disease stability, even without 
therapy, seen during plateau phase. Indeed, it has been shown that high serum IL-2 
levels in patients with MM correlated with other prognostic indices and were associated 
with improved survival (Cimino et al, 1990). However, despite these attempts at host 
immune regulation of the tumour clone, ultimately all patients progress to relapse and 
this suggests that the T cell responses which develop are unable to keep the disease in 
check in vivo. 
Induction of immune responses requires a two signal system for efficient activation 
(Schwartz, 1989). Following the interaction of cellular adhesion molecules and their 
ligands, the initial signal is generated by T cell recognition of antigenic peptides (Ag) 
presented with major histocompatibility complex molecules (MHC) via T cell receptors 
(Bjorkman et al, 1987). Following this AglMHC-restricted signal, a second signal (non-
MHC-restricted) is generated via co-stimulatory pathways which determines whether 
the TCR complex engagement results in functional activation or clonal anergy (Weaver 
et al, 1990). Of the several co-stimulatory pathways that exist the CD80/CD28 & 
CD86/CTLA-4 system is thought to particularly important (June et al, 1989). With TCR 
engagement and secondary co-stimulation, the T cells enter into two consecutive phases 
of response: activation and proliferation (Crabtree, 1989; Schwartz, 1992). 
Tumour cells, in particular myeloma cells, circumvent attempts by the host immune 
system at regulation of tumour growth and survival either by evading detection or 
actively suppressing any attempt by the host at immune regulation. In the case of 
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myeloma tumour cells, there are a number of possible mechanisms which may enable 
evasion of immune regulation (reviewed Cook & Campbell, 1999). There is a need for a 
second co-stimulatory signal by the APC to allow T cell activation and prevent anergy. 
However, myeloma cells, despite expressing an array of adhesion molecules (Cook et 
aI, 1997), generally lack the co-stimulatory molecules CD80 and CD86 on their surface 
(Schmiltze et al, 1996). It is of interest to note that malignant plasma cells express 
CD28, the ligand for CD80, and CD86 which is constitutively expressed on the majority 
of CD4 T cells and approximately half of CD8 T cells, on their surface (Pellat-
Deceunynck et al, 1994; Robillard et aI, 1998). The surface expression density and 
intracellular signalling capabilities of CD28 on myeloma cells is similar that of normal 
T cells, including binding to its ligand, CD80 (Zhang et al, 1998). Blocking experiments 
have shown that myeloma cells do not require CD28 for growth and differentiation 
though whether it has a role in auto-stimulation of the tumour clone or contributes to a 
down-regulation of the immune control of the malignant plasma cells in vivo remains to 
be established. 
In addition to evading detection, myeloma cells may influence the function of the 
immune effector cells directly, suppressing their capabilities to respond to the growing 
malignant clone. Evidence from patients with this disease indicate that the T cell 
compartment is compromised in a number of aspects. T cells from patients with MM 
have increased surface expression of Fas (APO-IICD95), and lower Bc1-2 expression 
and this may imply an increased susceptibility to apoptosis (Massaia et al, 1995). 
Myeloma tumour cells have been shown to constitutively express FasL on their surface 
which has been proposed by the authors to be a mechanism by which the tumour cells 
can disarm the host immune system (ViIIunger et ai, 1997). This "counter attack" or 
immune privilege mediated by FaslFasL interactions may not be the sole evasive tactic. 
The under-glycosylated surface molecule, muc-l, has been shown to efficiently mediate 
apoptosis of T cells (Agrawal et ai, 1998) and myeloma cells have been shown to 
express muc-l, which can be up-regulated by dexamethasone, and produce a soluble 
variant which is capable of suppressing an alloantigen T cell response (Treon et al, 
1999). 
In addition to the cell surface mechanisms indicated, modulation of T cell responses by 
soluble factors is commonly employed by malignant cells (Kolenko et aI, 1997). The 
production of imunosuppressive cytokines and molecules such IL-l 0, TGF~, PGE2, 
48 
VEGF, soluble CD27 and soluble muc1 and FasL may also play an important role in the 
suppression of an efficient host anti-tumour response. Evidence to implicate these 
soluble cytokines in the evasion of the host immune system is lacking and it is likely 
that MM tumour cells could adopt various defence mechanisms against rejection, 
allowing continued growth and dominance in a potentially hostile microenvironment. 
As yet, there is no clear evidence to indicate what, if any, direct effect the myeloma 
tumour cells have on the behaviour of T cells, especially in the process of activation. 
Experimental Design 
The aim of the experiments presented in this chapter is to investigate the effect, if any, 
that human myeloma cell lines have on the activation process of T lymphocytes from 
normal donors, stimulated with alloantigen and mitogen. Specifically, do MM tumour 
cells suppress T cell responses or induce programmed cell death? The experimental data 
and observations presented in this chapter will form the rationale for the investigations 
set out in subsequent chapters. 
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3.2 MATERIALS AND METHODS 
All peripheral blood mononuclear cells (PBMNC) used in these experiments were 
prepared from normal donors as described in chapter 2. The human myeloma cell lines 
(HMCL) used in these experiments were maintained in complete medium. 
3.2.1 MIXED LYMPHOCYTE REACTIONS (MLR). 
PBMNC were re-suspended in sterile complete culture medium (CM) at a concentration 
of 4x106/ml and used as responders in the MLR. 50J.ll of cell suspension was decanted 
into each well of a 96 well microtitre plate (Nalge Nunc, Denmark) resulting in a final 
concentration l x106/ml (2xl0scellslwell). Allogeneic PBMNC were incubated with 
mitomycin C at a concentration of 25J.lg/ml (Sigma,UK) at 37°C for 30 minutes. The 
cells were washed 3 times in CM and re-suspended at a concentration of 4xl06/ml for 
use as stimulators in one-way MLR. The HMCLs used both as stimulators and to 
suppress MLR reactions in a 3rd party manner were cultured as described in chapter 2. 
Cells were incubated with mitomycin C at a concentration of 50J.lg/ml at 37°C for 30 
minutes. The cells were washed 3 times in CM and re-suspended at a concentration of 
4x106/ml. Mitomycin C-treated HMCL and allogeneic PBMNC were used in the 
experiments in serial dilutions to give PBMNC:stimulator ratios of 1:5 - 1: 160. 50J.ll of 
the appropriate cell suspension was added to each well, in quadruplicate, of 96 well 
microtitre plates and CM was added to obtain a fmal reaction volume of 200J.l1. 
Responder and stimulator populations cultured alone served to quantitate the 
background proliferation. Reactions were cultured for 5 days in 5% C02 at 37°c. 
Proliferation was assessed by the addition of 0.5J.lCi of tritiated thymidine (CH]-dThd) 
in the last 18 hours of incubation. Incorporated radiolabel was assessed by harvesting 
the 96 well microtitre plate onto nitrocellulose filters (packard Instruments, The 
Netherlands) using a Micromaster 196 cell harvester (Packard Instruments) and 
analysed using a Packard Matrix 96 counter. 
3.2.2 MITOGEN STIMULATION ASSAYS. 
PBMNC prepared as described in chapter 2 were re-suspended in sterile complete 
culture medium (CM) at a concentration of 4x106/ml and 50J.lI of cell suspension was 
decanted into each well of a 96 well microtitre plate. Lyophilised Concanavalin A type 
so 
v -S (Con A, Sigma UK) was re-suspended in 1 ml of sterile PBS, as per the 
manufacturers instructions. This was diluted with CM to give a concentration of 
200Jlglml, aliquoted in 1 ml quantities and kept at -20°C until used in stimulation 
assays. Aliquots were recovered from frozen and diluted 1 :20 to a concentration of 
10Jlglml with CM. 50 JlI of Con A solution was decanted into each reaction well thus 
with a reaction volume of 200JlI, the final Con A concentration was 2. 5 Jlglml. For 
experiments using ConA 5Jlglml, aliquots recovered from frozen were diluted 1:10 prior 
to use. Cultures were incubated for up to 5 days as indicated in the results. Samples for 
proliferation assays were cultured in quadruplicate in 96 well microtitre plates, and 
proliferation assessed by the addition of O.5JlCi eH]dThd (Amersham Pharmacia 
Biotech, UK) in the last 18 hours of incubation. Incorporated radio label was assessed by 
a Packard Matrix 96 counter. Otherwise, cells were cultured in 24 well plates and 
harvested as indicated below. 
In the stimulation assays where PBMNC were separated from HMCLs by a 0.2Jlffi pore 
membrane (Life Technologies, Paisley, UK), cultures were initiated in 24 well plates 
(Nalge Nunc, Denmark) at the same final concentrations of responder PBMNC, HMCLs 
and ConA indicated in the results. The cells were harvested from the 24 well plates by 
pipetting and transferred to 96 well plates for the last 6 hours of a 72 hour stimulation 
assay.0.5JlCi eH]dThd was added to each well as above and proliferation assessed by 
incorporated radiolabel using a Packard Matrix 96 counter. 
3.2.3 FLOW CYTOMETRY. 
Stimulation assays performed to examine surface marker expression, apoptosis and cell 
cycle were cultured in 24 well (2mllwell) plates at the same fmal concentrations of 
responder PBMNC, HMCLs and ConA as per corresponding proliferation assay. Cells 
were harvested by pipetting and washed x3 in PBS. Cells were re-suspended in an 
appropriate volume of PBS to give a cell concentration of lx106/ml and 100JlI of cell 
suspension was decanted into 5ml Falcon BB tubes. The monoclonal antibodies 
(MoAb) used are listed in Table 3.1. The principles of flow cytometric analysis of cell 
suspensions including laser alignment, compensation, gating, setting quadrants/markers 
using isotype negative controls, acquisition and analysis are described in chapter 2. In 
brief, an appropriate quantity of the directly conjugated test antibody (as per the 
manufacturer's instructions), which ranged from 5-10JlI, was added to the tubes with 
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Clone Specificity Manufacturer Isotype Species 
S5.2 CD2(FITC) Becton Dickinson, UK JgGl MAH 
UCHTI CD3(FITC) PharMingen, Europe JgGl MAH 
SK3 CD4(PE) Becton Dickinson, UK JgGl MAH 
SKI CD8(PE) Becton Dickinson, UK JgGl MAH 
2A3 CD25(FITC) Becton Dickinson, UK IgGl MAH 
M-A251 CD25(PE) PharMingen, Europe IgGl MAH 
TIC-I CDl22 (PE) Immunotech, UK IgGl MAH 
L78 CD69(PE) Becton Dickinson, UK IgGl MAH 
FN50 CD69(FITC) PharMingen, Europe IgGI MAH 
WT3I TCRa~(FITC) Becton Dickinson, UK IgGI MAH 
MY3I CD56(PE) Immunotech, UK IgGl MAH 
L48 CD45RA(FITC) Becton Dickinson, UK IgGl MAH 
UCHLI CD45 RO(PE) PharMingen, Europe IgG2a MAH 
Table 3.1. Monoclonal antibodies used in cell surface marker identification using flow 
cytometry. Key: FITC- fluorescence isothiocynate, PE- phycoerythrin, MAH- mouse 
anti-human. 
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appropriate isotype controls being used as negatives to set gates and markers. For 2-
colour flow cytometry, compensation was set using a single positive conjugated test 
antibody with the opposite conjugated isotype control and the compensation controls set 
to limit spectral overlap, as described in chapter 2. Data was acquired and analysed 
using "Cell Quest" software (Becton Dickinson). For blastogenesis studies, the relative 
number of blasting cells in the different cultures were assessed by gating on the FSC v 
SSC parameters of the cells. The total lymphocyte population was gated and designated 
region 1 (Rl). Using the resting cells (cultured in CM only), a second region was 
delineated (R2) within Rl, which excluded resting lymphocytes, thereby acquiring 
blasting cells. Therefore, for quantification of blastogenesis, numbers of cells gated in 
R2 were expressed as a percentage of the total cell number of Rl (based on 10,000 
events measured). 
The MoAbs used in these experiments identify T cells in mononuclear preparations 
(CD3, TCR<x~), T cell subsets (CD4 versus CD8, CD45RA versus CD45RO) and 
activation markers (CD25 & CD69). CD3 consists of 5 separate non-covalently 
associated integral membrane proteins (y,a,E,S&ll) and with the 0./3 subunits of the T 
cell receptor (TCR), mediates antigen-specific signaling pathways (Weiss et ai, 1986). 
Antibodies specific for CD3 recognise the E-component of the TCRlCD3 complex on 
100% of primary T lymphocytes in the peripheral blood. Using the MoAb which 
recognises CD3, after 72 hours of culture in medium alone (resting) 50-60% ofPBMNC 
were CD3+ where as 60-75% were CD3+ after culture with Con A for the same period. 
The 95th centile range for the percentage of total lymphocytes which are CD3+ is 55-
82% (Kotylo et aI, 1992). The surface antigens CD4 and CD8, which are co-expressed 
on thymocytes during development, delineate distinct cellular groups on a functional 
level (cytokine production and cytotoxicity) and the ratio of these two groups ofT cells 
varies throughout life from a CD4/CD8 ratio of2.74:1 (whole blood) at birth to 1.4:1 in 
adult life (Kotylo et ai, 1992). The ratio of CD3+/CD4+ and CD3+/CD8+ T cells in the 
studies presented in this thesis are based on PBMNC isolated after density 
centrifugation and as such, are liable to subtle differences when compared to whole 
blood. The CD4:CD8 ratio was found to be 1.7: 1 when cultured in CM only for 72 
hours and 1.2: 1 after 72 hours stimulation with Con A. 
T cells in humans have been characterized as memory or naIve in phenotype based on 
their surface expression of differing spliced variants of the surface antigen CD45 
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(Thomas, 1989). The status of "memory" versus "naive" is conferred pending the 
surface staining with antibodies which recognize the CD45RA splice variant which 
. indicates these cells are of a "naive" phenotype whereas cells which do not stain with 
anti-CD45RA antibodies but stain with CD45RO antibodies are considered to be of a 
"memory" phenotype (Sprent & Tough, 1994). This phenotypic division can be seen in 
both CD4 and CD8 lymphocytes and the ratio of these two "sets" of lymphocytes varies 
greatly in adult peripheral blood depending on the state of activation of the immune 
system. Analysis of the PBL in these studies revealed that when cultured in medium 
alone, 50-64% of,CD3+ cells were CD45RA and when cultured in ConA for 72 hours 
this fell to 35-42% CD45RA + /CD3+ cells. It is worth noting that fluctuations in absolute 
values or ratios of T lymphocyte surface marker positive cells may in part be explained 
by in vitro apoptosis/necrosis of other constituent cellular components of PBMNC 
which alter the balance of cell types analysed after culture. 
3.2.4 APOPTOSIS ASSAYS. 
Apoptosis is a form of programmed cell death that is characterised by a variety of 
morphological features, including loss of membrane asymmetry (in particular the 
distribution of phospholipids between the inner and outer leaflets of the plasma 
membrane) cell shrinkage, chromatin condensation and chromosomal DNA 
fragmentation (Castedo et al, 1996). The membrane phospholipid asymmetry is not only 
true for the choline-containing phospholipids (phosphatidylcholine and sphingomyelin), 
which are predominantly exterior in location but also the aminophospholipids 
(phosphadtidylenthanolamin and phosphatidylserine (PS» which are exclusively found 
on the internal leaflet of the membrane (Bretscher, 1972). During the early phases of 
apoptosis, governed by the balance of bax and bcl2 gene families, PS is translocated to 
the external membrane leaflet, thereby exposing PS to the exterior milieu (Martin et aI, 
1995). Changes in the plasma membrane phospholipid constitution is recognised as one 
of the earliest events, where nuclear chromatin condensation is one of the later features 
of this cellular death pathway. 
Based on the physiological events that result in cell death, two assays were adopted to 
determine if apoptosis is an important feature of T celllHMCL interactions: DNA 
fragmentation assay and Annexin-V affinity assay. 
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DNA Fragmentation Assay. 
Culture reactions were carried out in 24 well plates for the time intervals described in 
the appropriate experiments. The cells were harvested from each reaction well by 
vigorous pipetting and decanted into autoclaved 1.5 ml tubes (Greiner). The cells were 
then washed 3 times in cold PBS and then re-suspended in 20J.lI of DNA Isolate solution 
(10 mM EDT A, 50 mM TrisHCL (PH 8.0), 0.5% SDS & 0.5 mg/ml proteinase 
K(Boheringer Manheim, Germany». The reaction mixture was then incubated for 105 
minutes at 50°C. RNAse (0.5 mg/mI) was heated at 95°C for 5 minutes and 10J.lI of 
heat-treated RNAse solution was added to each reaction mixture and incubated for 60 
minutes at 50°C. A 2% agarose electrophoresis gel was prepared, as described in 
chapter 2, and the gel was kept dry until samples were loaded. Loading buffer (10 mM 
EDT A, 1% w/v low melting point agarose, 0.25% w/v Bromophenol blue, 40% w/v 
sucrose) was heated to 70°C and 10J.lI of loading buffer was added to each reaction tube 
and loaded immediately into the dry wells. Once the loaded samples had set, the 
running buffer was added and electrophoresis was run over 90 minutes at 75 volts. The 
gel was then visualised as per chapter 2 and the ethidium-stained DNA was identified. 
Where apoptosis was present, the fragmented DNA produced a "ladder" effect, resulting 
from the different sized fragments running at variable speeds. To determine reliability 
of this assay, IDBL (chapter 2) were cultured in the presence and absence of IL-2 
20U/ml for 24 and 48 hours and DNA prepared as outlined. 
Annex-V Affinity Assay 
As indicated, one of the earliest events in the programmed cell death pathways is the 
externalisation of the aminophospholipds, in particular phosphatidylserine (PS) 
(Bretscher, 1972; Martin et aI, 1995). Annexin V is a 35-36 kD Ca2+-dependent 
phospholipid binding protein (Binding Kd of 5 xlO-10M) which under strict NaCI and 
Ca2+ concentrations can be used as a probe (directly conjugated to the fluorochromes, 
FITC or PE, PharMingen, UK) to detect PS externalisation early in apoptosis (Engel and 
et al, 1998). As PS externalisation occurs during necrosis, Annexin V -FITC is used in 
conjunction with a vital dye, propidium iodide (PI) thus identifying three populations of 
cells: live cells (An-lPn, early apoptotic cells (An+lPn and late apoptotic/dead cells 
(An + IPn. The An + IPt population contains not only cells that have died from necrosis 
but also cells in late apoptosis when they have lost their cellular membrane integrity. 
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For the detection of apoptosis in these experiments using the Annexin V-afflnity assay, 
cells were stained according to the manufacturer's protocol (R&D Systems, UK). Cells 
were harvested as per the DNA fragmentation assay and washed in cold PBS and re-
suspended at a concentration of lx106/ml in binding buffer (lOmM buffered 
HEPESINaOH (PH 7.4), 140 mM NaCI and 2.5mM CaCh). 100~1 of cell suspension 
was incubated with 1 O~l of FITC conjugated Annexin V (An V) and 1 O~l of 50~g/ml PI 
(Sigma,UK) solution for 15 minutes at 20°C. This was followed by the additIon of 
400~1 of binding buffer without washing. Cells were analysed within an hour by flow 
cytometry. Using the physical parameters of size (FSC) and granularity/vacuolation 
(SSC) on a linear dot plot, the PBL were gated and analysed for An V and PI staining, 
thereby excluding the HMCL (Figure 3.1). Using unstained cells, a log FLI and log FL2 
dot plot was generated on the PBL gated cells and the detectors were adjusted so that 
>98% of events were centrally distributed within the lower left quadrant bordered by the 
first log decade scale on both x and y axis, thus adjusting for auto-fluorescence. The 
AnV only stained population was run on the log FLI and log FL2 dot plot and spectral 
overlap was removed using the compensation controls (FL2-FL1, typically 15-22%). 
Next the PI only stained cells were run on the log FLI and log FL2 dot plot and the 
compensation controls adjusted to remove spectral overlap (FLI-FL2, typically 1-5%). 
The quadrants were set using a ''resting'' population of cells stained with both An V and 
PI. The vertical cursor was set 0.1-0.2 log units beyond the edge of the An V· 
population and the horizontal cursor was set 0.1-0.3 log units above the edge of the 
double negative cluster. The cells of interest were acquired and 10,000 events recorded 
and analysed using Cellquest software (Becton Dickinson, UK). To determine reliability 
of this assay, IDBL (chapter 2) were culture in the presence and absence ofIL-2 20U/ml 
for 24 and 48 hours and DNA prepared as outlined. 
3.2.5 Cell cycle assays. 
Cell proliferation is characterised by a process of DNA synthesis and division. The 
repetitive growth and division of cells is called cell cycle and can be divided into 5 
distinct phases: Ol(grOwth), S (DNA synthesis), 02 (growth following DNA synthesis), 
M (cell division) and 00 (quiescence). The number of cells in S phase represents the 
"proliferation potential" of any given population (Shankey et al, 1993). Using PI which 
stains DNA, a DNA histogram can be generated based on the DNA content of cells at 
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Figure 3.1. Rl was set to capture all PBL with R2 being set to capture the larger, 
blasting PBL. Using the physical parameters (FSC versus SSC) on a linear scale, PBL 
CRI +R2) can be differentiated from the HMCL cells and gates set to exclude the latter 
from analysis. 10,000 events in Rl were acquired for analysis. Key: FSC - forward 
light scatter, SSC - side light scatter. 
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Figure 3.2. A schematic representation of the principle of using cellular DNA content 
to determine the phase of cell cycle using flow cytometry. The cell cycle (A) is divided 
in to five phases: 0\, 02, S, M, and 00 (not shown). For analysis of DNA content, 3 
main areas of interest are generated on a histogram plot: The diploid spike, which 
represents 0\ (and 00) cells and the bulk of the cells in any given population which are 
coloured blue in (A)-(C), the mitotic peak, representing double the DNA content of the 
diploid spike, coloured in red in (A)-(C) and the cells in the area between representing 
those actively synthesising DNA prior to proliferation (S phase) coloured green in (A)-
(C). 
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differing stages of cell cycle (Figure 3.2). For cell cycle analysis, cells cultured in 24 
well plates for the time intervals stated in each experiment, were harvested by vigorous 
pipetting and washed in cold PBS. Cells were fixed in 2% formaldehyde at 4°C for 15 
minutes and permeablised in 70% ethanol at -20°C for 1 hour. Cells were then washed 
in cold PBS and incubated with RNAse (lOOJlg/ml) at 37°C for 30 minutes followed by 
PI (50 Jlg/ml) in PBS at 20°C for 30 minutes. Using the physical parameters of size 
(FSC) and granularity/vacuolation (SSC) on a linear dot plot (Figure 3.1), the gates 
were set to capture all the PBL and any contaminating tumour cells were excluded in 
the Modfit analysis on the basis of aneuploidy. Using the flow cytometer as described in 
chapter 2, PI fluorescence was detected using a filter at 570nm, equivalent to the FL2 
fluorescence on the cytometer. The principle behind cytometric DNA staining is 
illustrated in Figure 3.2. The large peak of PI-stained DNA is the diploid spike and 
represents cells in G"Go stages of cell cycle with mitotic cells containing double DNA 
content appearing as a small peak with x-axis values double that of the diploid spike. 
The intervening area contains the cells in S phase of cell cycle. The percentage of cells 
at different cell cycle stages determined using "Modfit" software (Verity Software 
House Inc.). 
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3.3 RESULTS 
3.3.1 MIXED LYMPHOCYTE REACTIONS 
The mixed lymphocyte reaction (MLR) is the proliferative response generated by 
lymphocytes, which encounter foreign major histocompatibility antigens presented by 
allogeneic lymphocytes, resulting in the expansion of alloreactive T cell clones. Such 
reactions employ stimulators that have been rendered incapable of proliferating by pre-
treating them with y-irradiation or mitomycin-C (Chanarin, 1989). The ability of human 
Myeloma cell lines (HMCL) to stimulate a lymphocyte proliferative response was 
examined using the MLR. 
PBMNC were separated from the peripheral blood of normal, healthy volunteers (n=3), 
as described in chapter 2, and were co-cultured with mitomycin C-treated allogeneic 
PBMNC. This resulted in a brisk proliferative response at day 5 of culture, as 
determined by 3H-Thymidine up-take (Figure 3.3). When the same PBMNC responders 
were co-cultured with 2 HMCLs (U266 and nMl) as stimulators, no proliferative 
responses were detected after 5 days of culture (Figure 3.3). This was tested further 
when normal, allogeneic PBMNC (n=5) were co-cultured with the HMCL U266, in 
increasing responder:stimulator ratios, proliferative responses in a 5 day one-way MLR 
were greatly suppressed. These PBMNC demonstrated normal proliferative responses 
(54,600±11,164 cpm - mean ±SEM) when cultured with the mitogen, Con A, alone 
demonstrating satisfactory functional activity (Figure 3.4). 
To examine whether this poor stimulatory function of HMCLs in a one-way MLR was 
the result of active immunosuppression rather than defective antigenicity, MLR 
reactions using normal allogeneic PBMNC as responders to mitomycin C-treated 
allogeneic PBMNC, were set up and HMCL were co-cultured in these reactions in 
reducing concentrations. The addition of the HMCLs in this 3rd party co-culture reaction 
greatly reduced the normal MLR proliferative responses suppressed (100% inhibition of 
response at highest HMCL concentration, IHMCL:5PBMNC), as determined by the 3H_ 
Thymidine up-take. This suppressive capability of the HMCLs demonstrated a dose-
dependent relationship, with full MLR responses only being regained at the lowest 
HMCL concentrations (1 HMCL: 80 PBMNC). as illustrated in Figure 3.5. 
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Figure 3.3. Net proliferation (counts.min- I) from 3 normal responder PBMNC in one 
way mixed lymphocyte reactions using mitomycin C treated allogeneic PBMNC 
(MLRl-3) or 2 HMCLs ( U266 and JIMl) as stimulators in a 5 day culture. Results 
represent 3H-Thymidine uptake, expressed as counts per minute (CPM). 
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Figure 3.4. MLR responses of normal, allogeneic PBMNC (n=5) to the mitomycin C-
treated U266 cells at 5 days. The responsiveness of these normal allogeneic PBMNC to 
mitogenic stimulation alone (Con A) was satisfactory. Results represent 3H_ Thymidine 
uptake, expressed as mean ±SEM counts per minute (CPM). Key: Con A: concanavalin 
A, 5R: IS: number of responder PBMNC to stimulator HMCL (U266). 
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Figure 3.5. MLR responses of normal PBMNC to allogeneic PBMNC at 5 days. MLR 
responses are completely inhibited when co-cultured with mitomycin-C-treated HMCL 
in a 3rd party effect. Responses are partially restored with reducing concentration 
HMCL as stimulators. Results represent 3H-Thymidine uptake, expressed as corrected 
counts per minute (CPM). Key: U: 4xlOI\5 -the number of HMCLs/ml added to the 
allogeneic MLR, U- U266, J- JJN3_ 
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3.3.2 MITOGEN STIMULATION 
MLR reactions vary in their magnitude depending on the frequency of allo-reactive 
precursors, which in the normal healthy individual range from 1:544 to 1:47,619 for 
cytotoxic T lymphocyte precursor (CTLp) frequencies and 1:385 to 1:50,000 for helper 
T lymphocyte precursors (HTLp) frequencies (Wang et aI, 1998). Further, variation in 
the strength of an alloreactive response depends on the degree of HLA disparity 
between the stimulator and responder MNC populations. Alternatively, the 
macromolecular mitogens non-specifically stimulate large numbers of T cell clones. 
These provide a convenient assay for polyclonal stimulation that is useful for studying 
the suppressive influences of varying chemical and cellular interactions. Such a mitogen 
is the extract from the plant Canavalia ensijormis, Concanavalin A (Con A). The 
physiological properties of Con A on human primary T cells have been well described 
(Cunningham et al, 1976). Stimulation of T cells by Con A demonstrates a saturation 
phenomenon with increasing concentrations of mitogen failing to result in any further 
effects (unimodal dose response curve). Con A shows a maximum stimulation at 
concentrations as low as 3-5 J.lg/ml. 
To demonstrate the kinetics of human T cell stimulation, PBMNC prepared as described 
in chapter 2, were cultured with complete medium only or two concentrations of Con A 
(2.5 and 5J.lg/ml , final concentration) and proliferation kinetics were examined daily for 
5 days of culture. Proliferative responses to ConA were maximal at 72 hours, as 
illustrated in Figure 3.6. Proliferation was still detectable at 96 and 120 hours though 
demonstrated great inter-donor variability (SEM- 7946 and 17892 cpm, respectively. 
The responses at 96 and 120 hours to Con A 5.0 J.lg/ml suggested a decay in the 
mitogen-induced proliferation. Based on these experiments, the optimal concentration 
and duration of stimulation with Con A was 2.5J.lg/ml for 3 days, which resulted in a 
mean proliferative response of 58,792cpm±4123 (mean±SEM) and was used in 
experiments to determine the effect of co-culture with HMCLs on the mitogen-induced 
proliferation of primary T cells form normal, healthy individuals. To calculate the 
percentage inhibition of proliferative responses by the HMCLs, the following formula 
was used: 
o./c,Inhibition = (Mean net cpm with ConAl - (Mean net cpm with ConA and HMCL) xl00(%) 
(Mean net cpm with ConAl 
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Figure 3.6. The proliferation of nonnal PBMNC (n=5) to the mitogen ConA assessed 
3H-Thymidine uptake at the time points indicated. ConA-induced proliferation peaks at 
72 hours with both 2.5 /lg/ml and 5.0 /lg/ml. Key: CM: complete culture medium, 2.5 : 
ConA 2.5 /lg/ml, 5: ConA 5.0 /lg/ml. 
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When PBMNC from nonnal donors (n=6) were activated with Con A for 72 hours, in 
the presence of the HMCL U266, a strong suppression of the proliferative response was 
seen compared to stimulation with Con A alone (p=0.02, Figure 3.7). Co-culture of Con 
A-activated PBMNC with U266 HMCL demonstrated a mean inhibition of 60%±5.9 at 
the highest HMCL concentration and this suppression was demonstrable even at the 
lowest concentrations with a mean inhibition of 32%±12.1 at 1U266:160PBMNC 
(Figure 3.8). When the effect of co-culture of HMCL with Con A-activated PBMNC 
from nonnal donors is examined at day 2, there is little evidence of suppression though 
a wide variation in the effect is seen from inhibiting by 31.2% to augmenting the 
proliferation by 41.6% at a 1 U266:5PBMNC ratio (Figure 3.9). When compared to day 
2 of culture, there is significantly more suppression of ConA-induced proliferation at 
day 3 (p<0.005). While continued evidence of suppression of the mitogen-induced 
proliferation was demonstrable by day 5 this was less marked than that seen on day 3 
(mean 37.7%±14.5, p=0.011). 
To detennine whether the observed suppression of mitogenic responses was an effect of 
this particular cell line, 3 other HMCLs in addition to U266 were co-cultured with 
ConA-stimulated PBMNC from nonnal donors (n=3). All 4 HMCLs (U266, JIM1, 
JJN3, RPMI8226) demonstrated suppression of Con A-induced proliferation of normal 
PBMNC with a mean inhibition of 71.9%±4.6 by U266, 93.3%±3.3 by nM1, 
68.4%±11.8 by JJN3 and 78.2%±19.5 by RPMI8226 at a responder: stimulator ratio of 
5:1 (Figure 3.10). 
The inhibition of mitogen-induced proliferation was seen when HMCLs were co-
cultured with the normal PBMNC. To examine whether the suppression resulted from 
direct cell-cell contact or from the production of a soluble factor or factors, the mitogen-
activation experiments were repeated with the HMCLs being physically separated from 
the PBMNC (n=3) by 0.2J.lffi pore membranes during stimulation. This experiment 
demonstrated that the suppression of proliferation induced by HMCLs is not reversed 
by physical separation (Figure 3.11). The mean percentage inhibition of proliferation 
with contact was 30.0% for U266 and 28.8% for JJN3. When the HMCLs and PBMNC 
were separated by the 0.2J.lffi pore membranes, there was evidence of further inhibition 
of ConA-induced proliferation, as demonstrated by the mean percentage inhibition of 
proliferation of53.8% for U266 and 71.8% for JJN3. This is represented in Figure 3.11 
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Figure 3.7. Inhibition of ConA- induced proliferation of normal donor PBMNC (n=6, 
p=O.059) after 72 hours by co-culturing with the HMCL, U266 at different 
concentrations (5PB:l T, p=O.02). Proliferation was measured by 3H-Thymidine uptake, 
Key: CA- ConA only, 5PB:IT - number ofPBMNC to HMCL (U266). 
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Figure 3.8. Inhibition of ConA induced proliferation in normal PBMNC at 72 hours 
(n=6) by the HMCL U266, expressed as percentage inhibition. (Key as per Figure 3.7 
legend). 
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Figure 3.9. Inhibition of ConA-induced proliferation by U266 HMCL at 48 and 120 
hours (Day 2 vs Day 5 p=O.Oll) stimulation, as measured by 3H-Thymidine uptake. 
Key: 5R: 1 S - number of responder PBMNC to stimulator HMCL (U266). 
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Figure 3.10. Inhibition of ConA-induced proliferation of normal PBMNC from 3 
different donors by 4 HMCLs, U266, JIMl , JJN3 and RPMI8226 (5PBMNC:IHMCL), 
at 72 hours as measured by 3H -Thymidine uptake. 
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Figure 3.11. The suppression of ConA-induced proliferation of PBMNC from normal 
donors (n=3) by HMCLs is not reversed by preventing physical contact. Proliferative 
responses were measured by 3H-Thymidine uptake in the last 18 hours of a 72 hours 
stimulation assay. Key: CA: PBMNC cultured with ConA, CA+U266: PBMNC 
cultured with ConA in the presence of HMCL either with cell-cell contact (Con) or 
separated by a 0.2/J.m pore membrane (N/C). 
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as absolute net counts per minute. This indicates that the inhibition of Con A induced 
proliferation is mediated by soluble factor (s). 
3.3.3 BLASTOGENESIS AND T CELL ACTIVATION 
To investigate the suppression of mitogen-induced proliferation of PBMNC by HMCL, 
it is important to determine the fate of the lymphocytes in this culture system. T cells 
activated by mitogens undergo blast transformation accompanied by cell cycle 
progression and division. PBMNC from normal donors were examined morphologically 
following stimulation with Con A in the presence and absence of HMCL. Cytospins 
stained with Geimsa's cytology stain were examined under high power light 
microscopy. When stimulated by Con A, the PBMNC demonstrate characteristic blast 
morphology with immature nuclei demonstrating fine chromatin pattern and nucleoli, 
basophilic cytoplasm and high nucleus:cytoplasm ratios (Figure 3.l2A and B). When 
stimulated with Con A in the presence of HMCL, the PBL characteristic blasting 
morphology is not seen. Instead, the PBL demonstrate morphological features more 
characteristic of resting PBL including mature nuclei with dense chromatin and lack of 
cytoplasmic basophilia; the HMCL are easily identified by their large diameter, 
immature nuclei, basophilic cytoplasm and prominent Golgi apparatus (Figure 3.13A 
and B). 
PBL were analysed by flow cytometry to detect the physical characteristics of the 
PBMNC stimulated by Con A using FSC versus SCC parameters. Cells were gated at 
acquisition to exclude dead cells and the HMCLs on the basis of physical size and 
cellular granularity/vacuolation. As indicated in the materials and methods (chapter 2) 
10,000 events within the gates were acquired and number of blasting cells within the 
cell population could be quantified and expressed as percentage of the number of gated 
cells. Con A stimulation of PBMNC from normal donors (n=7) resulted in a mean 
number of blasting cells of 56.5%±S.8 after 72 hours of culture (Table 3.2). When 
PBMNC were stimulated with ConA in the presence of the HMCLs, U266 and JJN3 (I 
HMCL:SPBMNC, final concentration), the number of blasting cells were significantly 
reduced to a mean of 28.2%±S.1 % (p<O.OOS, n=7) and 20.4%±2.3% (p<0.002, n=6), 
respectively. A representative example of the suppression of blastogenesis by HMCL, 
as detected by flow cytometry, is illustrated in Figure 3.14 (A and B) with the 
summarised results of all normal donors tested (C). 
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Figure 3.12 Cytospins of PBMNC activated with ConA in the absence of HMCL CA, 
X400; B, XIOOO, Geimsa). Lymphocytes (Lc) are seen with mitogen-activated 
lymphoblast (Lb). Apoptotic cells (arrow) are occasionally seen and mitotic figures 
eMt) are frequent. 
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Figure 3.13 Cytospins of PBMNC activated with ConA in the presence of the HMCL, 
U266 (A, X400; B, XIOOO, Geimsa). Lymphocytes (Lc) are seen with only occasional 
mitogen-activated lymphoblast (Lb) when co-culture with myeloma cell lines (Tc). 
Apoptotic cells (arrows) are occasionally seen when PBL are mitogen-activated in the 
presence of HMCL. Mitotic figures were infrequent. 
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A 
BLASTING (%) CD2S+ (%) CD69-/CD2S+ (%) 
CA CA CA 
DONOR CA CA CA 
+U266 +U266 +U266 
1 86.39 14.8 60 24 43 6 
2 43 25.32 70 49 69 20 
3 67.2 31.22 89 31 53.5 6 
4 71 43 82 53 53 28 
5 43 23 46 25.6 31 24 
6 46 23 53 41.1 30 21 
7 41 37 69 58 40 27 
Mean±SEM 56.5±5.8 28.2±5.1 67±5.8 40.2±5.1 45.9±5.3 18.9±3.5 
p <0.005 <0.005 <0.001 
B 
BLASTING (%) CD2S+ (%) CD69-/CD2S+ (%,) 
CA CA CA 
DONOR CA CA CA 
+JJN3 +JJN3 +JJN3 
1 86.39 31.8 60 6 43 18 
2 43 25 70 20 69 12 
3 67.2 15.74 89 6 53.5 4.5 
4 71 14 82 28 53 8.5 
5 43 16.5 46 24 31 9.7 
6 46 19.3 53 21 30 
-
Mean±SEM 59.4±7.4 20.3±2.3 66.7±6.8 18.9±3.5 46.6±6.1 10.5±2.2 
p <0.002 <0.001 <0.001 
Table 3.2. Physical characteristics and surface expression of activation markers by 
nonnal PBMNC activated by ConA in the presence and absence of the HMCLs, U266 
and JJN3, after 72 of culture. Results represent identified cells expressed as a 
percentage of gated cells (10,000 events). Key: SEM- standard error of the mean, CA-
ConA activated PBMNC. 
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Figure 3.14 Representative dot plots of PBMNC activated by ConA in the absence (A) 
and presence (B) of the HMCL, U266. The results of suppression of ConA-induced 
blastogenesis by HMCL U266 and JJN3 are summarised in (C), where n=7 for U266 
and n=6 for JJN3. Region l(Rl) was set to gate all (both resting and activated) PBL and 
region 2 (R2) was set within Rl to gate on blasting cells, indicated by increase in size 
and granulation/vacuolation. Values indicate the percentage ofR! cells in R2. 
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The activation of PBMNC was examined by flow cytometry. When PBL are activated 
in vitro they rapidly up-regulate surface expression of CD69 (within 24 hours) which is 
closely followed by activation of interleukin-2 receptor a (IL-2Ra./CD25) gene 
transcription and surface expression of the protein. This is followed by rapid 
degradation of the CD69 mRNA and subsequent loss of surface expression of the 
protein. Thus the activation process of T cells, in terms of surface marker expression, by 
stimuli such as mitogens results in cells progressing from a CD69+/CD25- state at 24 
hours to a CD69+/CD25+ double positive state at 48 hours progressing thereafter to a 
CD69-/CD25+ state (Figure 3.15). When PBMNC are activated with Con A in the 
presence of HMCLs, the rapid expression of CD69 and initiation of CD25 was 
unaltered at 24 hours and many cells remained CD69+/CD25+ at 48 hours. However, the 
cells appeared to arrest at this stage of development with <20% of cells reaching the 
CD69"1CD2S+ state at 72 hours (Figure 3.16; Table 3.2). When PBMNC from normal 
donors (n=7) are activated with Con A for 72 hours, 12.4%±2.7 of cells are 
CD69+/CD2S-, 21.1%±5.4 are CD69+/CD25+and 45.9%±5.8 are CD69-/CD25+. In 
contrast, when the same PBMNC from normal donors are activated with ConA in the 
presence of the U266, for 72 hours, 30.0%±5.1 of cells are CD69+/CD25-, 21.4%±5.8 
are CD69+/CD25+and only I8.9%±3.8 are CD69-/CD2S+ (p=0.OI5, p= not significant 
and p<O.OOI, respectively; Figure 3.17). 
It was important to establish the activation pattern of the main T cell subsets, the 
CD3+/CD4+ and CD3+/CD8+ T cells. Initially the activation of CD4+ cells at 24, 48, 72 
and 96 hours was examined by surface expression of CD25, when activated with Con A 
in the presence or absence of HMCL (1 HMCL:5PBMNC, final concentration). At 24 
hours, there was little difference in the CD25 surface expression of CD4+ cells when 
activated in the presence or absence of U266 (43.8% cf 49.4%, respectively) as 
illustrated in Figure 3.18. However at 72 and 96 hours there was a significant difference 
in the CD25 surface expression when the T cells were activated in the presence ofU266 
(72 hours: 33.1% cf69%, 96 hours: 29.6% cf 97%). To determine if this was a specific, 
differential effect on CD4+ T cells, both CD3+/CD4+ and CD3+/CD8+ T cells from 
normal donors (n=3) were examined after 72 hours stimulation with Con A in the 
presence or absence of U266 (I HMCL:5PBMNC, final concentration). As illustrated, 
the CD2S surface expression was significantly suppressed (CD3+/CD4+cells, 
p<O.OOland CD3+/CD8+ cells, p<0.006) when the cells were stimulated with Con A in 
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Figure 3.15. Representative dot-plots of CD69 and CD25 surface expression In 
response to ConA at the time periods. Surface expression of activation markers is 
analysed on cells gated within the Region 1 ,Fig 3.12A. 
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Figure 3.16. Representative dot-plots of CD69 and CD25 surface expression In 
response to ConA at the time periods indicated in the presence of U266 cell line. 
Surface expression of activation markers is analysed on cells gated within the Region 1, 
Fig 3.14A. 
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Figure 3.17. The surface expression of activation markers CD69 and CD25 when 
PBMNC from normal donors (n=7) are activated with ConA in the absence (CA) or 
presence (CA+HMCL) of U266 in 72 hour cultures. The natural progression from 
CD69+/CD25- to CD69-/CD25+ is arrested when PBMNC are co-cultured with HMCL. 
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Figure 3.1S. The activation of CD4+ T cells, as represented by surface expression of 
CD25, following culture with complete medium (CM), ConA (CA) or ConA and the 
HMCL, U266 (CA+HMCL) at 24 hour time intervals. 
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the presence of U266 compared to stimulation with Con A alone (Figure 3.19). 
Representative dot-plots of CD25 surface expression on CD4 and CD8 PBL when 
cultured with medium, Con A and Con A and HMCL are illustrated in Figures 3.20 and 
3.21. 
3.3.4 APOPTOSIS DETECTION 
A recognised standard assay for detecting apoptosis is the visualisation of DNA 
fragmentation on ethidium bromide stained 2% agarose gels and this was used at the 
start of the project. To validate this technique, DNA was prepared, as outlined in 
material and methods, from an IL-2- dependent cell line (lDBL, chapter 2), which were 
cultured in the presence or absence of IL-2 for 24 and 48 hours (Figure 3.22). As 
indicated, apoptosis in cytokine-starved cells could be visualised faintly at 24 hours and 
more clearly at 48 hours. Using this assay, I examined whether increased apoptosis 
could explain the noted HMCL-induced suppression of proliferative response to Con A 
of normal PBMNC. PBMNC from a normal donor were activated with Con A in the 
absence or presence of the U266 and JJN3 (1 HMCL:5PBMNC, final concentration), 
for 72 hours and DNA was prepared and loaded onto a 2% agarose gel. U266 cells were 
also incubated in CM supplemented with Dexamethasone (1 00~g/m1 final 
concentration) to induce apoptosis as a positive control. As illustrated, no increase in 
apoptosis was demonstrated when PBMNC were stimulated ConA in the presence of 
HMCL compared to stimulated with Con A alone (Figure 3.23). 
There are many difficulties with DNA Fragmentation as a detector of apoptosis. Firstly, 
this is a non-quantitative method. Secondly, DNA fragmentation is a relatively late 
phenomenon in the process of apoptosis. Thirdly, this method is laborious, time-
consuming and prone to technical variation. The Annexin V Affinity assay detects one 
of the earlier events in apoptosis- the externalisation of phosphatidylserine residues, 
whilst maintaining cell wall integrity. As described in material and methods, using this 
assay, cells that are undergoing apoptosis can be identified (An+IPf). To validate this 
assay, IL-2- dependent cells (IDBL) were cultured in the presence or absence of IL-2 
for 24 hours and prepared as outlined in material and methods (Figure 3.24 A and B). 
PBMNC from normal donors (n=8) were stimulated with ConA for 72 hours in the 
absence or presence of the HMCLs, U266 and JJN3 (1 HMCL:5PBMNC, final 
concentration). No 
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Figure 3.19. The effect of ConA-induced activation on CD4+ and CDS+ PBL from 
normal donors (n=3) in the absence (CA) or presence of the HMCL, U266 
(CA+HMCL). The surface expression of CD25 was measured by FACS and results are 
expressed as CD25+ cells as a percentage of the gated CD4+ or CDS+ cells. (*-p<O.005). 
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FIGURE 3.20. Expression of CD25 on CD4+ PBL when cultured in medium alone (A), 
cultured with ConA (B) and culture with ConA and the HMCL, U266 (C) for 72 hours, 
as determined by flow cytometry. 
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FIGURE 3.21. Expression of CD25 on CD8+ PBL when cultured in medium alone (A), 
cultured with ConA (B) and culture with ConA and the HMCL, U266 (C) for 72 hours, 
as determined by flow cytometry. 
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Figure 3.22. Apoptosis detected by DNA fragmentation and visualised by ethidium 
bromide staining of nucleic acid gel electrophoresis. Gel demonstrates the apoptosis of 
the IDBL cells when cytokine starved for 24 and 48 hours. Key: Lane 1: IDBL + IL-2 
(24 hours), IDBL + IL-2 (48 hours), Lane 3: IDBL (24 hours), Lane 4: IDBL (48 
hours). 
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Figure 3.23. Apoptosis detected by DNA fragmentation and visualised by ethidium 
bromide staining of nucleic acid gel electrophoresis. The gel demonstrates that no 
obvious increase in apoptosis is seen when PBMNC from normal donors are stimulated 
with ConA in the presence of HMCL (U266) compared with stimulation with ConA 
alone. Dexamethasone-treated U266 included as a positive control. Key: Lane 1: 
PBMNC + CM, Lane 2: PBMNC + ConA, Lane 3: PBMNC + ConA + U266, Lane 4: 
PBMNC + ConA + JJN3 Lane 5: U266 + Dexamethasone. 
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Figure 3.24. Apoptosis as detected by the Annexin V affinity assay, when IDBL cells 
are cultured in presence (A) or absence ofIL-2 (B) for 24 hours. 
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difference in the percentage of PBMNC undergoing apoptosis (An+ cells) was seen 
when cultured with Con A and U266 (21.06%±3.4), with Con A and JJN3 
(20.45%±3.9) or Con A alone (22.4%±4.6), as illustrated by representative examples in 
figure 3.25 and summarised in Figure 3.26. 
3.3.5 CELL CYCLE ANALYSIS 
The data presented thus far indicates that PBMNC from normal donors fail to proliferate 
to appropriate stimuli when co-cultured with HMCLs, which is neither due to failure of 
activation nor increased apoptosis. Therefore. I examined the cell cycle status of the 
heterogeneous population of cells contained in the PBMNC fraction cultured with ConA 
alone or Con A and HMCLs. Cell cycle status was analysed by propidium iodide 
staining of nucleic acid and the DNA content of the cells was measured by flow 
cytometry and analysed using Modfit software. 
When the cell cycle status of PBMNC activated with Con A (n=5) was examined at 72 
hours, a mean of 48%±8.2 cells were determined to be in the Gol Gl phase of cell cycle. 
In contrast, when PBMNC were either stimulated with complete medium only or with 
Con A and U266 (1 HMCL:5PBMNC, final concentration), the greatest proportion of 
cells remain in the Gol Gl phase of cell cycle at 72 hours (mean 82%±7.55 for CM and 
77%±8.2 for ConA and U266). The proportion of cells that remain in Gol G1 phase of 
cell cycle after stimulation with Con A alone is significantly lower than after 
stimulation with CM only (p<O.02) but when stimulated with Con A and U266. the 
proportion of cells that remain in Gol G1 phase of cell cycle are not significantly altered 
when compared to stimulation with CM alone (Table 3.3). Representative DNA 
histograms of PBMNC stimulated with Con A and Con A with U266 are illustrated 
Figure 3.27. 
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Figure 3.25. Representative examples of apoptosis ofPBMNC, as detected by Annexin 
V+ surface staining on gated cells, when stimulated in the absence (A) or presence of 
U266 (B). Figures displayed as dot plots to demonstrate the apoptotic (An+jpr) and 
necrotic (An + /PI) cell populations in each set of culture conditions. 
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Figure 3.26. Apoptosis of PBMNC from normal donors (n=8) when cultured with 
ConA alone or with ConA and the HMCLs, U266 and JJN3. Gates were set to exclude 
the HMCL, based on physical parameters. Results indicate that the apoptosis rate is 
unaltered when co-cultured with HMCLs . 
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Figure 3.27. Representative DNA histograms of PBMNC from normal donors 
stimulated with ConA (A) or ConA and U266 (B), analysed by ModFit software to 
delineate the phases of cell cycle. Histograms were generated from gated cells, 
excluding tumour cells on physical parameters. The cells contained within the Diploid 
peak represent cells in the Go! G, phase (blue arrows) of cell cycle, with cells to the 
right of the diploid peak representing cells that have progressed into the S (green 
arrows) and G2/M phase (red arrows) of cell cycle. 
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CM ConA ConA+U266 
DONOR % Go/G. phase % Go/G. phase % Go/G. phase 
1 74.2 47.6 76.7 
2 85.99 55.88 72.91 
3 80.61 64.07 85.85 
4 94.06 60.72 77.7 
5 88.74 83.93 84.96 
Mean±SEM 82±7.5 48±8.2 77±8.2 
p 
-
<0.02 >0.5 
Table 3.3. Cell cycle distribution of PBMNC (N=5) stimulated with CM, ConA or 
ConA and the HMCL, U266 (1 HMCL:5 PBMNC, final concentration). Results 
represent the percentage of cells calculated to be in the Go/G} phase of cell cycle. 
Statistical analysis was performed using a student t test and p values represent 
comparison with CM alone. 
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3.4 DISCUSSION 
Myeloma tumour cells suppress activating T cells. 
Although there is little doubt that tumour-specific antigens exist for most human 
cancers, it is still unclear why these antigens do not cause rejection in the tumour 
bearing host. A successful immune response against a tumour is dependent on the 
detection of that tumour and the ability of the host immune system to mount an effective 
response. In multiple myeloma many defects in the host immune system have been 
identified including phenotypic and functional changes in T -cells, B-cells, macrophages 
and NKJLAK cells (Lauria et ai, 1984; Massaia et ai, 1988; Mellstedt et aI, 1982; Wen 
et ai, 1990). Several investigators have studied different mechanisms which could 
explain the abnormalities of the peripheral blood immune cells including evasive tactics 
by the tumour cells and apoptosis induction of the immune cells by the tumour (Janson 
et ai, 1991; Massaia et ai, 1995). However, to date, no evidence has been presented to 
demonstrate the exact nature of the effect that myeloma tumour cells have on primary 
immune cells. The data presented in this chapter demonstrates that the myeloma tumour 
cells can directly affect primary immune cells from normal, healthy volunteers resulting 
in reduced responses to alloantigen and mitogen stimulation. 
The HMCLs did not stimulate primary MLR when used in similar concentrations to 
non-transformed allogeneic stimulators (PBMNC), despite the high alloreactive CD8 
precursor frequencies seen in the peripheral blood of normal, healthy individuals (CTLp 
frequencies in the range of 1:544 -1:47619; Wang et ai, 1998). This raises two broad 
issues: firstly, are myeloma tumour cell incapable of presenting antigen to effector T 
cell and secondly, are myeloma cell capable of suppressing the proliferative response to 
appropriate stimulation? As previously indicated, effective T cell activation requires the 
presentation of a suitable antigen with co-stimulation. It has been shown that myeloma 
tumour cells demonstrate suitable levels of HLA class I and n molecules on their 
surface but no expression of the co-stimulatory molecules, CD80 and CD86, could be 
detected either at the protein level by FACS or mRNA level by RT-PCR (Cook & 
Campbell, 1999). However, other investigators have shown that myeloma tumour cells 
can act as antigen presenting cells which suggested that the tumour cells possessed 
competent antigen processing and presentation capabilities, perhaps utilising a 
supplementary co-stimulatory system (Yi et aI, 1997). Therefore, myeloma cells may be 
able to present antigen in a suitable form to activate T cells and, as such, the second 
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issue of active suppression of the T cells becomes a more dominant explanation of the 
experimental data. The suppression of one-way allogeneic MLR by HMCL in a 3rd 
party/bystander manner supports the theory that HMCL can suppress alloreactive T cell 
responses. Once again this phenomenon demonstrates a dose effect with reducing 
concentrations of HMCL being associated with a reduction in the suppression of the 
MLR proliferative responses. 
However, in these experiments, the MLR responses were varied which may reflect the 
degree of HLA-disparity amongst the normal donors used in these studies. As such, to 
gain further understanding of the effect HMCL have on activating T cells, mitogen 
stimulation was used to obtain a more uniform activation of the normal, primary T cells. 
Once again, the HMCL demonstrated a potent suppressive effect on the activation of the 
T cells in response stimulation with mitogen, which also demonstrated a dose-effect. 
This suppressive effect was not a biological anomaly related to this one HMCL, U266 
as similar results were obtained when a total of 4 HMCLs (U266, RPM! 8226, JJN3 & 
JIM1) were co-cultured with 3 different, healthy donors. This suggests that this 
immunosuppressive function may be a characteristic of the B cell malignancy that these 
transformed cell lines represent. 
However, as with all research using in vitro models based on transformed cell lines, the 
behaviour of cell lines may represent either a feature of their in vitro transformation or 
an exaggerated response in comparison to their true malignant counter parts. Myeloma 
cell lines are generated from patients with advanced disease, usually with leukaemic 
phase or body-cavity infiltration such as peritoneal or pleural deposits. The 
extramedullary dissemination of myeloma tumour cells is associated with alterations in 
phenotype and biology compared with malignant plasma cells obtained from the bone 
marrow cavity of patients (San Miguel et al, 1995). For example, the NK cell associated 
surface antigen, CD56 (NCAM) is expressed by malignant plasma cells in up to 67% of 
patients with myeloma but is not detected on normal plasma cells (Harada et aI, 1993). 
This is an adhesion molecule that with other adhesion molecules such as VLA-4 
(CD49d), VLA-5 (CD4ge), CD44 (RCAM) and CD54 (ICAM), may facilitate 
"anchorage" to the bone marrow stroma (San Miguel et aI, 1995; Cook et al, 1997). 
However, extramedullary spread is associated with a dramatic down-regulation of both 
CD56 and VLA-5 (Drewet aI, 1996; Cook et aI, 1997). These VLA-5- plasma cells 
detected in peripheral blood have been shown to have a higher proliferative potential 
and response to exogenous JL-6 than the VLA-5+ plasma cells though the latter group 
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secrete higher amounts of paraprotein (Kawano et al, 1993). The use of transfonned 
cells lines pennit the initiation of experimental investigations to establish theories of 
behaviour and function, aiming to extend these studies to true patho-physiological 
material. These experiments have indicated that myeloma-derived cell lines are capable 
of suppressing activation of T cells from nonnal healthy volunteers. Evidence does exist 
to demonstrate that T cell subsets are disrupted in patients with multiple myeloma, in 
particular a deficit ofCD4+/CD45RA+ cells, and this is more commonly associated with 
advancing disease stage, associated with poor prognostic markers such as a high ~r 
microglobulin and signs of bone marrow failure (San Miguel et al, 1992). This suggests 
a link between advancing disease state, alterations in the host immune system and the in 
vitro behaviour of HMCLs presented in this chapter and implies, though does not prove, 
that the observed effect on the activation of nonnal T cells is in fact related to the in 
vivo tumour cells which the cell lines represent. Clearly, the identification of the 
mediating factor(s) from the HMCLs and its subsequent identification in clinical 
samples fonn patients with multiple myeloma is essential. It would be important to 
demonstrate the effect that serum, both peripheral blood and bone marrow, not only 
contain the putative mediator of immunosuppression but also do in fact prevent 
activation of nonnal T cells, as described here and this is the subject of parallel studies 
to this project. 
The observed suppression of Con A-induced proliferation by HMCLs was maximal at 3 
days, though a suppressive effect could still be detected, to a lesser extent, at day 5. The 
timing of the maximal suppression coincides with the kinetics of Con A induced 
proliferation, which is maximal at day 3 and starting to fade by day 5. This suggests that 
the suppressive effect of HMCLs on the mitogen-induced proliferation of nonnal 
peripheral blood lymphocytes is dependent on the initiating of the activation sequence. 
This is supported by the data presented here and by parallel data which demonstrates 
that, suppression is inversely related to the degree of initiation of the activation process 
(Campbell et aI, unpublished observation). 
Perturbation of the TCRlCD3 complex by antigen or mitogen results in the activation 
of at least two interrelated second messenger systems: a protein tyrosine kinase (PTK) 
pathway and a membrane polyphosphoinositides hydrolysis pathway mediated by 
phospholipase CyL (PL CyL) (Chan et al, 1994). The activation of both these pathways 
and the activation of p21 ras pathway mediate tyrosine phosphorylation of multiple 
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substrates including the IL-2R~ RYe subunits, JAK3/JAKlIp561ck kinases and 
ST AT3/ST AT5 (Kolenko et aI, 1997). These latter events result in up-regulation of 
gene transcription including IL-2Ra, IL-2 and other cytokines. The fact that the degree 
of suppression of T cell responses to mitogen and alloantigen are related to the degree 
of activation implies that this effect is dependent on blocking these mediators of 
lymphocyte activation. There are many known factors, which are capable of suppressing 
T cell activation by blocking different stages of the activation and/or proliferation 
phases of lymphocyte responses. One such example is TGF~ which can inhibit T cell 
proliferation by down-regulating IL-2 mediated-signals mediated through reduced 
tyrosine phosphorylation of proteins of 50- 120 kDa range and inhibition of IL-2 
mediated phosphorylation of the retinoblastoma susceptibility gene product, which is 
pivotal in the progression through the cell cycle (Fontana et al, 1989; Ahuja et al, 1993). 
The experiments using a 0.2J.llll pore membrane demonstrate that physical cell-cell 
contact is not required for the mediation of the immunosuppressive effects. FasL, which 
is a member of the TNFRlNGFR family, can mediate T cell inactivation through 
inducing apoptosis. This can act via direct cell-cell contact of the membrane forms with 
its receptor, Fas on activated T cells (O'Connell et al, 1999). It is worthy of note that a 
soluble form of FasL has been shown to be effective in countering T cell survival 
mediated by apoptosis (Tanaka et al, 1996). However, it does indicate that a soluble 
factor or factors are produced by the HMCL that directly suppress the proliferative 
responses of normal PBL in response to appropriate stimulation. Identification of such 
factor or factors is the subject of further experiments presented in chapter 5. 
Myeloma cells prevent T cell transition from activation to proliferation phases. 
To understand the possible effects that myeloma cells may have on normal T cells when 
appropriately stimulated, it is important to understand that the T cell response to 
antigen/mitogen occurs in two contingent phases comprising distinct molecular events: 
an activation phase and a subsequent proliferation phase (Crabtree, 1989). Important 
activation phase events include the induction of IL-2 genes, its high affinity receptor 
(lL-2Ra.~yc) and CD69 surface expression (Testi et al, 1994). The proliferative phase 
takes place when IL-2 engages its receptor and initiates cell cycle progression - entry 
into the IL-2 autocrine growth pathway. CD69, a 27/33 kDa homodimeric surface 
glycoprotein, is rapidly expressed on the surface of T cells (mRNA detected 30-60 
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minutes after stimulation, surface protein detected 2-3 hours) following appropriate 
stimulation with a variety of agents including anti-CD3ffCR, activators of protein 
kinase C and mitogens (Testi et aI, 1994). Whilst the natural ligand for CD69 is not 
known, cross-linking studies demonstrate a rise in intra-cellular Ca2+, synthesis of 
cytokines and their receptors (IL-2, IFNy, TNFa), the expression of c-myc and c-fos 
proto-oncogene and proliferation (Carmen et aI, 1997). The association of c-fos with c-
jun results in the AP-l complex, which through the co-operation with NF-AT (nuclear 
factor of activated T cells) activates gene transcription of IL-2Ra (Kuo & Leiden, 
1999). This explains in part, at a molecular level, the normal sequence of surface 
expression of activation markers. That is, from a CD69+/CD25- state to CD69+/CD25+ 
upon activation. By 72 hours, however, these cells normally become CD69-/CD25+ after 
72 hours of stimulation owing to the rapid degradation of CD69 mRNA resulting from 
selective destabilisation associated with several AU-rich sequence motifs within the 3'-
untranslated region (Testi et aI, 1994; Santis et aI, 1995; Castellanos et aI, 1997). This 
transition in the surface activation marker composition reflect the entry into the IL-2 
autocrine growth pathway and of cell cycle progression and proliferation. 
When T cells are stimulated with mitogen in the presence of HMCL, entry into the 
activation phase, as represented by up-regulated surface CD69 expression, is seen. 
However, unlike the normal transition of T cells under stimulation, the T cells co-
cultured with HMCL fail to up-regulate IL-2Ra (CD25) and remain, largely, CD69+ 
after 72 hours of stimulation. This coupled with the data demonstrating poor 3[H]dThd 
uptake indicating poor S phase entry, strongly suggests that the cells initiate their 
response pathways, enter the activation phase but fail to progress to the proliferation 
phase because of failure to enter the autocrine IL-2 growth pathway. The disruption of 
the IL-2 autocrine pathway is fundamental to the regulation of clonal expansion in 
response to suitable stimuli, both proliferation and apoptosis associated with activation 
(both passive "lymphokine-withdrawl" and active "antigen-induced" forms) which aim 
to co-ordinate the immune response to achieve the most effective clonal expansion 
(reviewed by Lenardo et al, 1999). 
Myeloma cell-derived/actors induce cell cycle arrest rather apoptosis. 
The data presented here demonstrate that normal primary T cells fail to proliferate in 
response to allogeneic and mitogenic stimuli as a result of arrest in the GdGo phase of 
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cell cycle rather than activation-associated apoptosis. As indicated above, activation-
associated apoptosis of T lymphocytes, both active and passive fonns, is more 
pronounced in the proliferation phase when a balance between antigen and cytokine are 
important in regulating the immune response (Boehme et al, 1993). T cells are sensitive 
to activation-associated apoptosis when they have at least traversed the cell cycle 
several times, particular when in the S phase. The T cells in these experiments 
demonstrate poor 3[H] dThd uptake indicating failure to enter S phase of the cell cycle 
which is corroborated by the reduced DNA synthesis indicated on the DNA cytometry 
analysis. The finding that T cells undergo cell cycle arrest rather than apoptosis when 
stimulated in the presence of HMCL is in contradiction to the published data which 
suggests that HMCL induce T cell apoptosis mediated by the FasIFasL system (Massaia 
et aI, 1995). 
Myeloma cells have been shown to express FasL on their surface, as detected by flow 
cytometry. However, as myeloma cells also express Fas, then why do the tumour cells 
that are Fas+lFasL+ not commit autocrine "suicide" or juxtacrine "fractrlcide"? Many 
theories have been suggested to account for this including expression of antagonistic 
soluble Fas, failure to establish death-inducing signalling complexes (DISCs) and 
altered regulation and function of the caspases (Nagata, 1996; Villunger et al, 1997; 
Debarats et al, 1998). One possibility is that the FasL on the surface of myeloma cells 
may have reduced functional capability. Experiments to date to determine the 
functionality of myeloma-expressed FasL have relied on cytotoxicity assays using a T 
cell lymphoma-derived cell line that is exquisitely sensitive to FasL-mediated apoptosis. 
It is important to note that T cells which are activating, whilst expressing Fas on their 
surface are not susceptible to Fas-induced apoptosis in these initiation phases however 
when stimulated repeatedly with antigen and IL-2, the then become susceptible to 
activation induced cell death (Chappell et aI, 1999; Leonardo et al, 1999). In the in vitro 
assays described here, the T cells from nonnal healthy volunteers are not being exposed 
to chronic antigenic stimulation in the presence of IL-2 and as such, it is not surprising 
that FaslFasL-mediated apoptosis does not appear to playa significant role in mediating 
the tumour-induced immunosuppression. 
Furthennore it has been shown in a melanoma model that it is FasL expressed on the 
surface of activated CTLs that induce FaslFasL-mediated apoptosis in T cells rather 
than tumour derived FasL (Zaks et al, 1999). If the apoptosis-induction in tumour-
reactive T cells arises from activated T cells, then interaction between tumour cells and 
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T cells would induce apoptosis owing to T cell activation as an initial step. The data 
presented here strongly suggests that T cells are prevented from becoming activated as a 
primary event when co-cultured in the presence of HMCL, thus negating the T cell-T 
cell FaslFasL induced apoptosis. This is supported by the absence of increased 
apoptosis of T cells in the culture system when HMCL are added. However, in vivo the 
role of the FasIFasL system remains to be clarified. The T cells in this situation are 
exposed to chronic antigen stimulation, in the form of the tumour-related idiotype, 
which may render the T cells from patients more susceptible to Fas mediated apoptosis 
(Massaia et aI, 1995). However, it is likely that the weakened T cell response seen in 
patients with myeloma represents an orchestration of immunosuppressive strategies 
employed by the malignant clone. 
Therefore, from this data it can be concluded that the T cells under go cell cycle arrest 
when stimulated in the presence of the HMCLs owing to a soluble factor (s). These 
observations may be the effect of a single cytokine such as transforming growth factor ~ 
(TGF~) which has been described as promoting T cell survival by inducing a resting 
state and even synergising with IL-2 to prevent apoptosis, particularly of Th2 cells 
(Zhang et al, 1995). It is also possible that the observed effect may be the result of an 
orchestration of cytokines and antigen such as quiescence-inducing and apoptosis 
protecting abilities of IL-15 in antigen-experienced T cells without cell cycle 
progression and proliferation (Dooms et al, 1998). The role of muc-l in inducing 
apoptosis in T cells has been shown in an in vitro breast cancer model, however it may 
also cause T cell anergy and quiescence (Agrawal et al, 1998). The role of other 
cytokines such as IL-I0 acting alone or in synergy with other molecules and cytokines 
needs further attention. 
The data presented here indicating the effect that myeloma cells have on the activation 
process of T cells are novel. Defects in T cells from patients with other malignancies 
have been described. For example, T cells from patients with intracranial glioblastoma 
have been shown to have defective TCR -mediated signalling and renal carcinoma cell 
supemates are capable of suppressing the mitogen-induced activation of T cells from 
normal volunteers (Kolenko et al, 1997; Morford et al, 1997). If the tumour cells of 
myeloma are capable of an array of defence mechanisms which can prevent the 
generation of an immune response or switch off an established response, then this is 
important for physicians and scientists who are devising immunotherapy strategies. The 
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design of immunotherapy regimes will need to overcome the effects of a hostile 
microenvironment in terms of developing immune responses and this may require a re-
evaluation of the vaccination strategy dogma which has been learned from 
microbiological vaccination protocols and which have been adopted in cancer trials in 
favour of new approaches which aim to circumvent the tumour-associated hostility 
towards the hosts immune system if the true potential of immunotherapy is to be 
maximised. 
The data presented in this chapter clearly demonstrate that HMCL, an in vitro model of 
multiple myeloma, prevent T lymphocytes from normal, healthy donors from activating 
when stimulated with alloantigen and mitogen. This effect results from cell cycle arrest 
and failure to progress to the proliferation stage of activation, mediated by soluble factor 
or factors, as yet to be determined. Before investigating the potential factors which 
could explain the observations, it is necessary to develop an in vitro model to mimic the 
two contingent phases of T cell responses to stimulation, activation and proliferation. 
The establishment and validation of such a model is the subject of the chapter 4. 
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CHAPTER 4 
An in vitro model of T lymphocyte activation for investigating the 
immunosuppressive effects of myeloma cell lines. 
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4.1 INTRODUCTION 
The data presented in chapter 3 demonstrate that myeloma tumour cells, at least 
HMCLs, can interrupt the activation process of T cells from healthy donors in response 
to alloantigen and mitogen. This effect is mediated by a soluble factor(s) and in order to 
investigate this effect, an in vitro model system based on the activation process of 
peripheral T cells is necessary. To establish such a model system to mimic the 
activation process of T cells, an understanding of the homeostasis of T cells in terms of 
regulating activation and apoptosis is required. 
The immune response involves an impressive expansion of specific T cell clones with 
potent effector functions (pantaleo et aI, 1994). The doubling time of mature T cells in 
response to antigen has been shown to be as little as 4.5 hours with the estimation that 
after 7 days, one T cell could produce up to 1012 progeny though with a single protein 
having up to 10 different epitopes, as many as 10-100 naive T cells could be activated in 
anyone immune response (Kurts et aI, 1997; Murali-Krishna et aI, 1998). A balance of 
cell production and destruction is needed to ensure that the T cell compartment is 
maintained and can respond to appropriate stimuli and that such a response is not 
excessive. It is not known whether like other formed elements of blood, T cells have a 
predetermined life-span. However, under specific conditions, the T cell growth factor 
IL-2 and antigen can induce apoptosis and to understand this relationship, it is important 
to recognise that T cell response to antigen occurs in two contingent phases 
characterised by distinct molecular events: an activation phase and a subsequent 
proliferation phase, schematically represented in Figure 4.1 (Crabtree, 1989). Contrary 
to popular moniker, "activation-induce cell death", there is little or no apoptosis in this 
phase of stimulating resting T cells, which aims to allow a protective immune response 
to develop (Radvanyi et al' 1996). The proliferative phase takes place when IL-2 
engages its receptor and initiates cell cycle progression - entry into the IL-2 autocrine 
growth pathway. Once cells have progressed through the cell cycle, perhaps more than 
once and have entered late G I or S phase, they become exquisitely sensitive to apoptosis 
(Boehme et aI, 1993). This cell cycle progression and susceptibility to apoptosis both 
involve the proto-oncogene c-myc (Boehme et al, 1996). 
This propriocidal or "feed-back response" regulation of T cells determines the fate of 
cycling T cells in the prevailing conditions of the immune response. In particular, when 
there is no further antigen the expression of IL-2 and its receptor are down-regulated 
resulting in "passive" or cytokine-withdrawal apoptosis. In contrast, if cycling cells are 
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FIGURE 4.1. chematic repre entation of the propriocidal paradigm of T lymphocytes. 
T cell activati n urs in 2 phase : activation leading to entry into the IL-2 autocrine 
pathway and pr liferati n re ultin fr m cell cycle progression. 
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re-exposed to antigen, "active" or antigen-induced apoptosis can occur mediated by 
FaslFasL system and TNFa (Alexander-Miller et ai, 1996; Zheng et ai, 1998). 
Primary peripheral blood T cells (PTC) which are rendered IL-2 responsive could be 
used in vitro to model this process. As indicated, IL-2 acts to drive clonal expansion 
after the initiation of activation by TCR-Ag engagement (Haynes et al, 1999). 
Therefore, to use IL-2-responsive PTC to mimic the activation stage of the propriocidal 
model requires a sequence of activation, resting then re-stimulation with IL-2. The use 
of mitogens to activate resting PTC in this setting prior to IL-2 re-stimulation has been 
described, though not well characterised (Bright et ai, 1997). For this purpose, in the in 
vitro model system described in this chapter, I have used Con A. The purpose of 
"resting" these mitogen-activated cells is to synchronise the cell cycle of PTC prior to 
re-stimulation with IL-2. 
The use of these mitogen-activated, IL-2 re-stimulated PTC as a model of T cell 
activation/proliferation is limited if the immunosuppressive factor(s) from HMCLs can 
act at several points in this activation/proliferation process and therefore, may mask 
other potential sites of disruption to the T cell homeostatic pathways. As such, the use 
of human transformed T cell lines which represent arrested development at specific sites 
in this activation/proliferation pathway would be useful. lurkat E6.1 is an IL-2-
producing cell line derived from a patient with T lymphoblastic leukaemia (Sladowski 
et ai, 1993). This cell line could be used to simulate cells in the autocrine IL-2 phase of 
activation. IDBL is a human T lymphoblast cell line generated using repeated mitogenic 
stimulation, as described in chapter 2, which is IL-2 dependent. This cell line could be 
used to simulate cells which have progressed through this activation process and which 
are susceptible to "passive" cytokine withdrawal apoptosis. Thus the use of this three 
cell model could be used to examine the exact effect that HMCLs have on the 
activation/proliferation and maintenance of human T cells in relation to IL-2. 
Experimental Design 
The aim of the work presented in this chapter was to establish an in vitro model of T 
cell activation, which will permit detailed investigation of myeloma-derived mediators 
of immuno-suppression. The development of such a model will enable the delineation 
of the precise point in the activation process where such mediators act and provide a 
model to examine the molecular events that are disrupted. 
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4.2 MATERIALS AND METHODS 
4.2.1 GENERATION OF IL-2 RESPONSIVE T CELLS. 
PDMNC were prepared from peripheral blood of normal healthy volunteers as described 
in chapter 2. PBMNC were re-suspended at a concentration of 4x106/ml and stimulated 
with 5Jlglml of Con A for 5 days in CM. Following this culture period, the cells were 
washed three times in cold PBS. The cells were then re-suspended in one of the 
following culture media: CM, RPM! supplemented with 0.5% FCS or X-Vivo 1 5 culture 
medium (BioWhitaker, UK). The effect that these media had on resting proliferation 
rates, as determined by eH]-dThd uptake, and ability to support re-stimulation was 
tested, as described in the results section. This culture period without stimulation was 
intended to synchronise the cell cycle staging of the activated PDL. The optimal 
duration of this cell cycle synchronisation phase was assessed by eH]-dThd uptake as 
an indicator of S phase entry and proliferation. Cell cycle analysis was performed by 
flow cytometry analysis of PI DNA staining, as described in chapter 3. 
Following the cell cycle synchronisation period, the viable cells were purified by 
density-gradient centrifugation using Ficoll-Hypaque (Sigma, UK). Recovered cells 
were washed twice in PBS before being re-stimulated in CM supplemented by rhIL-2 
(Sigma, UK) at the dose and for the duration described in the results section. 
Proliferation was determined by 3[H] thymidine uptake. 
The phenotypic characteristics of the IL-2-responsive primary T cells were analysed by 
flow cytometry. Cells (5xlOs/sample) were stained by direct immunofluoresence for 
two-colour flow cytometry using isotype-matched controls, as described in chapter 2. 
Monoclonal antibodies used are listed in chapter 3 and data was analysed using Cell 
Quest software (Becton Dickinson). 
4.2.2 GENERATION AND MAINTENANCE OF HUMAN TRANSFORMED 
CELL LINES. 
The IDBL cell line was generated as described in chapter 2. The cell viability and 
proliferation were maintained in CM supplemented with hrIL-2 20U/ml. Cells were 
maintained at a concentration of 104-lOslml and were sub-cultured twice per week when 
fresh eM supplemented with rhIL-2 20 Vlml was added. Once a week, dead cells and 
debris were removed by density-gradient centrifugation using Ficoll-Hypaque. On 
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recovering the viable cells from the Ficoll-Hypaque, cells were washed three times in 
PBS before being re-suspended in CM supplemented with IL-2 20U/ml. IDBL cells 
were used at low passage numbers, i.e. 2-30, and prior to use in the experiments, cells 
were washed three times in PBS before being re-suspended at the cell concentrations 
indicated in the result section in CM supplemented with IL-2. Experiments to establish 
the cell division kinetics were conducted with varying doses and exposure of IL-2, with 
the proliferative responses assessed by eH]-dThd uptake and cell cycle analysis 
performed by flow cytometry analysis of PI DNA staining, as described in chapter 3. 
The effect of cytokine starvation on the apoptosis of IDBL cells was assessed by the 
Annexin V affinity assay. 
Jurkat cells are cytokine-independent cells, which produce IL-2 and interferon-a.. Cells 
were maintained at a concentration of 104_10slml and were sub-cultured twice per week 
when fresh CM was added. Once a week, dead cells and debris were removed by 
density-gradient centrifugation using Ficoll-Hypaque. On recovering the viable cells 
from the Ficoll-llypaque, cells were washed three times in PBS before being re-
suspended in CM. Prior to use in experiments, cells were washed three times in PBS 
and re-suspended in CM at the cell concentrations indicated in the results section. Cell 
division kinetics was examined in proliferation experiments where proliferation was 
assessed by eH]-dThd uptake. Cell cycle analysis was analysed by PI DNA staining. 
The phenotypic characteristics of the transformed human T cell lines were analysed by 
flow cytometry. Cells (5xlOslsample) were stained by direct immunofluoresence for 
two-colour flow cytometry using isotype-matched controls, as described in chapter 2. 
Monoclonal antibodies used are listed in chapter 3 and data was analysed using Cell 
Quest software (Becton Dickinson). 
4.2.3 INTRACELLULAR CYTOKINE STAINING. 
Intracellular cytokine staining is a method that allows a snapshot in time of the protein 
content of a single cell. The aim is to make use of the rapid flow cytometric analysis of 
cells to provide both surface phenotype and intracellular cytokine content of single cells 
within a population of cells responding to antigenic or mitogenic stimulation. The 
technique initially requires fixation of cells in paraformaldehyde, which cross-links 
proteins and prevents their loss through leakage. Secondly, permeabilization of cellular 
membranes with a detergent generates pores in the membrane, allowing specific 
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cytokine antibodies access to the cells' interior. The cytokine specific antibodies are 
fluorochrome-conjugated thus fluorescent labelled cells are indicative of cytokine 
production with the intensity of staining being proportional to the amount of cellular 
protein present. This technique ultimately allows for the investigation of the cytokine 
secretory pattern of individual cells along with their surface phenotype features. 
Northern blotting, in situ hybridization, RT-PCR, cellular bioassays and sandwich 
ELISAs, which have been recognised as suitable assays for studying the cytokine 
profile of activated cells, are time consuming, labour intensive and in some cases only 
give information that reflects the properties of the entire population of cells being 
analysed. In contrast, intracellular cytokine staining of cells and subsequent flow 
cytometric analysis can yield rapid and specific information on the cytokine production 
properties of individual cells within a mixed population of cells. 
Cells to be analysed by intracellular cytokine staining were first washed three times in 
cold PBS and re-suspended at a concentration of lxl06/ml in Fix and Perm solution 
(Beckton Dickinson, USA). If cells were to be surface stained, then this antibody was 
added and the cells washed before re-suspending in Fix and Perm solution. Cells were 
incubated in this solution for 10 minutes at room temperature. The cells were then 
washed three times in PBS. 2.5 J,ll of the anti-cytokine antibody conjugated to a 
fluorochrome (Anti-IL-2 conjugated with FITC) was added to the cells and incubated 
for 20 minutes at room temperature in the dark. Appropriate isotype control antibodies 
were used to determine auto-fluorescence. Cells were then acquired using a FACScan 
(Beckton Dickinson) and analysed using Cellquest software. 
4.2.4 MAGNETIC CELL SORTING OF CELL POPULATIONS. 
After 5 days of in vitro stimulation with Con A, subsets of PBL were separated on the 
basis of surface expression of IL-2Ra (CD25) using the MACS magnetic cell sorting 
system by Miltcnyi et al, (1990). This system differs from other magnetic separation 
techniques in that the magnetic beads conjugated to the secondary antibody are 
extremely small which allows cells to analysed by flow cytometry immediately post 
separation as the beads do not have to become detached from the cells and membrane 
perturbation is kept to a minimum. In brief, the basic principle of MACS cell separation 
results from cells being labelled with a specific primary monoclonal antibody - in this 
instance anti-human CD25 - which is PE-conjugated. A secondary antibody directed 
against PE and conjugated to metal beads is added and the cell suspension is passed 
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through a column containing plastic coated steel wool in the presence of a powerful 
magnet. This results in positively labelled cells being retained within the column with 
non-magnetic cells being flushed out. The magnetic-labelled cells are then recovered by 
removing the magnetic source and flushing the cells out, as summarised in Figure 4.2 
(A-K). 
The autoclaved column was assembled with a sterile 3-way-stopcock. A leur-lock 
syringe filled with ice-cold PBS/} %BSA was attached to the side port and the 
assembled column was placed into the MACS magnetic separator and filled with the 
PBS/l %BSA solution from the syringe (Figure 4.2 A & B). The column was allowed to 
soak in PBS/l %BSA until use allowing protein to coat the column and minimise 
cellular damage. Immediately prior to use, the syringe was then refilled with ice-cold 
PBS/l %BSAand several volumes were passed through the column (Figure 4.2 C). To 
restrict the flow maximising the positive selection of magnetic bead-labelled cells, a 
hypodermic needle (retained within its sheath) was attached to the down port of the 3-
way-stopcock, with the flow indicator in the ''no flow" position and the tip of the plastic 
needle sheath was cut using pliers (Figure 4.2 D). The column was then ready to receive 
appropriately labelled cell suspensions. 
Labelling of PBL was performed using cells that had been washed in PBS/} %BSA three 
times and kept on ice until required. The cells were counted and the cell suspension was 
centrifuged at I,SOOG for S minutes. The supernatant was decanted and 1 0JlVI 07cells of 
mouse-anti-human CD25 monoclonal antibody conjugated to PE (pharMingen, Europe) 
was added. After 30 minutes incubation on ice the cells were washed twice with 
PBS/l %BSA and re-suspended with anti-PE monoclonal antibody conjugated metal 
beads (10 I,d per 107 cells), which was free of sodium azide (removed as per 
manufacturers instructions). The cells were incubated in the dark at 4°C (in a 
refrigerator) for } 5 minutes. The cells were then washed in PBS/l %BSA and re-
suspended at 107/ml and added to the prepared column (Figure 4.2 E). 
Once the labelled cells were added to the column, S volumes of ice-cold PBS/l %BSA 
were added from the top of the column allowing the cell suspension to drip through the 
column and the non-magnetic population (negative fraction: CD2SDim) were collected 
via the down-port (Figure 4.2 F). The column was then removed from the 
lOS 
A. Assemble 
E. Apply caDs 
F. Add buffer G. Back.ftush 
I. Back-flush K. EIute 
FIGURE 4.2. Diagram summarising the procedure for sorting cells using magnetic 
beads coated with MoAb directed against FITC or PE conjugated primary MoAB). 
106 
magnetic source, the cells flushed back using the side port mounted syringe and the 
column was replaced in the magnetic source with a new, faster flow-resistor (Figure 4.2 
G & II). The negative fraction was collected once more. The column was then removed 
from the magnetic source and the cells were flushed back using the side-port mounted 
syringe and the positive cell fraction (CD2SBright) was then allowed to flow freely 
(without a flow-resistor) into to separate collection tube. This was repeated with 2 
column volumes of PBSII %BSA (Figure 4.2 I & K). Cells were counted and 
representative samples of pre-sort, post-sort positive fraction (CD2SBright) and post-sort 
negative fraction (CD2SBrigh,) were analysed on the F ACScan for recovery and purity, 
respectively. The remainder of cells were re-suspended in CM at a concentration of 
4x106/ml. 
4.2.5 RT-PCR ANALYSIS OF CYTOKINE AND CYTOKINE RECEPTOR 
PRODCUTION. 
The expression of cytokine and cytokine receptor mRNA was detected by reverse 
transcription-polymerase chain reaction (RT-PCR) as described in chapter 2. All 
glassware, tubes and aqueous solutions were autoclaved prior to use in RNA isolation 
and cDNA synthesis. Cells were washed twice in ice cold PBS and adjusted to 107/ml. 
Cell suspensions were transferred to 1.5ml autoclaved Eppendroftubes. Total RNA was 
extracted from a minimum of 5xl06 cells using Trizol (Gibco, UK) and eDNA was 
synthesized from 3-5J.lg of mRNA using the "Superscript" system (Life Technologies). 
Primers specific for human cytokine and cytokine receptor sequences were used in the 
PCR reactions and the sequences, predicted fragment sizes and melting temperatures 
(Tm) are listed in Table 4.1. The primer pairs (sense and antisense primers) which 
identify P-Actin, a constitutive element of the cell cytoskeleton, were used as a positive 
control for amplification and loading in all PCR reactions. 
PCR amplification was performed using 2J.lI of cDNA solution. The PCR reaction was 
carried out in SOJ.l1 volumes as described in chapter 2 and control samples, which 
contained all reaction constituents except cDNA, were used to exclude environmental 
contamination. The PCR primers were in-house sequences with known optimal reaction 
conditions except the sense and anti-sense primer pairs to amplify IL-2RP and 'Yc chains 
that have previously been described by Steinberger et al (1997). The samples were 
heated to 9SoC for 5 minutes to ensure that all the RNAIDNA complexes were 
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AT Size 
Strand C-C) (bp) 5' -Seqnuence-3' 
I3-Actin Sense 60 548 GTGGGGCGCCCCAGGCACCA 
Anti-sense CTCCTTAATGTCACGCACGATTTC 
IL-2 Sense 55 266 ACTCACCAGGATGCTCACAT 
Anti-sense AGATAATCCATCTGTTCAGA 
IL-2Ra Sense 60 781 CCTGCTGATGTGGGGACTG 
Anti-sense GTCTCCGCTGCCAGGTGA 
IL-2RYe Sense 60 420 CCAGAAGTGCAGCCACTATC 
Anti-sense TCACTCCAATGCTGAGCACT 
IL-2RI3 Sense 60 531 ACCTCTTGGGCATCTGCACC 
Anti-sense CGTCTCCAGGCAGATCCATT 
IL-4 Sense 60 456 ATGGGTCTCACCTCCCAACTGCT 
Anti-sense CGAACACTTTGAATATTTCTCTCTCAT 
Interferon-y Sense 60 494 ATGAAATATACAAGTTATATCT1GGCTTT 
Anti-sense GATGCTCTTCGACCTCGAAACAGCAT 
> 
""If'\'I' 
TABLE 4.1 Oligonucleotide primers used for RT-PCR. Key: AT- annealing 
temperature. 
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completely denatured and amplification consisted of 30 cycles as follows: 9Soe for 1 
minute (denaturation), 600e for 1 minute (primer annealing) and 720e for 1 minute 
(primer extension). A final step at 720e for S minutes was carried out to ensure 
complete extension of products. Following amplification, samples were visualised by 
2% agarose gel electrophoresed. peR amplification for IL-2R subunits were conducted 
using the above cycle conditions but 35 cycles were performed. peR products were 
visualised by 2% agarose gel electrophoresis at 100V and the image captured using 
UViphoto software. 
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4.3 RESULTS 
4.3.1 SUPPRESSION OF T CELL ACHV ATION BY HMCL IS NOT RESCUED 
BY INTERLUEKIN-l 
As discussed in chapter 3, PB T cells activated by mitogen in the presence of HMCLs 
fail to proliferate which is associated with a lack of entry into the IL-2 autocrine 
pathway. This posed the question whether these cells could be rescued by exogenous 
IL-2, allowing entry into the IL-2 autocrine pathway, cell cycle progression and 
proliferation. Therefore, the mitogen-activation of PBMNC from normal healthy 
donors in the presence and absence of HMCLs, as described in chapter 3, was repeated 
with the addition of human recombinant IL-2 20 Vlml (rIL-2, Sigma, UK). Proliferation 
was measured by 3[11] thymidine uptake in a 3 day assay. The suppression of 
proliferation of normal PBL in response to mitogen induced by the HMCLs, V266 and 
JJN3 was not reversed by the addition of rIL-2 (Figure 4.3). This demonstrates that 
HMCLs produce a suppressive factor(s), which controls the T cell activation process 
including cell cycle progression and proliferation. In order to investigate the 
mechanisms involved and to identify, in functional assays potential mediators of this 
immunosuppression, an in vitro model of T cell activation/proliferation needed to be 
established as stated. 
4.3.2 GENERATION OF IL-l RESPONSIVE PRIMARY T CELLS. 
Culturing PBMNC with Con A for 5 days as described in the material and methods of 
this chapter, results in a purified population of activated primary T lymphocytes. At the 
end of the S-day stimulation period, the surface phenotype of the viable cells was 
examined using the MoAb described in Table 3.1 using flow cytometry. This population 
of cells represented an enrichment of CD3+ T cells (89.7%±4.l, n=4) with a mean 
SO.S%±6.1 CD3+/CD4+ cells and a mean 33.2%±3.6 CD3+/CD8+ cells. The CD3- cells 
were identified as NK cells by their surface expression of CD2 and CD56 with a lack of 
expression of TCRa~. Most cells (72.6%±12.4) demonstrated CD45RO surface 
expression and 63.9%,±2.3 CD3+ cells demonstrated surface expression of the a subunit 
of the IL-2R. These results are summarised in Table 4.2 and representative dotplots are 
shown in Figure 4.4. 
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FIGURE 4.3. Inhibition of ConA-induced proliferation of PBMNC by HMCLs, U266 
and JJN3, is not reversed by exogenous rhIL-2 in a 72 hour stimulation assay. Key: 
IM:5P - indicates the timulator:responder ratio, filled diamond - JJN3, filled square-
JJN3+rhIL-2 filled circle - U266, filled triangle - U266+rhIL-2. 
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FIGURE 4.4. Representative dotplots of surface phenotype of PBL stimulated with 
ConA for S days. Immuno-fluorescent surface staining analysed by flow cytometry 
(F ACScan, Becton Dickinson). 
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(0/0) 01 02 D3 D4 MEAN±SEl\1 
COJ+ Cells 98.1 81.3 82.17 97.3 89.7±4.1 
CD3+ IC04+ Cells 30.01 53.6 56.99 61.4 50.5±6.1 
CD3+ IC08+ Cells 42.1 28.8 26.18 35.7 33.2±3.6 
CD3+ ICD2S+ Cells 63.83 57.44 67.08 67.13 63.9±2.3 
CD3+/CDI21+ Cells 46.2 12.6 54.3 37.8 37.7±9.1 
CD3+/CD4SRO+ Cells 76.6 94.8 37.4 81.5 72.6±12.4 
TABLE 4.2 Surface phenotype of viable cells following 5 day culture of PBMNC from 
healthy donors (n=4) with ConA. Results are expressed as percentage of total cells 
expressing the indicated surface antigens as determined by isotype control MoAb, using 
flow cytometry. 
DI D2 03 MEAN±SEM 
CD2SunKbi 
C02S+ 89.6% 90.6% 87.9% 89.4%±O.8 
C04+ 92.2% 88.8% 86.5% 89.4%±1.9 
CD45RA+ 35.1% 42.2% 39.7% 39.0%±2.1 
CD69+ IC02S- 21.1% 18.73% 19.6% 19.81%±0.7 
CD69+ IC02S+ 53.26% 62.47% 64.8% 60.84%±2.9 
CD2S lJim 
CD2S+ 33.3% 26.6% 23.3% 27.7%±3.0 
CD4+ 55.78% 62.1% 57.1% 58.94%±2.6 
CD45RA+ 64.2% 55.8% 61.3% 60.4%±2.5 
C()69+ ICIl2S- 3.1% 2.53% 4.6% 3.41%±O.6 
CD69+ ICIl2S+ 7.53% 8.69% 9.1% 8.44%±O.5 
TABLE 4.3. Phenotypic analysis of T cells sorted on surface expression of IL-2Ra 
(CD25) after culture in 0.5%FCSIRPMII640. Results are expressed, as the percentage 
of cells deemed positive for the surface expression of the antigen indicated based on 
comparison to the isotype control. 
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Mitogenic stimulation of PBMNC results in polyclonal proliferation of lymphocytes 
which will have widely differing proliferation and cell cycle kinetics, owing to many 
factors including whether they have prior exposure to specific antigen (i.e. memory 
cells). As a result, at the end of a 5-day stimulation culture using Con A, the cells will 
be at various stages of activation and cell cycle. In order to synchronize these cells in 
terms of cell cycle distribution, a "rest period" was employed to allow maximisation of 
the cells to the GoIGlstage of the cell cycle. However, the optimal medium to allow 
synchronization of cycling cells whilst maintaining viability had to be discerned. Using 
PBMNC from healthy donors (n=4), after a 5 day stimulation with Con A, as described 
above, cells were washed x3 with cold, sterile PBS. The cells were re-suspended at a 
concentration of Ix106/ml and split into to three samples with each sample being 
incubated with one of three test media: CM, RPMIl640+0.5%FCS (with 2mM L-
glutamine, 100 ulml penicillin, 100J-lg/ml streptomycin) and X-Vivo. The basal 
proliferation was determined by 3[H]tThd up-take in the last 6 hours of the ""rest 
period". 0.5%FCS-supplemented RPMIl640 resulted in lower mean basal proliferation 
(691±287 cpm) than CM (2922±1553 cpm, p=0.137) and X-Vivo15 (2488±592 cpm, 
p=O.072), as illustrated in Figure 4.5. 
The effect that resting in 0.5%FCSIRPMII640 had on cell cycle distribution was 
examined using PI DNA-staining analysed by flow cytometry before and after the 24 
hour resting incubation. The mean number of cells in GoIGlstage post Con A-
stimulation was 65.49%±13.6, which rose to 85.4%±8.8 following resting in 
0.5%FCSIRPMII640 (Figure 4.6). Representative DNA histograms are illustrated in 
Figure 4.7. 
It was important to determine the appropriate rhIL-2 dose and duration of exposure for 
the re-stimulation phase. When PBL from normal healthy donors (n=3) were rested in 
0.5%FCSIRPMII640 24 hours and the dead cells and debris were removed by density 
gradient separation, the PBL were re-stimulated with incremental doses of recombinant 
human rhIL-2 for 24, 36 and 48 hours with proliferative responses being measured by 
3[H] thymidine up-take. No significant difference in proliferative responses were noted 
between 20 Ulml and 100 U/ml at 24 or 48 hours ( p=0.197 and p=0.338, respectively). 
When the proliferative response to 20U/ml of rhIL-2 was compared at 24, 36 and 48 
hours, it was demonstrated that this was significantly higher at 36 hours compared to 24 
hours (p=0.014) though no significant difference in proliferative responses were noted 
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FIGURE 4.5. The effect of three "resting" media on the basal proliferation of mitogen 
activated PBMNC from nonnal donors (n=4). O.5%FCS-supplemented RPMI1640 
resulted in a lower mean basal proliferation than 10%FCS-supplemented RPMI1640 
(p=O.l37) and X-Vivo. 
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FIGURE 4.6. The effect on cell cycle synchronisation of ConA-activated T cells from 
nonnal donors (n=4) by culturing in 0.5% FCS-supplemented RPMI1640. Cells 
accumulate in GoG, phase of cell cycle following culture for 24 hours (p=0.147). 
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FIGURE 4.7. Repre entative DNA histograms of cell cycle analysis of primary T cells 
post-stimulation (A) and post-resting in O.5%FCSIRPMI1640 (B). Marker Ml 
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FIGURE 4.8. PBL from normal donors (n=3) re-stimulated with incremental doses of 
human recombinant IL-2 for 24, 36 and 48 hours duration. No statistical difference in 
proliferative responses was observed between 20 and 100 Dlml at each time point, as 
determined by 3[H] thymidine uptake. 
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between 36 and 48 hours stimulation (p=0.157), as illustrated in Figure 4.8. Therefore, 
0.5%FCS-supplemented RPMII640 was adopted for the resting period followed by 
rhIL-2 20U/ml for 36 hours for the re-stimulation conditions in all subsequent 
experiments. 
4.3.3 MITOGEN STIMULATION GENERATES A HETEROGENEOUS 
PRIMARY T CELL POPULATION IN RELATION TO IL-2R KINETICS. 
Mitogen-induced T lymphocyte activation is a polyclonal event and invariably results in 
the activation of the majority of T cells unlike superantigens such a Staphylococcal 
enterotoxin 11 (SEll) which may only activate approximately 30-40% of the peripheral 
blood T cells, dependent on their surface expression of selective TCR Vp chains, 
namely Vp 3, Vp 12, Vp 14, Vp IS, Vp 17 and Vp 20 (Marrack & Kappler, 1990). 
However, as indicated above, only 63.9%±2.3 of CD3+ cells expressed the a subunit of 
the high affinity IL-2R after 5 days of mitogen-stimulation. This suggests that the T cell 
population is heterogeneous rather than homogeneous in terms of their activation 
kinetics. To investigate this further, T cells were sorted using the MACS magnetic cell 
sorter on the basis of bright and dim surface expression of CD2S (IL2Ra) following a 5 
day stimulation with Con A and resting in 0.5%FCSIRPMII640 for 24 hours. The 
efficiency of this system in terms of purity and recovery were assessed then the 
activation kinetics and phenotype of both T cell populations were examined. 
PBMNC from normal donors (n=8) were stimulated with Con A for 5 days and rested in 
O.5%FCSIRPMII640 for 24 hours. Dead cells and debris were removed using density 
gradient separation, as previously described. The celts were then stained for surface 
expression of CD25 using a PE-conjugated MoAb and CD25Bright were selected using 
MACS. Prior to sorting, 64.4%±5.5 celts demonstrated CD2SBright surface staining and 
following sorting, the positive fraction contained a mean 87.9%±l.O CD2SBright T cells 
whereas the negative fraction contained a mean 30.2%±3.7 CD25Bright T cells (Figure 
4.9, p<O.OOl). Whilst providing a purification of T cells on the basis of surface 
expression of CD25, the recovery of cells from this system is of equal importance. 
When the absolute numbers of CD2SBright and CD25Dim T cells were calculated pre-
sorting and in the positive and negative fractions respectively, a mean recovery of 
34.6%±6.3 CD25Bright celts and 56.1 %± 7.8 CD2SDim cells was noted (Figure 4.10). 
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FIGURE 4.9. The surface phenotype of peripheral T cells from normal donors (n=8) 
stimulated for 5 days with ConA then sorted according to CD25 surface expression. 
Key: Pre - Percentage CD2SBright T cells prior to sorting, Post-Bright- Percentage 
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FIGURE 4.10. The recovery of CD25 Bright and CD25Dim T cells in the positive and 
negative fraction re pectively. 
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A representative histogram of CD2S surface expression pre- and post-sorting IS 
illustrated in Figure 4.11. 
It was important to examine the physical characteristics and proliferative capacity of 
these sorted cells. The proliferation observed when these two groups of T cells were 
cultured in complete medium alone was a mean of 761.2±308 cpm for CD2SDim T cells 
and a mean of 2,643.2±1218 cpm for CD2SBrighl cells, which did not reach statistical 
significance (n=8, p=O.093). When re-stimulated with rhIL-2 (20U/ml), the CD2SBrighl 
cells demonstrated proliferative responses with a mean 20,922.2±2034.2 cpm compared 
to a mean of7,837.S±2224.3 cpm by the CD2SDim cells (n=8, p<O.OOI), as illustrated in 
Figure 4.12. 
To further characterise these two groups of cells, their surface phenotype was examined 
by flow cytometry analysis following culture in O.S%FCSIRPMIl640 for 24 hours. 
CD2SBright cells contained more CD4+ T cells than the CD2SDim population (89.4%±1.9 
vs. 58.94%±2.6, p<O.OOI, n=3) with fewer cells with the naive surface phenotype 
(CD45RA+: 39.0%±2.l vs. 60.4%±2.5, p=O.0013. n=3). When the surface activation 
marker CD69 was examined in conjunction with CD2S surface expression, more 
CD25 Bright cells had progressed to the CD69+/CD25+ and CD69-/CD2S+ stages of 
activation following the 5 day culture with ConA (p<O.OO 1, n=3 for both). These results 
are summarised in Table 4.3 (page 113) and representative histograms and dot plots of 
CD25Bright and CD2SDim cells are illustrated in Figures 4.13 and 4.14 respectively. 
The kinetics of IL-2Ra up-regulation in response to re-stimulation with rhIL-2 IS 
difficult to determine by flow cytometry analysis as surface expression of the a subunit 
of the IL-2R remains for up to 48 hours after suppression of gene transcription 
following the initial stimulation (Minami et al, 1993). Therefore. to detect IL-2Ra gene 
up-regulation, IL-2Ra mRNA expression was examined by RT-PCR. In addition, IL-2 
mRNA expression was examined together with the Yc subunit of the IL-2R, which is 
constitutively expressed, and the house-keeping gene, ~-Actin. Following 24 hours 
incubation with rhIL-2 (20U/ml), IL-2Ra and IL-2 mRNA could be detected in 
CD25Bright cells along with IL-2Ryc and J3-Actin whereas CD25Dim cells did not express 
detectable levels of IL-2Ra or IL-2 mRNA but still expressed IL-2Ryc and J3-Actin 
mRNA (Figure 4.15). 
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FIGURE 4.11. R pr ntati e histograms of CD25 surface expression of peripberal 
blood T cells timulat d with onA for 5 days. Histograms indicate CD25 surface 
expression before rting and after rting. Hollow histogram represents isotype control 
MoAb. 
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FIGURE 4.12. Proliferation kinetics of CD25Bright and CD2SDim T cells upon re-
stimulation with rhIL-2. The difference in proliferation with complete medium alone 
between the two T cell populations did not reach statistical significance (p=O.093) 
whereas the difference in proliferation in response to rhIL-2 was statistically different 
between the two cell group (p<O.OO 1). 
123 
A 
CD25Bright 
CD4 
B 
CD25Bright 
o 
CD45RA 
c 
CJ)69 CD25BriKht 
for 24 hour . (A) 
expression. 
I • 
.. ,'. " 
.', ' .. ~.' .. :,'~: ':" :.: 
J.t;1~~~~}~~·~,~: ': .\ ...! ":::::.~~; .:\ ~ ... '. 
f D25Bright cells cultured in O.5%FCSIRPMIl640 
4 e pre i n, (B) D45RA expression and (C) CD69 and CD25 
124 
A 
B 
c 
CD25Dim 
M1 
1 
CD4 
CD25Dim 
M1 
CD45RA 
C))69 CD25Dim 
o 
for 24 hour . (A 
expression. 
4 
phen type f 25 D1m cell cultured in O.5%FCS/RPMI1640 
4 expr i n, ( D45RA e pression and (C) CD69 and CD25 
125 
M 
P-Actin 
( , 
B D 
IL-2Ra 
( , 
B D 
IL-2Ryc 
( , 
B D 
IL-2 
( , 
B D 
FIGURE 4.15. xpre i n ofIL-2Ra., IL-2Ryc, and IL-2 mRNA detected by RT-PCR. 
After stimulation with rhlL-2 fi r 24 hour CD25Bright cells expressed the IL-2R a. and Yc 
sub-units whereas only th IL-2Ryc could be detected in CD2SDim cells. P-Actin mRNA 
was used as an amplification and loading control. Unlike the CD2SBright cells, no IL-2 
mRNA could be det t d in D25Dim cell . Key: B - CD2SBright cells, D- CD2SDim cells, 
M- markers. 
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4.3.4 CHARACTERISATION OF A HUMAN IL-2-DEPENDENT T CELL LINE. 
An IL-2-dependent blast cell line (lODL) was generated as described in chapter 2. Cells 
were used in these experiments were maintained in complete medium supplemented 
with rhlL-2 and used at low passage numbers (2-30). I sought to characterise this cell 
line in terms of the surface phenotype, expression of cytokines and their ligands and the 
proliferation kinetics. Phenotypically, IODL consistently expressed low levels of CD3, 
IL-2RP (CDI22) and CD4 but no detectable levels ofCD2, or IL-2Ra (CD2S) could be 
demonstrated (Table 4.4, Figure 4. t 6). The IDDL cells expressed high levels of Fas and 
the activation marker, CD69, on their surface (Figure 4. t 6). 
By RT-PCR, IODL did not express the mRNA of the cytokines IL-2, interferon-y or IL-
4 (Figure 4.17). When analysed after 24, 48 and 72 hours of culture with rhIL-2, no 
expression of 1L-2Ra mRNA could be detected by RT-PCR (Figure 4.18). Whilst IL-
2Ryc mRNA could be detected after 72 hours of culture with rhIL-2, IL-2RP mRNA 
could not be amplified by RT-PCR on bulk-populations despite detection of surface 
expression, albeit at a low level (Figure 4. t 9). 
The proliferation kinetics of IODL to cytokine stimulation was assessed by 3[H]dThd 
uptake. When assessed at differing time intervals, IDDL demonstrated maximal 
proliferation to rhlL-2 at 72 hours with a mean 265,1 59±t2594 cpm compared with a 
mean 202,658±13,897 cpm at 48hours (p=O.02) and a mean 75,046±9,097 cpm at 24 
hours (p<O.OOI) as illustrated in Figure 4.20. It is worthy of note that the proliferation in 
CM without IL-2 steadily decreased over the time of the experiment. When the 
proliferative response to increasing doses of rhlL-2 was tested, it was shown, using a 
linear regression analysis model, that IODL demonstrated a linear relationship with the 
concentration of rhlL-2 (~=O.616, p=O.007; Figure 4.21). Therefore the optimal 
experimental conditions in terms of proliferation for this cell line are 20U/ml of rhIL-2 
for 72 hours culture. Ilowever, o\\;ng to the magnitude of proliferation and the extent of 
3[H]thymidine incorporation seen when IODL cells were cultured at a final 
concentration of lxt06/ml, then IODL cells were used at a final concentration of 
IxtOS/ml. 
The proliferative response to another T cell stimulatory cytokine, IL-t2, was important 
to establish. 1L-12 signals gene transcription through different intra-cellular signals to 
that associated with IL-2IIL-2R interactions: Jak2ffyk2/STAT4 cf. 
Jakl/Jak3/STAT3/STATS (Leonard & O'Shea, 1998). 
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MARKER (%) (%) (%) MEAN±SEM 
IDBL Cells 
CD2 0 2.3 3.75 2.0±1.9 
CD3 84.89 92.1 87.3 88.2±3.7 
CD4 47.95 10.5 27.5 36.0±11.0 
CD25 0 2.19 1.12 0.4±0.6 
CD122 70.8 74.6 67.9 71.1±3.4 
CD69 81 74.6 78.6 78.1±3.2 
CD45RA 72 69.6 81.6 74.4±6.3 
CD95 (Fas) 100 94.7 97.5 97.4±2.7 
Cyto IL-2 1.25 2.80 0.9 1.6±0.8 
Cyto IFNy 3.5 2.7 1.8 2.7±0.9 
Jurkat Cells 
CD2 94.07 83.6 99.08 92.3±4.57 
CD3 46.17 98.73 98.03 81.0±17.43 
CD4 39.55 92.3 92.18 74.7±17.58 
CD25 2.46 4.89 0.06 2.5±1.4 
CD122 4.91 2.74 5.96 4.5±0.95 
CD69 13.44 83.08 70.45 55.7±21.45 
CD45RA 98.02 67.6 70.78 78.8±9.66 
CD95 (Fas) 60.6 98.46 99.40 86.2±12.79 
Cyto IL-2 89.4 94.5 99.82 94.6±3.01 
Cyto IFNy 3.62 2.01 4.41 3.4±0.71 
TABLE 4.4. Phenotypic characteristics of two hwnan T cell lines, IDBL and Jurkat 
E6.1 as determined by direct immuno-fluorescence staining and flow cytometry. 
Surface phenotyped examined on 3 different occasions. 
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FIGURE 4.16. Surface phenotype of the human IL-2 dependent cell line, IDBL 
analysed by flow cytometry. Key: cytIFNg- intracellular interferon-y, cytlL-2-
intracellular IL-2 
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FIGURE 4.17. Expression of cytokine mRNA (IL-2, IL-4, IFN-y) by IDBL cells (ID) 
after culture with rhIL-2. No IFNy mRNA transcripts were detected in all 3 cell 
populations. ~-Actin was used as an amplification and loading control. PBMNC 
cultured in the presence (peA) and absence (P) of ConA for 72 hours were used as 
positive and negative controls respectively. 
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FIGURE 4.18. Expre i n ofIL-2Ra mRNA in IDBL cells after 24,48 and 72 hours of 
culture with rhIL-2 20U/mI. ~-Actin was used as an amplification and loading control. 
Resting and onA activated PBMNC from normal donors was used a controls. Key: M-
markers; B-blank; 0- at time 0 hours; 24 48,72 - at the specified time in hours; PB-
resting peripheral blood lymphocytes; PBCA- peripheral blood lymphocytes stimulated 
with ConA for 3 days. 
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FIGURE 4.19. xpre i n of IL-2 receptor sub-unit mRNA by IDBL cells. RT-PCR 
detection of IL-2R ub-unit aft r timuJation with rhIL-2 for 72 hours. f3-Actin was 
used as an amplification and I ading control. PBMNC stimulated ConA for 72 hours 
(PBCA) were u d as po iti e c ntr 1 . KEY: M-markers, B- negative control, Act-
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FIGURE 4.20. Proliferation of IDBL (106/ml) when stimulated with CM alone or CM 
supplemented with rhIL-2 for the time intervals indicated. IDBL cells demonstrate 
greater proliferation at 72 hours compared with 24 hours (p<0.001) and 48 hours 
(p=0.02). Proliferation was measured by 3[H]thymidine uptake. 
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FIGURE 4.21. Proliferation of IDBL (106 Iml) stimulated with varying doses of rhIL-2. 
Proliferation was measured by 3[H]thymidine uptake (r2=0.616, p=0.007). 
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Thus the effect that IIMCL have on the IOBL cells could be localised to a specific 
signal transduction pathway or be the result of converging pathways. As such the 
response of IOBL cells to rhIL-2, rh1L-12 and a combination of the two was assessed 
using 3[H]thymidine incorporation. It was demonstrated that rhIL-12 alone resulted in 
minimal proliferation at 48 and 72 hours but an additive effect in terms of proliferation 
ofIOBL cells could be seen when both cytokines were added simultaneously to the CM 
(Figure 4.22). When 20 Ulml of rhlL-2 and 20U/ml of rhIL-12 were used 
simultaneously to supplement the CM, an increase of 23.3% in proliferative response 
was demonstrated above the response to rhlL-2 alone. 
The cell cycle kinetics was examined in IOBL cells using propidium iodide - DNA 
staining as described in chapter 3. When IDBL cells are stimulated with rhIL-2 in CM, 
there is a significant increase in the number of cells which are identified as being in the 
G2/SIM phase of cell cycle compared to those which were cultured in medium alone 
(35.6%±3.87 cf. 1.79%±0.421, p=0.0063; Figure 4.23). A significant difference in the 
number of cells in Go/G. phase of cell cycle when stimulated with rhIL-2 compared to 
eM alone was observed (35.7%±2.06 cf. 14.5%±2.06, p=0.0106). 
When apoptosis was analysed using the Annexin V assay, it was found that culturing 
IDBL cells in CM resulted in a significantly higher rate of apoptosis when compared to 
those cultured in CM supplemented with rhlL-2 (63.44%±20.13 cf. 15.99%±5.6, 
p=O.04, Figure 4.24). Representative Annexin V assay dot plots are illustrated in Figure 
4.26. Thus IOBL cells progress through the cell cycle in response to exogenous rhIL-2 
and are susceptible to cytokine-withdrawal apoptosis. 
4.3.5 CHARACTERISATION OF A HUMAN T CELL LINE IN THE IL-2 
AUTOCRINE PATHWAY. 
The Jurkat E6.1 cell line is a well-characterised human T cell line established from a 
patient with Adult T lymphoblastic leukaemia at the Fred Hutchinson Cancer Research 
Centre, Seattle, USA (Sladowski et ai, 1993). To examine the proliferation kinetics of 
the Jurkat cell line, cells were washed three times in PBS then re-suspended in CM at 
reducing concentrations: 106, lOS, 104, 103 and 102 cells/ml. The proliferation of each 
cell suspension was measured at 24 , 48 and 72 hours by 3[H]dThd uptake. When 
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FIGURE 4.22. Proliferation of IDBL to stimulation with a combination of rhll.,-2 and 
rhIL-12, as measured by 3[H]thymidine uptake. IDBL at a concentration of lOs/ml were 
stimulated with rhIL-2 20 Iml and rhll.,-12 lOOD/ml for 48 and 72 hours. 
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FIGURE 4.23. ell cycle analy i of IDBL cells culture in medium alone (lDBL) or 
with rhIL-2 20 D/ml (IDBL+lL-2). Significantly more cells were identified in Go/G) 
(p=O.0106) and 0 21 1M (p=O.0063) when rhIL-2 was added to the CM, compared to 
CM alone, the main deficit re ulting from apoptosis owing to cytokine withdrawal. 
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FIGURE 4.24. Analysis of the effect of culturing IDBL cells ill the presence 
(IDBL+IL-2) and ab ence (IDBL) of rhIL-2 on the rate of apoptosis, as determined 
using the Annexin V affinity assay. Whilst a difference in the mean number of apoptotic 
cells was demonstrated, this just reached statistical significance (p=O.042). 
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FIGURE 4.25. Representative Annexin V dot plots of IDBL cells cultured in the 
presence (A) and absence (B) of rhIL-2. Early apoptotic cells are identified as An+lPr 
and late apoptotic and necrotic cells are identified as An + !Pr. 
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cells were cultured at the highest concentration (106 cells/ml) maximal proliferation was 
lower than lOs cells/ml , resulting from cell overgrowth and competition for CM (Figure 
4.26). At loscells/ml however, no appreciable change in proliferation was seen at the 
time points indicated unlike 104 cells/ml, which demonstrate a linear proliferation/time 
relationship (~=O.994, p=O.049). Therefore, all experiments using Jurkat E6.1 cells 
were conducted at a cell concentration of 104 cells/ml. 
The surface expression of T cell markers by Jurkat cells was examined, including 
components of the IL-2R and Fas (CD95). The Jurkat cells demonstrated surface 
expression of CD2, CD3 and CD4 (92.25%±4.57, 80.98%±17.43 and 74.68%±17.58 
respectively; Table 4.4). The majority of cells demonstrated a naive phenotype through 
the expression of CD45RA (78.8%±9.66). The Jurkat cells failed to express the IL-2R 
components, CD25 (IL-2Ra) and CD122 (IL-2RP) by flow cytometry analysis 
(2.47%±1.4 and 4.54%±0.98, respectively). The expression of the activation marker, 
CD69 was more heterogeneous within the cell population with a mean of 55 .66%±21.45 
of cells expressing this marker on their surface. The Jurkat cells expressed surface Fas 
(APO-lICD95) though the degree of expression was variable amongst the cell 
population (86.1 5%±1 2.79}. Representative examples of Jurkat E6.1 cell surface 
phenotype are illustrated in Figure 4.27. 
The Jurkat cells were examined for the mRNA transcripts of the IL-2R subunits. 
Compatible with absent surface expression of the a-subunit (CD25), no mRNA was 
detected by bulk-population RT-PCR (Figure 4.28). In contrast, the P subunit mRNA 
transcripts were detected by RT-PCR on bulk populations but were not detected at the 
protein level by F ACS. This suggests that the p subunit of IL-2R may be modulated on 
these cells at a low level, depending on the cycling of individual cells. The Yc subunit of 
IL-2R was detected by RT-PCR on bulk populations. 
Jurkat E6.1 cells are cytokine-indepcndcnt resulting from the autocrine production of 
IL-2. The cells were examined for the expression of IL-2 both at the mRNA and protein 
level. Using intra-cellular cytokine immuno-fluorescence staining, Jurkat cells 
demonstrated a uniform expression of IL-2 (94.57%±3.09; Table 4.4 (page 128) and 
Figure 4.29). Cytokine mRNA expression could be detected by RT-PCR (Figure 4.30). 
By comparison, the cells were examined for the production of interferon-y (IFN-y). The 
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FIGURE 4.26. Proliferation kinetics of the human T cell line, lurkat E6.1. Cell 
proliferation was measured by J[H]dThd uptake after 24, 48 and 72 hours culture at 
reducing cell concentration. Key: 1.00E+07 - 106cells/ml, 1.00E+06 - 10scells/ml, etc. 
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FIGURE 4.28. Expression of IL-2 receptor sub-unit mRNA detected by RT-PCR on 
bulk-populations. J3-Actin was used as an amplification and loading control. PBMNC 
stimulated ConA for 72 hours (PBCA) were used as positive controls. KEY: M-
markers, B- negative control, Act- J3- Actin, Ra- IL-2 receptor subunits a,J3 & 'Y. 
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FIGURE 4.29. IL-2 (cytIL-2) and interferon-y (cytlFNg) production at the single cell 
level by Jurkat cells detected by intra-cellular cytokine FACS analysis. 
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The cells were found neither to produce the protein or mRNA transcripts for this 
cytokine (3.37%±0.73, Table 4.4; Figure 4.30). 
The cell cycle distribution of lurkat cells cultured in eM were examined at various time 
points over a 72 cultured period suing PI-DNA staining. Analysis revealed that a mean 
of 26.03%±3.47 of cells were in the S/G2/M phase of cell cycle at anyone time point. A 
representative DNA histogram is illustrated in Figure 4.31. 
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FIGURE 4.31. Repre entative cell cycle analysis of lurkat cells using PI-DNA 
staining. 
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4.4 DISCUSSION 
The data presented here characterise the phenotype, cytokine/cytokine receptor and 
proliferation profiles of three populations of human T lymphocytes - IL-2-responsive 
primary T cells and two T cell lines, lurkat E6.1 and IDBL cells. These three cell types 
represent T cells at various stages of the activation process as illustrated in Figure 4.1. 
The IL-2-responsive primary T cells generated from the peripheral blood of healthy 
volunteers when stimulated with rhIL-2 represent an in vitro model of the 
initiation/activation process which results in cells up-regulating several key genes and 
entering the IL-2 autocrine pathway. The Jurkat E6.1 cells by virtue of being a 
transformed cell line derived from primary malignant T lymphocytes, are cytokine-
independent and produce IL-2. Thus they represent cells that have entered into the IL-2 
autocrine pathway and exist without progressing to either the "antigen-induced" or 
"cytokine-withdrawal" apoptosis phases. The IDBL cells have been generated by 
repeated mitogen and cytokine stimulation resulting in a cell which is beyond the IL-2 
autocrine pathway and dependent on exogenous T cell-stimulating cytokines such as IL-
2, IL-12 (and IL-15, data not shown here). Thus this cell represents an in vitro model of 
the T cell that is susceptible to cytokine-withdrawal or "passive" apoptosis. 
Furthermore, both JurkatE6.1 and IDBL cells by virtue of high levels of functional 
surface Fas (CD95) expression are susceptible to FaslFasL mediated apoptosis and this 
can be utilised to represent an in vitro model of "active" apoptosis. Thus using these 
three T cell populations an in vitro model of the propriocidal model of T cell 
homeostasis in response to antigen can be generated, encompassing three key areas: 
activation accompanied by distinct molecular events, proliferation resulting from IL-2 
autocrine pathway entry and apoptosis susceptibility resulting from both "active" and 
"passive" pathways (Crabtree, 1989; Boehme et ai, 1993; Radvanyi et aI, 1996). 
Why is a three-cell model required to investigate the interaction of HMCLs and 
activating/proliferating T lymphocytes? As discussed in chapter 3, HMCLs suppress the 
proliferative responses of normal T lymphocytes to alloantigen and mitogen by inducing 
cell cycle arrest. However is not known which agent or indeed agents are responsible 
for these observed effects. In fact, the tumour cells in myeloma may produce several 
factors, which could act at several points in the homeostatic pathway of T lymphocytes. 
For example, FasL has been shown to be expressed by a number of malignant cells 
including melanoma (Ilahne et ai, 1996), hepatocellular carcinoma (Shiraki et ai, 1997), 
lung cancer (Niehans et ai, 1997) and myeloma cells (Villunger et aI, 1997). By binding 
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to Fas (CD95) on T cells, FasL can induce activation-induced apoptosis particularly in 
the presence of antigen or IL-2. However, this form of activation induced cell death, or 
active apoptosis in the propriocidal regulation model, necessitates the T cells to become 
activated by antigenic stimulation or to have progressed into the second phase of the 
activation process. If HMCLs could both inhibit the activation process and augment 
active apoptosis mediated by FasL, then using primary T cells alone as the in vitro 
model would not permit the full dissection of the suppressor capacity of HMCLs. Thus 
using the two cell lines, IDBL and Jurkat E6.1, provide a suitable in vitro model to 
permit a closer examination of the effects of co-culturing with HMCLs. 
Another known potent suppressor of immune effector cells is Transforming growth 
factor beta (TGF-~). TGF-~ influences all stages of T lymphocyte development and 
differentiation through to their activation and proliferation, the exact effect being 
determined by the stage of maturation of the T cell. TGF-~ inhibits T cell proliferation 
by down-regulating IL-2 mediated-signals mediated through reduced tyrosine 
phosphorylation of proteins of 120, 100, 85, 75 and 50 kDa and inhibition of IL-2 
mediated phosphorylation of the retinoblastoma susceptibility gene product, which is 
pivotal in the progression of cell cycle (Wahl et al, 1989; Fontana et aI, 1989; Ahuja et 
aI, 1993). Furthermore, TGF-~ prevents activation-induced apoptosis by preventing 
activation-associated FasL up-regulation, which results from TGF-~-induced down-
regulation of c-myc (Genester et aI, 1999). This, it is proposed, has an effect of 
augmenting the memory T cell pool. In addition, TGF-~ has been shown to induce cell 
cycle arrest at the G1 stage in T cells that have been stimulated with mitogen, 
superantigen or anti-CD3 MoAb (Ewen et aI, 1993). Thus TGF-~ does exert differing 
effects on T cells dependent on their position in the propriocidal regulation pathway of 
T cell homeostasis and using either transformed T cells such as Jurkat E6.1 or T cell 
hybridomas alone in studies to examine the effect of tumour-derived TGF-~ may not 
pennit full study of the effect of this pluripotent cytokine. 
Both these examples demonstrate the need for an in vitro model that permits dissection 
of the stages of T cell activation and apoptosis as proposed in the propriocidal model of 
homeostasis. The three cell model developed in this chapter has the advantage of being 
able to permit such a dissection of immuno-suppressive effects which could be induced 
by tumour cells and thus lend itself to the further study of the interaction between 
HMCLs and T cells. 
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Transfonned cells provide a readily available, often reliable and predictable cellular 
population for in vitro studies examining cell-to-cell interactions. The use of 
transfonned T cell lines in the study of tumour cell-lymphocyte interactions have been 
reported widely in the literature (Villunger et ai, 1997; Zaks et ai, 1999). Investigators 
often use one cell type, which is sometimes modified by gene-transfection, in these 
reported studies. and this poses a problem. Transfonned cell lines by the nature of their 
in vitro immortalisation may be limited in their representation of the in vivo activity and 
behaviour of primary T cells (Lu et ai, 1999). These cell lines may have aberrant intra-
cellular signalling pathways or may be exquisitely sensitive to apoptosis-inducing 
signals or indeed insensitive to similar signals and thus do not truly represent primary T 
cells. Furthennore, transfonned T cell lines are cells which are actively traversing the 
cell cycle, either under the influence of exogenous or autocrine cytokines. They are thus 
limited in the study of those early molecular events involved in the initiation/activation 
phase of T cell activation including up-regulation of IL-2Ra. gene and the oncogene, c-
myc. This is crucial in the study ofT cell-HMCL interactions as this is likely to be a key 
area of T cell suppression induced by the HMCLs. The model proposed in this chapter 
aims to circumvent these problems by utilising primary T cells to study these early 
activation events and to use two transfonned T cell lines which is aimed at examining 
key areas of the propriocidal model of T cell homeostasis. It is accepted that, as stated 
above, the transfonned cells whilst providing a useful study population are limited in 
terms of their true reflection of primary T cells, the advantage of the proposed model 
using the three cell types is that this system is not totally reliant on transformed cell 
lines and their use is specific to examine exact points in the activation/deletion 
pathways of T lymphocyte homeostasis. 
The in vitro model system described in this chapter utilises IL-2-responsive primary T 
cells to study the initiation of activation and how this may be suppressed, if at all, by 
HMCL. These IL-2 responsive primary T cells have several advantages over the 
mitogen-activated PBMNC described in chapter 3. Firstly, by activating PBMNC from 
normal donors using a mitogen followed by a resting period and removal of non-viable 
cells by density gradient centrifugation, the PBMNC are purified into T cells 
(89.7%±4.l). This is advantageous, as I will explore the effect that HMCLs have on the 
activation, proliferation and survival of T lymphocytes in subsequent chapters. By 
purifying the T cells the influence that HMCLs can have on the functional integrity of 
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essential antigen-presenting cells required for pnmary activation using mitogens, 
antigens or super-antigens. Secondly, pre-activated T cells re-stimulated with IL-2 
produces a more reliable response with less inter-donor variability that is seen with 
primary activation using mitogen alone: IL-2-induced proliferation mean 23,250±3,775 
cpm and Con A-induced proliferation 70,459±13,670 cpm with significant variance 
(p<O.OOI, n=13). This is important; it has been shown that the degree of suppression of 
proliferative responses induced by HMCL directly correlates with the degree of 
activation (Cook & Campbell, unpublished results). This therefore generates a more 
reproducible in vitro assay system on which to examine potential tumour-derived 
suppressive factors and to study their effect at the sub-cellular level. Furthermore, these 
proliferative responses are seen following a shorter assay duration (36 hours versus 72 
hours) which is important when setting up blocking experiments to identify potential 
suppressive factors as many of these blocking agents have short half-lives in culture 
conditions (24-48 hours). 
The data presented in this chapter characterise a three cell in vitro model of the 
propriocidal model of T cell homeostasis with each cell type representing key stages of 
this process of activation and cell death which regulate peripheral T pools in vivo. This 
model will be useful for the identification of suppressive factors produced by HMCLs 
and to permit the study of the mechanisms by which these factors influence T cell 
proliferation. 
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CHAPTERS 
Human Myeloma Cell Line-derived Transforming Growth Factor Jl inhibits 
T lymphocyte IL-2 responsiveness. 
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5.1 INTRODUCTION 
Data presented in chapter 3 demonstrate that HMCLs can suppress primary T cells 
responding to alloantigen and mitogens by inhibiting the progression into the S phase of 
cell cycle. Successfully stimulated T lymphocytes transmit signals from their surface 
membrane to the nucleus via pathways which involve numerous signal transduction 
molecules and protein tyrosine kinases (especially JAKs, STATs, p56Lck and ZAP70; 
reviewed by Robey & Allison, 1995). These act on many intra-cellular pathways 
culminating in the up-regulation of new genes required by T cells to become activated, 
including proto-oncogenes (pim-l, c-fos, c-myc) and cytokines involved in propagating 
the immune response e.g. IL-2, IL-3, IL-4, IL-5, IL-6 (Ullman et ai, 1990). This early 
activation is followed by DNA synthesis, proliferation and the up-regulation of genes 
expressed in late T cell activation e.g. RANTES, Granzymes, Perf orin, 519/granulysin 
(Oritz et ai, 1997). Myeloma tumour cells could interfere with this activation process at 
any stage either by a single method or by an orchestrated manipulation of the effector 
mechanisms. 
An array of cytokines and immune-modulating agents has been reported by many 
investigators in the field of tumour immunobiology (Johnston et ai, 1996). In particular, 
B cells can produce a large number of cytokines both in disease and health (Pistola, 
1997). These immune modulators include IL-IO, the Fas (CD95/Apo-l) and FasL 
system, vascular endothelial growth factors (VEGF), the under-glycosylated surface 
peptide muc-l and the transforming growth factor-p family of cytokines (TGF-P). IL-
10, a pleiotropic cytokine produced by B cells, monocytes, macrophages and 
keratinocytes, inhibits synthesis of the pro-inflammatory cytokines (e.g. IL-l, IL-6, IL-
8, IL-l2, TNF-a and GM-CSF) and is one of the most potent inducers of 
immunoglobulin synthesis, which may be important in the pathogenesis of multiple 
myeloma (Rousset et ai, 1992). However, inhibition of T cell proliferation is not a 
recognised function of IL-l ° (Weigh et al, 1995) though has been shown to inhibit the 
generationldifferentation of cytotoxic T lymphocytes (Fiorentino et aI, 1989; Becker et 
aI, 1994). 
The FasIFasL system has been shown to be an important lymphocyte inactivation 
pathway in both physiological and pathological immune regulation (Alderson et aI, 
1995; Rensing-Ehl et al, 1995). It has been proposed that FasL on the myeloma cells 
can mediate T cell suppression by apoptosis induction (Villunger et aI, 1997) and while 
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apoptosis does not playa significant role in mediating the myeloma-induce suppression 
described in chapter 3, other investigators have demonstrated that FasL can mediate cell 
cycle arrest in T cells (Desbarats et ai, 1998). The role that FaslFasL plays in the 
suppression of the immune response by myeloma tumour cells therefore remains to be 
clarified. 
VEGF is a cytokine produced in large amounts by many tumours and its 
immunosuppressive effects are primarily restricted to manipulating the maturation of 
antigen presenting cells and are limited with respect to T cells (Gabrilovich et aI, 1996; 
Ferrara et ai, 1997). The role ofmuc-l in the modulation of the immune system and, in 
particular, its role in suppressing anti-tumour responses remains unclear. Muc-l 
expression may induce immunosuppression, though this has been shown to be mediated 
through apoptosis and is reversible by the actions ofIL-2 (Gimmi et aI, 1996; Agrawal 
et aI, 1998). However, as indicated in chapter 3, the addition of exogenous IL-2 fails to 
restore mitogen-induce proliferation of primary T cells when co-cultured with HMCLs. 
The TGF-~ family of cytokines have been shown to inhibit T cell proliferation, CTL 
generation and down-regulate co-stimulatory molecules (Letterio & Roberts, 1998). 
Furthermore, in relation to the cytokine production of T cells in response to activation, 
TGF-~ has been shown to induce a shift from the Thl to Th2 phenotype, (Wahl et aI, 
1989; Bridoux et ai, 1997). However, of the immune modulators indicated above, only 
TGF-~ has been shown to inhibit T cell activation through down-regulating IL-2-
mediated signals associated with reduced tyrosine phosphorylation of numerous 
proteins e.g. 120, 100, 85, 75 and 50 kDa (Fontana et ai, 1989; Wahl et ai, 1989) 
Furthermore, TGF-~ inhibits IL-2-mediated phosphorylation of the retinoblastoma 
susceptibility gene product (Rb), which is pivotal in the progression of cell cycle (Ahuja 
et aI, 1993). 
Thus several potential modulators of T cell activation and cytokine production exist, 
many produced by malignant cells, though their modes of action vary considerably. A 
key element of tolerance induction, whether to "self' antigens or in the context of my 
studies, tumour cell evasion of the host immune system, is the inhibition of the effector 
arm of the immune response (Goodnow, 1996). The profile of the T cell suppressing 
effects of the TGF-~ family of proteins are of interest in my model system in respect to 
my observations, as set out in chapter 3. The TGF-~ family of proteins alter T cell 
function in different ways depending on their state of activation. In particular, for T 
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cells that are activating in response to an appropriate stimulus, they are capable of 
blocking IL-2-mediated signalling pathways and blocking gene transcription and 
proliferation. Therefore, in the search for potential mediator(s) of the T cell suppression 
induced by myeloma cells, this information forms the rationale for systematised 
investigations. 
Experimental Aims 
The aim of the studies presented here were to identify which T cell modulatory factor 
(s) are produced by HMCLs and to determine which of these is responsible for the 
suppressive effect HMCLs demonstrate on the activation ofT cells. Furthermore, using 
the in vitro model developed in chapter 4, it was aimed to identify where in the process 
of T cell activation and homeostasis these modulators of T cell function, allowing 
further examination of the molecular events involved in subsequent studies. 
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5.2 MATERIALS AND METHODS 
5.2.1 REAGENTS 
Culture conditions and media are described in chapter 2. Recombinant human TGF-f31 
was obtained from R&D systems (UK), which is produced by protein purification of 
acidified culture medium from Chinese hamster ovary cell (CHO) transfected with the 
human precursor protein DNA sequence. The anti-pan TGF-f3 monoclonal antibody was 
purchased from Sigma (USA) which was developed in rabbits using a mixture of 
recombinant human TGF-f31, porcine TGF-f31.2, porcine TGF-f32 and recombinant 
amphibian TGF-f35 as immunogens. Rabbit anti-pan TGF-13 monoclonal antibody 
demonstrates blocking activity against all these TGF-13 species. The NDso of the 
antibody is defined as the concentration of antibody resulting in a one half maximal 
inhibition of bioactivity of recombinant, human TGF-131 when the cytokine is present at 
a concentration high enough to elicit an inhibition of the murine IL-4-dependent cell 
line, HTI (1.5J.1g1ml). Recombinant human Latency Associated Peptide (LAP) was 
purchased from Sigma (USA) who developed it from a DNA sequence corresponding to 
the 278 amino acid residues of the pre-pro- TGF-131 terminating prior to the mature 
TGF-I31. The ECso of recombinant LAP is defined as the effective concentration of 
growth factor that elicits a 50% inhibition of cell growth of MvlLu cells (8-40 nglml). 
The anti-human LAP (TGF-131) monoclonal antibody was purchased from R&D 
systems (UK) who generated the antibody in goats immunised with purified, CHO cell-
derived recombinant human LAP and chromatography purified the specific IgG. The 
NDso of the antibody has been shown to approximately 0.05-0.15 J.1g1ml. 
Cytokine and Cytokine Receptor Expression 
The expression of cytokine and cytokine receptor mRNA was detected by reverse 
transcription-polymerase chain reaction (RT-PCR) as described in chapter 2. All 
glassware, tubes aqueous solutions were autoclaved prior to use in RNA isolation and 
cDNA synthesis. Cells were washed twice in ice cold PBS and adjusted to 10'/ml. Cell 
suspensions were transferred to 1.5ml autoclaved Eppendorf tubes and total RNA 
extracted as described before. Primers specific for human cytokine sequences were used 
in the PCR reactions and the sequences, predicted fragment sizes and melting 
temperatures (Tm) are listed in Table 5.1. These PCR primers were in-house sequences 
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AT Size 
Strand (C) (bp) 5'-Sequence-3' 
J3-Actin Sense 60 548 GTGGGGCGCCCCAGGCACCA 
Anti-sense CTCCTTAATGTCACGCACGATTTC 
IL-la Sense 60 421 GTCTCTGAATCAGAAATCCTTCTATC 
Anti-sense CATGTCAAATTTCACTGCTTCATCC 
IL-IJ3 Sense 60 802 ATGGCAGAAGTACCTAAGCTCGC 
Anti-sense ACACAAATTGCATGGTGAAGTCAGTT 
IL-6 Sense 60 628 ATGAACTCCTTCTCCACAAGCGC 
Anti-sense GAAGAGCCCTCAGGCTGGACTG 
IL-I0 Sense 60 352 TCTCAAGGGGCTGGGTCATATCCCA 
Anti-sense ATGCCCCAAGCTGAGAACCAAGACCCA 
TNF-a Sense 60 695 ATGAGCACTGAAAGCATGATCCGG 
Anti-sense GCAATGATCCCAAAGTAGACCTGCCC 
TGF-J31 Sense 60 181 AACATGATCGTGCGCTCTGCAAGTGCAGC 
Anti-sense AAGGAATAGTGCAGACAGGCAGGA 
TABLE 5.1 Oligonucleotide primers used for RT-PCR. Key: AT - annealing 
temperature used. 
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with known optimal reaction conditions. The primer sequence for the proto-oncogene, 
pim-J, are described in chapter 2 along with the PCR product verification by restriction 
enzyme digest. Using 2,.d of cDNA solution (equivalent to O.5J.f.g of mRNA) the PCR 
reaction was carried out in 50J.f.1 volumes as described in chapter 2 and control samples, 
which contained all reaction constituents except cDNA, were used to exclude 
environmental contamination. PCR products were electrophoresed by 2% agarose gel 
electrophoresis at 1 OOV and the imaged as described in chapter 2. 
5.2.2 HMCL CLONING 
CelIlines can be grown in a semi-solid culture system such as methyl cellulose, which 
is a gelling agent that immobilizes cells in discreet positions. As such, celIs can be 
cloned by removing single cells from the methyl cellulose culture system and re-plating 
in methyl cellulose when subsequent colonies which appear after culture being derived 
from the initial single cells. Using this technique, the HMCL, U266 was sub-cloned by 
Mrs CE Carr with the resultant sub-clones being designated with unique clone suffixes. 
In brief, cells were recovered from suspension by centrifugation at 1500g for 5 minutes. 
0.9mls of a 2.1% methyl cellulose stock solution (Life Technologies) was added to 
2.4mls of CM to give a final concentration of 0.9% methyl cellulose. The cells were 
then washed three times in PBS and re-suspended in 0.9% methyl cellulose at a 
concentration of lx103/ml, with 3mls being loaded into each well on a 6 well plate. The 
plates were incubated for 72 hours when the six well plates were removed from the 
incubator and placed on the stage of an inverted microscope. Using a sterilised, filtered 
2J.11 pipette tip, single cells were aspirated and transferred to sterile petri dishes 
containing 0.9% methyl cellulose. The cells were incubated for a further 72 hours and 
single colonies were aspirated suing the same sterile technique. The aspirated colonies 
were then disrupted and the cells were re-suspended in CM and transferred to 96 well 
plates and cloned using a limiting dilution technique. The cells were then expanded in 
CM and when bulk cultures were achieved the properties of each cell line sub-clone 
were assessed by their ability to stimulate MLR reactions, to suppress the mitogen-
induced proliferative responses of nonna! T cells and their cytokine profile examined by 
RT-PCR. 
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5.2.3 SINGLE CELL PCR 
Bulk cell population studies of cytokine mRNA expression in the HMCLs using RT-
PCR was performed as described in chapter 2. For single cell and limited colony RT-
PCR, the HMCL U266 were cultured in 0.9% methyl cellulose, as described in section 
5.2.2. Cells grown in CM were recovered from suspension by centrifugation at 1500g 
for 5 minutes. The cells were then washed three times in PBS and re-suspended in 0.9% 
methyl cellulose at a concentration of IxlO3/ml, with 3mls being loaded into each well 
on a 6 well plate. The plates were incubated for the times specified in the results section. 
At the appropriate time points, the six well plates were removed from the incubator and 
placed on the stage of an inverted microscope. Using a sterilised, filtered 2,....1 pipette tip, 
single cells (x3) and colonies (x3) of <10 cells in diameter were aspirated in a volume 
of 1,....1. Each 1,....1 aspirate was transferred to a separate autoclaved PCR tube. 
To each 1,....1 of cell suspension, was added 4 ,....1 of T lysis buffer {Tlysis buffer: 100,....1 
made freshly consisted of 20,....1 of SSII 1st strand buffer (Gibco)/2.5%NP40 (Sigma), 
66,....1 H20, 10,....1 O.1M DIT (Sigma), 2,....1 RNase and 2,....1 dTN (lO,....gI,....1 oligo dT(2oy 
O.5M dNTP)}. The samples were pulse spun (14,OOOg) in a microfuge and chilled on ice 
before being put into the PCR Express (Hybaid) thermocycler. The samples were then 
run on a cycle of 65°C for 1 minute followed by 20°C for 3 minutes, at which point the 
samples were then pulse spun in the microfuge and chilled on ice. To each sample, 
0.5,....1 of reverse transcriptase (Gibeo) was added and the samples were pulse spun in the 
microfuge and chilled on ice. The samples were run on a program as follows: 37°C for 
15 minutes, 65°C for 10 minutes and 4°C for 4 minutes, following which the samples 
were pulse spun and chilled on ice. To each sample, 4,....1 of Tail buffer {Tail buffer: 
100,....1 freshly made consisted of 40,....1 (5x) TdT buffer, 2,....1 100mM dATP, 57.6,....1 of 
H20 and 0.4,....1 of 0.1 M DTT} was added and the samples were pulse spun and chilled 
on ice. The samples were then run on a program as follows: 37°C for 20 minutes 
followed by 65°C for 10 minutes, which generated the poly A eDNA. 10,....1 of poly A 
cDNA solution was then added to a new autoclaved PCR tube and to this was added 
10,....1 Taq buffer (Hybaid), 10,....1 MgCh, 10,....1 Brady primer (100 pM; 5' 
CATGTCGTCCAGGCCGCTCTGGACAAAATATGAATTCTTTTTTTTTTTTTTTT 
TI I I I I I), 1,....1 dNTPs (10mM), 57,....1 of H20 and 2,....1 of Taq (Hybaid). The samples 
were loaded on to the PCR Express and the following programme was run: 94°C for 2 
minute, 42°C for 2 minutes and 72°C for 6 minutes with 10 second increments/cycle for 
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25 cycles. The samples were then removed, pulse spun and 1).11 of Taq was added and 
the above program was repeated. Samples were then ready to be used in standard PCR 
reactions for amplification of cytokine cDNA or stored at -70°C until required for 
analysis. 
5.2.4 TGF-(n ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
The detection of active TGF -~ 1 in the supernates of HMCLs was analysed by Mrs CE 
Carr using a Promega TGF-~1 ELISA system. In brief, myeloma cell suspensions were 
centrifuged at 1500g for 5 minutes, washed three times in PBS and re-suspended in CM 
at a concentration of lxl06/ml. CM with no added cells was set up to monitor the 
background TGF-~ 1 level in FCS. The cells were cultured at 37oC/5% C02 for 72 
hours. The supernates were removed and snap frozen immediately in liquid N2 and 
stored at -70°C until required for analysis. The supernates on recovery from frozen 
storage wer acid activated and diluted up to 11100 in PBS to obtain results within the 
linear working range of the ELISA system (16-1000pg/ml). The samples were analysed 
using the Promega ELISA system, following the manufacturers instructions and the 
results from the cell line supernates were expressed minus the background level of CM. 
5.2.5 IMMUNOHISTOCHEMISTRY 
To detect the presence of latent TGF-~1 in the HMCLs, cell cytospins were stained 
immuno-histochemically using an anti-LAP antibody. Cell suspensions of the HMCL 
U266 were centrifuged at 1500g for 5 minutes and then washed three times in cold PBS. 
Following this, cells were fixed in 10% paraformaldehyde (Sigma) in PBS pH7.6 for 24 
hours. Cells were then filtered and pelleted by centrifugation before being embedded in 
paraffm wax. 2.5).lffi sections were cut using a microtome (Leica RM2135) and the 
sections were floated in a water bath (50°C) and collected upon Poly-I-lysine coated 
slides (Sigma). The slides were then baked at 56°C for a minimum of 24 hours. 
Prior to staining either for conventional histology or immunhistochemistry, the sections 
were de-paraffinized in xylene (3 changes) followed by rehydration through graded 
alcohols - 1000/0/95%170%150% ethanoIldH20. For conventional histology, the 
sections stained with Haematoxylin and Eosin (H&E) as follows: after rehydration, the 
sections were rinsed in running tap water before being immersed in Haematoxylin for 4 
minutes (Sigma). The sections were rinsed in running tap water, immersed in "Scott's 
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Tap Water" (saturated lithium carbonate solution) for 1 minute and stained with Eosin 
for 30 seconds. The sections were then washed in running tap water before dehydrating 
through graded alcohols followed by clearing in xylene (2 changes) and being mounted 
in DPX mounting medium (BDH). 
For immunohistochemical staining, the sections were de-paraffinised and hydrated as 
for the conventional staining. Following re-hydration, endogenous peroxidase activity 
was blocked to reduce false positive reaction by incubating sections in 3% hydrogen 
peroxide solution (3mls hydrogen peroxide in lOOmis methanol) for 10 minutes. The 
sections were then washed in running tap water for 3 minutes. The sections were then 
blocked by incubating in 20% normal rabbit serum (NRS) in TBS for 30 minutes. The 
primary antibody (diluted 1: 1 00 in 20% NRS) was added to the appropriate sections 
with an appropriate isotype control MoAb being used for background staining 
assessment. The sections were incubated in a sealed container at 4°C overnight (18 
hours) and were subsequently washed thoroughly in TBS. The secondary antibody, a 
biotinylated rabbit anti-goat immunoglobulin (Dako, Denmark), was diluted 1 :500 in 
20% NRS and added to the sections which were incubated for 30 minutes at room 
temperature. The sections were then washed thoroughly in TBS (5 minutes). Staining 
was visualised using the ABC Complex/HRP system (Dako) prepared according to the 
manufacturers instructions. One drop of avidin (in 0.001 molll PBS, pH 7.2) and 
biotinylated horseradish peroxidase (in 0.001 moIll PBS, pH 7.2) were added to 5 mls of 
0.05 moIll TrislHCL (PH 7.6) and mixed. The ABC complex was mixed and added to 
the sctions and incubated for 30 minutes. The sections were then washed thoroughly in 
TBS then incubated for 5-15 minutes with the enzyme substrate diaminobenzidine-H202 
which was freshly made-up prior to use, according to the manufacturers instructions 
(Sigma Fast DAB). The sections were then washed in tap water, counter-stained using 
haematoxylin and dehydrated and mounted as described for conventional histology. 
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5.3 RESULTS 
5.3.1 HMCL SUPPRESS THE PROLIFERATIVE RESPONSE OF PRIMARY T 
CELLS BUT NOT T CELL LINES JURKAT E6.1 AND IDBL. 
Primary T cells from normal, healthy donors (n=8) re-stimulated with rhIL-2 
demonstrated brisk proliferation at 36 hours (38820±8775 cpm). When co-cultured with 
the HMCLs U266, 11M 1 and RPMI8226, inhibition of the proliferative responses was 
demonstrated: U266- 1 4917±6754 cpm (p=0.025), JIMI- 15899.7±3574 cpm (p=O.019) 
and RPMI8226- 15662.2±4475 cpm (p=0.020) (Figure 5.1). When expressed as the 
degree of inhibition, all three cell lines inhibited the proliferative responses of primary T 
cells (U266- 68.8%±8.8, JIMI- 60.2%±4.01 and RPMI8226- 62.9%±1O.4; Figure 5.2). 
Primary T cells (n=3) expressing high levels (CD25bright) of the a-subunit of the IL-2R 
(CD25) were sorted from those expressing low levels (CD25dim) and both populations 
were re-stimulated with rhIL-2 in the presence and absence of HMCLs. There was a 
marked inhibition of proliferative responses of the CD25bright population from 
21039±4386 cpm to 10720±6133 cpm, although this did not reach statistical 
significance (p=O.152), as opposed to the CD25dim T cells which essentially 
demonstrated no change in 3[H]dThd uptake (4848±2438 cpm to 5468±5101 cpm, 
p=0.465; Figure 5.3). When the cell cycle distribution and apoptosis was examined 
using PI-DNA staining and Annexin V-affinity assays, respectively, primary T cells 
(n=8) when re-stimulated with rhIL-2 in the presence of U266 cells induced a 
significant increase in the number of cells remaining in the GoIG1 phase of cell cycle 
(74.2%±3.7 versus 49.7%±1.37, p=0.004; Figure 5.4). This was associated with a 
significant reduction in the number of cells progressing into the S/G21M phase of cell 
cycle (12.9%±3.9 versus 24.9%±5.0, p=O.0398). No difference in the rate of apoptosis 
was seen when primary T cells were re-stimulated in the presence or absence of U266 
cells (20.0%±5.0 versus 14.0%±4.4, p=O.2). 
When the T cell lines, IDBL and lurkat E6.l were co-cultured with HMCL ,a different 
effect was observed. No inhibition of IDBL proliferative response to rhIL-2 was evident 
when co-cultured with the HMCL, U266 at a ratio of IHMCL:5 T cells after 72 hours 
(l95382±36574 cpm cf. 205529±25769 cpm; n=3, p=NS). The results are illustrated in 
Figure 5.5. Similarly, when lurkat E6.1 cells were co-cultured for 72 hours with U266 
cells at a ratio of IHMCL:5 T cells, no difference in the proliferation, determined 
by[H]thyrnidine uptake was evident (44339±1992 cj54087±1656; n=3, p=NS). 
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FIGURE 5.1. uppression of primary T cell proliferative responses (n=8) to re-
stimulation with rhIL-2 by co-culture with HMCLs, U266, JIMl and RPMI8226. 
Proliferation was assessed by 3H_ Thymidine uptake, expressed as mean ±SEM counts 
per minute (CPM) and background T cell proliferation is indicated by "CM", 
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FIGURE 5.2. Inhibition of proliferative responses of primary T cells (n=8) after 36 
hours re-stimulation with rhIL-2 when co-cultured with HMCLs. 
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FIGURE 5.3. Inhibition of rhIL-2-induced 3[H]dThd uptake of primary T cells (n=3) 
expressing high ( D25bright) and low (CD25dim) levels of surface CD25 when co-
cultured with HMCL (U266) for 36 hours. 
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FIGURE 5.4. Cell cycle di tribution and apoptosis in primary T cells (n=8) when re-
stimulated with rhIL-2 in the pre ence and absence of U266 cells, as detennined by PI-
DNA staining and Anne in V -affinity assay, respectively. 
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FIGURE 5.5. No inhibition of 3 [H]dThd uptake was seen when either IDBL or lurkat 
E6.1 cells were co-cultured with the HMCL, U266 after 72 hours. The Jurkat cells were 
cultured at a concentration of I05/ml and IDBL cells at 106/ml with a T cell:HMCL of 
5:1. 
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5.3.2 PRODUCTION OF T CELL-MODIFYING FACTORS BY HMCL. 
It was important to attempt to identify potential T cell modifying cytokines produced by 
the HMCL. Firstly, U266 cells were examined for cytokine mRNA transcripts oflL-la, 
IL-IP, IL-2, IL-4, IL-6, IL-IO, TNF-a and TGF-pl, by RT-PCR. This demonstrated that 
the tumour cells have strong mRNA transcripts for TGFpI, strong mRNA transcripts 
for IL-6, faint mRNA transcripts for IL-IP, IL-2 and no evidence of IL-4, or IL-I0 
(Figure 5.6). Seven IIMCLs - JIMl, JIM3. JJN3, RPM18226, U266 (parent line) and 
clones M5 and 5RS - were examined for evidence of IL-1O and TGF-pl mRNA 
transcripts. It was demonstrated that all cell lines had strong transcripts for TGF-pl 
mRNA but no band was demonstrated of 352 bps using the IL-IO primer pairs. 
However, the U266 parent cell line and clone M5 demonstrated faint bands of -550 bps 
which may represent contamination with genomic DNA (Figure 5.7). The expression of 
TGF-pl mRNA transcripts at the single cell and small colony level was assayed by 
single cell RT-PCR. U266 cells were cultured in methyl cellulose and single cells and 
small colonies (10 cells in diameter, approximately) were removed at various time 
points over a 10 day period and RT-PCR for TGF-pl mRNA was performed. The 
culture of this clone in methylcellulose did not generate any single cells or 10-cell 
colonies which became negative for TGF-pl mRNA by RT-PCR (Figure 5.8). No single 
cell or IO-cell colonies demonstrated evidence oflL-lO mRNA transcripts. 
The supemates from 3 of these IIMCLs, JIMI, JJN3 and U266, were examined for the 
production of TGF-pI protein after 72 hours culture by ELISA. This demonstrated that 
these cell lines produce significant quantities of TGF-pI when compared to the 
background content of FCS-supplcmented culture medium: lO.63±O.39nglml in JJN3 
supemates, 1O.79±4.07 nglml in JIM 1 supemates and 11.28±1.33 nglml in U266 M5 
supemates cf 3.78 ±I.O nglml in CM (p<O.OOI, Figure 5.9). 
When the U266 cell line was cloned on methyl cellulose, heterogeneity in the 
immunosuppressive properties were seen between clones. In particular, two clones 
U266M5 and U266M6 demonstrated marked differences in their immunosuppressive 
properties on recovery from methyl cellulose into CM. U266M5 was able to suppress 
the Con A-induced proliferation of PBMNC from a healthy donor whereas U266M6 did 
not (Figure 5.10). Furthermore, whilst U266M6 clone demonstrated a typical MLR 
response U255M5 demonstrated a reverse MLR response. 
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FIGURE 5.6. RT-PCR analysis of the HMCL, U266, for T cell-modifying cytokine 
mRNA. J3-Actin mRNA was used as an amplification and loading control. PCR of total 
RNA revealed transcripts for IL-6 and TGF-J31 with faint levels of IL-l~ and IL-2 
mRNA transcripts being detected. The proto-oncogene, pim-l , was constitutively 
expressed in this cell line. Key: M- markers, Act- ~-Actin, H20- negative control. 
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FIGURE 5.7. RT-PCR analysis of different HMCLs for the presence of IL-lO and 
TGF-pl mRNA. Prominent TGF-pl mRNA transcripts are seen in all cell lines but no 
evidence of IL-lO mRNA (352 bps) was detected. P-Actin mRNA was used as an 
amplification and loading control. Key: M- markers, H20 - negative control, lane 1 -
JIMl, lane 2- JIM3, lane 3 -1JN3, lane 4 - RPMI8226, lane 5 - U266 (parent line), lane 
6- U266 5R5 lane 7- U266 M5. 
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FIGURE 5.8. RT-P R Ii r th expression of TGF-f3 and IL-IO mRNA transcripts in 
single cells and 10-celJ colonie cultured in methyl cellulose at the time intervals 
indicated. Key: Ian 1- ingl cell, time O· lane 2- 10 cell colony, time 0; lane 3- single 
cell, 24 hours; lane 4- 10 ceU colony 24 hours· lane 5- single cell, 72 hours; lane 6- 10 
cell colony 72 h urs· Ian 7- ingle ceJI time 240 hours; lane 8- 10 cell colony, time 
240 hours. 
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FIGURE 5.9. The HMCLs JIM! JJN3 and U266 M5 produce significant quantities of 
TGF-pl protein in their supemates after 72 hours culture, compared with FCS-
supplemented CM (p<O.OOl). 
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FIGURE 5.10. uppre ion of Con A-induced proliferation of PBMNC from a normal 
donor when co-cultured with r ducing concentrations ofU266 clone M5. However, this 
is not evident when PBMN are co-cultured with reducing concentrations of the U266 
clone, M6. Proliferation was as e ed by 3[H]thymidine uptake and expressed as counts 
per minute. Key: PB A- PBMN - Con A, IM:5PB- ratio ofHMCL :PBMNC. 
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That is, with reducing concentrations of stimulator cells, an increase in the proliferation 
of the responders was demonstrated (Figure 5.11). When these clones were examined by 
RT-PCR for TGF-JH mRNA transcripts, U266M5 demonstrated strong levels of 
transcripts whereas U266M6 failed to demonstrate any mRNA transcripts (Figure 5.12). 
However, after culturing in CM for 14 days, both U266 M5 and U266 M6 could inhibit 
the Con A-induced proliferation of PBMNC from healthy donors and both sub-clones 
demonstrated TGFpl mRNA transcripts by RT-PCR. This suggested that TGF-pl 
mRNA may be modulated under certain culturing conditions. Further experimentation 
in this area is beyond the scope of the present studies. 
Conventional histological examination of paraffin-embedded sections prepared from 
U266 cell suspensions demonstrated characteristic heterogeneous morphology of the 
malignant plasma cells. Under light microscopy (xl 000), bi-and tri-nucleate plasma cell 
variants can be identified amongst the smaller plasma cells which demonstrate the 
characteristic features of mature plasma cells with eccentric mature nuclei, peri-nuclear 
golgi apparatus and a low nuclear:cytoplasmic ratio (Figure 5.13A & B). Amongst these 
smaller plasma cells, larger plasmablasts are identified demonstrating nucleolated 
nuclei. Apoptotic cells were easily identified in the sections with occasional mitotic 
figures. Immunohistochemical detection of latent TGF-p on sections prepared from 
U266 cell suspensions demonstrated that all cells stain for this cytokine (Figure 5 .13 D). 
The pattern of staining demonstrated localised cytoplasmic expression of the cytokine, 
suggestive of compartmentalisation in secretory vesicles. The immuno-reactivity pattern 
of the anti-LAP antibody was similar in the small mature plasma cells, the multi-
nucleated and plasmablastic fonns. It is important to note that the immuno-reactivity of 
the goat anti-human LAP MoAb is such that it detects not only LAP as a pro-peptide 
cleaved from the active TGF-p but also the latent fonn of the cytokine. Therefore, the 
activation state of TGF-p cannot be inferred using this antibody alone and the use of 
differential antibody immuno-detection has been describe to differentiate the activation 
status of the cytokine in histological preparations (Barcelionos-Hoff et al, 1994). 
5.3.3 RECOMBINANT TGF-p MIMICS HMCL-INDUCED T LYMPHOCYTE 
SUPPRESSION. 
The effect of recombinant human TGF-p 1 was investigated in the in vitro T cell model 
to determine whether this could mimic the growth retardation effect demonstrated by 
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FIGURE 5.11. U266 clon MS demonstrates a reverse MLR response with PBMNC 
from a normal donor after 5 day whereas U266 clone M6 exhibits a modest MLR 
response. Proliferation d terrnined by 3[H]thymidine uptake. 
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FIGURE 5.12. RT-PCR analysis of the two clones of U266, M5 and M6 for the 
presence of TGFJ31 mRNA. Prominent TGFJ31 mRNA transcripts are seen in M5 but 
not in M6. J3-Actin mRNA was used as an amplification and loading control. Key: M-
markers, lane 1 - M5 J3-Actin , lane 2 - M5 TGF-J3, lane 3 - M5 J3-Actin, lane 4 - M5 
TGF-J3. 
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FIGURE S.13. Immun hi t chemical localisation of latent TGF-f31 in U266 cells, 
using a goat-anti-human LAP MoAb. Paraffin embedded sections of U266 cell 
suspension tain d £; r hi t I gical examination with H&E (A & B; xlOOO), isotype 
control ( . xl 0 and intra-c llular TGF-f31 using an anti-LAP MoAB (D; xl000). 
Characteri tic malignant pi rna cell features are seen in the H&E stained sections (A & 
B) including bi- and tri-nu leat variant and plasmablasts with occasional apoptotic 
cells seen (arr w . 
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myeloma-derived TGF-p. When IL-2-responsive PBL (n=8) were re-stimulated with 
rhIL-2 in the presence of increasing concentrations of recombinant TGF-pl, 
suppression of the proliferative responses was demonstrated. This suppression 
demonstrates a dose response effect, with the greatest effect being seen with TGFp 1 10 
nglml with a reduction in 3[H]dThd uptake from 33915±6,099 cpm to 16501±1,542 cpm 
(p=0.0142), as illustrated in Figure 5.14. A direct correlation was demonstrated between 
the degree of suppression and the TGF-pl concentration (~=0.975, p=O.0l3). This 
suppression of IL-2 responsiveness was seen when 20 Vlml of rhIL-2 was used to 
stimulate the PBL. To determine whether increasing concentrations of IL-2 could 
overcome the suppression of proliferative responses, IL-2-responsive PBL were 
cultmed for 36 hours in increasing concentrations of both rhIL-2 and TGF-p 1 (Figure 
5.15). Increasing IL-2 concentrations could not overcome the suppressive effect of 
TGF-pI on PBL proliferation, even at the lowest TGF-plconcentration. However, 
incremental proliferative responses are still evident with increasing concentrations of 
rhIL-2. This agrees with data that I have presented in this thesis demonstrating that the 
addition of IL-2 to Con A could not overcome the suppression of proliferative responses 
ofPBMNC by HMCLs (Figure 4.3). 
Recombinant TGF-p 1 can suppress the activation stage of the in vitro model, so to 
determine the effect of TGF-p 1 on the IL-2 autocrine and cytokine-dependent stages, 
TGF-p 1 was co-culturcd with lurkat E6.1 and IDBL cells, respectively. When TGF-p 1 
was added in increasing concentrations to the culture of Jurkat E6.1 cells, at a 
concentration of 1 x 1 04/ml, no suppression of proliferation was detected after 72 hours 
ofcultme (n=3), by 3[II]dThd uptake (Figure 5.16). Similarly, when TGF-pl was added 
in increasing concentrations to IDBL cells cultured in 20 Vlml of rhIL-2, at a 
concentration of 1 x lOs Iml, no suppression of proliferation was demonstrated after 72 
hours (n=3). Thus using the 3 cell model ofT cell activationlhomeostasis, recombinant 
TGF-pl, like IIMCLs, specifically inhibit T cells entering the activation phase with 
little or no effect being demonstrated on cells which have traversed this phase and 
entered the IL-2 autocrine and cytokine dependent stages. 
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FIGURE 5.14. The effect of culturing mitogen activated PBL re-stimulated with 20 
Vlml rhIL-2 (n=8) in increasing concentrations of TGF~ 1 on proliferation, as measured 
by 3[H]thymidine uptake after 36 hours. Only TGF~1 IOng/ml demonstrated a 
statistically significant reduction in IL-2-induced proliferation (p=O.0142). 
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FIGURE 5.15. Th effect of culturing IL-2 responsive PBL in increasing 
concentrations of rhIL-2 and TGF-~ 1 for 36 hours. Increasing the concentration of rhIL-
2 does not completely reverse the uppressive effect of TGF-~l though incremental 
proliferative re pon are till een. Proliferation is represented by 3[H] thymidine 
uptake. 
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FIGURE 5.16. The effect of culturing IDBL (lOs/ml + rhIL-2 20 U/ml, n=4) and Jurkat 
E6.1 (104/ml + eM, n=4) cells in increasing concentrations of recombinant TGF-f3 1 for 
72 hours, as measured by 3[H]thymidine uptake. No suppression of proliferation was 
demonstrated even at the higher concentration of TGF -f3 1. 
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When IDBL cells (lOs/ml, n=3) were stimulated with IL-2, IL-12 or IL-2 + IL-12 in the 
presence and absence of TGF-~ 1 (5 ng/ml), distinct differences in the proliferative 
responses were observed. No suppression of the IL-2-mediated proliferative response 
was demonstrated when TGF-~ 1 was added after 72 hours (Figure 5.17). IDBL cells fail 
to demonstrate a proliferative response to IL-12 alone and a slight increase in 
proliferation was seen with the addition ofrhTGF-~l. When IL-2 and IL-12 were used 
to stimulate proliferation of IDBL cells, again a pronounced proliferative response was 
demonstrated compared with IL-2 alone. In a similar fashion to the effect that TGF-~ I 
demonstrated on the proliferation induced by IL-12 alone, the addition ofTGF-~1 to IL-
2 + IL-12 resulted in a 37.3% inhibition of the proliferation, after 72 hours. This 
experiment demonstrates that IDBL cells do possess functional TGF-~ receptors as 
evidenced by the inhibition of IL-12-induced proliferation. 
5.3.4 LATENCY-ASSOCIATED PEPTIDE (LAP) IS A SPECIFIC TGF~ 
ANTAGONIST. 
The presence of TGF-~l mRNA, TGF-~l protein in HMCLs and supernates and the 
fact that a similar effect can be demonstrated using recombinant human TGF-~l, does 
not confirm that tumour-derived TGF-~l is responsible for the suppressive effects 
exerted by I IMCL on activating T cells. Experiments were set up to directly block TGF-
~ 1 and examine the effect this has on immune suppression. A rabbit anti-pan TGF-~ 
monoclonal antibody was used to reverse the suppressive effect of HMCLs (JIMI, 
JIM3, JJN3, RPMI8226 and U266) and recombinant TGF-~ 1 on the IL-2 
responsiveness of primary T cells. The anti-pan TGF-~ antibody was added to the 
culture medium at 1.5J.1g1ml (NDso) and 2.0J.1g/ml and T cells were re-stimulated with 
rhIL-2 (20U/ml) for 36 hours in the presence and absence of HMCLs and recombinant 
TGF-~1. Proliferation was assessed by 3[H]dThd uptake. No reversal of the suppression 
of IL-2 responsiveness was demonstrated when the monoclonal antibody was added at 
either concentration to primary T cells stimulated in the presence of 
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FIGURE 5.17. The effect proliferation of culturing IDBL cells (lOs/mI, n=3) with IL-2, 
IL-12 and IL-2+IL-12 in the pre ence and absence ofTGF-pl (5 ng/ml) for 72 hours, as 
measured by 3 [H]thymidine uptake. 
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FIGURE 5.18. h additi n f rabbit anti-pan TGF-p (a-TGF) at the NDso dose 
(1.5~g/ml) and high r ha n effect on the immunosuppressive effect ofHMCLs on the 
IL-2 respon iv ne of primary T cell, As determined by 3[H] thymidine uptake. Slight 
improvement of uppre ion induced by recombinant TGF-pl was seen both at 
1.5Jlg/ml and 2.0Jlglml, whi h w n t tati tically significant. 
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HMCLs (Figure 5.18). A slight improvement in recombinant TGF-~I-induced 
suppression was seen, but this failed to reach statistical significance. 
TGF-~l is released from all cells in a biologically inactive form incapable of interaction 
with its receptor, which serves as post-transcriptional control (Letterio & Roberts, 
1998). This inactive fonn consists of TGF-~ 1 non-covalently bound to a proregion 
peptide referred to as latency associated peptide (LAP) which when present in excess 
can associate non-covalentIy associate with active TGF-~l and neutralise its biological 
activity (Bottinger et ai, 1996). Recombinant human LAP, a glycosylated disulfide 
linked homodimer, is a 249 amino acid peptide capable of specifically antagonising the 
biological activity of TGF-~ 1, with an ECso of 8-40 ng/mt. To determine the effective 
dose of LAP to antagonise TGF-~ in the in vitro model ofT cell homeostasis, the effect 
of increasing concentrations of LAP on the suppression of IL-2-induced proliferation of 
primary T cells by 5 ng/ml of TGF-~ I was assessed. It was shown that at 100ng/ml of 
LAP, the suppressive effect of TGF-~ 1 was abolished in a 36 hour culture, as 
determined by 3[11] thymidine uptake (Figure 5.19). When the effect of TGF-~ 1 on IL-
2-induced proliferation was expressed as percentage inhibition of proliferation, it clearly 
demonstrated that increasing the LAP concentration to 100-200 ng/ml abolishes the 
TGF-~ I-induced suppression of proliferation. Thus, LAP was used at a concentration of 
100 ng/ml in subsequent experiments. Primary T cells (n=4) were re-stimulated with IL-
2 (20U/ml) in the presence of IIMCLs (JIM 1, U266 and RPMI8226) with and without 
LAP 100ng/mI, for 36 hours. The co-culture with HMCLs induced a significant 
inhibition of the IL-2-induced proliferation, which was restored by the addition of LAP 
to the cultures (p<O.OO 1; Figure 5.20). It is interesting to note the slight rise in the 
proliferation of T cells stimulated with IL-2 in the presence of LAP 100ng/ml without 
HMCLs. This results from neutralisation of TGF-~l contained in FCS-supplemented 
CM (3.78±1.0 ng/ml). 
5.3.5 THE EFFECT OF TGF-~ BLOCKADE ON HMCL GROWTH AND 
VIABILITY. 
TGF-~ has been sho\\n to inhibit B lymphocyte proliferation and induce apoptosis in 
both B cells and mature plasma cells, which is thought to be an important negative 
regulatory feedback loop to limit expansion of activated cells (Letterio & Roberts, 
1998). IIowever, the importance of this inhibitory autocrine loop in malignant B cells 
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FIGURE 5.19. The effect of increasing concentrations of LAP on the TGF-~-induced 
(5ng/ml) inhibition of the pr liferative response to IL-2 by primary T cells, as depicted 
in Figure 5.18. 
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remains to be determined. The effect of TGF-(3 I autocrine secretion on the proliferation 
and survival of the HMCL, U266, was assessed. U266 cells were cultured in CM for 24 
and 48 hours with and without anti-pan TGF-(3 monoclonal antibody and LAP and the 
effect that these antagonists had on cell viability, as determined by trypan blue 
exclusion, and proliferation was determined. No significant effect on the U266 cell 
viability was seen when the cells were co-cultured with the monoclonal antibody (77%± 
3 at 500 nglml cf 83%±4.5 in CM) at 24 hours or 48 hours (71 %± 6 at 500 nglml cf 
85%±2 in CM). When proliferation was examined by 3[H]dThd uptake, a slight 
decrease in proliferation was seen at 24 hours with a concentration of monoclonal 
antibody below the NDso (1.5J.lglml), but no effect on proliferation was seen at 48 hours 
(Figure 5.21). When U266 cells were cultured with increasing concentrations of LAP 
for 24 and 48 hours, similarly, no significant alteration in the cell viability was seen at 
either time point (81%± 5 at 40 ng/ml cf83%±4.5 in CM at 24 hours and 73%± 6 at 40 
nglml cf 83%±4.5 in CM at 48 hours). When the proliferation of U266 cells was 
examined at 24 and 48 hours of co-culture with increasing concentrations of LAP, it 
was shown that there is a suppression of proliferation at a concentration of LAP below 
the ECso (IOng/ml), which recovers with increasing LAP concentration though does not 
return to the level seen with eM alone (Figure 5.22). 
180 
35000 
-+-24 hours - 48hours 
30000 • • .~ • 25000 
20000 
E 
C-
o 
15000 
10000 
5000 
0 1 r 0 0.75 1.5 7.5 10 
anti-TGF(microg/mI) 
FIGURE 5.21. Co-culture ofU266 with increasing concentrations of the anti-pan TGF-
~ monoclonal antibody. Proliferation was determined by 3[H] thymidine uptake. 
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5.4 DISCUSSION 
The role ofTGF-pl in manipulating the immune response 
Several established cytokine families are recognised by their role in manipulating the 
immune response (e.g. tumour necrosis factor-related molecules, the TGFJ3 family, 
interferons, interleukins and chemokines). Of these, the TGFJ3 family of cytokines have 
an unique position in the cytokine hierarchy by having pivotal roles in development, 
epithelial cell growth and differentiation, in carcinogenesis as well as regulating the 
immune system (Roberts & Spoon, 1990). 
There are five isoforms of this pleiotropic cytokine (TGFJ31-S) which signal through the 
same serine-threonine kinase receptors (TGFJ3R I and II). TGF-J3 brings together the 
two types of receptors, one kinase phosphorylates the other which in turn 
phosphorylates SMAD proteins (vertebrate homologues of the Drosophila gene Mad 
(mothers against dpp» which are novel signal transducers (Massague.1998). The 
SMADs, upon phosphorylation, migrate to the nucleus and generate transcriptional 
complexes of specific DNA-binding ability. Numerous gene responses to TGF-J3 have 
been described and include the cyclin-dependent kinase inhibitors plSInk4b and p21 cip1 
which mediate cell cycle arrest, and the genes coding for collagen al(I), collagen a2(I) 
and plasminogen activator type 1 (reviewed by Massague.1998). TGF-J3 and related 
factors can also cause rapid inhibition of gene transcription, including c-myc and 
cdc25A, mediating the anti-proliferative effects ofTGF-J3 (Ahuja et aI, 1993). 
TGF-J3 affects all of the mediators of the immune response - T cells, B cells, 
monocytes/macrophages and dendritic cells. TGF-J3 is a potent immunosuppressive 
cytokine and influences all stages of T lymphocyte development and differentiation 
through to their activation and proliferation, the exact effect being determined by the 
stage of maturation of the T cell (Letterio & Roberts, 1998). Exogenous TGF -13 inhibits 
T cell proliferation by altering IL-2 mediated-signals and inhibition of IL-2 mediated 
phosphorylation of the retinoblastoma susceptibility gene product (Fontana et ai, 1989; 
Wahl et aI, 1989; Ahuja et ai, 1993;Dccker et ai, 1994). Furthermore, TGF-J3 has been 
shown to reduce activation-induced apoptosis in T cells by down-regulating the surface 
expression of FasL in association with the down regulation of c-myc gene expression 
(Genestier et al, 1999). 
The generation of distinct T cell subsets, based on their cytokine production profiles, 
from nal"ve peripheral T cells is a process that is poorly understood in humans. There are 
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multiple pathways that facilitate the polarisation of T h subsets and certain cytokines 
have a role as inducers of either the Thl (IFN-y and IL-2) or the Th2 (IL-4) response 
(Seder et ai, 1994). Different experimental systems have produced conflicting and 
variable roles for TGF-p in Tb differentiation. TGF-pl can inhibit the production of, and 
response to cytokines associated with each T H subset. TGF-p is produced by an 
identified population of antigen-specific T cells, referred to as T H3 cells, which may 
represent a subset of cells that regulate the intensity of an immune response to specific 
antigen (Chen et ai, 1994; Bridoux et ai, 1997). More recent experimental evidence 
implicating a role for TGF-p t in manipulating the T H differentiation in human systems 
suggests that the effects of TGF-pi are mediated through mechanisms associated with 
abrogation of IL-12 production (Pardoux et ai, 1997). Neither exogenous IL-12 nor 
IFN-y can reverse this antagonistic effect ofTGF-P1. Furthermore, it has been shown in 
a murine experimental system. that the immuno-suppressive effect of TGF-p (tumour-
derived) is more marked on CD4+ T cells and that observed defects in CTL generation 
result from failure of the Tn cells to orchestrate a suitable response (Tada et ai, 1991). 
In the in vitro model system used in the experiments described in this chapter, TGF-pl, 
both tumour-derived and exogenous cytokine, reduced primary T cell responses to IL-2. 
Other investigators have suggested that TGF-pl suppresses IFN-y and IL-4 production 
by human T cells by interfering with the IL-2-signalling pathway (Ahuja et ai, 1993; 
Holter et ai, 1994). This is similar to effects demonstrated by IL-l 0, though this effect is 
mediated by suppressing antigen-presenting cell-derived IL-t2 (Korholz et ai, 1997). 
IL-tO mRNA was not demonstrated in the IIMCLs used in these experiments. It has 
been suggested that TGF-pi mediates its effects through tyrosine and Rb 
phosphorylation in association with suppression of IL-2Ra gene up-regulation (Ahuja et 
aI, 1993). Ilowever, it has not been determined whether such effects are mediated 
through the TCR and IL-2R pathways or IL-2R pathway 8Jone. In summary, TGF-pl 
regulates T cell proliferation, cell cycle progression and cytokine production through the 
inhibition of phosphorylation of molecules involved in cell cycle regulation. It 
particularly inhibits 1L-2-mediated proliferative signals through as yet unknown 
pathway(s). T cells both produce active TGF-pl and express TGF-pl receptors and thus 
under physiological conditions it represents a regulator of the immune response. 
However, produced in excess by a tumour, TGF-pl could be responsible for tumour-
associated immuno-suppression. TGF-p has been shown to be produced by many 
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different tumour cell types (Fischer et aI, 1994; Urishima et ai, 1996; Merogi et ai, 
1997). Many defects in T cell responsiveness have been reported in these settings, but in 
multiple myeloma, no such mechanism has been characterised to explain the observed T 
cell anergy. 
The role ofTGF-pl in the pathogenesis of Afultiple Myeloma. 
The synthesis of TGF-p 1 by B cells in health relates to their state of activation and 
differentiation. For example, when tonsillar B cells are stimulated by mitogens 
(staphylococcal antigen Cowan; SAC), a slight up-regulation of TGF-p 1 mRNA is seen 
but this is associated with a 7-fold increase in protein, most of which (>90%) remains in 
the latent/inactive fonn (Kehrl et aI, 1986). TGF-p typically inhibits proliferation in 
both B cells and mature plasma cells and therefore may act as a negative feedback to 
regulate the extent of the immune response (Lomo et ai, 1995). It has been proposed 
that some B cell malignancies (chronic lymphocytic leukaemia; CLL) have retained this 
negative feedback loop that might account for their reduced proliferative capacity (Lotz 
et aI, 1994). Ilowever, it is worthy of note that like many epithelial malignancies, 
several B cell malignant disorders have been identified as "insensitive" to the inhibitory 
effects ofTGF-p, perhaps resulting from loss or dysfunction of one or more components 
of the TGF-p receptor (Tada ct aI, 1991; Decoteau et aI, 1997). This has been proposed 
to contribute to the suppression of immune surveillance and associated with tumour 
progression. TGF-p was originally thought to suppress the secretion of 
immunoglobulins (reviewed in Stavnezer, 1996). However, it has been shown that the 
addition of anti-TGF-f} MoAb, which blocks the biological effect of TGF-p, to cultures 
of LPS-activated n cells, a reduction in the secretion of IgG 1, IgG2a, IgG3 and IgE is 
seen with no effect on the production of IgM nor IgA (Snapper et ai, 1993). This 
suggests that TGF-f} may have differing effects on B cell function at varying levels and 
may enhance the production and secretion of immunoglobulin under certain conditions. 
TGF-p has been shown not only to regulate the response ofT cells but also ofB cells to 
IL-2 (Kerhl et al. 1986). It was demonstrated that TGF-p 1 inhibits IL-2-dependent DNA 
synthesis in B cells though this effect was limited in EBV -transfonned B cell lines, 
owing to the absence ofTGF-p receptors on the transformed cell line. The production of 
TGF-p by B cells may be important in the cell-cell and cell-microenvironment 
interactions. TGF-p has been shown to accelerate wound healing and stimulate 
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fibroblasts and has been associated with the production of IL-6 by bone marrow stromal 
cells (Letterio & Roberts, 1998). As such TGF-p may function as an important B cell 
cytokine for the orchestration of the immune response in health, both in establishing and 
limiting the extent of the response in an autocrine fashion. However its role in the 
malignant variant of nonnal B cell physiology is clearly quite different and variable 
according to the malignant transfonnation. 
In multiple myeloma, a malignant disorder of tenninal B cells, several studies have 
shown TGF-p 1 mRNA in tumour cells and derived cell lines which correlates with 
secretion of active TGF-pl, as demonstrated in this chapter. (Matthes et ai, 1993; 
Portier et ai, 1993; Matthes et ai, 1995; Urashima et ai, 1996). Some investigators have 
shown that the level ofTGF-pl secreted by MM cells is greater than nonnal B cells and 
CD40L-activated 0 cells and that OM stromal cells from MM patients secrete more 
TGF-JH than OM stromal cclls from nonnal control subjects (Urashima et ai, 1996). 
Other groups have demonstrated high serum and urinary levels of TGF-J31 in patients 
with MM using ELSIA assays and there is a suggestion that serum levels correlate with 
the extent of myeloma bone disease (Jiang et aI, 1995; Kroning et ai, 1997). 
In contrast to its effects on nonnal 0 cells, TGF-J31 does not decrease the proliferation 
of MM cells and may even augment IL-6 secretion and related proliferation (Urashima 
et aI, 1996). It has been demonstrated that the lack of inhibition of proliferation is 
associated with a failure to inhibit Rb phosphorylation or DNA synthesis in both 
HMCLs and fresh tumour cells from patients with multiple myeloma. This insensitivity 
may in part be related to abnonnalities of both Rb and p53 tumour suppressor gene 
products, mutations of which have been reported in 35-40% and up to 52% of fresh 
myeloma tumour cells, respectively (Corradini et ai, 1994). TGF-J31 has been shown to 
induce both autocrine 1L-6 production by fresh myeloma tumour cells and HMCLs 
(Urashima et aI, 1996). The same authors demonstrated that TGF-p I induced paracrine 
IL-6 production from the stromal cells derived from bone marrow samples of patients 
with multiple myeloma. In addition, using anti-TGF-J31 MoAb, the authors 
demonstrated a reduction in the IL-6 production by both stromal cells and fresh 
myeloma tumour cells, perhaps mediated through alterations in cell-cell adhesion, 
though no alteration in surface density of adhesion molecules has been demonstrated. In 
this chapter I have shown preliminary experimental data suggesting that blocking TGF-
131 using LAP altered the proli fcration kinetics of the IIMCL, which may be influenced 
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by alterations in IL-6 production and signalling. However, further investigation of the 
role of TGF-p 1 in propagating the viability and growth of myeloma plasma cells in 
beyond the remit of this thesis. Clearly there is a need to examine in greater detail what 
effect TGF-p 1 has on myeloma plasma cell cytokine and chemokine production, cell 
division kinetics especially in relation to the cell cycle regulators Rb, c-myc, pS3 and 
E2F and the eyclin-dependent kinase inhibitors plSlnk4b and p21 Cipl • Furthermore, the 
relationship of TGF-Jl 1 and the homing/re-circulation of myeloma plasma cells 
including alterations in adhesion molecule profile and chemokines production and 
responsiveness remains to be explored. 
TGF-p is responsible for myeloma-induced immunosuppression. 
The data presented in this chapter strongly support the theory that myeloma tumour 
cells suppress the activation of T lymphocytes through the production of the pleitropic 
cytokine, TGF-p I. In consideration of this theory, there are a number of facts illustrated 
by this data worth noting. Firstly, both IIMCLs and recombinant TGF-pl suppress the 
IL-2 responsiveness of T cells from normal volunteers that have previously been 
activated by the Con A. Such suppression results in the accumulation of cells in the 
GoIGlphase of cell cyete with no significant increase in the apoptosis rate compared to T 
cells re-stimulated in the absence of IIMCLs. As the T cells are blocked from entering 
the activation phase, susceptibility to apoptosis is no different from that seen in the 
absence of IIMCLs. FaslFasL interactions may cause T lymphocyte cell cycle arrest 
rather than apoptosis dependent on the stage of activation, though this failure to 
progress through the stages of cell cyete can be reversed by IL-2 (Desbarats et aI, 1998). 
Secondly, TGF-p 1 was identified as the main mediator of the suppression T cell 
activation. The identification of cytokine mRNA in the tumour cells is in itself not proof 
of involvement of suppression of T cell responses. The primary level of control of TGF-
PI production is not regulated at the mRNA level but is subjected to post-transcriptional 
control by the process of secretion and activation of the TGF-p 1 protein (Letterio & 
Roberts, 1998). The IIMCLs do in fact secrete high levels of total TGF-pl, as 
evidenced by the ELISA assays that showed that levels up to 4 fold greater than that 
recorded in FCS-supplemcntcd CM. The involvement ofTGF-p 1 as a major mediator of 
HMCL-induce T cell suppression was further confirmed by the blocking experiments 
using LAP. TGF-p 1 and LAP are components of a pro-peptide which is cleaved in the 
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post-golgi compartment prior to secretion (Massaguc, 1998). LAP is a highly specific 
antagonist for TGF-p J, which binds the active cytokine and holds it in an inactive 
conformatio~ thus blocking its biological effects (Bottinger et aI, 1996). LAP 
demonstrates superior binding capacity to TGF-p 1 compared to the soluble extra-
cellular domain of the TGF-p receptor type II with a I5-fold (8nM versus I20nM) lower 
equilibrium dissociation constant. 
Thirdly, using the thrcc-cell modcl of T cell activationlhomeostasis, the data 
demonstrate that the effects of IIMCLs and rhTGF-p 1 are limited to the activation 
phase and not the IL-2-dcpendent phases as evidenced by the absence of suppression of 
lurkat E6.I and IDBL cell proliferation. It is accepted that using transformed cell lines 
in an in vitro cellular model in this setting is subject to limitations. The cellular 
characteristics, particularly in respect to suppressive factors, may not truly represent the 
in vivo behaviour of T cells at these phases of proliferation and cytokine homeostasis. 
Many potential reasons may exist to explain these including absent or dysfunctional 
receptors for immune modulating cytokines and chemokines, absent or defective intra-
cellular signalling pathways for transduction of immune mediator interactions with their 
respective receptors and altered activation signal transduction pathways. It is important 
to emphasise that IDBL cells were demonstrated to have functional TGF-p 1 receptors 
by virtue of the suppression of IL-12-mediated proliferative signals by exogenous, 
recombinant TGF-p I. Phenotypic analysis using immunofluorescent flow cytometry to 
detect TGF-p receptors was not performed on either cell line. 
Amongst the other possible explanations for the observed insensitivity of these cell lines 
to TGF-p 1 is the fact that both Jurkat E6.1 and IDBL cells do not express the IL-2Ra 
subunit, neither at the protein level nor the mRNA level, and thus do not signal through 
the high affinity receptor (IL-2Rapyc). Signalling through the high affinity IL-2R 
facilitates the entry into the IL-2 autocrine pathway (Minami et aI, 1993). However, 
both Jurkat E6.1 and IDBL cells arc beyond the entry point to the IL-2 autocrine 
pathway: Jurkat cells being immortalised in the IL-2 autocrine pathway and IDBL cells 
existing beyond this phase. demonstrating c)10kine-dependant susceptible apoptosis 
upon the withdrawal of exogenous IL-2. As such both lurkat E6.1 and IDBL cells may 
be resistant to the inhibitory eITects of I I MCL-dcrivcd and recombinant TGF-p 1 may 
relate to the absence of signalling through the IL-2Ra and this warrants further 
investigation. 
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The exact role of TGF-p 1 in the pathogenesis of multiple myeloma, including host 
tolerance of the malignant clone, remains to be clarified. The data presented in this 
chapter clearly indicates it is a major cytokine involved in modulation of T cell 
activation whilst other investigators have demonstrated its role in the maintenance and 
survival of the malignant B cell clone. It is also possible that TGF-pl contributes to the 
identified suppression of normal haematopoiesis frequently associated with the disease, 
especially in advanced stages. The molecular mechanisms which dictate the inhibition 
of T cells which are in the early activation phase prior to entry into the IL-2 autocrine 
pathway warrants closer examination including the relative resistance that transformed 
T cell lines which represent cells in the autocrine IL-2 pathway and at the cytokine-
dependent stage of T cell homeostasis demonstrate. This series of investigations will 
form the basis of the chapter 6. 
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CHAPTER 6 
Myeloma-derived TGF.p requires the a chain of the IL-2 receplor for 
T cell suppression 
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6.1 INTRODUCTION 
In chapter 3 and 5 it was demonstrated that HMCLs prevent the full activation of T 
lymphocytes associated with cell cycle arrest. This effect is mediated through the 
production of the potent immuno-suppressive cytokine, TGF-p 1. The effect of HMCL-
derived and recombinant TGF-p 1 is not observed on T cells which have committed to 
the IL-2 autocrine pathway or have progressed beyond this into the cytokine-dependent 
phase of T cell homeostasis. Other investigators have shown that TGF-p 1 can inhibit 
IL-2 production and the inhibitory effects have been mapped to the octamer element of 
the IL-2 promoter (Brabletz et aI, 1993; Rooney et aI, 1995). Furthermore this does not 
explain the exemption from suppression by TGF-p 1 of the cells in the IL-2 autocrine 
and cytokine dependent phases of activation. Therefore, as yet, the influence that TGF-
PI exerts on the IL-2 gene up-regUlation and entry of T cells into the IL-2 autocrine 
pathway remains to be detennined. 
Whilst there are many molecular differences between the three distinct phases ofT cell 
activation, as delineated in the in vitro model I have described, one major difference of 
note is the variation in the requirement of IL-2Ra subunit in supporting the high affinity 
interaction of IL-2 and subsequent progression into the IL-2 autocrine pathway. Primary 
T cells can up-regulate IL-2Ra in response to IL-2 as a prelude to autocrine production 
of IL-2. This is in contrast to both IDBL cells and Jurkat E6.1 which have no 
requirement for high affinity interactions with IL-2 and neither express nor up-regulate 
IL-2Ra. Most primary T cells rendered IL-2 responsive by mitogen activation express 
IL-2Ra but these cells still need to up-regulate IL-2Ra in order to progress to the IL-2 
autocrine pathway in response to exogenous cytokine. 
Interleukin-2 
The T cell growth factor, 1L-2, is produced by T cells upon antigenic stimulation and is 
vital for clonal expansion and survival (Minami et aI, 1993; Nelson & Willerford, 
1998). 1L-2 is a 15-18 kD (depending on the degree of glycosylation), 133 amino acid 
glycoprotein encoded by a single gene on chromosome 4 and acts in a monomeric form 
in its ligation with its receptor (Smith, 1993). IL-2 is a potent growth factor responsible 
for the promotion of cell cycle progression. in particular 01-S phase transition, in T 
cells. T cell antigen recognition by the TCR with appropriate co-stimulation results in 
the de novo transcription and translation of IL-2, mediated by the protein tyrosine 
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kinase, p561ck (Minami et ai, 1993 B). The production of IL-2 results in the up-regulation 
of the high affinity receptor, IL-2Ra, which mediates further IL-2 production by an 
autocrine loop (Nelson & Willerford, 1993). In addition, IL-2-mediated signal 
transduction results in functional uncoupling of the TCR complex through altering the 
sub-cellular distribution of kinase active lck, indicating the role of IL-2 in a negative 
feedback regulatory mechanism (Jlaughn et aI, 1998; Lenardo et aI, 1999). 
The exact signalling pathways involved in the actions of IL-2 remain unclear, especially 
in the context of inducing cell cycle progression and protection from apoptosis. In part, 
some of the uncertainty results from initial studies that examined sub-cellular signalling 
in transformed T cells. These indicated that IL-2-induced cell cycle progression and 
protection from apoptosis resulted from the up-regulation of c-fos and c-jun which 
resulted in the formation of the AP-l complex and the activation ofNF-KB (Guizani et 
aI 1996; Xie et ai, 1997). However, AP-l and NF-KB are not essential for the effect that 
IL-2 has on primary T cells, at least in respect to cell cycle progression and anti-
apoptosis (Iacobelli et ai, 1999). The differences may be explained by subversion of 
signalling pathways in in vitro transformed cells. Instead, the JakiSTAT pathway may 
playa pivotal role in mediating the IL-2IIL-2R interactions in primary T cells. Janus 
tyrosine kinascs (lak) are activated by phosphorylation mediated by receptor/ligand 
interaction. Subsequently, they phosphorylate the signal transducer and activator of 
transcription (STAT) molecules which translocate to the nucleus and initiate 
transcription of target genes (reviewed by Leonard & O'Shea, 1998; Table 6.1). In 
particular, Jak I and Jak3 are constitutively associated with the intra-ce11ular domains of 
IL-2RP and 1L-2Ryc chain~ respectively (Sugamura et ai, 1996). STATS and STAT3 
interact with the cytokine receptors via their SII2 domains and are subsequently 
phosphorylated by Jakl and Jak3, respectively. The phosphorylated STATS and STAT3 
molecules then fonn homo- and hctcrodimcrs and migrate to the nucleus and activate 
genes conataining STAT-binding sites, referred to as interferon-y activated sequences 
(GAS elements). 
Another potentia) mediator of IL-2-induced proliferation and survival signalling in 
primary T cells is the cell cycle regulator E2F (Brennan et ai, 1997). E2F, so named as 
the factor for adenovirus E2 gene transcription, heterodimerises with the 
hypophosphorylatcd retinoblastoma susccptibility gene product, Rb (Weinberg, 1995). 
As the Rb protein is hypcrphosphorylated. mediatcd by a number of kinases and cyclin 
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complexes, E2F is released and activated. The now activated E2F heterodimerises with 
members of the DP family of proteins thus facilitating the transcription of target genes 
involved in cell cycle progression. IL·2 has been shown to activate phosphatidylinositol 
3-kinase (PI-3K) that in tum activates AKTIPKB (protein kinase B). which is one of the 
key kinases involved in E2F activation (Kamitz & Abraham. 1996; Naheed et al. 1997). 
Essential to the activation process of T cells is the entry into the IL-2 autocrine pathway 
and this is facilitated by the up-regulation of the a subunit of the IL-2R. Data presented 
in previous chapters indicate that IIMCL inhibit the IL-2 responsiveness of peripheral T 
cells. The effect that IIMCLs exert on activating T cells. mediated by TGF-~I. may 
result from interference with the assembly of the high affinity IL-2 receptor, thus 
blocking the entry into the 1L-2 autocrine pathway. The effect that tumour-derived 
TGF-~ 1 has on the regulatory control of IL-2Ra expression and associated signalling 
pathways remains to be established. 
Experimental A ims 
The aim of the work presented in this chapter is to examine the regulation of IL~'lbx in 
relation to the inhibitory effect ofllMCL-derived TGF-~l. The effect that TqF-~i has > 
,I> 
on the signal transduction of the IL-2R will also be investigated. The exPerimellts 
presented here aim to explain, at the molecular level, the mechanism~ ~~if~ I!.':e 
involved in the mediation ofT cell suppression induced by myeloma-derived TQf~~. 
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Type I Cytokines Jab STATs 
Cytokines whose receptors share rc 
I~2,IL-7,I~9,I~lS Jakl,Jak3 ST AT5a, ST ATSb, STAT3 
I~4 Jakl,Jak3 STAT6 
IL-13 Jakl, Jak2, Tyk2 STAT6 
Cytokines whose receptors share Pc 
IL-3, I~S, GM-CSF Jak2 STATSa, STATSb 
Cytokines whose receptors share gplJO 
I~6, IL-ll, OSM, CNTF, LIF, CT-l Jakl, Jak2, Tyk2 STAT3 
IL-12 Jak2, Tyk2 STAT4 
Leptin STAT3 
Cytokines with homodimeric receptors 
Growth hormone ST ATSa, STATSb, ST AT3 
Prolactin Jak2 STATSa, STATSb 
Eryhtropoietin Jak2 STAT5a, STAT5b 
Tbrombopoietin Jak2 STATSa, STATSb 
Type II Cytokines 
Interferons 
IFNa,IFNp Jakt, Tyk2 STATI, STAT2 
IFNy Jakl,Jak2 STAT I 
IL-I0 Jakt, Tyk2 STAT3 
TABLE 6.1. The activation of Jaks and STATs by different cytokine families (Leonard 
& O'Shea, 1998). 
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6.2 MATERIALS AND METHODS 
6.2.1 REAGENTS & MATERIALS. 
Monoclonal Antibodies 
All cells were cultured in CM supplemented with recombinant human cytokines as 
indicated in the text Anti-human CD25 and IL-2 antibodies conjugated with PE were 
obtained from Pharmingen (UK). Recombinant human IL-2 and LAP were obtained 
from Sigma-Aldrich (USA) and rhTGF-J31 was obtained from R&D systems. Anti-
ST AT3, anti-phosphorylated ST A T3 and ST A TS antibodies were obtained from Santa 
Cruz Biotech and anti-phosphorylated STATS was obtained from New England 
Biolabs. The anti-bcl-2 monoclonal antibody for intra-cellular F ACS analysis was 
purchased from Dako (UK). 
Oligonucleotide Primers 
As indicated in chapter 2, the IL-2Ra sense and anti-sense oligonucleotide primers were 
designed to give a larger PCR product than the primer pairs reported in the literature. 
The verification of PCR products is discussed in chapter 2. Similarly, I designed and 
verified the sense and anti-sense primers for the IL-2-responsive protoncogene pim-l as 
described in chapter 2. All other sense and anti-sense primer sequences have been 
described elsewhere except the protoncogene, c-abl (A3): 
sense 5' TTCAGCGGCCAGTAGCATCTGACTT 
anti-sense S' GGTACCAGGAGTGTTTCTCCAGACTG 
which yielded a PCR product of213 bps. 
Clinical Samples 
Serum from bone marrow aspirate samples was prepared as follows: following informed 
consen~ 2 mls of bone marrow blood was aspirated at the end of the diagnostic 
procedure from the posterior superior iliac crest under local anaesthetic. The sample 
was immediately decanted into preservative-free heparin and transported to the 
laboratory. The serum and cellular elements were separated by centrifugation at 1,SOOG 
for 5 minutes and the serum was stored in a 1.8 ml Nunc vial at -10°C until required. 
The cellular component was re-suspended in RPMI 1640 supplemented with 10% 
autologous serum for 24 hours, then non-viable cells were removed by density gradient 
centrifugation. Recovered cells were then washed in PBS and re-suspended in 
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IO%DMSOIFCS and stored in liquid N2 until required. Serum from one of these 
patients, a 56-year old female with IgG myeloma, was taken at diagnosis (BM6) and 
used in the experiments described in this chapter. 
6.2.2 SEMI-QUANTITATIVE PCR FOR CYTOKINE RECEPTOR mRNA. 
Duplex PCR is a modification of the standard sequential amplification of DNA species 
where two distinct loci are simultaneously amplified from the one DNA species in a 
single reaction chamber, the subsequent products being distinguishable by differing 
sizes on gel electrophoresis (De Santis & Azzi, 1996). The PCR reaction is composed of 
three distinct phases in relation to the accumulation of oligonucleotide products: an 
initial exponential phase, a linear phase and a plateau phase. During the linear phase, as 
a result of the reaction kinetics and reduced competition of the primer pairs, semi-
quantitative comparisons of target sequences can be made using a duplex PCR assay 
(Sambrook et al, 1989). For the study of IL-2Ra up-regulation a ''partner gene" which 
is constitutively expressed in T lymphocytes was chosen. Three genes were selected: the 
housekeeping gene ~-Actin, the oncogene c-abl and the IL-2Ryc. The linear phase cycle 
range for all four primer pairs had to be established so that a suitable "partner gene" 
could be selected. cDNA synthesized from total RNA isolated from mitogen-activated 
lymphocytes was used in these assays. For each primer pair, 10 simultaneous samples 
were set up as follows: 5J.lI lOX peR buffer (Hybaid,UK), 2J.lI 50mM MgCh 
(Hybaid,UK), 2J.l1 cDNA, llli 25 J.lM Sense primer, IJ.l125 J.lM Anti-sense primer, IJ.lI 
IOmM dNTP (Life technologies Ltd), 0.4111 (2U) AGS Gold Taq polymerase 
(Hybaid,UK) and 37.6J.ll J.ll dlhO. Limited cycle PCR reactions were conducted as 
follows: 95°C for 5 minutes (double strand dissociation), n cycles (where n represents 
17 and with each successive sample n increases by 1) of 95°C for 1 minute 
(denaturation), 60°C for 1 minute (primer annealing), 72°C for 1 minute (extension) 
with a final incubation at 72°C for 5 minute to ensure complete extension of the PCR 
products. The 10 serial PCR samples were then visualized by electrophoresis on a 2% 
agarose gel and the volume of the peR product band was calculated using UViphoto 
software. 
As a result of these experiments, a partner gene was selected and the sensitivity of this 
reaction was dctennined by serial dilutions of cDNA derived from mitogen activated T 
cells (expressing both genes in the duplex peR) in cDNA derived from total RNA 
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isolated from the human leukaemia cell line, K562, which expresses the IL-2Ryc but not 
the IL-2Ra. The duplex PCR reactions were set up as follows: 5,....1 lOX PCR buffer, 2,....1 
50mM MgCh, 2,....1 cDNA, 1,....1 25 ,....M IL-2Ra sense primer, 1,....1 25 ,....M IL-2Ra anti-
sense primer, 1,....1 25 J!M IL-2Ryc sense primer, 1,....1 25 J!M IL-2Ryc anti-sense primer 
2,....1 lOmM dNTP, 0.4,....1 (2U) AGS Gold Taq polymerase and 34.6,....1 ,....1 dH20. Limited 
cycle PCR reactions were run as follows: 95°C for 5 minutes, 23 cycles of 9SoC for 1 
minute, 60°C for 1 minute, 72°C for 1 minute with a final incubation at 72°C for 5 
minute to ensure complete extension of the PCR products. Products were visualized by 
electrophoresis on a 2% agarose gel and the volume of each PCR product band was 
calculated using UViphoto software. A ratio of the two PCR product bands was then 
calculated to give the relative expression of the IL-2Ra in response to re-stimulation. 
6.2.3 GENERATION AND PURIFICATION OF TRANSFECfANT CELL LINE. 
The Chinese hamster ovary fibroblast cell line (CIIO-Kl) was transfected with the 
human IL-2Ra subunit by Dr Trevor Paterson, Academic Transfusion Medicine Unit, 
University of Edinburgh. In brief, the cDNA for human IL-2Ra (ATCC clone 39890) 
was cloned as a PSII(partial)-XbaI fragment into the polylinker of pCDNAJ expression 
plasmid (Invitrogen) under the control of the CMV IE promoter/enhancer. Cell surface 
expression of 1L-2Ra was detectable by F ACScan (Becton Dickinson) analysis of 
transiently transfected (Superfect, Qiagen) CHO-Kl cells upon staining with anti-CD25 
(lL2Ra) FITC conjugated monoclonal antibody (MCA1319F, Serotec). Stable CHO-Kl 
cell lines were selected with 750J.lglml G418 after transfection with circular or Real-
linearized plasmid DNA. Doth approaches produced stable populations in which 
approximately 25% of cells stained positively for surface IL2Ra. Single cell derived 
clones were isolated by limiting dilution of the G418 resistant populations in multi well 
plates. The CIIO-KI cells transfected with IL-2Ra (CIIO-KI125) and wild type/mock 
transfectants (CIIO-Kl/wt) were transferred to me at this stage for further selection. 
Stable CD25 transfcctant cells were purified by surface expression of the a subunit 
using the using the MACS magnetic cell sorting system by Miltenyi , as described in 
chapter 4. The resulting purified cells (CIIO-KI125) demonstrated stable high levels of 
CD25 surface protein (Figure 6.16). Cells were maintained in CM that was replenished 
once per week and the cells were sub-culturcd once per week. For use in experiments 
and for sub-culturing. the plastic adherent cells were treated with x I trypsinlEDT A at 
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37°C for 10 minutes to detach them. The cells were then diluted in xlO volume ofwann 
CM to inactivate the trypsin. The cells were then pelleted by centrifugation. For sub-
culturing, the cells were then split and re-suspended in CM, with plastic adherence 
being achieved within 15 minutes at 37°C. For use in the experimental studies, cells 
were pelleted by centrifugation, fixed in 2% formaldehyde at 4°C for 10 minutes then 
washed three times in CM before using in the experiments at the cell dilutions indicated. 
6.2.4. WESTERN BLOTIING FOR SIGNALLING MOLECULES. 
For the study of STAT signal transduction molecules, T cells activated by mitogen (Con 
A 2.5J1g/ml for 5 days), washed x3 in CM and serum starved for 24 hours by culturing 
the cells in RPMI1640/0.S%FCS. Viable cells were recovered by density gradient 
separation (Ficoll-Hypaque) and washed x3 in CM. The cells were re-suspended in CM 
at a concentration of 2x106/ml and re-stimulated with 20 V/ml rhIL-2 in the presence 
and absence of IlMCL at a concentration of 1 V266:S PBL. Cells were incubated for 4S 
minutes then washed x3 in ice-cold CM. Cell lysates were prepared from the cell pellet 
after centrifugation by the addition of 75J.ll of RIP A buffer containing 10J.ll of protease 
inhibitors (x50), followed by vigorous pipetting. The samples were incubated on ice for 
15 minutes then subjected to 3 rounds of freeze/thawing alternating between dry ice and 
a 37°C water bath. The samples were centrifuged at 4°C at 14,0000 and the supernates 
were decanted into a fresh tube and stored at -70°C until required. 
Samples were recovered from storage and thawed at room temperature. 5 J.lI of western 
loading buffer was added to 20J.ll of protein solution and the samples were denatured by 
heating at 100°C for S minutes before the samples were pulse spun and stored at 4°C 
until required. Denatured samples were then loaded onto a SDS-P AGE gel (10% 
running acrylamide gel and 5% stacking acrylamide gel) with pre-stained molecular 
weight markers. Proteins were then separated by electrophoresis in western blot running 
buffer (-IOOMv for 60-120 minutes). The gel was then removed from the stacking 
system, trimmed using a clean scalpel and the bottom right-hand comer was notched for 
orientation. The gel was then transferred on to BioTrace PVDF transfer membrane (pall 
Gelman Sciences, USA) pre-soaked in 100% methanol and transfer bufTerusing a semi-
dry Transfer Cell (BioRad Electro-Transfer SD). 
After successful gel transfer, the membrane was washed in distilled water and 
unoccupied protein binding sites were blocked with western blocking solution for 2 
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hours and then stained with the primary antibody (diluted in 20 mls of 1 %BSAffBST) 
at 4°C overnight (18 hours). The membrane was thenwashed in TTBS for 5 minutes 
and then stained with a HRP-conjugated secondary antibody (diluted 1 :2000 in 20 mIs 
of 1 %BSAlITBS) for 1 hour. HRP-conjugated anti-biotin antibody (diluted 1: 1 000 in 
1 %BSAfITBS) was used to detected biotinylated markers. The membrane was then 
washed in TTBS for 5 minutes before the membrane was incubated with 10mls of 
LumiGLO (O.Smls 20X LumiGLO, O.Sml 20X peroxide and 9.0mls Milli-Q water) and 
mixed by gentle agitation for 1 minute at room temperature. Excess LumiGLO solution 
was removed and whilst the membrane was moist, it was rapped in Saran Wrap and 
exposed to x-ray film. 
6.2.5. CELL TRACKING. 
PKH26 (pKH26-GL, Sigma-Aldrch, USA) is a red fluorescent cell linker which 
incorporates aliphatic reporter molecules into cell membrane by selective partitioning 
(Horan & Sle~ 1989). It has been found to be useful in in vitro cell labelling and in 
vitro and in vivo cell tracking. It was used in the experiments presented in this chapter 
for general cell labelling to identify secondary phenotypic changes in specified cells in 
mixed cellular populations e.g. bel-2 expression in IDBL (labelled) cells co-cultured 
with U266 (unlabelled) cells. The labelling is not a saturation reaction, the extent of 
surface labelling is a function of both dye and cell concentration. Over-labelling 
resulted in loss of membrane integrity and cell recovery. Therefore, the optimal cell/dye 
concentration was determined using PI exclusion and fluorescent intensity of IDBL 
cells stained by this protocol. It was found that the optimal cell concentration was 1-
Sxl06/ml and the optimal dye concentration was Sxl0-6M PKH26 (results not shown). 
Cells for labelling were harvested by centrifugation (1500G for 5 minutes) and the cell 
pellets were then washed in RPMII640 medium (serum-free) three times before being 
resuspended at l-Sx 1 06/ml in 1 ml of Diluent C (supplied with kit). Immediately prior to 
staining. 4 J-ll of PKI126 dye stock solution (1 xl 0.3 M in ethanol) was added to 1 ml of 
Diluent C and kept at room temperature. The 1 ml of dye was added to 1 ml of cell 
suspension (final concentration Sx IO-6M) and gently mixed at room temperature for 10 
minutes. Adding an equal volume of heat-inactivated FCS and mixing gently terminated 
the reaction. Cells were then recovered by centrifugation and washed in CM three times. 
Cells were then re-suspend",-d in the appropriate medium for subsequent experimental 
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studies. An aliquot of cells was immediately fixed in 2% fonnalin to represent the 
extent of surface staining prior to cell division under experimental conditions. Cells 
were stained with appropriate monoclonal antibodies after the experimental period with 
due care and attention being paid to compensation, as described in chapter 2. 
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6.3 RESULTS 
6.3.1 HMCL PREVENT ACTIVATING T CELLS FROM ENTERING THE IL-2 
AUTOCRINE PATHWAY 
In the previous chapter, the IL-2 responsiveness of mitogen-activated Iymphoblasts 
from healthy donors is impaired in the presence of HMCL. This was demonstrated 
using proliferation assays as a measure of cell cycle progression and cell division. A key 
feature of this activation process in T cells is the entry into the IL-2 autocrine pathway. 
Vsing intra-cellular cytokine immunofluorescent staining and flow cytometry, the entry 
into the IL-2 autocrine pathway of primary T cells in response to exogenous IL-2 was 
examined. When compared to resting T cells, the percentage of cells which were 
positive for intra-cellular IL-2 by flow cytometry after 36 hours of culture were 
significantly increased by the stimulation of exogenous, recombinant human IL-2 20 
Vlml (27.20%±6.74 c/70.6%±5.38, n=4, p=O.OOl1; Table 6.2). When the primary T 
cells from healthy donors (n=4) were re-stimulated with rhIL-2 (20 Vlml) for 36 hours 
in the presence of the IIMCL, U266, the bone marrow serum from a patient with 
multiple myeloma at diagnosis (BM6) and rhTGF-~-l, a reduction in the percentage of 
cells entering the IL-2 autocrine pathway was demonstrated (Table 6.3). Co-culturing 
with U266 cells resulted in a mean 33.7%±10.S reduction in the number of cells 
entering into the 1L-2 autocrine pathway, whilst co-culturing with the BM serum from a 
patient with myeloma resulted in a mean 30.2%±8.2. Two of the donor T cells (D} & 
D2) demonstrated a non-significant increase and two donors (D3 & D4) demonstrated 
only a slight reduction in the percentage of cells that stained for intra-cellular IL-2, after 
36 hours of stimulation with rhIL-2 in the presence ofTGF-~. This may reflect the half-
life of rhTGF-p in this culture system that un-like HMCL-produced TGF-~, is not 
constantly replenished in the culture medium. The fact that suppression is still seen with 
BM serum may reflect the relatively high level of the cytokine found in BM sera from 
patients with myeloma (5-12 nglmt; results not shown). 
6.3.2 INHIBTION OF 1L-2 AUTOCRINE PATHWAY ENTRY BY HMCL IS 
ASSOCIATED WITH FAILURE TO UP-REGULATE IL-2Ra. 
The entry of primary T cells into the IL-2 autocrine pathway is preceded by the up-
regulation of the high affinity chain of the IL-2R, IL-2Ra and thus, IL-2Ra controls, at 
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Dl D2 D3 D4 MEAN±SEM 
(%) (%) (%) (%) (%) P 
RESTING 33.38 37.49 36.48 7.46 27.20±6.74 0.001 
IL-2 64.57 67.85 63.48 86.49 70.6±5.38 
IL-2+HMCL 49.39 52.44 22.09 66.18 47.53±9.27 0.042 
IL-2+BM6 47.07 50.84 28.1 9.53 33.89±9.52 0.01 
IL-2+ TGF (5nglml) 75.65 78.59 60.2 61.3 68.9±4.8 0.41 
TABLE 6.2. The effect of co-culturing primary T cells re-stimulated with IL-2 in the 
presence of HM L 266), BM6 and rhTGF-p-1 on IL-2 autocrine pathway entry. P 
values repre ent the change in percentage cells positive for intracellular IL-2 compared 
with T cells re- timulated with rhIL-2 20 ulm\. 
IL-2 IL-2+HMCL 
22.090/0 
o~-..... 
cyto IL-2 cyto IL-2 
FIGURE 6.1. Repre ntati e hi t gram demonstrating the effect of co-culturing U266 
cells on the IL-2 aut rin pathway entry of primary T cells when re-stimulated with 
rhIL-2. The h II w hi t gram repre ent the isotype control MoAb and the filled 
histogram repre ent th yt pla mic IL-2 immunofluorescent staining. 
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least in part, the IL-2 responsiveness of T cells (Lowenthal et al, 1985). IL-2Ra chain 
expression is regulated at the transcriptional level (Meyer et al, 1997). Therefore to 
examine the effect that IIMCL-derived TGF-(3-1 exerts on the up-regulation of IL-
2Ra, a semi-quantitative duplex PCR assay was used. The linear phase of the PCR 
reaction for the IL-2Ra primers and each potential constitutively expressed partner gene 
primer pairs was determined using simultaneous, parallel samples set up as described in 
the methodology section. The volume of each PCR product band was assessed using 
UViphoto software and was plotted on a linear graph against the cycle number. For the 
IL-2Ra primer pairs, the linear phase of the PCR reaction was found to be between 20-
26 cycles (Figure 6.2A). Three constitutively expressed genes in T cells were tested for 
the linear phase of the PCR reaction for each of their respective primer pairs: (3-Actin, c-
obI and IL-2Ryc. The linear phase for the (3-Actin primer pairs was found to be <19 
cycles (Figure 6.2D), the linear phase of the c-abl primer pars was found to be >25 
cycles (Figure 6.2C) and the linear phase of the IL-2Ryc primer pairs was found to be 
between 21-25 cycles (Figure 6.20 and representative PCR product gel electrophoreses 
are illustrated in Figure 6.3). Thus, for the duplex semi-quantitative PCR assay, 
expression of the IL-2Ra and IL-2Ryc genes was measured and compared at 23 cycles. 
To determine the sensitivity of this assay, cDNA from mitogen activated peripheral 
blood T cells (PDL) was serially diluted with cDNA from K562 cells, a human 
leukaemia cell line which constitutively express IL-2Ryc but not IL-2Ra. Using the 
duplex PCR assay, the limits of detection of IL-2Ra transcripts was at a dilution of 1 :32 
(Figure 6.4 and Table 6.3). The reduction in the level of the IL-2Ryc product after 1: 16 
dilution may reflect the difference in IL-2Ryc expression between mitogen activated 
primary T cells and the leukaemic cells of the KS62 cell line. Thus the duplex PCR 
assay offers the potential to compare the level of IL-2Ra gene expression in primary T 
cells under differing experimental conditions with a modest level of sensitivity. 
avoiding the use of Northern blotting and the applications ofradio-nucleotides. 
Using the duplex assay, the effect of re-stimulating mitogen-activated T cells with rhIL-
2 in the presence and absence of rhTGF-(31, IIMCL and bone marrow serum from a 
patient with myeloma was examined in relation to IL-2Ra gene expression. PBL from 
normal donors (n=3: 106 cellslml) were re-stimulated with rhIL-2 (20 U/ml) in 24-well 
plates, with and without rhTGF-(31 (S nglml) for 24 hours. Total RNA was isolated and 
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FIGURE 6.2. Determining the linear phase of peR amplification using limited cycle 
peR. The linear phase of the peR reaction using IL-2Ra (A), P-Actin (B), c-ab/ (e) 
and IL-2Ryc sense and anti- ense primer pairs. Each peR product was visualised by 2% 
agarose gel electrophore is. The volume of each peR band was determined in arbitrary 
units by the gel documentation oftware (UViphoto). 
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P R Cycles 
21 22 23 24 25 26 
IL-2Ra 
23 24 25 26 27 28 
c-ab/ 
FIGURE 6.3. Electrophore is gel visualisation of limited cycle PCR using cDNA 
synthesised from mitogen-activated T cells from a healthy donor. Sequential cycle PCR 
products amplified with IL-2Ra, IL-2Ryc and c-ab/ sense and anti-sense primer pairs 
respectively as de cribed. 
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M N 1:2 1:4 1:8 1:16 1:32 1:64 1:128 
~IL-2Ra 
FIGURE 6.4. Serial dilutions ofPBL eDNA with K562 eDNA as indicated, used in the 
duplex peR (IL-2Rcx/IL-2Ryc) assay to detennine the level of sensitivity. peR assay 
was performed at 23 cycles of amplification. 
Dilution IL-2Ra IL-2Ryc Ratio 
Neat 57848 135721 0.426 
1 :2 42164 129061 0.327 
1 :4 43788 132198 0.479 
1:8 7847 138451 0.316 
1: 16 975 118412 0.066 
1:32 0 79158 0.012 
1:64 0 59395 0 
1 :128 0 59375 0 
TABLE 6.3. Serial dilutions of PBL cDNA with K562 cell cDNA used in the duplex 
peR assay to semi-quantitate the level ofIL-2Ra transcripts. 
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eDNA synthesised. The eDNA was then used in the duplex PCR assay to compare the 
level of expression of IL-2Ra and IL-2Ryc genes. The presence of rhTGF-pI reduced 
the up-regulated expression of the IL-2Ra gene in response to re-stimulation with rhIL-
2 whilst no appreciable effect was seen on the expression of the IL-2Ryc (Table 6.4 and 
Figure 6.S). When the ratio of gene expression was calculated, a downward trend in the 
IL-2RaIIL-2Ryc ratio was seen when re-stimulated with rhIL-2 in the presence of 
rhTGF-p 1. A representative example of the duplex PCR assay is illustrated in Figure 
6.6. When p-Actin was amplified under similar PCR conditions as that used in the 
duplex reaction, similar levels of product were detected, as a measure of amplification 
and loading control (figure 6.S and 6.6). 
The effect of re-stimulating mitogen-activated T cells with rhIL-2 in the presence and 
absence of the U266 cells and bone marrow serum from a patient with myeloma (BM6) 
was examined in relation to IL-2Ra gene expression using the duplex PCR assay. PBL 
from normal donors (n=3: 106 cells/ml) were re-stimulated with rhIL-2 (20 U/ml) in 24-
well plates, with and without mitomycin-C-treated U266 cells or BM6 at a 1: 1 0 dilution 
in CM. Total RNA was isolated, eDNA synthesized and then used in the duplex PCR 
assay. The presence of either U266 cells or the diluted bone marrow serum, BM6, 
resulted in a failure to up-regulate the IL-2Ra with a resultant reduction in the IL-
2RalIL-2Ryc ratio (Table 6.S & Figure 6.7). A representative example of the duplex 
PCR is illustrated in Figure 6.8. For confirmation, the eDNA from each of the 
respectively treated PDL samples were tested in a standard 30 cycle PCR reaction for 
the expression of IL-2Ra, 1L-2Ryc, p-Actin and the IL-2 responsive protoncogene, pim-
1 gene. The results indicate that rhTGF-p I, IIMCL and bone marrow serum from a 
patient with myeloma inhibit the up-regulation of both IL-2Ra and pim-l in PBL when 
re-stimulated with rhlL-2 (Figure 6.9 & Figure 6.1 0). The positive control used was 
CHO-KI cell line transfected with human cDNA encoding the IL-2Ra and interestingly 
whilst the p-Actin and 1L-2Ryc primers amplify products of similar size to the human 
cells, the pim-I primers amplifying two products both being smaller than the human 
PCR product. 
Corroboration of the PCR results by assessing IL-2Ra protein synthesis was hampered 
by the fact that surface expression analyses were inherently difficult. As described in 
chapter 4, 62.30/0;t2.3 ofCD3+ cells already expressed 1L-2Ra protein on their surface, 
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Dl D2 MEAN.:!:SEM 
IL-2Ra 
Resting 0 0 0 
IL-2 60977 70556 65767.:!:4803 
IL-2+TGF~ 27939 10961 19450±8514 
Control 57848 70958 64403±6574 
IL-2Ryc 
Resting 37662 70558 54110±16496 
IL-2 157186 86067 121627±35665 
IL-2+TGF~ 87719 42332 65026±22761 
Control 135721 105408 120565±15201 
IL-2RalIL-2Ryc ratio 
Resting 0 0 0 
IL-2 0.388 0.820 0.717±0.17 
IL-2+TGF~ 0.319 0.469 0.313±0.18 
Control 0.426 0.673 0.579±0.08 
TABLE 6.4. The comparative expression of IL-2Ra and IL-2Ryc genes in primary T 
cells re-stimulated with rhIL-2 using a semi-quantitative duplex peR assay. 
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300000 
P-Actin 
250000 
200000 
CI) 
E 
:J 150000 
0 
> 
100000 
50000 
o i --,-
Rest IL-2 IL-2+TGF Control 
0.9 
0.8 
0.7 
C) 0.6 a:: ("II 
I 0.5 ...J 
.. 
"' 
0.4 a:: 
("II 
I 0.3 
...J 
0.2 
0.1 
0 
-
-, -
Rest IL-2 IL-2+TGF Control 
FIGURE 6.5. The effect of re-stimulating primary T cells (n=2) with rhIL-2 20U/ml in 
the presence ofTGF-pl(5nglml) on the relative expression of the a chain of the IL-2R. 
The volume of peR products amplified using the f3-Actin sense and anti-sense primer 
pairs is illustrated as a amplification and loading control. 
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Control Re t IL-2 IL-2+TGFp 
IL-2Ra 
IL-2Ryc 
M B Control Rest IL-2 IL-2+TGFp 
p-Actin 
FIGURE 6.6. A repre entative duplex peR assay visualised on a 2% agarose gel. The 
lower gel indicates the P R products using p-Actin sense and anti-sense primers, as 
amplification and loading controls. Key: M- markers, B- negative (H20) control, Rest-
resting PBL, ontrol- rrutogen activated PBL. 
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01 02 D3 MEAN±SEM P 
IL-2Ra 
Re ting 0 0 0 0 
IL-2 64201 68527 61971 64900±1927 
IL-2+HMCL 1854 407 0 754±563 <0.001 
IL-2+BM6 225 279 205 236+22 <0.001 
IL-2Ryc 
Resting 63117 50997 45962 50025±2124 
IL-2 64936 65734 68214 66294±988 
IL-2+HMCL 59874 61001 58606 59827±692 NS 
IL-2+BM6 55105 56442 50967 54171±1650 NS 
IL -2RaflL-2Ryc Rati 
Resting 0 0 0 0 
IL-2 0.989 1.043 0.908 0.98±0.039 
IL-2+HMCL 0.013 0.016 0.012 0.011±0.003 <0.001 
IL-2+BM6 0.004 0.005 0.004 0.004±0.001 <0.001 
TABLE 6.5. Th mparati expression of IL-2Ra and IL-2Ryc genes in primary T 
cells re-stimu1at d with rhlL-2 u ing a semi-quantitative duplex peR assay. 
1.2 
1 
en 
a::: 0.8 N 
• 
...J 
::::: 0.6 cu 
a::: 
N 0.4 • 
...J 
0.2 
0 
-
Rest IL-2 IL-2+HMCL IL-2+BM 
FIGURE 6.7. h effe t of re- timulating primary T cells (n=3) with rhlL-2 in the 
pre ence f 2 6 cell (HM L) and bone marrow serum from a patient with myeloma 
(BM) on the relati e pre i n of the a. chain of the IL-2R. 
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ontr I 
FIGURE 6.8. A r r 
Control- mit gen a ti 
marrow erum. 
t I -2 IL-2+ IL-2+ 
IL-2Ra 
duplex P R as ay visualised on a 2% agarose gel. Key: 
, Re t- re ting PBL HMCL- U266 cells, BM6- bone 
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1 2 3 4 5 6 H20 
'- ./ V 
Pim-l 
FIG RE 6.9. xpr i n of the IL-2 responsive genes, IL-2Ra. and pim-l, in T cells 
when re- timulat d with rhIL-2 for 24 hours in the presence or absence of TGF-I31, 
U266 cells r b n marrow erum from a patient with myeloma. PCR products 
generated by 30 cycle of amplification and visualised by 2% agarose electrophoresis. 
Key: Lane 1- Re ting T cell' Lane 2- IL-2 stimulated; Lane-3 IL-2+rhTGF-I3; Lane 4-
IL-2+U266 cell; Lane 5- IL-2+BM serum; Lane 6- Positive control (CHO-KI/25 cell 
line); H20- egative control. 
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Re t 
IL-2Ra. (781 bp) 
lL-2Ryc (494bp) 
Pim-l (918bp) 
I3-Actin (548bp) 
IL-2 IL-2+ 
TGF 
30 cycles 
IL-2+ 
U266 
IL-2+ 
BM6 
FIGURE 6.10. ummary of the expression of the IL-2 responsive genes in primary T 
cells re-stimulat d with rhIL-2 in the presence or absence of TGF-131, U266 cells or 
bone marrow erum from a patient with myeloma. peR products generated by 30 cycles 
of amplification and visualised by 2% agarose electrophoresis. 
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thus invalidating up-regulated surface expression analysis as a methodology for de novo 
protein synthesis. 
6.3.3 INHIBITION OF IL-2Ra UP-REGULATION IN T CELLS INDUCED BY 
HMCL IS ASSOCIATED WITH FAILURE OF STAT3 AND STAT5 
PHOSPHORYLATION. 
Ligation of IL-2 with its receptor is associated with several different signalling 
pathways, of which the JaklSTAT pathways have pivotal importance. Jak3/STAT3 
activation through phosphorylation appears to be associated with the 'Yc subunit whilst 
JakllSTATS activation is associated with the intra-cellular domain of the f3 subunit 
(reviewed by Leonard & O'Shea, 1998). The effect on phosphorylation of STAT3 and 
ST ATS when primary T cells were re-stimulated with rhIL-2 in the presence and 
absence of U266 cells was studied using western blotting. When primary T cells were 
re-stimulated with rhIL-2, the presence of U266 cells resulted in failure of STAT3 
phosphorylation when compared to those T cells re-stimulated in the absence of U266 
cells (Figure 6.11). The total level of ST AT3 was unchanged in re-stimulated T cells 
either co-cultured in the presence of U266 cells or in CM only. The addition of LAP, 
the TGF-f31 antagonist, completely restored the ST AT3 phosphorylation in response to 
rhIL-2. Similarly, when re-stimulated T cells were co-cultured with U266 cells, there 
was failure of ST ATS phosphorylation despite similar levels of total STATS when 
compared to T cells re-stimulated with rhIL-2 in the absence of U266 cells (Figure 
6.12). Once again, the addition of LAP completely restored the STATS phosphorylation 
in response to rhIL-2. These results corroborate the RT-PCR data as STAT3 is central to 
the transcriptional regulation of the IL-2-induced protoncogene, pim-l, and ST ATS has 
a pivotal role in the activation of the PRRIII of the IL-2Ra gene (John et aI, 1996; 
Meyer et ai, 1997, Shirogane et ai, 1999). As has already been demonstrated, the co-
culturing ofT cells with HMCLs results in failure to up-regulate bothpim-l and IL-2Ra 
genes when responding to re-stimulation with rhIL-2. 
6.3.4 INTER-CELLULAR IL-2Ra ACTING in trans INDUCES HMCL AND 
TGF-f3 SUSCEPTIBILITY IN IDBL CELLS. 
Data presented in chapter S demonstrate that IDBL cells are resistant to the inhibitory 
effects of both rhTGF-f31 and HMCLs, in terms of cell cycle progression and 
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T cells 
U266 
IL-2 
LAP 
STAT3-P -7 
STAT3 -7 
+ 
+ 
+ 
+ 
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+ 
+ 
FIGURE 6.11. Phosphorylation of STAT3 in primary human T cells in response to re-
stimulation with rh-IL-2 in the presence and absence ofU266 cells. 
T cells 
U266 
IL-2 
LAP 
STAT5-P -7 
STAT5 -7 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
FIGURE 6.12. Phosphorylation of STAT5 in primary human T cells in response to re-
stimulation with rh-IL-2 in the presence and absence ofU266 cells. 
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proliferation. As indicated, these cells have progressed beyond the IL-2 autocrine stage 
and depend on exogenous IL-2 for proliferation and survival. These cells did not 
express the high affinity IL-2R but did express the IL-2R~ and IL-2Ryc subunits. It has 
been shown that IL-2Ra on one cell can present IL-2 to the ~ and Yc subunits on another 
cell and this in trans action results in inter-cellular cytokine augmentation which may 
influence the behaviour of cells which lack the IL-2Ra subunit (Eicher & Waldmann, 
1998). Therefore, the effect of providing the IL-2Ra subunit to IDBL cells was studied, 
in particular the influence this had on the susceptibility to HMCL and TGF-~ I-induced 
suppression. 
CHO-K1I25 are illustrated in Figure 6.13 demonstrating their typical morphological 
(Figure 6.13A) and surface phenotypic characteristics (Figure 6.13B). When this cell 
line, fixed in formaldehyde to prevent ligand binding and intemalisation, was added to 
IDBL cells (lCHO-K1I25:20 IDBL cells) cultured in rhIL-2, slight stimulation of 
proliferation was seen after 72 hours (Figure 6.14). When increasing concentrations of 
rhTGF-~1 was added to IDBL cells alone, no suppressive effect was seen, as has been 
demonstrated earlier. However, when CHO-K1I25 cells were added to the culture, this 
rendered the IDBL cells susceptible to the suppressive effect ofTGF-~l (Figure 6.14). 
Only a slight suppression of proliferation was seen when IDBL cells were co-cultured 
with fixed control CHO-KlIwt cells, IL-2 and TGF-~1. This susceptibility to TGF-~1 
induced by the inter-cellular presentation in trans of the a-chain was seen at varying 
concentrations of CHO-K1I25 (1:5-1:20) with a mean inhibition of proliferation of 
62.46%±2.03 compared with the mean inhibition of proliferation by TGF-~1 alone of-
1.0%±9.45 (p=O.002) after 72 hours, as illustrated in Figure 6.15. 
When IDBL cells were stimulated with rhIL-2 in the presence of mitomycin-C-treated 
U266 cells for 24 hours, minimal inhibition of proliferation was demonstrated 
(2.45%±6.47, n=4), as determined by 3[H]dThd uptake. However, when formalin-fixed 
CHO-KI125 cells were added to IDBL cells stimulated with rhIL-2 for 24 hours, 
marked inhibition of proliferation was demonstrated, with a mean inhibition of 
3[H]thymidine uptake of 44.65%±1O.5 (p=O.005; Figure 6.16). The effect on apoptosis 
of IDBL cells by co-culturing with formalin-fixed CHO-K1I2S cells in the presence of 
rhlL-2 and U266 cells was assessed using the annexin V affinity assay. The apoptosis 
rate of IDBL cells was measured by gating on PKH26+ cells and determining the 
surface staining of Annexin V-FITC. 
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FIGURE 6.13. CD25 (IL-2Ra) surface expression on CHO-Kl/25 cells (Geimsa, 
xlOOO, A) as determined by flow cytometry (B). 
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FIGURE 6.14. The effect of co-culturing fixed CHO-K1I25 or CHO-Kl/wt cells on the 
IL-2 responsiveness of IDBL cells (l 05/ml) in increasing concentrations of rhTGF-p 1 
(lCHO-K1I25: 20IDBL cells). Proliferation was determined by eH] thymidine uptake 
after 72 hours of culture. Key: IDBL2- IDBL cells with IL-2 20 U/ml, IDBL2/CHO-
Kl/25- IDBL cells with IL-2 & fixed CD25-transfected CHO cells, IDBL2/CHO-
Kl/wt- IDBL cells with IL-2 & fixed control-transfected CHO cells. 
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FIGURE 6.15. Inhibition of the proliferative response of IDBL cells (105 Iml) to rhIL-2 
20 V lml with increasing concentrations ofrhTGF-f31in the presence and absence of the 
IL-2Ra.-transfected cell line, CHO-K1/25 (fixed). Proliferation was determined by 
CH]thymidine uptake after 72 hours of culture. Ratios (e.g.1 :20) represent the number 
of CHO-K1I25 cells to IDBL cells. 
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FIG RE 6.16. Inhibition of IL-2-induced proliferative responses of IDBL cells 
(lOs/mt) when c -cultured in the presence of U266 cells. A significant (n=4, p=0.005) 
increase in the HM L-induced inhibition of proliferation was demonstrated after 48 
hour when fixed HO-K1I25 cells (1:10) were added to the cultures. Proliferation was 
asses ed by 3[H] thymidine uptake. Mitomycin-C treated HMCL used at a ration of 1 
HM L: 5 rDBL cell . 
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FIGURE 6.17 The effect on apoptosis of stimulating IDBL cells (n=3) with rhIL-2 in 
the pre ence and ab ence of U266 cells. The addition of the transfectant cell line, CHO-
Kl /25 to this culture system demonstrates a reduction (non-significant) in the apoptosis 
rate but does not alter the apoptosis rate of IDBL cells when stimulated in the presence 
of U266 cell . 
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A reduction in the resting apoptosis rate was seen upon stimulation with rhIL-2 
(72.9%±4.5 cf. 48.2%±12.4, p=O.08) with no impact on the apoptosis rate being 
demonstrated by the addition of fixed CHO-K1I25 cells (Figure 6.17). The co-culture of 
IDBL cells with mitomycin-C-treated U266 cells did not alter the apoptosis rate 
(36.6%±8.5 cf. 48.2%± 12.4, p=NS). The addition of CHO-K1I2S cells to the culture 
system did not alter the apoptosis rate either (36.6%±8.5 cf. 36.9%±11.5, p=NS; Figure 
6.17). Representative histograms are illustrated in Figure 6.18). It is worthy of note that 
the overall apoptosis rate of IDBL cells in this assay was higher than those illustrated in 
chapter 4. This is related to the use of the membrane staining dye, PKH26, which results 
in a modest reduction in cell viability post-staining (data not shown). 
The molecular events involved in the signalling pathways of IL-2-stimulated IDBL cells 
were examined next. Similar to the effect that U266 cells exert on primary T cells, 
IDBL cells when stimulated with IL-2 in the presence of U266 cells fail to 
phosphorylate STAT5 (Figure 6.19). However, the phosphorylation of STAT3 was 
unaltered by the co-culture with tumour cells, unlike primary T cells. The co-culture 
with CHO-KI125 cells in the presence ofU266 cells results in failure to phosphorylates 
ST AT3, similar to the effect that U266 cells exert on the re-stimulation of primary T 
cells (Figure 6.19). Thus the inter-cellular a chain presentation in trans to a cell line that 
is IL-2 dependent and lacks the a chain, induces tumour-derived TGF-(31 suppression 
resulting from failure to phosphorylate ST A T3. 
The signalling pathways which converge on the expression of bel-2 are numerous and 
include STAT3 (Shirogane et al, 1999). Pim-l can also be up regulated by STAT3 in 
addition by STAT5. The expression of bel-2 and Pim-l in IDBL cells was examined 
when stimulated with IL-2 in the presence and absence of U266 cells and CHO-K1I25. 
Using the cell tracking dye, PKH26, the expression of bel-2 in IDBL was analysed by 
flow cytometry. IDBL cells increased bel-2 expression in response to IL-2 stimulation, 
which was amplified by the co-culture with fixed CHO-K1I25 cells (Figure 6.20). The 
co-culture of IDBL cells with fixed CHO-K1I25 cells resulted in increased expression 
of bel-2, though only in resting IDBL cells was this significant (p=O.05). The co-culture 
of IL-2-stimulated IDBL cells with U266 resulted in no change in the expression of bel-
2 except when co-cultured with fixed CHO-K1I2S cells when a reduction in the 
expression was seen (not statistically significant, p=O.33). Representative histograms 
are illustrated in Figure 6.21. 
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FIGURE 6.18. Representative histograms of Annexin V staining of PKH26-stained 
IDBL cells stimulated with 1L-2 in the presence and absence of U266 cells and 
formalin-fixed CHO-K1I25 cells (CHO). 
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Figure 6.19. The phosphorylation of STAT3 and STAT5 in IDBL cells in response to 
stimulation by rhIL-2 in the presence or absence ofU266 and CHO-Kl/25 cells. 
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FIGURE 6.20. Effect on bC/-2 expression by IDBL cells (n=3) when co-cultured with 
IL-2 and U266 cells in the presence and absence of CHO-KI/2S. An increase in the 
expression of bC/-2 in IDBL cells is seen when co-cultured with fixed CHO-K1I25 
except when co-cultured with U266 cells, when a reduction is seen. However, these 
results failed to reach statistical significance. 
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FIGURE 6.21. Representative examples of bcl-2 expression ill IDBL cells when 
stimulated with IL-2 in the presence of U266 cells with and without fixed CHO-KlI25 
cells. 
225 
The effect that U266 cells exert on the expression of Pim-l mRNA in IDBL cells was 
analysed by RT-PCR. In order to maximise the specificity of the RT-PCR assay, U266 
supemates were used, as U266 cells express Pim-l at the mRNA level. It was important 
to demonstrate that the effect on IDBL proliferation exerted by U266 cells was similar 
to that exerted by supemates. The supemates from U266 cells cultured in 
RPMIII0%FCS for 72 hours were collected by centrifugation of cell suspensions. The 
supemates were then used fresh in the proliferation assays at a final dilution of 1:2. For 
comparison, U266 cells were mitomycin-C treated and co-cultured with IDBL cells. It 
was shown that U266 cells did not suppress the proliferation of IDBL cells to rhIL-2 
unless co-cultured with fixed CHO-K1I2S cells, as detennined by 3[H]dThd uptake after 
24 hours. When IDBL cells were stimulated with rhIL-2 in the presence of U266 
supemates, a minimal stimulatory effect could be demonstrated. This may either be due 
to the consumption of suppressive factors that are maintained at stable levels when 
whole cells are used or represents the presence of additional stimulatory factors that can 
exert an effect in the absence of the whole cells. The addition of fixed CHO-KI125 cells 
did induce a suppression of proliferation, similar to whole tumour cells: 2.4%±6.47 
inhibition with U266 cells alone compared with 44.65%±10.8 inhibition with the 
addition of fixed CHO-K1I25 cells. This is compared to -9.9%±3.2 inhibition with 
supemates alone rising to 22.2%±0.8 inhibition with the addition of fixed CHO-KI125 
cells (Figure 6.22). Using fresh U266 supemates, IDBL cells were stimulated with rhIL-
2 for 24 hours in the presence and absence of supemates and fixed CHO-KlI2S cells 
and total RNA isolated. Using RT-PCR, the expression of Pim-l under each culture 
condition was examined. Faint transcript bands were seen in resting IDBL cells and 
resting IDBL cells cultured with fixed CHO-K1I2S cells. The stimulation with rhIL-2 
failed to up-regulate Pim-l expression, even in the presence of fixed CHO-K1I2S cells. 
Co-culture with U266 supemates resulted in up-regulation of Pim-l at the RNA level 
which was down-regulated when stimulated with rhIL-2 in the presence of U266 
supernates and fixed CHO-K1I25 cells (Figure 6.23). These results suggest that a 
stimulating factor(s) produced by U266 cells induces Pim-l expression in IDBL cells 
which may counterbalance the suppressive effect ofHMCL-derived TGF-p but which is 
down-regulated by the inter-cellular presentation of the a chain of the IL-2R. 
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Figure 6.22. The effect on proliferation of co-culturing IDBL cells (n=3) with U266 
cells and U266 cell supemates. U266 cells and supemates minimally suppress 
proliferation, however, when membrane bound IL-2Ra (CHO-K1I25) is present then 
suppression is demonstrated. Proliferation was assessed by 3[H]thymidine uptake. Key: 
U266- mitomycin C-treated U266 cells, U266 sn - supemates from freshly cultured 
U266 cells after 72 hours. 
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Figure 6.23. The expression of the protoncogene, Pim-l by IDBL cells when co-
cultured with U266 cell supemates and fixed CHO-K1I25 cells, as detected by RT-
PCR. Co-culture of IDBL cells with IL-2 and U266 supemates up-regulated the 
expression of Pim-l which was abrogated by the presence of membrane-bound IL-2Ra 
(CHO-K1I2S). Key: M- markers, H20- negative control, Lane 1- IDBL cells, Lane 2-
IDBL + fixed HO-K1I2S cells, Lane 3-IDBL cells + IL-2, Lane 4- IDBL, IL-2 + 
CHO-KII2S Lane 5- IDBL, U266 supemates + IL-2, Lane 6- IDBL, U266 supemates, 
IL-2 + CHO-KII25, Lane 7- U266 cells as a positive control. 
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6.4 DISCUSSION 
The data presented in this chapter gives an unique insight into the mechanisms that may 
be involved in mediating the suppressive effects that myeloma cells exert on activating 
T lymphocytes. Using the complex in vitro model developed in chapter 4, the effect of 
HMCLs on activating T cells has been studied. In addition, a bone marrow plasma 
sample was included in this chapter to demonstrate that this effect is not unique to the 
transformed cell lines used in these studies. In consideration of the results presented in 
this chapter, the central role of. the a chain of the IL-2R in the activation and 
proliferation ofT cells warrants discussion. 
Interleukin-2 Receptor (IL-2R) 
The IL-2R complex consists of a combination of 3 distinct subunits or chains - IL-2Ra, 
IL-2RJ3 and IL-2Ryc. The high affinity (Kd = 10·11M) receptor consist of a 
heterotrimeric complex whereas the intermediate affinity (Kd = 10-9M) receptor consists 
of IL-2RJ3 and IL-2Ryc subunits only (Minami et al, 1993). The IL-2Ra subunit alone 
forms the low affinity (Kd = 10·8M) receptor and its biochemical characterisation was 
greatly facilitated by the use of the monoclonal antibody directed against the antigen 
expressed on activated T cells (reviewed by Sugamura et al, 1996). The IL-2Ra gene is 
organised into 8 exons spanning more than 35 kb localised on chromosome 10p14-15 
and is under the control of three distinct enhancer regions (Leonard et al, 1985; Meyer 
et al, 1997). The mature form of IL-2Ra, deduced from the nucleotide sequence, 
consists of 251 amino acid residues, sharing sequence and structural homology only 
with the IL-15a subunit (Giri et aI, 1995). The cytoplasmic domain of the IL-2Ra 
conatins only 13 amino acid residues with no inherent signal transduction capability 
(Sugamura et al, 1996). 
The surface expression of IL-2Ra is regulated mainly through gene transcription and 
whilst mitogenic stimulation induces a transient up-regulation of IL-2Ra, sustained up-
regulation and thus surface expression requires IL-2 (Meyer et al, 1997). Transcriptional 
regulation is controlled by three positive regulatory regions: PRRI, PRRII and PRRIII. 
Mitogenic stimulation resulting in IL-2Ra up-regulation results from the interaction of 
NF-KB, c-Rel and SRF with PRRI together with interaction of Elf-l and HMG-l(Y) 
with PRRII (John et al, 1995). PRRIII, located 1.3 kilobases upstream of PRRI and II, 
has three distinct binding sites that bind STATS, GATA-like factors and Elf-l (John et 
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ai, 1996; Meyer et ai, 1997). It has been demonstrated that the ability of mature T cells 
to proliferate to IL-2 correlates with IL-2Ra. expression and thus IL-2Ra. controls, at 
least in part, the IL-2 responsiveness ofT cells (Lowenthal et aI, 1985). 
The human genomic IL-2R~ gene is partitioned into 10 exons spanning 24 kb on 
chromosome 22q 11.2-12 which encodes a mature protein consisting of 525 amino acid 
residues (Sugamura et ai, 1996). Characterised as a member of the haematopoietic 
cytokine receptor family, the subunit has two pairs ofN-terminal cysteine residues and 
a tryptophan rich WS motif near the transmembrane region. The cytoplasmic domain 
does not contain inherent signal transduction capability within the 286 amino acid 
residues, there are three regions which are closely involved in activating several signal 
transduction pathways: the serine rich region (aa 267-322) are involved in c-myc and 
Jakl activation, the acidic region (aa 345-390) is assocaited with Src type kinases (Lck, 
Fyn & Lyn) and T~92 which is associated with phosphatidylinositol 3-kinase 
(Sugamura et ai, 1996). The third subunit, IL-2Ryc, is also a member of the cytokine 
receptor family and the mature protein is 347 amino acid residues in size. The 
cytoplasmic domain consists of 86 amino acid residues containing two sub-domains of 
the Src homology region 2 (SH2) which are important for signaling. IL-2Ryc is a 
common receptor for a number of cytokines (IL-2, IL-4, IL-7, IL-9, IL-13 & IL-15) and 
signalling is effective through this receptor only when heterodimerized with the IL-2R~ 
subunit. The IL-2-induced activation of c-myc, c-fos and c-jun result from interaction 
with the SH2 regions. In addition, the SH2 region is also involved in the activation of 
Jak3 which is associated with IL-2-induced cell growth and whose activation via IL-
2Ryc is independent of interaction with other cytokine receptor subunits. 
Using the in vitro model system described in this thesis, primary T cells activating in 
response to re-stimulation with exogenous rhIL-2, fail to enter the autocrine IL-2 
pathway associated with failure to up-regulate the a. chain of the IL-2R. This may result 
in failure of IL-2R sub-unit clustering which in-turn may be associated with failure of 
cell cycle progression and the activation of IL-2 responsive genes, such as Pim-l. This 
may explain the suppressive effect of HMCLs on primary T cells and relative 
insensitivity of IDBL and Jurkat cells. Jurkat cells are transformed T cells immortalised 
in the IL-2 autocrine pathway and as has been discussed in chapter 5, the effect ofTGF-
P is especially determined by the stage of activation of the T cell (Letterio & Roberts, 
1998). IDBL cells have been generated beyond the IL-2 autocrine pathway and no 
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longer require the high affinity receptor for IL-2-mediated proliferation and viability 
and this may explain the insensitivity of these cells to myeloma cell-derived TGF-~. 
Inter-cellular IL-2Ra presentation mediates HMCL-induced immuno-suppression. 
Receptor aggregation within the immune system is a common feature. For example the 
interaction of CD28 with CD80/CD86 and CD4 and CD8 with MHC class II and I 
molecules respectively represent physiological receptor aggregation (Germain, 1997). 
These receptor/counter receptor interactions demonstrate the inter-cellular transmission 
of information however, in the case of the TCR and MHC molecule, a third molecule, 
namely antigenic peptides, participate in the inter-cellular signalling. It has been shown 
that the IL-2R components can behave in a similar fashion, in particular, the a. chain on 
one cell can present IL-2 in trans to IL-2~'yc expressed on another cell thus augmenting 
IL-2-medaited signalling (Eicher & Waldmann, 1998). In this model, the IL-2 acts like 
the antigenic peptide in TCRlMHC interactions linking the two receptors and thus 
determines the specificity of the reaction. The presentation ofIL-2 to IL-2Ra.-' IL-213'y/ 
cells by the a. chain in trans results in amplification of the IL-2 proliferative signal and 
may have important physiological implications. Antigen activated T cells, by way of 
up-regulation of the a. chain and entry into the IL-2 autocrine pathway may also induce 
proliferation and differentiation of by-stander cells (cytotoxic T cells, NK cells, 
granulocytes and monocytes) which constitutively express IL-2/3fyc but not the a. chain 
of the receptor (Girard et al, 1995; Espinoza-Delgado et al, 1995). This, at least in 
theory, could lead to an amplification of the immune response. 
The data presented in this chapter demonstrates that the co-culture of cells expressing 
the IL-2Ra. with cells that are IL-2Ra.-' IL-2j3'y/ neither induced cytokine-
independence nor altered the cell cycle kinetics in response to IL-2 of the latter cells. 
However, an increase in the expression of bC/-2 was evident whether these cells were 
stimulated with IL-2 or CM alone. This is further evidence to support the inter-cellular 
signalling model of IL-2IIL-2R proposed by Eicher and Waldmann (1998). Using an in 
vitro model system, I have shown that IL-2Ra.-IIL-2~'y/ cells are immune to the 
suppressive effects of HMCL-produced TGF-p, which is reversed when the a. chain is 
presented in an inter-cellular fashion. This extends the model proposed by Eicher and 
Waldmann by suggesting that the inter-cellular clustering of the 1L-2R mediated by IL-
2 can mediate tumour immuno-suppression. When primary T cells were studied, the 
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2 can mediate tumour immuno-suppression. When primary T cells were studied, the 
immuno-suppressive effect of HMCLs may have been augmented by the inter-cellular a 
chain presentation as this population demonstrated a significant number ofIL-2Ra+1 IL-
2,31yc+ cells (60-70%). However this was not tested in these studies using agents to block 
a chain involvement in inter-cellular signalling e.g. anti-CD2S monoclonal antibody. 
The exact mechanism by which inter-cellular presentation of the a chain induces TGF-p 
susceptibility in IL-2Ra-/lL-2p/y/ cells is not known. It may represent changes in the 
tertiary structure of the IL-2P/yc+ receptors when engaged by its ligand that in turn may 
influence the use of particular signalling pathways. Further investigations in this area 
may help to clarify this issue. 
Previous studies have examined the role of CD2S+ CD4+ T cells in suppressing the 
activation of T cells in the context of tumour immunity and autoimmunity. Both in the 
in vitro model systems and in vivo murine models, these CD2S+ T cells playa pivotal 
role in suppressing both tumour and self-directed immune responses (Shimizu et al, 
1999; Thornton & Shevach, 2000). These experimental systems demonstrated that these 
"professional" suppressor T cells mediate their immunosuppressive effects by 
specifically inhibiting IL-2 production and polyclonal T cell proliferation. This 
phenomenon is not mediated by cytokine production by these CD2S+ cells, is dependent 
cell-cell contact and these CD2S+ T cells act in an APC-independent manner. It has 
been shown that these CD2S+ ICD4+ T cells required to be activated by their TCR but 
once activated, their suppressor function is completely non-specific. (Thornton & 
Shevach, 2000). Such CD2S+/CD4+ T cells account for up to 10% of CD4+ T cells in 
lymphoid tissue in both mice and humans and exhibit potent immuno-regulatory 
functions in vivo (Suri-Payer et al, 1996). Though not confirming the role of the a 
chain, this evidence taken with the data presented in this chapter suggests a potential 
role of this molecule in cell-cell interactions mediating immuno-suppression. In the 
context of the myeloma-immune system conflict, the IL-2Ra chain may mediate the 
non-specific suppression ofT cells mediated by tumour-derived TGF-p. 
IL-2Ra-induced susceptibility of IDBL cells to HMCLs is related to Pim-l expression. 
Pim-l is a protoncogene that was first identified as a common insertion site in Molony 
murine leukaemia virus-induced T cell lymphomas (Cuypers et aI, 1984). It encodes 
two cytoplasmic serine/threonine protein kinases generated by alternative splicing. 
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remained speculative. The Pim-l gene expression is regulated by either STAT5 or 
STAT3 depending on the cytokine receptor pathway involved. For example, Pim-l 
expression induced by IL-3, IL-2, IL-5 and IL-15 is dependent on STAT5 signal 
transduction whereas gp130-mediated and interferon-a.-induced expression is dependent 
on STAT3 (Matikainen et aI, 1999; Shirogane et aI, 1999). The Pim-l promoter 
contains a OAS element which facilitates the binding of STAT proteins (Yip-Schneider 
et aI, 1995). Pim-l has been shown to promote cell cycle progression especially 01 to S 
phase transition, by activating Cdc25A (Mochizuki et aI, 1999; Shirogane et aI, 1999). 
Furthermore, Pim-l has been shown to promote factor-independence in several cell 
lines and inhibits apoptosis (Lilly & Kraft, 1997). The expression of Pim-l correlates 
with bcl-2 induction in the murine myeloid cell lines studied and more recent evidence 
demonstrates a primary role for Pim-l in the expression of bcl-2 and synergism with c-
myc in anti-apoptosis (Shirogane et aI, 1999). In the context of these studies, Pim-l 
represents a potential target gene for HMCL-induced suppression, affecting T 
lymphocyte cell cycle progression and proliferation. 
In the in vitro model ofT cell activation presented in this thesis, the effect of co-culture 
with HMCL on Pim-l expression was studied. In human primary T cells, Pim-l was 
induced, at the mRNA level, by re-stimulation with rhIL-2. This up-regulation was 
abolished by the co-culture with HMCLs. When the expression of Pim-l was studied in 
the Human T cell line, IDBL, only a faint trace of the protoncogene was seen in both 
resting and IL-2 stimulated cells, suggesting that Pim-l does not playa significant role 
in the proliferation and survival of IOBL cells. When the supemates from U266 cells 
were added to the culture system, marked up-regulation of Pim-l was seen which was 
abolished by IL-2 stimulation in the presence of intercellular IL-2Ra. presentation in 
Irans. This effect, as discussed, was associated with a reduction in the proliferative 
capacity of IOBL cells but not associated with any significant alteration in the apoptosis 
rate. This is particularly interesting as the expression of Pim-l in IOBL cells is not 
necessarily IL-2-dependent, unlike in primary T cells. However, several cytokines can 
stimulate Pim-l expression, including cytokines that signal through the gp130 receptor 
(Yip-Schneider et ai, 1995). HMCLs produce many cytokines and may in fact secrete 
soluble gp130 that may potentially augment the signalling through this pathway. Indeed, 
the addition of U266 supemates to IOBL cells stimulated with rhIL-2 demonstrates a 
modest stimulatory effect. The exact factor(s) which are responsible for this remain to 
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be identified and are beyond the scope of this thesis but will form the basis of 
subsequent investigations. 
In addition to the effect of Pim-l on cell cycle progression, Pim-l expression has been 
associated with bel-] expression and protection from apoptosis (Shirogane et aI, 1999). 
Despite increased expression of bel-] in IDBL cells, no anti-apoptosis effect was 
demonstrated. Furthermore, the intercellular presentation of IL-2Ra reduced the bel-] 
expression when IDBL cells were cultured with U266 cells though no effect on 
apoptosis was evident. The expression of bel-] is associated with phosphorylation of 
STAT3 and I have shown that HMCLs do not prevent phosphorylation of STAT3 in 
IDBL cells, unlike the effect they exert on primary T cells. However the intercellular 
presentation of IL-2Ra in the presence of HMCLs resulted in failure of STAT3 
phosphorylation, in addition to ST AT5 which may account for the effect on bel-] 
expression. 
It is clear from the data presented in this chapter that HMCL-derived TGF-JH mediates 
its effect through the failure to phosphorylate key signalling molecules. In primary T 
cells this is associated with failure to express the high affinity IL-2R and up-regulation 
of the proto-oncogene, Pim-l. The effect on IDBL cells is different and susceptibility to 
HMCL-derived TGF-~ 1 can be induced by inter-cellular presentation of the a subunit 
resulting in similar inhibition of phosphorylation of STAT3. The nature of the 
contribution of IL-2Ra presentation in trans has on TGF-~ susceptibility is unknown 
but may represent a conformational change in the P/Yc chains which alters the signalling 
pathway emphasis. However, clear molecular differences exist in these two cell groups 
and this may reflect inherent signalling pathway aberrations in IDBL because it is a cell 
line. It may also represent differing emphasis placed on alternative signalling pathways 
used by cells at the cytokine withdrawal stage of activation, as IDBL cells represent. 
The extension of the signal transduction studies and consequent molecular events 
presented here will help to clarify these differences and lead to a greater understanding 
of what potentially could be a differential suppressive effect that myeloma tumour cells 
may exert on T cells at varying stages of activation. 
The molecular studies presented here provide an insight into how myeloma cells may 
influence the activation of T cells. In addition, the data suggests that the tumours 
mediate this not only through the production of TGF-J3 but by utilising the cell-cell 
interactions which occur naturally within the immune system, perhaps via inter-cellular 
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interactions which occur naturally within the immune system, perhaps via inter-cellular 
IL-2Ra presentation. This understanding will greatly assist in the design of 
immunotherapy strategies to maximise the perceived clinical efficacy. 
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CHAPTER 7 
Summary and Conclusions 
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Although there is little doubt that tumour-specific antigens exist for most human 
cancers, it is still unclear why these antigens do not cause tumour rejection. A 
successful immune response against a tumour is dependent on the detection of that 
tumour and the ability of the host immune system to mount an effective response. 
Clearly malignant cells have evolved to evade the natural host defence mechanisms 
resulting in growth and dissemination at the expense of the host. It is essential that the 
mechanisms employed by tumour cells to avoid immune regulation be elucidated so that 
immunotherapeutic strategies can be designed which will realise their true potential for 
eradicating the malignant clone. 
Multiple Myeloma (MM), a mature peripheral B cell malignancy remains essentially 
incurable despite massive escalation in treatment intensity. In addition to the associated 
paraproteinaemia, bone marrow failure, destructive bone disease and renal impairment, 
this disease is also associated with many defects in the host immune system. Such 
defects include quantitative and qualitative abnormalities of cell mediated immunity 
and secondary hypogammaglobulinaemia (Mellstedt et al, 1982). However, as yet, the 
mechanism that induces these abnormalities of the immune system remain to be 
determined. 
Experimental animal model systems have provided an insight into the role of T cells in 
the development of B cells and the orchestration of the normal immune response. The 
role of such mechanisms in human malignant disease of B lymphocytes is uncertain. 
However, the question that remains fundamental to innovative treatment strategies in 
MM is: if the immune response can be restored to recognise the "aberrant" B cells, will 
this induce control over the malignant clone? Circumstantial evidence is available to 
demonstrate that immune effectors can be directed towards the malignant cells of 
myeloma. Allogeneic bone marrow transplantation (BMT) does cure some patients due 
to the combination of intensive therapy plus a graft-versus-tumour effect mediated in 
part through minor histocompatibility antigen mismatching but also through tumour-
specific antigen expression (Gahrton et al, 1995; Bensinger et al, 1996; Bjorkstrand et 
al, 1996; Corradini et al, 1999). Certainly, donor lymphocyte infusions can re-instate 
remission after relapse following allogeneic BMT in the absence of GvHD (Bertz et al, 
1997). In the autologous setting, peripheral blood lymphocytes from patients with 
myeloma have been shown to be capable of proliferative responses to autologous 
tumour cells and, with high effector:target cell ratios, cytotoxicity can be demonstrated 
(MacKenzie et al, 1977; Paglieroni et aI, 1979). Such responses could explain the 
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disease stability, even without therapy, seen during plateau phase. Furthennore, it has 
been shown that a higher serum level ofIL-2 is associated with earlier stage disease and 
a better prognosis suggesting a potential role for immuno-regulatory control of the 
malignant clone (Cimino et al, 1990). These features suggest that the immune system, 
either the host's immune effector cells or adoptively transferred donor immune effector 
cells, can be utilised to regulate and even eradicate the malignant clone of multiple 
myeloma 
Tumour immunotherapy remains the "Holy Grail" of tumour immunologists and 
clinical oncologists alike. However, before such treatments can be applied on an 
entirely rational basis and achieve their optimum efficiency in eradicating the tumour 
clone, more knowledge is required as to why the immune system fails to identify 
multiple myeloma plasma cells as foreign. With this understanding, it is envisaged that 
such tumour defence mechanisms could be by-passed or over-come not only in the 
allogeneic but especially the autologous setting thus targeting a greater number of 
patients with this disease. The experimental data presented in this thesis has addressed 
the issue of the interaction of myeloma tumour cells with T lymphocytes, indicating a 
potential mechanism that may propagate the immune privilege of the tumour clone and 
thus highlight areas that might be targeted when designing new therapeutic strategies. 
Myeloma Tumour Cells Inhibit T cell Activation via TGF-ftl 
The data presented in this thesis demonstrate that the malignant plasma cells of mUltiple 
myeloma are capable of suppressing the activation of T lymphocytes. The myeloma 
cells prevent activation of T cells from healthy donors by allo-antigen, mitogen and IL-
2, mediated by the production of a soluble, immuno-suppressive factor. This soluble 
factor was responsible for inducing cell cycle arrest and failure of the T cells to progress 
into the IL-2 autocrine pathway, which is of critical importance in the activation of T 
cells. The myeloma cells constitutively expressed high levels of TGF-~ 1 mRNA 
transcripts as detected by RT-PCR, which were translated into latent protein detected by 
immunohistochemistry and secreted as detected by ELISA. The identification of a 
potential mediator of the suppressive effects alone is insufficient proof. However, the 
reversal of the immuno-suppression induced by the myeloma cells using the specific 
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using the specific TGF-~ antagonist, LAP, confirms that TGF-~1 is a major factor in 
myeloma-associated suppression of T lymphocyte activation. The use of a bone marrow 
serum sample (BM6) in chapter 6 sought to demonstrate similar effects to that induced 
by the HMCLs. Clearly, the BM6 serum was capable of suppressing the expression of 
the a subunit of the IL-2R and as such this indicates that the suppressive effects induced 
by the HMCLs is not a function of being a cell line. However, demonstrating the 
suppression of primary T cells using one sample is by no means conclusive and work is 
on-going to demonstrate such effects with a large cohort of BM sera and to determine 
whether these suppressive effects are altered in severity with varying tumour burdens as 
indicated by clinical staging. 
The studies presented in this thesis strongly implicate TGF-~1 in the suppression of T 
cell activation. Others have proposed a role of FasL and the underglycosylated surface 
mucin, muc-I, in myeloma-associated immune dysfunction (Villunger et al, 1997; 
Treon et al, 1999). The evidence presented here however opposes these potential 
mediators for the following reasons. Firstly, in previous reports of the role of FasL, the 
authors used a Fas-sensitive target (CEM-C7H2 cell line) in their model which at least 
demonstrates that HMCLs express (and even secrete) functional FasL. In my in vitro 
model system, I used another Fas-sensitive T cell line, Jurkat E6.1, with no resulting 
decrease in proliferation and increase in apoptosis seen when co-cultured with HMCLs. 
Secondly, FasL has previously been shown to induce cell cycle arrest in primary T cells 
and whilst this was demonstrated in my in vitro model, the reversal by the TGF-~­
specific antagonist LAP demonstrates that the major mediator of the suppressive effects 
seen in my studies is in fact TGF -~. The issue of muc-l remains to be clarified. Other 
investigators have shown that it induces cell cycle arrest and apoptosis in primary T 
cells. However, this effect can be overcome by increasing concentrations of IL-2. In the 
studies presented in this thesis, not only did apoptosis not play a significant role in 
mediating the HMCL-induced suppressive effects, increasing concentrations of IL-2 
could not over-come these effects. This suggests that, at least in my in vitro model, 
muc-l does not playa significant role. However, the in vivo role ofmuc-l remains to be 
clarified in on-going studies with clinical material. 
T lymphocytes utilise many different intra-cellular signalling cascades when activated 
which vary depending on the stimulus and the receptor complex involved, i.e. IL-2IIL-
2R cf. mitogen-TCRlCD3 activation (Kuo & Leidin, 1999). Data presented in this thesis 
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demonstrates that the myeloma cells prevent the T cells, upon activation, from up-
regulating the surface expression of the a-chain of the IL-2R thus preventing the 
formation of the high-affinity receptor. This results from failure to up-regulate the 
transcription of the a-chain gene in response to re-stimulation of primary T cells with 
IL-2. The transcriptional regulation of the a-chain gene is complicated and requires an 
orchestration of several gene transducers. Of these, STATS has been shown to be 
important in mediating up-regulation of genes involved in activation and cell division. 
The evidence presented here demonstrate that primary T cells, when responding to re-
stimulation with IL-2, fail to phosphorylate both STAT3 and ST ATS, mediated by 
myeloma-derived TGF-~. However, using a novel IL-2-dependent T cell line, IDBL, it 
was shown that these cells are insensitive to the myeloma-derived TGF-~, in terms of 
DNA synthesis and proliferation, despite demonstrating failure of phosphorylation of 
STATS. It was demonstrated that phosphorylation of STAT3 was unchanged when 
IDBL cells were co-cultured with myeloma cell lines. However when the a-chain of the 
IL-2R was presented inter-cellularly in trans, this induced a susceptibility of the IDBL 
cells to HMCLs. This resulted from failure of STAT3 phosphorylation associated with 
down-regulation of bC/-2 and pim-l genes. As a consequence, the IDBL cells 
demonstrated reduced DNA synthesis and proliferation, similar to that seen with 
primary PBL, when IL-2Ra was presented in an inter-cellular fashion. Taken together, 
these features demonstrate that the presence of the a-chain of the IL-2R presented inter-
cellularly in trans, from a transfectant in the case ofIDBL cells assists the susceptibility 
of activating T cells to myeloma-derived TGF-~1 resulting in growth arrest and failure 
to enter the IL-2 autocrine pathway. The contribution of CD2S+ T cells in the 
heterogeneous population of primary T cells used in these studies, remains speculative. 
This data supports the role of the a-chain of the IL-2R in regulating the immune 
responses, here potentiating the T cell suppressive effects of myeloma-derived TGF-~I. 
Implications for Immunotherapy 
The improved disease control associated with allogeneic HSe transplantation is in part 
related to the direct effect of the graft-versus-myeloma effect that has been reported by 
several investigators (Tricot et al, 1996; Verdonk et al, 1996). A close relationship 
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between Graft-versus-host disease (GvHD) and GVM in these studies suggests that the 
latter effect is mediated by donor aHo-reactive T cells directed against minor 
histocompatibility antigens present on both normal and myeloma cells. Some 
investigators have demonstrated the successful transfer of myeloma idiotype-specific 
immunity from an actively immunised bone marrow donor and showed the recovery of 
a CD4+ T-cell line generated from the peripheral blood of the recipient which 
demonstrated specific idiotype sensitivity (Hornung et ai, 1995; Kwak et al, 1995). 
These immunotherapy strategies have been tested in the relapsed or resistant setting and 
the role of such strategies in the setting of minimal residual disease following 
conventional chemotherapy or HCT offers an increased potential for tumour cell control 
by adoptively transferred immune effectors. 
However, these attempts at immunotherapy are empirical and the true effector cells are 
not known. The role of adoptive immunotherapy in MM may be developed more 
appropriately in the setting of directed immune effectors. Many investigators have 
turned to generating professional antigen presenting cells such as dendritic cells which 
have been pulsed with tumour derived peptides or idiotype (Reichardt et al, 1999; 
Dabadghao et ai, 1998; Wen et ai, 1998; Zeis et aI, 1998; Hart et al, 1999). These 
studies demonstrate that idiotype-reactive T cells can be generated using such systems, 
although the results of pre-clinical studies have failed so far to be translated into 
meaningful improvements in overall and event-free survival of patients with MM 
(MacKenzie et ai, 1998). 
Early pre-clinical experience using adenovirus to transfect plasma cells with immuno-
stimulatory genes (e.g. IL-2, IL-12 and CD80; Wendtner et al, 1997) has lead a phase I 
clinical trial which injected an IL-2 gene directly into the tumours of two patients with 
multiple cutaneous plasmacytomas with resultant evidence of successful tumour cell 
transfection using PCR and work has now started on IL-2 gene transfected autologous 
plasma cell vaccines. Other investigators have utilised similar gene transfectant systems 
to transfer suicide genes e.g. herpes simplex thymidine kinase gene, which may have 
therapeutic potential (Stewart et al, 1998). These advances in the field of 
immunotherapy hold great potential and it is hoped that the success in the pre-clinical 
models can be translated into efficacious treatment modalities. 
All these immunotherapeutic strategies have focussed on providing appropriate 
stimulation for the immune effectors cells but have not taken into consideration the 
fundamental defect in the host immune system. As has been shown in this thesis, 
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myeloma cells impair the response of T cells to allo-antigen, mitogen and re-stimulation 
with IL-2, mediated by TGF-~ I. This may account for the peripheral tolerance induced 
by the MM tumour-bearing host. As TGF-~ is a pleiotrpic cytokine with many 
functions, blocking its in vivo effect may be both difficult and may be associated with 
numerous unwanted side-effects. However, as shown in this thesis, the effect of TGF-~ 
is particularly pronounced when T cells either require the assembly of the high affinity 
receptor for activation or are presented with the a-chain in trans, which results in 
failure of phosphorylation of both STAT3 and STAT5. This induces the pronounced T 
cell suppressive effects through targeting the entry of cells into the IL-2 autocrine 
pathway. As such, activation of T cells outside this IL-2 autocrine pathway may offer a 
means to by-pass the suppressive effect of the tumour cells on the activating T cells and 
potentially result in anti-tumour immune responses. For example, Interleukin-15 (IL-15) 
is a monocytelmacrophage-derived T cell stimulatory cytokine that can enhance T cell 
proliferation and up-regulation of IL-2Ra expression (reviewed by Ma et ai, 2000). 
Experimental studies conducted in the research laboratory of the ATMU has suggested 
that IL-15 can render T cells resistant to suppression by tumour-derived TGF-~, 
mediated, at least in part, by phosphorylation ofSTAT3 and STAT5. This may provide 
a useful mechanism that may be exploited in the design of immunotherapy for MM. 
Whatever the mode of activation of the T cells in the afferent phase of an evolving anti-
tumour response, one thing is clear. In light of the evidence presented in this thesis and 
published by other investigators, the micro-environment in patients with MM is hostile 
to activation of T cells and any immunotherapy strategy needs to take this into account 
if the true efficacy of such treatment is to be realised. Therefore, it would seem rational 
to concentrate on ex vivo induction of the afferent anti-tumour immune response with 
the expectation that this will allow for the generation of a more effective anti-tumour 
effect in vivo. 
It is worthy of note that if the wild type tumour is capable of an array of defence 
systems which can prevent the generation of an immune response or switch off an 
established response, then the design of immunotherapy intervention will need to 
overcome these. It is evident from the data available that multiple myeloma tumour 
cells adopt numerous mechanisms to avoid regulation by the host immune system. The 
tumour cells evade detection through alterations in their phenotype whilst at the same 
time switch off any immune effector cells directed against them using 
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immunosuppressive cytokines and other molecules (Figure 7.1). It is likely that more 
than one of these pathways is responsible for the failure of the host immune system to 
regulate the growth of the tumour clone. As more research in this field unfolds and 
more evidence of the established pathways emerges, or newer mechanisms of 
immunosuppression are discovered, physicians can use this information to design new 
immunotherapy strategies that may maximise such treatment modalities, especially in 
patients with minimal residual disease. 
The Role ofTGF-pl in the Pathology of Myeloma 
The data presented in this thesis strongly supports TGF-~ as a major immune 
modulating cytokine produced by the malignant clone in myeloma. However, what role, 
if any, does this pleiotropic cytokine play in the pathogenesis of the disease? Whilst 
functioning as an immunosuppressive factor thus permitting the malignant clone to 
escape regulation and thus rejection in a potential hostile environment, it is probable 
that TGF-p has a more central role in maintaining clonal growth and survival. For 
example, multiple myeloma is frequently associated with a normochromic/normocytic 
anaemia which has been presumed to result from bone marrow infiltration, especiaUy as 
it is more prominent in advance disease (Tricot, 2000). This may not simply be a 
physical phenomenon as TGF-~ 1 has been shown to suppress haematopoiesis mediate 
through inhibition of the expression for the gene products for steel factor and its 
receptor (c-kit) and has been suggested to cause the bone marrow failure associated with 
B cell chronic lymphocytic leukaemia (Heinrich et al, 1995). Similarly, secondary or 
acquired hypogammaglobulinaemia associated with a non-specific polyclonal B cell 
defect results in poor primary immune responses to infection and significant morbidity 
and mortality (Tricot, 2000). This was originally thought to relate to tumour burden. It 
has been demonstrated that TGF-pl suppresses the proliferation of normal B cells and 
immunoglobulin production though it has been shown that fresh myeloma cells and 
patient-derived cell lines are not inhibited by TGF-pl, either in terms of DNA synthesis 
or immunoglobulin production (Kerhl et aI, 1986; Urashima et al, 1996). Also, TGF-pl 
has been shown to inhibit IL-2-dependent T cell proliferation and cytotoxic T cell 
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Dendritic 
cell 
"-------'-----> 
Stromal cells 
T cell 
FIGURE 7.1. Multiplicity of interactions between MM plasma cells and their 
environment. In addition to defects in co-stimulatory molecules and antigen 
presentation MM tumour cells may utilise numerous "counter attack" mechanisms to 
suppre sion the host immune system. Key: TGFf3: transforming growth factor beta; 
VEGF: vascular endothelial growth factor; ILl f3: interleukin 1 beta; IL6: interleukin 6. 
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generation related to the fact that activated T cells increase their surface expression of 
TGF-p receptors (KerhI et aI, 1986; Letterio & Roberts, 1998). 
It is clear that TGF-~ 1 can mediate some of the major clinical manifestations of the 
disease but does it enhance survival and dissemination of the tumour cells in myeloma? 
Some investigators have shown that myeloma tumour and stromal cells produce higher 
levels of TGF-~ 1 than their non-malignant counterpart (Urashima et al, 1996). 
Production of IL-6, the main growth factor for myeloma cells, is enhanced by TGF-~I 
both from stromal cells and myeloma plasma cells and this may facilitate autocrine and 
paracrine tumour growth and survival (Urashima et al, 1996). TGF-~1 has also been 
shown to alter the array of adhesion molecules on myeloma cells, which would facilitate 
greater contact of the myeloma cell with its microenvironment, a feature that has been 
shown to both promote the survival and induce the propagation of the clonal plasma 
cells (Tricot, 2000). 
It has been shown that TGF-~ 1 inhibits normal B cell proliferation and that myeloma 
cells appear to be "insensitive", at least in vitro, which may be attributable to failure of 
TGF-~I-induced inhibition ofRb phosphorylation and thus cell cycle arrest. This may 
be result of aberrant TGF-~ 1 receptor expression, deviant intra-cellular signalling of the 
TGF-~ 1 receptors or fundamental cell cycle regulatory gene defects associated with the 
malignant transformation of the B cell in multiple myeloma. Whilst this is 
circumstantial evidence that indicates TGF-~ 1 is a major cytokine involved in the 
maintenance and survival of the malignant B cell clone, the exact role ofTGF-(31 in the 
pathogenesis of multiple myeloma remains to be clarified. 
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CM 
Cryopreservation 
medium 
dNTP 
DNA gel 
lOX MOPS 
Northern Loading 
Buffer 
PBS 
Propidium iodide 
RIPA buffer 
RNA gel 
10% Acrylamide gel 
5% Acrylamide gel 
10XTBE 
TBS 
TIBS 
TE 
WB Blocking Buffer 
WB Loading Buffer 
10XWB Running Buffer 
WB Transfer Buffer 
Key: WB - Western Blot, 
MATERIALS AND SOLUTIONS 
RPMI1640, 10% heat-inactivated foetal calf serum (FCS), 
2mM L-glutamine, 100 ill/ml penicillin and 100 
Jlglml streptomycin. 
Equal volumes of20% DMSO in heat-inactivated FCS and 
50% FCS in RPMI1640. 
20JlI of 100mM dA TP solution, 20JlI of 100mM dGTP 
solution, 20JlI of 100mM dCTP solution, 20JlI of 
100mM dTTP solution and 120 JlI RNAse-free H20 
== IOMm of each base. 
l.4g agarose, 70 mls xl TBE and 1 JlI ofethidium bromide 
(10 mg/ml). 
0.2M MOPS( 3-(N-morpholino )propansulphonic acid), 50 
mM sodium acetate, IOmM EDTA (all Sigma) pH7 , 
autoclaved and stored in the dark. 
0.75 ml deionised formamide, 0.15ml IOxMOPS, 0.24 
37% formaldehyde, 0.15ml DEPC-treated H20, 
O.IML glycerol, 50JlI Bromophenol BluelXC 10% 
dye mix and stored at _20DC. 
0.9% NaCI, 0.107% Na2HP04 and 0.051%NaH2P04 (all 
Fisons) w/vaqueous solution. 
50Jlglml aqueous solution of propidium iodide (Sigma) 
with 0.04% RNAse (Sigma). 
50 mM Tris-HCL (pH 8), 150 Mm NaCI, 1 % NP40, ImM 
EDTA, O.OS% SDS and dH20. 
1.2g agarOse (Sigma), lOml 10xMOPS, 8Sml ultrapure 
dH20 and Sml 37% formaldehyde. 
12.Smls Acrylamidelbis 40%, 20.8mls H20, 16.7mls I.SM 
Tris HCL (PH 8.8), 0.5mls SDS, O.5ml Ammonium 
Persulphate & 40JlI TEMED. 
3.125mls Acrylamidelbis 40%, 18.37Smls H20, 3.Smls 
0.5M Tris HCL (PH 6.8), 0.2Smls SOS, 0.2SJll 
Ammonium Persulphate & 20JlI TEMEO. 
108g Tris, 55g boric acid (both Sigma), 40ml 0.5M EOTA 
(PH8) in 1 litre of dH20. Equivalent to 0.045Tris 
borate, O.lmM EDTA when diluted to IX TBE. 
0.9% NaCI buffered with 50 mM Trizma base (Sigma), 
adjusted to pH 7.6 with 1 N HCL. 
TBS with 0.05% Tween 
10mM Tris-HCL pH 7.6 and ImM EDTA in dH20. 
1 X TBS, 0.1 % Tween-20 with 5% w/v nonfat dry milk. 
62.5Mm Tris-HCL (PH 6.8) 2% w/v SDS, 10% glycerol, 
50Mm dtt, 0.1 % w/v bromophenol blue. 
15.15g Tris, 72g glycine, 5g SDS, 500 ml H20 
3.03g Tris, 14.4g glycine, 200 ml methanol and 800 ml 
H20 
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Haematological oncology 
Immune regulation in multiple myeloma: 
the host-tumour conflict 
G. Cook, 1. D. M. Campbell 
Multiple myeloma (MM) remains essentially incurable by conventional anti-tumour therapy. This has 
led to increased interest in the possibility that forms of immune therapy might be effective. The 
successful use of donor lymphocyte infusions (DLI) in a few cases of MM relapse following allogeneic 
bone marrow transplantation have added weight to this view. MM is characterized by several defects in 
the host's immune system. The influence of the malignant clone on the function of the immune effector 
cells results from both passive and active suppression. Despite an array of functional adhesion molecules 
and HLA class I and II molecules on their surface and the secretion of a tumour-specific peptide, they 
fail to express adequate levels of co-stimulatory molecules thus inducing anergy in potentially tumour-
specific T cells. In addition to this passive evasion of immune regulation, MM tumour cells are capable 
of producing a number of immunologically active agents which can induce immunosuppression such as 
transforming growth factor-beta, Fas ligand (FasL), vascular endothelial growth factor and Muc-!. It is 
postulated that these agents may be produced by the tumour cell to influence the microenvironment to 
support growth and differentiation of the clone but may have the additional benefit of altering the 
function of the host immune effector cells and thus preventing tumour rejection. This duality of 
function is important if clinicians are to design immunotherapy strategies which will achieve the true 
potential and result in improved survival in MM. © 1999 Harcourt Publishers Ltd 
INTRODUcrIO~ 
Although there is little doubt that tumour-specific 
antigens exist for most human cancers, it is still 
unclear why these antigens do not cause tumour rejec-
tion. A successful immune response against a tumour 
is dependent on the detection of that tumour and the 
ability of the host immune system to mount an effec-
tive response. Clearly, malignant cells have evolved to 
evade the natural host defence mechanisms resulting 
in growth and dissemination at the expense of the 
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host. It is essential that the mechanisms employed by 
tumour cells to avoid immune regulation are eluci-
dated so that immunotherapies can be designed which 
will realise their promise. 
Multiple myeloma (MM) is a mature, peripheral B 
cell malignancy and remains essentially incurable 
despite massive escalation in treatment intensity. 
Allogeneic bone marrow transplantation (BMT) does 
cure some patients owing to the combination of inten-
sive therapy plus a graft-versus-tumour effect. In addi-
tion to the associated paraproteinaemia, bone marrow 
failure, destructive bone disease and renal impair-
ment, this disease is also associated with many defects 
in the host immune system. In patients with MM, evi-
dence exists to suggest that phenotypic and functional 
changes occur in T-cells, B-cells, macrophages and 
NKiLAK cells. l -<4 While this evidence suggests an 
152 Blood RevielVs 
attempt at immunoregulation of tumour cell growth 
and differentiation by the host, their in vivo and thus 
clinical relevance has yet to be proven. However, it has 
been shown that a higher serum level of interleukin-2 
is associated with earlier stage disease and a better 
prognosis suggesting a potential role for immunoregu-
latory control of the malignant c1one.s 
Destruction of immune targets requires the activa-
tion of efficient, immune competent T cells. Such an 
induction is postulated to require a two-signal system 
for efficient activation.6.7 Following the interaction 
of cellular adhesion molecules and their ligands the 
initial signal is generated by T cell recognition of ~nti­
genic peptides (Ag) presented with major histocom-
patibility complex molecules (MHC) via T cell 
receptors.s. Following this AglMHC-restricted signal, 
a second sIgnal (non-MHC-restricted) is generated via 
co-stimulatory pathways which determines whether 
the TCR complex engagement results in functional 
activation or clonal anergy.9 Several co-stimulatory 
pathways may exist but one important pathway is the 
interaction of B7-1 and B7-2 (CD80 and CD86 
~espectively) expressed on B cells and antigen present-
Ing cells (APC) with their ligands CD28 and CTLA-4, 
expressed on T cells. 10 12 Providing that this second or 
co-stimulatory signal is received, then signalling from 
the TCR-CD3 complex (particularly via CD3~ 
c~ains) is .tran~mitted from the cell membrane to pro-
teIn tyrosIne kInases (especially p56 Lck and ZAP70 
reviewed by ref 13). These act on many intra-cellula; 
pathways culminating in the upregulation of new 
genes required by T cells to become activated includ-~ng proto~oncogenes (Fos, Myc) and interleukins (lL) 
Involved In the immune response e.g. IL-2 and its 
receptor complex (lL-2Ra~'Yc)' IL-3, IL-4, IL-5, IL-
6. 14 This early activation is followed by ONA synthe-
sis, proliferation and the up-regulation of genes 
expressed in late T cell activation, e.g. RANTES, 
Granzymes, Perforin, 519/granulysin. ls 
Clearly tumour cells can interfere with this activa-
tion process at any stage either by a single method or 
an orchestrated manipulation of the recognition and 
effector mechanisms (Fig. 1.). This review aims to dis-
cuss the current understanding of how myeloma 
t~mo.ur ~ells interact with the host immune system, 
hIghlIghtIng areas which might be useful in de igning 
new therapeutic strategies. 
EVADING DETECTION 
T-Iympbocytes: ineffective policemen? 
Patients with MM have altered distribution of CD4 
and 08 lymphoid subsets.3 The imbalance of the 
TUMOUR CELL ........... 
Fig I Interaction between tumour cells and the host immune 
system. Key: I. Defects in inter-cellular adhesion; 2. Lack of 
MHC ~olecules: defective antigen processing/presentation, 
absent/sllen.t antigens; 3. Absence of co-stimu latory molecules; 
and 4. Mediation of apoptosis (+) or prevention of activation ( ) 
by soluble factors or cytokines. 
CD4:C08 ratio relates predominantly to a reduction, 
both in percentage and absolute numbers of CD4'" 
cells particularly the naive CD4"'/CD45RA'" cells. 16.17 
These reports demonstrate that the observed decrease 
in CD4'" T cells is more pronounced in patients with 
advanced disease and decreased numbers of CD4'" T 
cells «700xI06/1) are associated with a significantly 
lower survival rate and increased probability of 
~elapse.16.17 With regards to CD8+ T cell s, although 
Increased numbers of cytotoxic T cells have been 
reported in patients escaping from plateau phase 
this increase is only in percentage and not absolute 
numbers. ls 
T cells within bone marrow mononuclear cell frac-
tions from patients with myeloma showed increased 
proliferative responses to CD3 monoclonal antibody 
stimulation compared with healthy, age-matched con-
trols with demonstrable anti-plasma cell activity. This 
was thought to imply an immunoregulatory role for 
such T cells. 19 Certainly, peripheral blood lymphO-
cytes from patients with myeloma have been shown to 
be capable of proliferative responses to autologoUS 
tumour cells20 and with high effector:target cell ratioS 
cytotoxicity can be demon trated .21 Peripheral blood 
T cells with idiotype specificity capable of down-regu-
lating growth and differentiation of the myeloma 
clone have been demonstrated .22 
The idiotypic immunoglobulin may be regarded as 
a tumour specific antigen and as such, proliferation 
and differentiation of idiotype-expressing malignant 
B cells may accordingly be under regulation by idio-
typic reactive T cell. In animal plasmacytoma mod-
els, T cells can be shown to regulate the growth of the 
plasma cells by specific recognition of the idiotype 
antigen.22 Furthermore, evidence of T cell tumour 
recognition is suggested by the growth of T cell 
clones by timulation with IL-2 and F(ab') fragmentS 
derived from autologous idiotype, and the ~roduction 
--------------------------------------------------------
of cytokines such as interferon-y, IL-2 and IL-4 by 
peripheral blood T cells after stimulation with autol-
ogous idiotype.23.24 However, when TCR variable 
region repertoires were analysed in peripheral blood 
T cells of myeloma patients with low tumour burden, 
oligoclonal CD8+ cell expansions with VIB and 
V135.2 restricted usage did not demonstrate idiotypic 
reactivity but non-expanded V1322 restricted CD8+ 
cells did.25 
The antigen specificity of the clonal CD8+ cells 
remain uncharacterized but may represent chronic 
antigenic stimulation by other tumour associated 
antigens. TCR beta gene rearrangements can be 
detected in 32% of patients more commonly found in 
disease progression.26 The presence of these oligo-
clonal T cells was identified as an independent prog-
nostic factor and correlated with the presence of 
peripheral blood T cells which are reactive to the 
tumour idiotype detected by autologous F(ab2) frag-
ment binding to CD3+ cellsY The ability to generate 
'tumour reactive' T cells in vitro whilst clinical evi-
dence fails to demonstrate that these cells have an abil-
ity to keep the disease under control in vivo serves to 
suggest that tumour cells are often antigenic but not 
immunogenic. The ability to recognize and eliminate 
tumour cells may be compromised in cancer patients 
by many factors including inadequate antigen presen-
tation and tumour-derived immunosuppressive fac-
tors. T cells of patients with myeloma have 
abnormalities in signalling molecules particularly 
PKC-a and NFKB and enhanced susceptibility to 
apoptosis resulting from increased surface Fas expres-
sion and reduced intracellular bcl-2 levels.28-30 Taken 
together, these features represent a fundamental 
defect in the T cells. In order to achieve the maximal 
effect from immunotherapy strategies, a fuller under-
standing of the biological interplay between myeloma 
tumour cells, which cause these defects, and immune 
effectors is mandatory. 
Altered co-stimulation molecules: the unseen enemy 
T cell activation is accomplished with specific antigen 
presentation associated with co-stimulatory cell--cell 
interaction.6,1 Tumour cells may evade detection by 
disrupting this three - stage process; cell--cell interac-
tion, antigen processing/presentation and co-stimula-
tion. Myeloma tumour cells express an array of 
surface adhesion molecules involved in both 
cell-stroma and cell--cell interaction (reviewed in 31). 
Using a panel of human myeloma cell lines we have 
detected surface expression of both HLA-ABC and 
HLA-DR (Table 1) which reflect studies of MHC sur-
face expression on freshly isolated cells from patients 
with multiple myeloma.32•33 However, we did not 
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detect significant surface expression of the co-stimula-
tory molecules, CD80 and CD86 nor did we detect 
expression of CD80 mRNA by RT-PCR (Table 1). 
These results are similar to that reported by other 
groups though variable expression has been reported 
between human myeloma cell lines (HMCL) and fresh 
tumour cells from patients which might represent the 
level of maturation or the state of activation.34-36 In 
addition it has been demonstrated that surface expres-
sion of CD80 can be up-regulated on myeloma cell 
lines by co-stimulation through CD40L.37,38 
Interestingly, plasma cells from myeloma patients, 
plasmacytomas and HMCL demonstrate surface 
expression of CD28 which is constitutively expressed 
on the majority of CD4 T cells and approximately 
half of CD8 T cells. 35,39 Myeloma cells expressed a 
similar density of CD28 antigen to that of normal T 
cells and it has been demonstrated to be able to bind 
B7-lg molecules.40 Blockade of CD28 signalling failed 
to alter the proliferation, survival, differentiation or 
surface expression of antigens and cytokine receptors. 
However, the CD28 molecule was demonstrated to be 
functionally active by binding of the p85 sub-unit of 
PI3 to CD28 being triggered by CD80-transfected 
cells. Whether CD28 has a role in autostimulation of 
the tumour clone or contributes to a down-regulation 
of the immune control of the malignant plasma cells 
in vivo remains to be elucidated. However, fresh 
tumour cells from patients with early and plateau 
disease are CD28- compared with fresh tumour cells 
from patients with aggressive disease which were 
CD28+.35 The relevance of these findings in vivo and 
their effect on the hosts ability to generate competent 
immune responses remains unclear. 
Can myeloma cells present antigen? 
The myeloma-derived idiotype (Id) is a tumour-spe-
cific antigen that can be recognized by antigen-specific 
T cells in the form of peptides bound to MHC 
molecules (class I and II). Professional antigen pre-
senting cells such as dendritic cells can efficiently pre-
sent the Id.41 However, despite the high production of 
Id by the clonal plasma cells, a clinically significant 
naturally occurring immune response has rarely been 
demonstrated. In addition to the variable surface 
expression of co-stimulatory molecules and the 
potential for an immunologically hostile microenvi-
ronment (see below), MM tumour cells may function 
as poor antigen presenting cells. Several studies have 
shown that fresh MM tumour cells can induce an allo-
geneic MLR which was augmented by anti-CD28 
MoAb or pre-treating the tumour cells with CD40L 
~r TNFa and interferon:Y2.43 with the T cell prolifera-
tIve responses seen bemg predominantly from the 
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Table 1 Expression of surface molecules involved in secondary costimulation of T lymphocytes in human myeloma cell lines using 
monoclonal antibodies. The presence of CD80 and CD86 mRNA by RT-PCR 
Surface antigen expression 
CD80 CD86 CD80 CD86 CD28 CD40 HLA-ABC HLA-DR 
Cell Line mRNA mRNA 
JIM-3 Neg Neg N N ++ ++ +++ N 
JIM-! Neg Neg N N +++ ++ +++ ++ 
JJN Neg Neg N N ++ ++ +++ +++ 
U226 Neg Neg N N +++ ++ +++ +++ 
RPMI-8226 NT NT N N ++ ++ +++ +++ 
EJN NT NT N N ++ ++ +++ ++ 
Key: N <20% cells positive, + 20-40% cells positive, ++ 40-70% cells positive, +++ 75-100% cells positive, NT not tested. 
CD8+ lymphocyte compartment. However, we have 
shown that HMCL when used in a one-way MLR do 
not induce an allogeneic response which may reflect 
the fact that the HMCL are derived from patients 
with aggressive, often terminal phase disease and thus 
the tumour cells may have adopted additional evasive 
measures.44 
The ability of malignant plasma cells to process 
and present recall antigens (purified protein derivative 
and tetanus toxoid) to autologous T cells with the 
generation of proliferative responses and IFN-y secre-
tion has been demonstrated.42 However, when MM 
cells alone were used to stimulate autologous T cells, 
no proliferative response directed towards the tumour 
cells was demonstrated despite the addition of anti-
CD28 MoAb.43 This unresponsiveness was partly 
reversed when the tumour cells were pre-activated 
with CD40L then used to stimulate an autologous 
reaction. These features suggest that myeloma tumour 
cells have the capacity to process and present antigens 
that can be recognized by T cells, at least in vitro. This 
implies that T cells, especially tumour-specific T cells, 
may playa role in the in vivo tumour regulation of 
growth and differentiation. However, the fact that 
large number of tumour cells are not destroyed in 
patients with MM suggests that in vivo, this attempt 
at regulation may indeed be hampered either by insuf-
ficient co-stimulatory molecules in vivo or that spe-
cific peripheral tolerance has been induced, as has 
been observed in other human B cell malignancies.45 
Antigen silencing 
Assuming there is a clonal ongm and a series of 
genetic modifications involved in the development of 
neoplastic cells it is reasonable to expect that tumour 
cells express mUltiple cellular proteins that are distinc-
tive from the tissues from which they are derived. 
However, cytotoxic T lymphocytes (CTL) are not 
active in vivo against most of these epitopes despite 
the association of these antigens with MHC 
molecules.46 This results in limited T cell responses to 
a reduced number of antigens out of a larger available 
pool- a phenomenon known as 'immunodominance'. 
Silent tumour antigens are natural peptides presented 
in association with MHC molecules that are not 
immunogenic during the clonal expansion of the 
tumour cells .. Despite these antigens failing to be 
immunogenic in vivo, they are fully competent targets 
for CTL lysisY 
Many factors contribute to antigen silencing 
including altered TCR ligand peptide affinity, TCR 
occupancy thresholds, levels of co-stimulatory and 
adhesive molecules and the status of the T cells (nai've 
vs. memory). When taken together, a 'compensation 
model' of CTL activation is evident: weak antigenic 
signals may require a larger degree of adhesion/co-
, stimulation than stronger antigenic signals. This cou-
pled with a potentially immunologically hostile 
environment may provide a route for evading 
immunological surveillance. In respect to multiple 
myeloma, little if any data exist regarding the exis-
tence of silent antigens. If present then these might 
provide a useful source of antigenic material to stimu-
late CTL responses in vitro particularly if the amino 
acid structure can be subtly modified to improve their 
immunogenicity and dendritic cells are employed as 
professional antigen presenting cells.48,49 This is partic-
ularly important as silent antigens work in the induc-
tion phase, not in the effector phase and thus 
pre-activated CTLs against these antigens may oper-
ate with improved efficiency as has been shown in a 
murine lymphoma model.so Further research in 
myeloma is needed to identify silent antigens, if such 
exist, which might provide the tumour immunothera-
pist with an additional weapon in their armoury. 
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Table 2. The effects of cytokines on immune effector cells 
Effect TGF-13 IL-IO VEGF Ref. 
Inhibition of T-cell growth + + 65,107 
Inhibition of CTL differentiation + + + 54,59,107 
Inhibition of T cell cytokine production + + 53 
Induction of T-cell anergy + 65,73,74 
Shift in the Th 1-Th2 balance towards Th2 + + 54,70 
Down-regulation of adhesion/co-stimulatory molecules + + 60,65 
Key: IL, interleukin; TGFI3, transforming growth factor beta; Th, T helper lymphocyte; VEGF, vascular endothelial growth factor. 
ATTACK IS THE BEST FORM OF DEFENCE 
Tumour-induced cytokines and immunosuppression 
An array of cytokines and immune-modulating 
agents have been reported by many investigators in 
the field of tumour immunobiology.sl In particular, B 
cells can produce a large number of cytokines both in 
disease and health (reviewed in 52). These cytokines, 
plus a range of immune-modulatory molecules 
including interleukin 10 (IL-IO), transforming growth 
factor beta (TGF~), Fas and FasL, vascular endothe-
lial growth factors (VEGF), and MUC-I warrant par-
ticular attention. The effects of the cytokines are 
summarised in Table 2. 
IL-I0 
This is a pleiotropic cytokine produced by B cells, 
monocytes, macrophages and keratinocytes which 
inhibits synthesis of the pro-inflammatory cytokines 
IL-I, IL-6, IL-8, IL-12, TNF-Cl and GM-CSEs3 
Originally identified in mouse T helper cells, murine 
IL-1O was referred to as CSIF (cytokine synthesis 
inhibitory factor) and was shown to be a product of 
Th T helper cells which inhibited cytokine produc-tio~ by Th cells. 54 Murine and human IL-1O share 
73% amin~ acid homology including hydrophobic 
leader sequences and although hulL-1O is active on 
murine T cells, mulL-IO appears not to be signifi-
cantly active in human cells. 55 It is interesting to note 
that IL-1O proteins and cDNA reveals a strong pre-
dicted amino acid sequence to BCRFI (84% amino 
acid homology), an uncharacterized open reading 
frame in the Epstein-Barr viral genome. It has been 
proposed that that the BCRFI gene represents a 
cytokine gene that assists the virus to evade or attenu-
ate the host defences. 56 Multiple roles have been 
, suggested for IL-IO including inhibition of mono-
. cytes/macrophages and T cell effector function. 
However, IL-IO's effects are not all inhibitory since it 
can enhance the viability and proliferation of B cells 
and differentiation. 53 IL-IO is the most potent inducer 
of immunoglobulin secretion in various B cell activa-
tion systems in vitro. 57 
IL-IO is spontaneously secreted by a variety of 
human tumours and local secretion by tumour cells 
can render themselves insensitive to CTL lysis.s9.60 In 
multiple myeloma the role of IL-1O is less clear. 
Normal B cells differentiating to Ig-secreting B cells 
lose IL-IO mRNA transcripts, though terminally dif-
ferentiated plasma cells retain expression of the IL-
IOR.61.62 We have not found evidence of IL-IO mRNA 
in five human MM cell lines assayed. Other investiga-
tors, whilst confirming these observations, demon-
strated that IL-1O is a growth factor for malignant 
plasmablastic cell lines and that IL-IO-dependent 
MM cell lines can be obtained.63 This growth promot-
ing activity is independent of IL-6, though these IL-
10 dependent MM cell lines demonstrated a 
plasmablastic morphology and low Ig secretion. This 
suggests that these cell lines were more primitive than 
the mature malignant plasma cells seen in the disease 
in vivo and the addition of IL-IO to the culture system 
did not induce terminal maturation of these cell lines. 
These same investigators, using a sensitive ELISA 
assay, demonstrated a low level of serum IL-IO in 
patients with stable disease (3.3%) compared to a 
higher level of detection in patients with terminal 
phase disease and plasma cell leukaemia (60%). 
Similarly, other investigators have demonstrated that 
serum IL-IO levels are higher in patients with multiple 
myeloma compared with control patients and that 
serum IL-IO levels correlate with the paraprotein 
level.64 Thus the role of IL-IO in the pathogenesis and 
immune dysfunction in MM remains uncertain. 
However, this cytokine may be involved in the later 
phases of the disease associated with widespread 
dissemination of tumour cells and deterioration of 
clinical status. 
Transforming growth factor beta 
Transforming growth factor beta (TGF~) was origi-
nally purified from platelets and found to mediate 
anchorage-independent growth of fibroblasts and play 
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a key role in the growth and differentiation of epithe-
lial cells (reviewed in 65). TGFp is a pleiotropic 
cytokine that can affect a wide variety of tissues and 
cells. There are five isoforms of TGFp (TGFpl-5) 
which signal through the same serine-threonine kinase 
receptors (TGFpR I and 11). TGFp has effects on all 
of the mediators of the immune response - T cells, 
B cells, monocytes/macrophages and dendritic cells. 
TGFp is a potent immunosuppressive cytokine and 
influences all stages of T lymphocyte development and 
differentiation through to their activation and prolifer-
ation, the exact effect being determined by the stage of 
maturation of the T cell. A subset of T helper cells 
(Th3) produce TGFW6-70 upon activation, in addition 
to IL-4 and IL-IO, and these may represent a sub-
group of cells capable of suppressing the inflammatory 
response to limit tissue damage, though their exact 
function is not known. Exogenous TGFp inhibits T 
cell proliferation by down-regulating IL-2 mediated-
signals mediated through reduced tyrosine phosphory-
lation of proteins of 120, 100, 85, 75 and 50 kDa and 
inhibition of IL-2 mediated phosphorylation of the 
retinoblastoma susceptibility gene product, which is 
pivotal in the progression of cell cycle.59,7!-73 However, 
in contrast to these inhibitory functions, a growing 
body of evidence is being produced to suggest that 
TGFp can also enhance T cell growth, especially those 
with naIve phenotypes and promote effector function 
through enhancement of cytokines and inhibition of 
apoptosis.74-76 TGFp suppresses normal B cell prolifer-
ation and immunoglobulin production, induces apop-
tosis of pre-B cells mediated through interactions with 
stromal cells and suppresses haemopoiesis through 
antagonism of stem cell factor.65,77-79 TGFp has been 
reported to account for the profound suppressive 
effects on normal haemopoietic stem cells and B cell 
function associated with malignancy.8o,8! 
In multiple myeloma, several studies have shown 
TGFp mRNA in tumour cells and derived cell lines, 
and we have shown this correlates with secretion of 
TGFp.6!,82-85 Some investigators have shown that the 
level of TGFp secreted by MM cells is greater than 
normal B cells and CD40L-activated B cells and that 
BM stromal cells from MM patients secrete more 
TGFp than BM stromal cells from normal control 
subjects.85 Other groups have demonstrated high 
serum levels of TGFp in patients with MM using 
ELSIA assays and there is a suggestion that serum 
levels correlate with the extent of myeloma bone dis-
ease. 86,87 In contrast to its effects on normal B cells, 
TGFp does not decrease the proliferation of MM cells. 
and may even augment IL-6 secretion and related pro-
liferation.85 We have shown that MM tumour cells can 
inhibit T cell activation and induce a G! cell cycle 
arrest of T cells mediated by TGFp.84 However, the 
exact role of TGFp in the pathogenesis is unclear, 
although data are emerging that indicate TGFp to be 
a major cytokine involved in the maintenance and 
survival of the malignant clone in myeloma, perhaps 
mediated through autocrine/paracrine IL-6 and other, 
as yet poorly understood, interactions with the stro-
mal elements in the bone marrow micro-environment. 
It is also possible that TGFp contributes to both the 
identified. cellular and humoral immune deficiencies 
associated with this disease. 
Fas/Fas ligand 
Fas (Apo-lICD95) is a member of the TNF recep-
tor/nerve growth factor receptor family and it regu-
lates apoptosis through interaction with its ligand, 
FasL, which is also a member of the TNFR/NGFR 
family and can act both in the membrane bound and 
soluble forms. 88-92 Fas is present on the cell surface of 
a variety of cells including activated T cells. FasL is 
constitutively expressed in sites of immune privilege 
such as the eye, the spleen and at a low level in the thy-
mus and more recently it has been described on the 
surface of tumour cells.93,94 The recognized role of 
Fas/FasL in the immune system lies in the process of 
acquisition of self tolerance through clonal deletion 
of thymocytes and T cell mediated cell killing as part 
of the host defence against virally infected or trans-
formed cells.95-97 Recently it has been shown that FasL 
engagement inhibited CD4+ T-cell proliferation, cell-
cycle progression and IL-2 secretion in vitro and pre-
vented superantigen-mediated CD4+ T-cell expansion 
in a murine model.98 Thus with the acquisition by 
tumour cells of FasL, the active suppression of 
tumour-specific Fas+ T cells might be an active mech-
imism of escape from immune surveillance. However, 
this 'counter attack' or immune privilege mediated by 
Fas/FasL interactions in immune evasion by human 
cancers is more complicated than first thought and is 
rapidly becoming an established area of tumour 
immunology research. Disarming this counter-attack 
might offer a potential for therapeutic intervention 
(reviewed in ref. 99). 
In myeloma, some investigators have demonstrated 
the expression of both Fas (CD95/Apo-l) and its lig-
and, FasL on the surface of myeloma celllines.!OO The 
FasL was shown to be functionally active in inducing 
apoptosis in Fas-sensitive T-cell acute lymphoblastic 
leukaemia cell line. One question is raised by these 
and other similar findings: why do the tumour cells 
which are Fas+/FasL + not commit autocrine 'suicide' 
or juxtacrine 'fractricide'? They do not because of an 
intrinsic resistance to Fas-mediated apoptosis. Many 
mechanisms have been proposed to account for this, 
e.g. expression of antagonistic soluble Fas, failure to 
establish death-inducing signalling complexes 
(DISCs), altered regulation and function of the cas-
pases, the exact pathways involved remain uncer-
tain.9s.99.101 The understanding of Fas resistance and 
counterattack is fundamental to designing interven-
tional strategies to disarming this system for effective 
cancer management and we await the developments in 
this field with anticipation. 
Vascular endothelial growth factors 
Vascular endothelial growth factor (VEGF) is a 34--42 
kDa cytokine produced in large amounts by most 
tumours and previously recognized mainly for its 
angiogenic properties. 102 It stimulates the proliferation 
of endothelial cells and thus has a pivotal role in 
tumour neovascularisation. More recently it has been 
shown to have a profound inhibitory effect on 
haemopoiesis. 103.104 In particular, VEGF has been 
shown to responsible for defective dendritic cell (DC) 
maturation in vivo. VEGF binds to haemopoietic pro-
genitor cells through specific binding to its receptor, 
FIt-l which blocks activation of the transcription fac-
tor NF-KB.IOS NF-KB is composed of 50--65 kDa sub-
units which bind to a 10 bp motif in the promoter 
sequence in responsive genes and include p50, p52, 
p65 (ReIA), cRel and RelB. It has been shown that 
reduced DC generation results from targeted disrup-
. tion of RelB. 106 Similarly, disruption of NF-KB 
expression has been shown to result in dysregulation 
of T cell growth and development. 107 
VEGF mRNA transcripts have been detected in 
both fresh MM tumour cells and HMCL.108 
Interestingly, the investigators demonstrated that when 
HMCL were cultured with excess rhIL-6, there was an 
increase in the level of VEGF mRNA, and when 
VEGF was added to cultures of human bone marrow 
stromal cells there was an increase in IL-6 production. 
Thus MM tumour cells may produce VEGF to stimu-
late the stromal cells to produce the growth and differ-
entiating agent, IL-6, for the malignant clone and in 
addition, this cytokine may serve to 'disarm' the 
potent antigen-presenting DC from stimulating a host 
reaction. Despite this in vivo effect on progenitor cells, 
DCs can be generated from the peripheral blood DC-
progenitor cells of patients with MM and that these 
DCs are both functionally and phenotypically similar 
to those generated from healthy donors. I09•lIo This is an 
area of the biology of multiple myeloma that warrants 
further investigative research. 
Muc-l 
Cell surface mucins play a significant role in cell-cell 
communication. I I I The muc-! mucin is a high molecular 
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weight glycoprotein consisting of a core protein with 
highly branched carbohydrate side chains and is 
expressed on the apical surface of a number of epithe-
lial cells, including malignant cells. II2- 114 A high level 
of muc-! expression is associated with high metat-
static potential and poor prognostic index in epithelial 
malignancies."S-117 Muc-! is a ligand for ICAM-l and 
high levels of expression may induce immunosuppres-
sion or anergy by interaction with its ligand on T 
cells. II8 Furthermore, muc-l expressed and shed by 
breast cancer cells has been shown to induce apopto-
sis in T cells which may be rescued by IL_2."9.120 
Myeloma tumour cells, both fresh cells and 
HMCL, express muc-l which can be upregulated by 
dexamethasone and produce a soluble variant which 
is capable of suppressing an alloantigen T cell 
response.12H23 It has been shown that HLA-unre-
stricted CTL can be generated from PBMNC of some 
MM patients which directly recognise the under-gly-
cosylated form of muc-l and demonstrated direct 
cytotoxic capability against muc-l + MM and breast 
cancer cell lines. 124 However, it is worthy of note that 
this phenomenon was demonstrated in only 2 of the 6 
patients tested which may suggest that muc-l may 
limit the generation of adequate populations of 
immune effector cells. Clearly the role of muc-l as an 
immunosuppressive agent warrants further attention, 
particularly its potential as a tumour-specific target. 
IMMUNOTHERAPY IN MM 
The use of the immune system to treat human malig-
nancies has attracted much interest by cancer physi-
cians. Evidence exists demonstrating the potential of 
the immune system to eradicate haematopoietic 
malignancies, particularly in relapse post-BMT and in 
the setting of minimal residual disease. 125 In myeloma, 
the use of allogeneic haemopoietic cell transplan-
tation (HCT) has resulted in lower relapse rates and 
disease progression with higher molecular remission 
rates. 126-129 However, these clinical effects are achieved 
with higher treatment-related morbidity/mortality in 
the first year than is seen in the autologous setting. In 
those patients who survive one year there IS signifi-
cantly improved disease-free survival. The improved 
disease control is partly related to the intensive 
chemo-radiotherapy but is also a direct effect of the 
graft-versus-myeloma effect which has been reported 
by several investigators. 130.131 A close relationship 
between graft-versus-host disease and GVM in these 
studies suggests that the latter effect is mediated 
by dohor - allo-reactive T cells directed against 
minor histocompatibility antigens present on both 
normal and myeloma cells. Further evidence for the 
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graft-versus-myeloma can be deduced from the use of 
donor lymphocyte infusions to induce similar effects 
to that achieved after allogeneic HST in conjunction 
with high dose therapy or following relapse in the 
post-transplant period. 132- 134 Some investigators have 
demonstrated the successful transfer of myeloma 
idiotype-specific immunity from an actively immu-
rused bone marrow donor and showed the recovery of 
a CD4+ T-cell line generated from the peripheral 
blood of the recipient which demonstrated specific 
idiotype sensitivity.1 35,136 Other groups have studied 
the effect of immunizing the donor using the tumour-
specific idiotype and GM-CSF.137 All patients demon-
strated evidence of de novo anti-idiotype T cells and a 
transient rise in IgM anti-idiotype antibodies which is 
suggestive of successful primary immunisation. These 
immunotherapy strategies have been tested in the 
relapsed or resistant setting and the role of such 
strategies in the setting of minimal residual disease 
following conventional chemotherapy or haemopoi-
etic cell transplantation offers an increased potential 
for tumour cell control by adoptively transferred 
immune effectors. 
However, these attempts at immunotherapy are 
empirical and the true effector cells are not known. 
The role of adoptive immunotherapy in MM may be 
developed more appropriately in the setting of 
directed immune effector. Many investigators have 
turned to generating professional antigen presenting 
cells such as dendritic cells which have been pulsed 
with tumour derived peptides or idiotype.138-143 These 
studies demonstrate that idiotype-reactive T cells can 
be generated using such systems, although the results 
of pre-clinical studies have failed so far to be translo-
cated into mearungful improvements in overall and 
event-free survival of patients with MM.I44.145 An 
alternative approach in immunotherapy is the use of 
adenovirus-infected autologous plasma cells to trans-
fect immunostimulatory genes for IL-2, IL-12 and B7-
1,146 HMCL and primary plasma cells can be infected 
by adenoviral vectors containing marker genes or 
genes with therapeutic potentia1. 147 A recent phase I 
clinical trial injected an IL-2 gene directly into the 
tumours of two patients with multiple cutaneous plas-
macytomas with resultant evidence of successful 
tumour cell transfection using PCR and restriction 
enzyme digestion. 148 Work has now started on IL-2 
gene transfected autologous plasma cell vaccines. 
Other investigators have utilized similar gene transfec-
tant systems to transfer suicide genes, e.g. herpes sim-
plex thymidine kinase gene, which may have 
therapeutic potential. 149,1 50 These advances in the field 
of immunotherapy hold great potential and it is 
hoped that the success in the preclinical models can be 
translated into efficacious treatment modalities. It is 
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Fig 2 Multiplicity of interactions between MM plasma cells and 
their environment. In addition to defects in co-stimulatory 
molecules and antigen presentation, MM tumour cells have 
numerous 'counter attack mechanisms' available to suppress the 
host immune system. Key: TGF~: transforming growth factor . 
beta ; VEGF: vascular endothelial growth factor; ILI~: mterlellkm 
I beta; IL6: interleukin 6. 
worthy of note that if the wild type tumour is capable 
of an array of defence systems which can prevent the 
generation of an immune response or switch off an 
established response, then the design of immunother-
apy intervention will need to overcome these if the 
true potential of targeted immune effector cells is to 
be maximised. 
CONCLUSIONS 
It is evident from the data available that MM tumour 
cells adopt numerous mechanisms to avoid regulation 
by the host immune system. The tumour cells evade 
detection through alterations in their phenotype 
whilst at the same time switch off any immune effector 
cells directed against them using immunosuppressive 
cytokines and other molecules (Fig. 2). It is likely that 
more than one of these pathways is responsible for the 
failure of the host immune system to regulate the 
growth of the tumour clone. As more research in this 
field unfolds and more evidence of the established 
pathways emerges, or newer mechanisms of immuno-
suppression are discovered, physicians can use this 
information to design new immunotherapy strategies 
that may maximise such treatment modalities, espe-
cially in patients with minimal residual disease. 
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Transforming growth factor ~ from multiple myeloma cells 
inhibits proliferation and IL-2 responsiveness 
in T lymphocytes 
Gordon Cook, John D. M. Campbell, Christine E. Carr, Kelly S. Boyd, and Ian M. Franklin 
Academic Transfusion Medicine Unit, Department of Medicine, University of Glasgow, 
Royal Infirmary, United Kingdom 
Abstract: Multiple myeloma (MM) is a cancer of 
plasma cells, characterized by profound suppres-
sion of host immune responses. Here we show that 
MM cell lines significantly suppress the prolifera-
tion, blasting, response to interleukin-2 (IL-2), and 
expression of CD25 by concanavalin A (Con A)-
activated or allostimulated peripheral blood T lym-
phocytes. T cells arrest in the G 1 stage of the cell 
cycle, and do not enter the IL-2 autocrine growth 
pathway. T cell inhibition was mediated by a soluble 
factor. MM cell lines did not produce IL-IO but did 
produce large amounts of transforming growth 
factor 131 (TGF-IH). T cells were assessed for their 
ability to respond to IL-2 when co-cultured with 
MM cells in the presence or absence of the TGF-13 
inhibitor, TGF-l3latency-associated peptide (LAP). 
MM cells suppressed IL-2 responses but this inhibi-
tion was completely reversed by TGF-13 LAP. A 
CD25 -, IL-2-dependent blast cell line was not 
inhibited by MM cells or rhTGF -13, confirming the 
specificity of tbe inhibition mechanism for the IL-2 
autocrine growth pathway. We conclude that MM 
cells suppress T cells in their entry into the auto-
crine IL-2/CD25 pathway and in response to IL-2, 
and that TGF -13 has a significant role to play. J. 
Leukoc. Bioi. 66: 981-988; 1999. 
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INTRODUCTION 
Multiple myeloma (MM) is a clonal malignant disorder of 
terminally differentiated B cells (plasma cells) characterized by 
bone marroW plasmacytosis, lytic bone lesions, the production 
of a paraprotein, and secondary hypogammaglobulinemia [1]. 
In addition to these altered antibody responses, patients 
demonstrate quantitative and qualitative defects in their cellu-
lIar immune responses. T cells from patients have impaired 
responses to mitogens [2] and significantly lowered ability to 
generate LAK cells in response to interleukin-2 (IL-2) [3]. T 
cells from patients with MM have increased surface expression 
of Fas (APO-lICD95), lower Bcl-2 expression, and are suscep-
tible to apoptosis [4]. 
Suppressing T cell responses is of great potential benefit to 
the tumor. It has been unequivocally demonstrated that T cells 
can recognize the tumor paraprotein antigen. Expanded CD4 + 
and CD8+ T cell [5, 6] subsets with restricted usage of Va and 
VI3 segments [7, 8], which produce high levels of IL-2 and 
interferon-'Y in response to idiotype, have been isolated. High 
serum IL-2 levels in patients with MM correlated with other 
prognostic indices and were associated with improved survival 
[9]. Also, donor lymphocytes infused after chemotherapy and 
allo BMT can demonstrate anti-myeloma effects [10], and 
transfer of immunity with idiotype-specific T cells has been 
demonstrated [ll]. There is therefore no doubt that the immune 
system has the capacity to reject this tumor. However, despite 
these attempts at host immune regulation of the tumor clone 
ultimately all patients progress to relapse. Escape from immun; 
surveillance is therefore an essential strategy for survival of the 
tumor. 
There are a number of possible mechanisms that tumor cells 
may adopt to evade immune detection. Although myeloma cells 
express an array of adhesion molecules [12] they generally lack 
the co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86) on 
their surface, which are essential for the induction of T cell 
responses [13]. Myeloma tumor cells have been shown to 
constitutively express FasL on their surface and produce the 
MUC-l antigen, both of which may mediate apoptosis ofT cells 
[14, 15]. Myeloma tumor cells have also been reported to 
produce potentially immunomodulatory cytokines, including 
IL-6 and transforming growth factor 13 (TGF-I3) [16]. 
Thus MM tumor cells could adopt various defense mecha-
nis~s against rejection by t~e host immune system, allowing 
contmued growth and dommance in a potentially hostile 
microenvironment. As yet, there is no clear evidence to indicate 
which of these mechanisms is used by the tumor cells. In this 
study we have investigated the interaction between human MM 
cell lines and normal peripheral blood T cells to determine how 
MM cells can interfere with T cell responses, independently of 
any acquired defect in patient'sl cells. The study was designed 
to examine the effect that exposure to MM tumor cells has on 
the initiation and maintenance ofT cell activation. Specifically, 
do MM tumor cells suppress T cell responses or induce 
programmed cell death? 
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MATERIALS AND METHODS 
Myeloma cell lines 
The MM cell lines (MMC) U266, JJN3, and JIM 1 were used in these 
experiments. Cell lines were maintained in complete tissue culture medium: 
RPMI-1640 medium, 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 
IU/mL penicillin, 100 I'glmL streptomycin. 
Peripheral blood mononuclear cells (PBMC) 
Venous blood was collected from healthy volunteers with the use of sodium 
heparin as anticoagulant. PBMC were separated over FicolllHypaque (Lympho-
prep, Nycomed, Oslo, Norway) and washed four times in phosphate-buffered 
saline (PBS). 
Mitomycin C treatment 
MMC or PBM to be used as stimulators in mixed lymphocyte cultures were 
treated with mitomycin C (Sigma). PBM (2 X 107/mL) were treated with 25 
\1g1mL mitomycin C in complete medium for 30 min at 37°C, followed by two 
washes in RPMI-I640 medium. MMC were treated as above, except that 50 
\1g1mL mitomycin C was used. 
Cytokines 
Recombinant human IL-2 (rhIL-2) and TGF-I) latency-associated peptide 
(TGF -1)-LAP) were purchased from Sigma. rhTGF -I) 1 was purchased from R & 
D Systems. 
IL-2-dependent Con A blasts 
Long-term IL-2-dependent Con A blasts were generated as follows: 2.5 X 106 
PBMC/mL were cultured for 7 days with 5 \1g/mL concanavalin A (Con A; 
Sigma), followed by stimulation with 20 UlmL rhlL-2 for 7 days. After 
purification over FicolllHypaque, blasts were re-seeded at 105 cells/mL with an 
equal number of mitomycin C-treated autologous PBMC and 2.5 \1g1mL Con A 
for 7 days. Blasts were then separated over FicolllHypaque and re-stimulated 
with 20 UlmL rhIL-2. Growing cells were maintained in medium containing 20 
UlmL IL-2 twice weekly. Dead cells were removed from the culture by 
centrifugation over FicolllHypaque before use in any assays. 
Mixed lymphocyte assays 
PBMC (4 X 106/mL) were incubated with mitomycin C-treated MMC andlor 
allogeneic PBMC in serial dilutions to give PBM/stimulator ratios of 1:5 to 
1:160. Samples were also prepared as above, but with the addition of 2.5 \1g1mL 
Con A or 20 UlmL rhIL-2. Cultures were incubated for 1-5 days. Samples for 
flow cytometry and cell cycle/apoptosis assays were cultured in 24-well (2 
mLlwell) plates. Samples for proliferation assays were cultured in quadrupli-
cate in 96-well microtiter plates, and proliferation assessed by the addition of 1 
\1Ci [3H]thymidine in the last 6 h of incubation. Incorporated radiolabel was 
assessed in a Packard Matrix 96 counter. 
Assays were also performed with the PBMC separated from the stimulator by 
a 0.2-\1m-pore membrane (Life Technologies, Paisley, UK). Because membrane 
inserts were too large to use in 96-well plates, cells were grown in membranes 
for the desired period of time, plated in 96-well plates at the same dilution as 
normal assays, pulsed, and counted. 
IL-2 re-stimulation assay 
The ability of normal T cells to respond to IL-2 was assessed essentially as 
described elsewhere [17]. Briefly, PBMC (4 X 106/mL) were stimulated with 5 
\1g Con A for 5 days. The cells were then washed twice in complete medium 
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followed by 24-h culture in complete medium alone. The cells were then 
purified over Ficoll-Hypaque, washed twice in complete medium (resulting 
cells were >9S% CD3+, results not shown), and re-stimulated in complete 
medium containing 20 UlmL rhlL-2 for 24 h. Proliferation was assessed by 
[3H]dThd counting. These cultures were also performed with the addition of 
mitomycin C-treated MMC as above. TGF-I) LAP was also added to these 
cultures at SO nglmL [an approximate ED7s for neutralization of the anticipated 
TGF-I) production by the MM cell lines (see below)]. 
Flow cytometry 
Cells (5 X lOS/sample) were stained by direct immunofluorescence for 
two-color flow cytometry using isotype-matched controls. mAb used were as 
follows: anti CD3, CD4, CDS, CD25, CD69, CD95, and HLA-DR (Becton 
Dickinson, Oxford, UK). Data were analyzed using Cell Quest software (Becton 
Dickinson). The relative numbers of blasting cells in the different cultures were 
assessed by gating on the FSC vs. SSC parameters of the cells. 
Apoptosis and cell cycle assays 
Apoptosis was assessed by Annexin V-affinity assay and cells were stained 
according to the manufacturer's protocol (R & D Systems). Cells were washed in 
cold PBS and then incubated with 10 \1L of fluorescein isothiocyanate 
(FITC)-conjugated Annexin V (An) and 10 \1L of 50 \1g1mL propidium iodide 
(PI; Sigma) solution for 15 min at 20°C. This was followed by the addition of 
400 \1L of binding buffer (buffered HEPES and 25 mM CaCI2) without washing. 
Cells were analyzed within 1 h by flow cytometry revealing three cell 
populations: live cells (An-/PI-), necrotic cells (An+/PI+), and apoptotic cells 
(An+IPI-). PBMC were analyzed for apoptosis after 72-h culture with Con A or 
Con A + MMC. IDB were analyzed after 36 h culture with no cytokine; IL-2; 
IL-2 and U266 cells; and IL-2 and rhTGF-I)I, 10 \1g1mL. 
For cell cycle analysis, cell~ were harvested, washed in cold PBS, and fixed 
in 2% formaldehyde at 4°C for 15 min and permeabilized in 70% ethanol at 
-20°C for 1 h. Cells were washed in cold PBS and incubated with RNase (100 
\1g1mL) at 37°C for 30 min followed by PI (50 \1g1mL) in PBS at 20°C for 30 min. 
The DNA content of cells was determined by flow cytometry and the percentage 
of cells at different cell cycle stages determined using "Modfit" software (Verity 
Software House, Inc.). 
Reverse transcriptase-polymerase 
chain reaction (RT-PCR) 
The exp;ession of cytokine and cytokine receptor mRNA was detected by 
RT-PCR. Total RNA was isolated using the Quiagen RNEasy system according 
to the manufacturer's protocol. Five micrograms RNA was synthesized to cDNA 
using the "Superscript" system (Life Technologies) and oligo dT 12-18 primer. 
Two microliters (equivalent to 0.5 \1g total RNA) of cDNA were used in RT-PCR 
reactions (50-\1L reaction volume). Primers specific for human cytokine 
sequences were used to amplify cDNA during a 30-cycle PCR program with the 
use of AGS Gold Taq polymerase (Hybaid, UK). Primers for IL-la, IL-2, IL-4, 
IL-6, IL-I0, IFN-,(, TNF-a [IS], IL-l1), and TGF-I) 1 (Clontech Inc.) were used. 
Primers for CD122 (IL-2 receptor I)-chain) and CD132 (common '(-chain 
cytokine receptor) were run in a 35-cycle PCR program [19]. I)-Actin was used 
as an amplification and loading control. All primers were run at an annealing 
temperature of 60°C (except IL-6 and IL-I0, run at 65°C). Twenty microliters of 
PCR product was visualized on a 2% agarose gel under ultraviolet illumination. 
TGF-131 enzyme-linked immunosorbent 
assay (ELISA) 
Cell culture supernates were assayed for the presence of TGF-I)l using a 
Promega TGF-I)l ELISA system. MM cells (106) were cultured for 72 h in 
complete tissue culture medium. Samples were acid activated and diluted up to 
11100 in PBS to obtain results within the linear working range of the system 
(16-1000 pglmL). The background levels of TGF-I) 1 in normal tissue culture 
medium were also assayed, and the results from the cell lines expressed minus 
the levels in normal medium. 
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Statistical analysis 
Stati sti cal analysi s was performed using the Student's t tes!. Means are 
expressed :': SEM. 
RESULTS 
MMC suppress MLR responses 
When PBMC from normal, healthy, volunteers were co-cultured 
with mitomycin C-treated allogeneic PBMC, brisk proliferation 
was observed at day 5 of culture (Fig. 1). In contras t, PBMC 
failed to show any proliferation in one-way MLR with the MMC 
U266, JIM1, and JJN3 (data not shown). When MMC were 
co-cultured in MLR reactions between normal allogeneic 
PBMC, tritiated thymidine uptake was greatly suppressed, with 
the degree of suppress ion correlated to the numbers of MMC 
added to the MLR (Fig. 1). MLR responses were completely 
suppressed at ratios of 1 MMC:5 PBMC. Full responses were 
only regained at the lowest concentration of MMC (1 MMC:80 
PBMC). MMC therefore are capable of suppressing MLR 
reactions. 
MMC cells suppress mitogen responses 
When PBMC were activated with Con A, maximal proliferation 
was seen 72 h post-stimulation (data not shown). Co-culture of 
Con A-activated PBMC with MMC lines (U266, JIM 1, and 
JJN3) strongly suppressed Con A-induced proliferation at 
MMC/PBM ratios of 1:5 and 1:10 at 72 h (Fig. 2). The 
suppression of responses was still present after 5 days of culture 
(results not shown). Using a panel of normal donors, the mean 
inhibition of Con A-induced proliferation after co-culture with 
U266 was 59.7 :±: 4.9% at a ratio of 1:5 (six individual donors, 
illustrated in Fig. 3A) dropping to < 10% at 1:80 (results not 
shown). The addition of 20 UlmL rhIL-2 (the standard T cell 
stimulation dose, see above) did not reverse the suppression of 
Con A responses by U266 or JJN3 (Fig. 3B). When PBMC were 
separated from MM cells by a 0.2-pm pore membrane during 
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Fig. 1. Representati ve data of MLR responses of two different donor's PBMC 
aga inst allogeneiC PBMC at S days. MLR responses are completely inhibited by 
the addition of U266 and JJ N3 MMC at ratio of 1 MMC:S responder PBMC. 
Responses are partially restored at lowering MMC concentrations. Tritiated 
thymidine uptake measured as counts per second. U, U266; J, JJN3. 
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Fig. 2. Inhibition of Con A·induced thymidine uptake of normal PBMC from 
the same donor by different MMC at 72 h. 
Con A stimulation , equal levels of inhibition to those co-
cultured in contact with U266 and JJN3 cell s was seen. (Fig. 
3B). This indicates that inhibition of Con A·induced prolifera-
tion by MMC was mediated by soluble factors. 
MMC induce cell cycle arrest rather 
than apoptosis 
The lack of proliferation in Con A/MMC cultures was due to cell 
cycle arrest rather than apoptosis. The percentages of Annex-
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h). (B) The abi lity of U266 or JJ N3 to reduce thymidine uptake by Con 
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]:5 at 72 h. (n = 7). 
in V+ cells in Con A/MMC cultures were not significantly 
different from PBMC cultured with Con A alone (Fig. 4). Cell 
cycle analysis showed that, although large numbers of Con 
A-treated PBM had left the CO/C1 phase of the cell cycle, cell s 
in the Con A/MMC cultures remained largely in the GO/CI 
phase (Table 1). 
MMC inhibit blasting and the expression 
of activation markers on T cells 
Con A activation of PBMC led to an increase in the numbers of 
blasting cells to 56.5 ± 5.8% (n = 7). This was signifi cantl y 
inhibited by incubation with MMC, dropping to 28.2 ± 5.1% 
with U266 (P < 0.005, n = 7) and 20.4 ± 2.3% (P < 0.002, 
n = 6) with JJN3. The mean ex pres ion ofCD25 post-activation 
of PBMC was 67 ± 5.3% (n = 7), and thi s dropped 
signifi cantly to 40 ± 5.1% after incubation with U266 (P < 
0.005, n = 7) and 37 ± 2.7% with JJN3 (P < 0.01, n = 5). 
The reduction in CD25 expression was seen equally on CD4 + 
and CD8+ cells within the CD3+ population (result not 
shown). 
When activated with Con A, T cell s in PBMC rapidly 
expressed CD69, followed by CD25, becoming largely CD69+ 
CD25+ within 48 h of activation (Fig. 5). CD69 expression 
waned by day 3 (Fig. 5) with a mean of 45.9 ± 5.3% (n = 7) of 
all PBMC expres ing the CD69-/CD25+ phenotype. The rapid 
expression of CD69 and the first appearance of CD25 + cells at 
24 h was unaltered in Con A-activated PBMC co-cultured with 
U266, and many cells remained CD69+/CD25+ at 48 h (Fig. 5). 
Howev r, the cells expressing these T cell activation markers 
an-ested at thi s stage of development. CD69 expression re-
mained hi gh at 72 h, mean numbers of only 18.9 ± 3.5% (U266 
P < 0.001, n = 7) and 10.54 ± 2.2% (JJN3 P < 0.002, n = 5) 
Med 
Con A 
U2 
TABLE 1. Cell Cycl.e Analysis 
% Cells in CO/Cl 
82 
48 
77 
SEM 
7.55 
8.2 
8.2 
p. 
<0.02 
> 0.5 
Mean numbers of PBMC remaining in GOICl of the cell cycle after cu lture 
with medium alone, Con A, or Can A + 266 cells at a ratio of 1 MMC:5 
PBMC. U2-U266. 
• Compared to medium control, n = 5. 
984 Journal of Leukocyte Biology Volume 66, December ]999 
Con A Con A +MMC 
CD69 
CDlS ----. 
Fig. 5. The percentages of C069+/C025- and C069+/C025+ PBMC after 
culture with Con A or Can A and MMC are identical at 24 h. By 48 h the Can 
A-treated cells are largely double positive, and more cell s have become C025+ 
than in the Can A/MMC culture. By 72 h the vast majority of nOl1nal Can 
A-activated cell s are C069- /C025+, whereas Can A/MMC cells remain at the 
C069+/C025- or C069+/C025+ stage. C069, y-axis; C025, x-ax is. U266 1 :5. 
Quadrants are set on appropriate negative control samples. 
of PBMC progressed to the fully acLivated CD69- CD25+ 
phenotype (Fig. 5). 
IL-2-dependent blasts are not inhibited by MMC 
or recombinant TGF-13 
The IL-2-dependent blast line (IDB) showed maximal prolifera-
tion to IL-2 at 72 h (data not shown). IDB constitutively 
expressed mRNA for CD122 and the common "V-chain cytokine 
receptor (results not shown) and expressed CD3 (results not 
shown), CD95, but not CD25 on their surface (Fig. 6). 
Withdrawing IL-2 from IDB led to rapid apoptosis/necrosis 
(Fig. 6). Co-culture of IDB with U266 did not induce apoptosis 
(Fig. 6). Co-culture of IDB with U266 (Fig. 7) or recombinant 
TCF-13 (results not shown) did not signifi cantly suppress 
proliferation to IL-2 at any of the dilutions tested. 
Expression of T cell response modifying 
factors by MMC 
Strong transcripts for TCF-131 were detected in all MMC lines 
assayed (Fig. 8). IL-6 was also detected, although the intensity 
of amplified products was variable (results not shown). 0 other 
cytokine transcripts were routinely detected, although very 
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faint products for IL-la, IL-2, and TNF-a were detected, 
espec iall y from the U266 line (results not shown). 
MMC supernates contained high net levels of total TFG-(31 
protein a follows: U266, 8.62 nglmL; JJ 3, 1] .02 nglmL; JIM 
1,6.72 ngimL. 
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T cell IL-2 responses are inhibited by MMC 
and restored by LAP 
T cells re-stimulated with IL-2 proliferated briskly, and thi s was 
again s ign ifi can tl y inhibited by co-culture with MM cells (Fig. 
9A). The ability ofT cells to respond to IL-2 when co- ultured 
with MM cells was completely restored by the addi tion of 
TGF -(3 LAP (Fig. 9B). 
DISCUSSION 
Although there is good evidence that T cells have at least 
initially responded to the disease [4-8], these responses 
ultimately do not control MM. Failure to express costimulatory 
molecules by MM cells, and the induction of apoptosis in T 
cell s by MM cell s have been put forward as possible mecha-
ni sms for tumor c 1I to avoid or interfere with T ell respons s. 
In this study we have shown for the first time that MM cell lines 
directly disrupt the ac ti vation and proliferation ofT cell s. 
MM cells did not stimulate a primary MLR when us d at the 
same effector/target ratios as non-transformed allogen ic cell s . 
Thus, even with the high allorea ti v CD8 precursor frequency 
in the periphery, MM cell s do not readily induce ac ti vation of T 
cells. This is lik ly to be due to activ suppression rath r than a 
lack of immunogenici ty (MM cell express HLA -A BC and 
HLA-DR molecules [20]) because MM ells can also fully 
uppre s normal MLR reactions, mitogen activation, and re-
sponse to IL-2 as bystanders. Because eparati on of the MMC 
from the responding T cell by a membrane did not affect the 
suppressive capacity of MMC, the suppressive factors appear to 
be soluble. The increasing levels of inhibition of T cells with 
increasing numbers of MMC are likely to be due to intensifying 
levels of suppressive soluble factor. 
There was no ignificant difference in apoptosi levels 
between normal activated p ripheral blood T cells and MMC-
inhibited cells. Thi is not surpri si ng b caus a activation of 
the T cell s was blocked they should not be usceptible to 
ac ti vation-induced death. Although FasL or MUC-l-induced 
apoptosis ha been put forward a a possible T cell inhibitor in 
MM [14, 15], it does not have a role to play in the inhibition ofT 
cells seen here. In add ition, Fas/FasL interactions may cause T 
cell s to cell cycle arrest/fail to proliferate (rather than apop-
tose), but thi can be overcome by addi ng IL-2 [21], which is 
not the ca e here. U266 also fai led to induce apoptosis in the 
Fas+ IL-2-dependent blast cell line. U266 has been shown 10 
express FasL [14.] and our results showing that a Fas+ line i not 
induced to apoptose by MMC are at odds with previous findings 
[14]. However, the strong ongoing response to IL-2 by the IDB 
may contribute to re istance to Fa -induced apopto is [22] and 
this area merits further investigation. 
MMC stopped T cells from entering S-phase of the cell cycle. 
The failure to enter S-phase was not due to a complete lack of 
activation because T cell s expressed similar levels of CD69 
when cultured in the presence or absence of MMC. CD69 is the 
ear1iest cell surface ac ti va ti on Ag to b express dafter T c II 
ac ti vation [23]. ormally the expression of CD69 at 24 h po t 
mitogen activation correlates with maximal thymidi ne incorpo-
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Fig. 8. RT-PCR analysis of different MMC for IL-lO and TGF-f3. Strong transcripts for TGF-f31 are detected in all cell lines, whereas no product for IL-lO i found. 
Cell lines (reading left to right for each primer set): lane 1, JIM 1; lane 2, JJN3; lanes 3-5, U266. 
ration at 72 h [24]. The exact role of CD69 in T cell activation is 
unclear, but it is thought to synergize with signaling through 
TCRJCD3 [25]. Signaling through CD69 results in the synthesis 
of IL-2 and its receptors and cell proliferation [26-28]. Thus 
the T cells that are inhibited by MMC have received the signal 
to proliferate and produce IL-2, evidenced by the normal 
expression of CD69, but have failed to progress beyond thi s 
point because they have low thymidine incorporation and 
reduced S-phase by DNA contenl. 
Normal T cells in these experiments progressed through from 
a CD69+/CD25- state to being largely CD69-/CD25+ by 72 h 
of activation. The large increase in CD69-/CD25+ cells 
indicates that the T cells have entered the IL-2 autocline 
pathway of growth. CD69 is largely lost on these cells by 72 h, 
as progression into activation and proliferation pathways leads 
to the rapid degradation of CD69 mRNA [29]. The expression of 
significantly lower levels of CD25 by MMC-inhibited cells, 
coupled with their persistent expression of CD69 and lack of 
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Fig. 9. (A) T cells re-stimulated with lL-2 are significantly inhibited by MMC 
(means of three normal donol's). (B) Addition of TGF-f3 LAP completely 
reverses MMC-induced inhibition oflL-2 responses in T cells (n = 4). Tritiated 
thymidine uptake 24 h, 20 U/mL IL-2, 1 T cell:S MMC. CPM, counts per . 
minute. Note that LAP elevates responses slightly higher than IL-2 alone; LAP 
neutralizes the small amounts of active TGF-f3 present in FCS. 
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thymidine incorporation, strongly suggests that the majori ty of 
these cells have not entered the IL-2 autocrine growth pathway. 
The fai lure of MMC-inhibited T cells to respond to exogenous 
standard doses of IL-2 either during mitogen stimulation or 
re-stimulation post-activation strongly suggests disruption of 
the IL-2 autocrine pathway. 
MMC or rhTGF-[3 failed to inhibit proliferation of the 
IL-2-dependent blast cell line (IDB) or induce apoptosis. IDB 
did not express IL-2 or CD25, but used the [3 and 'Y chains 
(CD122 and CD132) of the IL-2 receptor. Thus the IDB were 
independent of the CD25/IL-2 autocrine pathway and could 
only respond to exogenous IL-2. Removing IL-2 from IDB 
resulted in cell death. Clearly MMC or rhTGF-[3 (even at the 
lOX EDso dose used here [17]) did not reduce the ability of 
IL-2 to signal through [3 and 'Y chains because no apoptosis or 
loss of proliferation was seen. Because IL-2-induced-prolifera-
tion of IDB was completely unaffected by MMC, it appears that 
the suppression of IL-2 pathways by MMC (and similarly 
TGF-(3) is dependent on signaling through the CD25 molecule. 
The principal cytokine produced by the MMC was TGF-[3l. 
No other cytokines, such as IL-IO, that can be instrumental in 
suppression ofT cell responses [30] were detected. The TGF-[3 
family of cytok ines is thought to play an important down-
regulatory role in the control of both Thl and Th2 T cell 
responses [31]. TGF-[3 is produced by many different types of 
tumor, including myeloma cell lines [16], a result confirmed 
here, and has been reported to be elevated in MM patients [32]. 
TGF-[3 med iates suppression of IL-2 responses in T cells [33] 
and prevents T cell proliferation by inhibiting the phosphoryla-
tion of 1ak-l kinase and activation of STAT 5 transcription 
factor [17]. These factors control the entry of the cell into the 
IL-2 autocrine growth pathway and TGF-[3-treated T cells fail 
to progress to S-phase of the cell cycle [17]. The characteristi cs 
of TGF-[3-inhibited cells, failure to progress through the cell 
cycle or become fully IL-2 responsive, are therefore identical to 
those of MMC-inhibited cells. 
Indeed, TGF-[3 appears to be the principal immunosuppres-
sive soluble factor active in our assay systems. Suppression ofT 
cell responses was highly specific to the IL-2 pathway: pure 
CD3 + cells re-stimulated with IL-2 were significantly inhibited 
by MMC. TGF-[3 LAP could completely reverse thi s inhibition 
of IL-2 responses. Highly specific to TGF-[3, binding active 
cytokine and holding it in an inacti ve form, the ability of LAP to 
reverse immunosuppression strongly suggests that TGF-[3 is 
mediating the inhibition of IL-2 responses assayed here. This 
aJso indicates that the large amounts ofTGF-[3 protein detected 
http://www.jleukbio.org 
in the supernates ofMMC contain biologically significant levels 
of active cytokine: LAP is only effective against active TGF-13· 
This study has shown that myeloma cells, in sufficient 
concentrations, can very efficiently shut off T cell responses, 
and that the IL-2 autocrine loop is inhibited. Low levels of 
tumor cells had little effect on the proliferation of T cells. High 
IL-2 serum concentration correlates with long-term survival of 
MM patients, whereas patients who progress to bulk disease 
show a marked decrease in IL-2 serum levels [9]. Conversely, 
high serum levels of immunosuppressive TGF -131 correspond to 
a poor prognosis [32, 33]. When the tumor mass is reduced in 
conjunction with autologous BMT, infusion of donor lympho-
cytes leads to strong anti-myeloma responses [10]. Although 
patients remain disease free for some time, the vast majority of 
cases eventually relapse. Drawing a crude analogy to the 
experiments described here, a low tumor burden. (re~~esented 
by low MMC/PBMC ratios) is unlikely to greatly Inhibit T c~ll 
activation and IL-2 production. Increased tumor numbers Will 
ultimately lead to a profound suppression of T cell activation 
and IL-2 production. Thus, while low levels of tumor are 
present, T cells are able to expand and develop anti-tumor 
activity. Although these expanded T cell populations are still 
detectable from patients with advanced disease [5, 6], it is 
likely that their lack of function is due to the large-scale 
production of immunosuppressive ~ytok.in~s. Our results s~ow 
that TGF-13 has a major role to play In thiS ImmunosuppressiOn; 
the role of other factors such as MUC-1 and FaslFasL has still 
to be fully elucidated. ' 
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